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INTRODUCTION 
Since the first implantation of a Pahnaz Schatz coronary stent in Qur department. in January 
1990, we were confronted with both the beneficial and detremental properties of the device. 
\Ve experienced that this slent was of great value in stabilizing patients with an occlusive dis-
section after balloon angioplasty (PTCA) [chapter 2.1 and 2.2] and we shared the opinion that 
the stellt had the potential to reduce restcnosis after balloon angioplasty, as was demonstrated 
later in the Benestent-I (I) and the STRESS (2)- stndies. Because of its thromhogenicity, we 
adhered to the stringent anticoagulation regimen. which was advised to prevent stellt throm-
bosis (3), Despite this strategy, stellt thrombosis could not be prevented in the bailout situ-
ation (chapter 2.2) and, to a lesser extent, in the ideal study population, slich as defined in the 
Benestent-I study (chapter 2.3 and 3.1). The combination of antiplatelet and anticoagulant 
therapy also resulted in a high incidence of entry-site related bleeding complkations (chapter 
2.2, 2.3 and 3.1). 
In the course of 5 years, optimalization of clinical outcome aftcr coronary stenting was explo-
red in 5 dirc<.::tions: 
[1] 1991-1992: Improvement of stellt implantation technique by intravascular ultrasonic 
guidan<.::e 
[2] 1991-1992: Improvement of anticoagulation monitoring by prothrombin fragment Fl+2 
assessment. 
[3] 1991-1992: Improvement of local hemostasis and anticoagulation by application of colla-
gen plugs. 
[4] 1992-1995: Selection of a safer entrysite. 
[5] 1994-1995: Implantation of l1on-thrombogenk stents. 
f l}lmproyement of stcnt implantation tcchniquc by intravascular ultrasonic guidancc. 
The risk for subacute stellt thrombosis is reduced when larger tlnal stent diameters are obtain-
ed (4,5,6). Although the angiographic appearan<.::c after stenting may be acceptable, stent 
expansion can be incomplete, when assessed with intravascular ultrasound (lVUS). 
Stent dilatation with larger balloons at high intlation pressures does result in improved stellt 
expansion (7). Since the Palmaz Schatz stent, incorporated in the prefabricated Stent Delivery 
System (SDS), is mounted on a compliant low pressurc- balloon, we postulated that the stent 
could not be properly expanded after initial deployment with this SDS. 
In the early years of stent experience, we compared stent expansion with IVUS after delivery 
with the SDS and after high pressure inflations with less compliant balloon material (chapter 
4.1). 
[2J Impl'ovement of monitoring of anticoagulation by assessment of prothrombin fl'ag~ 
ment Fl+2, 
At the same time attention was focused on the importance of optimal anticoagulation to pre-
vent stent thrombosis. From Swars et al. (8) and Hafner et aI. (9) came promising news on the 
assessment of prothrombin fragment FI +2, as spedfic markers for impending stellt thrombo-
sis. In retrospective studies a rise of Fl +2 was detectable in patients who developed stent 
thrombosis. By giving additional heparin if a rise in Fl+2 was detected, stent thrombosis 
could be prevented (9). 
However, administration of extra heparin, also in paticnts with Activated Partial 
Thromboplastin Times (APTT) within the therapeutic range, may further increase the risk of 
bleeding complications. Therefore, we performed a prospective study, to explore the practical 
value of this assessment by establishing the relation bet\veen prothrombin fragment Fl+2-
levels and the occurence of subacute thrombosis (chapter 4.2). 
II 
[3] Improvcmcnt of local hemostasis and anticoagulation by application of collagen 
plugs at the puncturcsitc. 
Ernst et al. (10) and Sanborn et al. (II) reported on the value of collagen plugs, percutaneous-
ly inserted at the pUllcturesite after coronary angiography and PTCA. 
These promising results, stimulated tis to explore the value of this hemostatic device in the 
prevention of bleeding complications at full heparinization after coronary stenting (chapter 
4.3). 
[4] Selection of a safer cnh·l'site. 
In 1992, 6 French (F) guiding catheters became commercially available on a larger scale. By 
combining these guiding catheters with miniaturized balloon catheters, having a low profile 
even at larger balloon diameters, PTCA could he performed for a \vide range of coronary a1ie-
ry sizes. As a prerequisite for PTCA through 6F guiding catheters, we considered the preser-
vation of the possibility to offer the patient the same standard bailout techniques (perfusion 
balloons and stents), in case of a PTCA complication. \Ve performed a study on the elective 
use and on emergency use of perfusion balloons as well as stenls through 6F guiding catheters 
(chapter 4.4.1 and 4.4.2). 
Based on work of Campeau, who reported in 1989 011 the feasibility of transradial artery coro-
nary angiography with SF catheters (II), we decided to explore the feasibility of transradial 
PTCA and stenting using 6F guiding catheters. \Ve finalized n feasibility study in 100 patients 
who underwent transradial PTCA (chapter 4.5.1). High success rates and absence of major 
bleeding complications, made us decide to compare the transradial 6F PTCA technique with 
6F PTCA via the femoral or brachial arteries. A randomized trial in 900 patients is currently 
conducted in our department; the ACCESS- study. \Yc performed all interim analysis at inchl-
sion of 450 patients (chapter 4.5.2). 
In the mean time another feasibility study was completed in 100 patients who were selected 
for transradial coronary stellt implantation (chapters 4.6.1, 4.6.2 and 4.6.3). 
Since the role of TVUS, guiding coronary stenting, may remain an important issue, we explo-
red the feasibility of ultrasound guided transradial coronary stenling, during stent implanta-
tion, with a miniaturized ultrasound transducer (chapter 4.6.4). 
Immediate mobilization of the patient after effective hemostasis following a transraclial stent 
implantation, will be associated \vith considerable cost-savings. 
We performed a retrospective comparison of patients who underwent traditional SF, transfe-
moral, sheath-protected, stent implantation, derived from the BCllestent popUlation, included 
in our center and transradial stenting. Costs associated with material COIl-
sumption, diagnosis and treatment of bleeding complications and hospital stay were compared 
(chapter 4.6.5). To push cost-savings a little further, we conducted a pilot study to the feasibi-
lity of coronary stenting on an outpatient basis in a carefully selected group of patients, since 
an optimal transradial stent result protects the patient against acute stent occlusion and a 
major bleeding (chapter 4.6.6). 
[5] Implantation of lInn-thrombogenic stents. 
Finally Van del' Giessen et al. (12) directed attention towards the use of non-thrombogenic 
heparin-coated Palmaz Schatz coronary stents, with the potential to prevent stent thrombosis, 
local hleeding complications and to further reduce restenosis, Tn the pilot-study of the 
Benestent-Il trial, heparin-coated stents \\~ere implanted in human coronary arteries. In 4 
groups of patients, systemic heparinization was gradually delayed to 36 hours after sheath 
removal. In the fourth group, no heparin was administered after the procedure and patients 
were treated with Aspirin and Ticlopidine, instead of antivitamin-K. Results of this pilot-study 
arc given in this thesis (chapter 4.7). 
Thus this thesis provides an overview of our 5 years of experience with Palmaz Schatz coro-
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nary stenling and of the backgrounds and results of 5 strategies, aimed at an improvement of 
the clinical outcome of this technique. 
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First Dutch 
experience with 
Palmaz-Schatz stent 
in treatment of acute 
occlusion after PTCA 
Aeute occlusion after PTCA is an t'mcr-
genc)' situation, often necessitating cntel'-
genc), corollllf)' bypass grafting (CAll G). 
Restoration of hlood now in the occluded 
vessel nfter failed PTCA can favourably 
inOuence Ihe prognosis. Unli! rcccntly, on-
ly emergenc,r CAllG seemed to nchiew this 
goal; implantation of an inlramscular 
prosthesis (stent) however, can also obtuin 
wssel patency, thcreby obviating the need 
for emergcncy CAnG, and possibly for 
t.'Icdh·c CAllG <L'i well. In six consecutil"e 
patients nith acute ischaemia eaused br 
corollary artcry disscction during PTCA, 
a I>alloun-expandable Palmaz-Schatz stent 
wm. used. In one patient the stent could not 
be implanted, probably becnusc of guiding 
catheter inshlbility. ]n the olht'r fivc 
p:ltients stent deJil"ery was successful in 
the absence of cardiac complications dur-
ing hospilali:llliion. Neither emergcllcJ 
CAllG, nor ('(cd in' CAllG, was dcemed 
necessary. Locttl bleeding complications 
occurred frequently, due to a rigid anli· 
thrombotic regime. ]n Ihis articlc the tech· 
nique of stent implantntion is described in 
a representntil"e patient, followed by the 
initial results of this small series. 
K('),\\ords: I~TCA,~ten( 
Introduction 
Acute coronary occlusion after percuta-
F. Ki~m<'IIl'ij 
G.), LtlOfmtlll 
L.R.l'lIl1drrWick<'1I 
J,S,.\I.SI/I\'(/r-
gill/dat 
Sumll1ar), 
* (}I/ze Lie\'e Vrrlll-
wc (;(1_1/11/11.1, tlm-
I{,'rdam 
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nl'otls coronary angiopl<l~ty (PTCA) oc-
curs in 2 - 12 pen:ent of procedures and 
lIlay he due to dissedion, thromhus, 
spasm Of a combination of tIH'~l' fal'lofs. 1 
In the first years of the PTCA-era, pa-
tknts with acutl' ischaemia after PTCA 
would have undergone emergcncy coro-
nary bypass surgery (CABO). However, 
rompan:d to electivc CAUG, mortality 
and morhidity in emergency CABO in 
these cases is high .. ~·s This is prcsumably 
due to dcterioration of cardiac perfor-
mance hecause of acute ischaemia, or 
fresh infarction of the myocardium. 
Timely rL'storation of the blood !low to 
the jeopardized myocardium after failed 
PTCA should influence the occurrence of 
ischaemia, infarl'lion, and the outcome of 
sur~ery. Ideally it should he able to post-
pone, or even obviate, the necessity of 
surgery. Onc way to reston: the blood 
flow is the use of perfusion catheters. 
Another, newer method to achicve this 
goal is the implantation of an endovast.'u-
Jar prosthe~is (~tent), supporting the dis-
sected arterial wall and safeguarding pa-
tency, possibly even in the long run rende-
ring emergency - and elective CABO un-
necessary. In this article wc describc this 
treatment in one typical patient, followed 
by tlw initial rl'suits for six patients with 
acute occlusion after PTCA. 
i'llatl'rial and nll'lhuds 
The Pahnaz-Schatz stent is a halloon-
expandable articulated stent, consisting of 
a stainless steel· Ille"h of 11.015 !lUll fila-
Illents, 15111111 in length and measuring 1.5 
111111 in diameter in collapsed state. The 
stent is mounted on a I,PS dilatation ea-
theter (USCI-Division, CR Bard Ine., 
Billerica, ~\'IA). This catheter i~ ~elected 
for its rompliant material (polyvinyl chlo-
ride), the halloon lell~th (25111111) and the 
presence of a proximal and distal halloon 
marker, facilitating stent-positioning. 
Compared to the coronary diameter the 
balloon catheter must he ~lightly over-
sized, to compensate for ~{)Jl1\.' inevitahle 
dccrease in diameter after stent delivery 
due to recoil and endothelial covering (If 
the stent. 
If occlusion oecurs during PTCA the 
guide wire slHluld he left in placc, across 
the occlusion, in order to safeguard di~tal 
access. Over the cxtendl'd guide wire 
(USC!) thc det1ated halloon, without 
stent, is first ad"anced towards the occlu-
sion in order to te"t the ability of the 
halloon cathdt'r tneross the stenmis. 
After this is confirmed the balloon ca-
thl't\.'r is withdrawn. loaded with the stellt 
and situated in the stenotic area. Then the 
stent-Ioaded balloon is inflated up to 10 
atmospheres during ]() - 30 seconds there-
by compressing the stenosis and deliver-
ing the hlown-up stenl to the dilated arte-
rial wall. Following this the balloon is 
detlated lind withdrawll. Theil the re~llh i~ 
seflltinizcd angiographical1y. 
In case of insufficient steno~is reduction 
the same, or a largef, halloon catheter is 
advanced into the stell ted segment and 
several rcdilatations call be performed in 
order to incrcase the ve~sel diarnder. Fur-
tha pharmacologic treatment is aimed at 
the prevention of thrombmis and ~pasTl1 
and consisb of the following: 
- Rheol11<1erodex...jO lOll ml/hour ttl a to-
tal ()f one litre, started at thc heginnin~ of 
the proo.:dure. 
- lleparin 10,000 IU iv, followed hy 2500 
It! per hOllr up to four hours after the 
procedure and adjusted to maintain 
APT!' (activated partial thromho-plastin 
time) hetween t\O ,lIld 100 scconds. The 
arterial sheath is removed after the hepa-
rin had been discontinued for illort' than 
three hOllrs. This is followcd after three 
hours hy heparin 2500 III iv and a hcpllrin 
illrll~ion of ](HH) IU per hour until the 
patient is on full oral anticoagulation. 
Acellocoumarol (Sintrom) during six 
lIlonths: () mg the first day, <1 mg till' 
second day, 2 mg the third day followed by 
a dosage adjusted to maintain a Tr (trom-
hott'st 'Ouick') of approximately fifteen 
percent. 
- Dipyridamole 225 mwday during six 
IlH)nths. 
- Aspirin 300 mglday during six months. 
Diltiazelll IHO mg/day. 
Immediately before and after stent im-
plantation 2110 microgram nitroglycerin is 
administered intracoronary. 
Case history 
A 70-year-old man, with severc ;lngina 
(NYHA III) and a positive stre~s test, 
underwent cardiae catheterization in No-
vemher 1%9. This showed a normal left 
ventricular function in the presenee of a 
prmimally occluded right coronary arte-
ry, rt'trogfessi"ely filled by cotlaterais 
from the left anterior descending (LAD) 
artery, as well as all eighty percent ~tell()­
sis in the LAD (fig. I). It was decided to 
perform PTeA of the LAD, which wa~ 
attempted in Fehruary ]l)l)(). Throu~h a 
USCI FL 3.5 HF large lumen guiding ca-
theter and over an USC! O.OI...j ineh very 
tlexihle guide wire. a SL'l1l1cider 3.0 )llono-
rail balloon catheter was advanced into 
the .qenosis withollt problems. After 
three dilatation~ (maximally eight at-
Tl1o~phen's, I()O seconds), the LA D occlu-
ded. Another dilatation rc~tored the nnw 
temporarily, hut finally the \'e~sel reocdu-
tied, showing poor anlegradc filling in the 
presence of a dissectioll (fig. 2). Several 
intracoronary injcction~ of nitroglycerin 
were of IlO avail. 
13y this time there WHS constant l'h\.'~t 
.\'oJl!'rialll/l .fol/fllal or Crmli"logl' \'0/. 3. No]"cmht'f }')1)1I1I II} I 
hg. I, IkJ"''' 
l'ICA:lc/I{/IIol1(1ry 
IIrlay ill fe/I Ull/t'riO{ 
ohlilll1{' pmj('djoll 
,flowing !I ligl1ifiulIIl 
jI/'Iuill1al LltO-sIC-
IImil (arrow). 
fig. 2. Aflal'TCtt: 
If,tal (lnllOillll of lilt' 
I.AD. 
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Fig. 3. Aft,'r.l/clI/ 
imp!ul//flliul/:pll!('1I1 
LAO. Nolem·f/,i· 
zing oflht' IIt'lllfd 
ICgll1('11/ (<IIml,·.I). 
pain as well as STeievations in the precor-
dial leads. It was decided to implant a 
Palmaz-Schatz stent, which was mounted 
on an USCI 3.0 LPS balloon catheter. 
Over the extended guide wire the balloon 
catheter was advanced towards the lesion 
without prohlerns. After one dilatation 
(ten atmospheres during ten seconds) the 
balloon was deflated and withdrawn over 
the guide wirc. 
The pain subsided and the ECG retur-
ned to normal. Angiographic control sho-
wed no residual stenosis and normal ante-
rograde flow. Diameter in the sten! region 
was ahout 120 percent of the vessel diame-
ter just proximal and just distal to the 
stent, uue to the fact that the balloon, at 
ten almo.-.pheres, was oversized, compa-
red to the diameter of the LAD (fig, 3). 
The clinical course was complicated by 
Table 1 
bleeding from the right groin, some hours 
after removal of the arterial sheath. The 
bleeding could be stopped by firm and 
prolonged compre~sion, Blood transfusi· 
on was not necessary. There was no elec-
trocardiographic or enzymatic evidence of 
myocardial infarction. Angiographic COIl-
trol of the LCA, five days later, showed 
no residual stenosis at the implantation 
site. The situation was similar to the 
angiogram immediately nfter stent im-
plantation. 
The patient was free of symptoms al 
discharge, ten days after stent implanta-
tion. 
Results 
In six patients, two women and four 
men, with acute ischaemia after PTCA, 
caused hy dissection of the dilateu corona-
Pati~llt data and re~"Ull~ {If lIngiognlphy hefore and after attempted PTCA 
rlT. ~ex ;lg~' NYHA n;"eI before PTCA :lfter PTeA 
'Y., TIMI '";-;, TII'.I1 
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Ie/I ,'Of/}lIl1t)' IIl1gio-
gUIll/. 
ry artery, a Palmaz-Schatz stent was inser-
ted (table I). In patient nr. 2 the right 
coronary artery (RCA) was involved, in 
all other patients the LAD. 
Severity of the stenosis is expressed by 
percent-diameter stenosis and hy the 
Thrombolysis in J\'lyocardial Infarction 
(TIMI) grading systeOlfo before and after 
the last balloon intlation, prior to stent 
implantation (table I). 
In patient nr. 5, whose LAD showed a 
large dissccton after PTCA - although 
without total occlusion - the stent could 
not be delivered. The ostium of the left 
coronary artery could only be reached 
with an usel FL5 !JF guiding catheter. 
The naked halloon, though in an un stahle 
position, passed the occlusion without 
problems, but stent-loaded this proved to 
be impossible despite several attempts, 
presumably mainly due to the instahility 
of the guiding catheter in the coronary 
Tah/e 2 
ostium. The balloon catheter with stellt, 
the guide wire and the guiding catheter 
were withdrawn and the veso,;el dit not 
occlude. The patient then had successful 
and uncomplicated bypass surgery on the 
same day. 
In our other patients stent delivery was 
performed within thirty minutes from the 
start of the initial preparations. No com-
plications were encountered during the 
procedure, the immediate angiopgraphic 
results were excellcnt and no residual ste-
nmi~ wa~ ~een (tuble 2). 
In patient nr. 3, a previously normal 
first diagonal branch, at the site of the 
implanted stent, showed only slow Imtero-
grade filling after stent placcment. This 
did not result in angina or in myocardial 
infarction. At recatheterization five days 
later, the filling of this branch was nonnal. 
Angiographic control was performed 
four to twelve days after stellt implanta-
I~esull~ of anglopgraphy lmnwtllaldy nfler ~Ient implantation and al time of repraillngiography 
nr. po<;l-slcnl 
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1':r: 
I. h:ll'mat"ma: pUnl'lUK ,ill' 'II<:lioll 
2. nonl' 
3. hal'lllal"Ill:! PUlll'Wll' ,ill': r,H1Wll'ali\'l' trl'at-
nll'nt 
4 hal'mahllila pUrll'lUrl' ,ill': <:,m,l'nalil'l' tn:al-
n1l'llt 
S. implalltation or ,knt not po"ihk 
(,. h'll'malnlll~ plJnl'turl' ,ik: l·'l11',-'r\'ati\'~' trl'al· 
1lll'1l1 
tion (table 2). In all patients the stented 
segment showed no signs of stenosis, 
thrombus, Jissedion or spasm. All pa-
tients with a successful stent placement 
had a stable :tnd uncomplicated dinical 
coursl', I-I{l\\'c\'l~r, in four patients local 
h!t:eding was a major c(lI11plicatioll; in one 
patient lleces<;itating percLltaneom suc-
tion of thl' haclllatoma (table 3). 
No hlond transfusions or surgical inkr-
ventions were needed. The short folio\\'-
lip perinJ (2-5 wCl.'ks) revealed no stent-
related complications. Patient nr. I still 
had anginalcomplainls due to a significant 
stenosis in a large first diagonal branch, 
already pfcsenl at the time of PTeA. She 
had a succes\ful PTC;\ of this branch 
when re-angingraphy control was Iwrfor-
met! twelve days aftt..'r stent implantation. 
All other patients were free of angina. 
Discussion 
SilH:e their introduction hy Dotter, a 
variety (If cndov<.\s(ular prmthe~e~ afe un-
der experimental and clinical evalua-
tion .7,X Emergencycoronary stent in aUlle 
occlusion after PTCA was fir:.t described 
hy Sigwart eI al.') In their series of nine 
patients implantation of a self-expanding 
wallstent was technically successful and 
there were no death:., myocardial infarc-
tions nor \Va:. thcre need fill' emcrgency 
byra~s surgery. Pue! et aI., \lowever, fe-
ported early stellt occlusion in twelve of 33 
patients treated with the silllle device.lII 
Parly acute thrombotic rcocelusions have 
also he!:!} desl'l"ihl'd hy Bertrand et al. in 
four of fourteen patients with a wall-
stent. ll 
The most extensive elinkal experietH't.' 
with hall{l()n~expandahlt' stt~nts is obtain-
ed with the Palmaz-Schatz stellL Schatz 
reported 011 355 del'livc Palrnaz-Sehatz 
halloOlH.'xpandabk stent implantations 
in native coronary arteries in 203 pa-
tients, 12 Patients with sucecssful stent ddi-
very (n = 183) were divided in two groups. 
Forty-five patients were treated with aspi-
rin and dipyridamo\c, while I3X others 
were treated additionally with coumarine 
derivatives during three months. No aLLlte 
rcocdusions occurred in the first 4X hours, 
hut in the ensuing four to ten days closure 
was !loted in sewn patients (I() percent) of 
the first group, hut in only five patients 
(3,(1 pl'fcent) of the sl'wnd group. 
Thc prm'l'ss of stl'nt rl':.tcllosis is vt.'ry 
complex. x Suhacute occlusion is frt.'t(ucllt-
Iy caused by thrombus, Lcon e.a. found a 
higlll'r platdet count and a smallcr stcnt 
size to he predictors of subacute thromho-
tic events after placement of the PaI1ll<l7-
Schatz c(lronary stenl. n Other suggcstive 
predictors seem to he the absence of anti-
coagulants, multiple ()wrlapping stcnts 
and presence of thrombus immediatt:ly 
hefore and after stent placelllent.1.1 
During the short follOW-lip period in 
ollr series no clinical or angiographil' signs 
of restellosis or reocdusion were seen. In 
four patients significant bleeding occurrcd 
on the site' of arteriHI pUlletufl'. In one 
case, 10nl1 slletion of the haematoma was 
deemed neccssary, in all others local pres-
sure sufficed. No blond transfusions were 
llct.'tkd. Thus, in oL1rsmall serics, implan-
tation of a stellt in an acutely dis'iecling 
coronary artery appeared to bt.' feasihle, 
and in nlOst C<l'iCS helpful, in avoiding 
emergency bypass surgery. Short tt'rm pa-
tellcy was excellent, therehy at least tem-
porarily ohviating the nt.'ed for surgery. 
Pallllaz-Schatz stcnts haw proved to bc 
useful in postponing emergency CAB(; in 
failed PTCA. The capacity of entirely oh-
viating tile nccessity of coronary surgery 
of the PTCA-Jetl'riofated vcssd nCl'ds to 
be elucidated hy long-term results in lar-
ger series. 
Rt'fen'Il('t's 
J, I)oll,),(i, (,'l\\k), 1\.tJ. Sillll"on J ( .. I ;d. (','l<:ula· 
nC,Hh t!an,lllIllin'll ,',II,H1:11), !lllgi')pl:l,ty: r~'p"i1 
01 l'olllpikalil,n, frollllhl' Natioll.d Hl'!lll.I,Ull,l! 
auJ I:llulld In'lilllk I'rCA i{q;hlr)" l"iJ,'UI'ltioll 
l')i\J: (,7:72J-Jtl 
2. lkul (il. Cuol..:)' DA. 1I~lIlllan (iL l'I a1. ("OHl-
n~I)' arll'l)' h} pa" h>r un,ul"·l'"fuip..:rcUlanl'IHI' 
lr,m,luminJI (oron;ll)' angiupl'l'l) 1 'IlWfdl' 
CanJima,l' Surg 1')"'·./: X'<;:(,S.~·I)-I. 
.1. Norell MS. Lyon, I. I a) hm!11 (" fl~kon R. 
OU1,'Ollll' of l'arly ,urgl'I)' afkl (oJIInal)' ;lngiop' 
)a'ly. flr Ill"lrt.l J'!.WI: SS:22J,(,. 
.j. Yahih'l'kh V, 1"111.11,'1 1\.\. ~!ilkl H. Vidnl' B. 
Slll!!k,lIll'\;N'ul;1l i/aliol1 ro\lo\\ing laik,1 pl'leU' 
1;111<,011' 11all,llllllin:rl r,))(ln;11} ;lIlgi,'pl:i,ty. 
Se,Hlti J 'I hOhll' CarJiI,\';I'l' SUig 1')1'7; 21 
(2): 1..j.'-7. 
LaLar IIL.llaan (·K. Dl'Il'mlinanl",1 m}I,c~rdi­
al infardilln loil-illint! l'1ll~rgl'nq l'llron~I)' ~rll'­
ry h) p:l" for LlikJ pnclllancoll' coronaT)' angi~ 
opl'i,ly, Ann Th'll;ll' Sill)! 1').'a:..j4 ((,):f,-If,·.'tl. 
6. (,h,',,'hIO .lH, Knalkrlld (;, H"b~'rh R l'1 ;11. 
I hrllllli>ol),i, ill ~t)ol'anlial Infalclioll (1 l1\.tl) 
(rial. pha'l' !: a e,mlp:lri",n i>d\\l'l'n inl!;ll'l'rHlll' 
li"u..: pJa,minllgl'n ;ll'lil'alllr ,II1U inlr,ll'l'nOll' 
'treplohirM'e, CJrnll'llion 1').'>7: 7(,: 1-I2-S-I. 
7, f)ol1l'f(T. Tr.II1,luminHlly pl;il·~'\Il'oil·'rringl'n· 
d:111,'lial tlille' glafh: long-kIm p.t1,'nl')' inc.mill<' 
poplik'il arkl)'. /1lIl"1 /{,luiIlJ 1')6'): ..j:.~2')-.12. 
,,> Scrru}, P\\'. Bl'all KJ. (iil'''l'n \\'.1 \;!1l un. 
Sknling or l'oron;!T)' :li1l'rie',. An: Wl' tIn: ,llTl'(-
J<:r', ;Ipprl'nlil"~''! ['111 I kart.1 1'1)-;<): 10:7]..)·,<;2. 
'J. Sig\\alt U. UiI,.1Il 1', Goll S 1'1 :11. Fml'ft!~'ncy 
'killing IIlI al'Uk IIcriU,ioll al1<'1 r"nnwr)' 1>,,1-
IlIlIn angillpl~'lY. ('irculatioll I'):-IS: 71' (S):II]I-
7. 
10. Pul'lL Il<nl<l:ul J. ('1I11rl;ulll ,\ l'l al. Angiogr.Jp-
hie 1I111<)\\'-liP "I P"I,'lIt;lllnl\!' ("(11<lllar), ,1l'nling 
(al"lr).l"irnlialilll1 I'),'>S: 7,,> ('l1pplll):II-·IIIS, 
II I:ll'Tlrand 1\11::. Rid,ard, AF. Serru)~ P\\', Cor,,· 
n:lI)' ~h.'ntln).! implanl<lli()n tor prilll:IIY and '<.> 
l"IHI:II~ 1'1<'H'nti,)n ,)f n:,lo.:n,),i, ,lft<"1 PT('A: 
r<",Uih of;! pilot IIllIlticc'nt<"r Irial (i()Sh/I(J,~7) 
(('ASIS rri.lI) (a["II) 1'111 Ik.1I1 II().~~: () ('"ppl 
1 ):.''is. 
I~. Sclla\? RA. Lcon ,\IB, Bairn ilS d!ll. fl~lIoon 
c\p:lndahk intra(tlrtln~r)' qellh: inili.1i re,ulh "I 
a lIlulticenter 'Iud\,. ('in:ul~lion I')S'!; .~Il H) 
,ujlpl II: 11~17·L . 
1.1. L~'OIi ,\IB, Alm:!!!or Y. f:rlld R, Teir,tl'in PS. 
l't:rcl J, ':il'h~1L I{A, SIIIl'KIlI.: thrombotiL' e\,~'llh 
aftcr mrunary ,lelll plal·,'ll\L·nt: diniccli 'pn'!rlll\\ 
:Ind pr.:dkli\c f~cl"r~. ("il(lIlaloll I'}:-I'): ,~Il (.J) 
,upplll:II·17.J. 
',il! 
'\ 'I' c .. ",! r.' "'f > ' ! ,f ) 1 ,j L . /' 1 }, ,( ,\, c ( ! 
{i;, J: ',: :(\/,' ;[i\}i i 
\,j"II';',IW" ;1 (.ilnll1l\ 11;:1\111'! 1,1,:; !,"I 
'Ii)d "I'li 11\ ,Ii 'h dl:I,,!i\ ,;n il!( ill!!· 
j\I; II .Ind IL' :;'1: ,\egil klil''I il"p ( "ii, 11 
"HI i'~ 11\,,;1 I" 1,1 Hlip:!ii' "II ")'\ Inn\ "'11<"111 
LI<,!,\;.ild" '1I1':\;I,)lill";1I lip' ,1Ii"'.("1I1Ii 
(;11;;( :Iwk, i1 ,dH ;·j.n ,'<11'; 11;)111" 
i;:kli1 PII "iLli,;;; '1" P'i'ild;1 <,(J' 
\,i'.iu'I'1< 11:<111',1\ <inld \\1>\11 )';;!i.i!i·"'i 
'\\ '.\Ii 1"1I!" 1II,>,I:,;n ,\,il,!h il"!'" 
HH ul Lu Ii" :lldi:I" ;1', 1'11\"',1'1" I("dl'. llIiii:1 
li·;1I,',; d'·!I!!'-I'I". 
I· .. 
'Ii' "h 
'i I 
('I I" 
"I" 
Ii' 
Ii Ii' 
101'" 'i I 
Id 
m'- :,II! 
" .1,1" 
I'; c, \.1. I 'I '1', 
II ,; 
'.) 1;(1"". J I,' i'li., 
I I', 1')1 
\\ 
'I'U:)II 
I'L', Ii 
d, 
j': !In' (><,. ,'I;, qi\i' 
"I ,\' "'d;) ,',\1' !I 
i<l.' 
" 
1'1 i,li\ 'I" ,; '\ r,·' 
'!loII ,"~:, ,nil 
,\',.t/I<"/IIIi1" JOllnla/"{ COIdio/OKr \/0/, 3, ,\'O\'l'111/,,'r /1)Y!i II ]W) 

CHAPTER 2.2 
TWO MAJOR CLINICAL APPLICATIONS OF PALMAZ SCHATZ CORONARY 
STENTS 
SUBOPTIMAL PTCA RESULTS 
EMERGENCY CORONARY STENTING WITH THE PALMAZ SCHATZ STENT FOR 
FAILED TRANSLUMINAL CORONARY ANGIOPLASTY: RESULTS OF A LEARNING 
PHASE 
F. Kicmcncij, OJ, Laarman, L.R. van del' \Vicken, l.S .. M. Suwarganda 
Am Heart Journal 1993; 126:23-31 
Presented during the Scientific Sessions of the European Society of Cardiology 199 t and of 
the American College of Cardiology 1992 
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Emergency coronary stenting with the 
Palmaz-Schatz stent for failed transluminal 
coronary angioplasty: Results of a learning 
phase 
This study describes initial results 01 Palmaz~Schatz slent implantation in our deparlmenllO 
restore and maintain vessel patency in 52 patients with obstructive dissection, defined as an 
intraluminal fiHing defect with coronary flow impairment after percutaneous Iransluminal coronary 
angioptasty (PICA). The majority of patients (62%) underwent PICA for unstable angina (n - 28), 
defined as angina al rest with documented ST segment changes resislanllo nitrales, or acule 
myocardial infarction (n 4). In six patients (11%) the slent could nol be delivered. Seven 01 the 
remaining 46 pallents (15%) had coronary artery bypass surgery performed because of 
increased risk for subacute stent occlUSion, residual thrombosis, residual obstruction near the 
stent, coronary artery diameter less than 3.0 mm, or mu1liple and overlapping stents. One patient 
(3%) died in hospital from intracranial bleeding. Nine patients (23%) had subacute stent 
occlusion, retrospectively unpredictable in four patients. Nine of 29 patients (29%) with an 
uncomplicated clinical course alter stenting had angiographic restenosis at a mean follow-up of 
6.0 + 1.4 months (range 12 days to 8.3 months). Two patients (P/o) died 3 months after 
successful slenting: one patient because of stent thrombosis after stopping warfarin before an 
abdominal operation and one patient after acute vascular surgery for late traumatic groin 
bleeding. Of the 39 medically treated patients with a stent, three (8%) had major bleeding 
complications. 11 is concluded that stent implantation is feasible in most patients with obstructive 
dissection after PTCA. After successful stent delivery, coronary flow is temporarily restored. 
However, during this early experience with emergency stenting, it was shown that non-surgical 
treatment of these patients resulted in substantial subacute stent occlusion rates. Accordingly, 
stabilized patients should be considered as a high-risk population for subacute stent thrombosis, 
needing careful monitoring of anticoagulant treatment and ambulation. Semieleclive bypass 
surgery after emergency slenting may be the treatment of choice. With a combination of an 
optimal angiographic result and an optimal clinical infrastructure and patient management, a 
more conservative treatment after emergency stent implantation may be advocated. (AM HEART J 
1993; 126:23-31.) 
Ferdinand Kiemeneij, i\ID, Cert ,JOIl Laannan, i\ID. HOIl van del' Wieken, i\'ID, ond 
,Jo Suwarganda. l\'ID l\msll'rdam. Tht' Nct}/f'/,!rll1ds 
The early National Hi'RIt, Lung, and Blood Illst it ute 
(j\'HLllJl percutoll8oUs transluminal coronary angi-
oplosty (PTCA) registry (W7H to 1!JR:3) reported Oil 
the PTCA experience ill the United Stotes. With a 
primary succe.~s rote of 67', , myocardial inf(ll'('tions 
occurred in fiJi' ( of patients, urgent bypass surgery 
Fr",,, lh~ .\llH"ld,HIl I ),'p,lTlm"nl "t JII!~r'Ul1i"H.11 (·.lHliol'.~_, (),,'~ I ,ie' ~ 
\',,,,,\~~ (;,hth1li, 
H'-,c'i,~d tor pul!li"l1i •• " ,'.;"y,:.I1. lll:ll: ,",']>1'.1 ,I.U], .'\. 1!':ll. 
H"l'rj,,! "'1"'-1-' FHdiJ'dnd Ki,,,lt,,,,j,l. :\ID, .\IlH""I;'IllIJ~I'''II<I~1l1 "I 
11I1trun!i"",d ('.LI.]i"!"~\'. 0",,· I.;,,,, \""01\\',· (;",111,,;-. I", (),,.It'·I',,,k-
_If,l,lI 1;:1.111'11 11,\ .\llhi,·,d,"n. '11w \"Hh~rlalld, 
('"p,\r;~h! l!l'llh,1 ,\I".I!I,-Yt.<r B",,~.III(', 
1I1'll'1'>~III/l,!I.~I.I>" I .Ii) j/llj!j',\\lil 
was necessary in G,\)', , and death occurred in 0.0', .1 
In the later registry (] ~lH.') to 1986)' the success rate 
was 88', ; 'I.:~' of the patients suffered from nonfa-
tal mYCl('arcliai infarction, .'l,.J' ( needed emergency 
hypass surgery, and the death rate was 1.()I,.~ De-
spite ad\'ances ill \('chnolof{Y in PTCA equipment 
and despite in(,l'ea.~ed ope-rotor skill, PTCA still car-
ries the risk of acute postpro('edural coronary artery 
ocdusion, which occurs in :l', to 7.:1' ( of pat ients.:P ; 
ScW'ralmechanisms contri1)Ute alone or in comhina-
tion In ohrllpt r!osure: disruption of tile plot/ue with 
intimal ciissection, subintimal hematoma, coronary 
thl'omho.-;is, and spasm. Emel'g-ency hypass surg-ery 
after failed PTCA has cOllsidpwble risk for perioper-
23 
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ative myocardial infarction, with mortality rates of 
3~';J to 1R,/;, of patients. fi -lU Ongoing h;chemia espe-
cially contributes to perioperative mortality and 
mOl"bidit.y.~ Therefore stabilization of the patient 
with acute occlusion after PTCA may improve the 
outcome of surgery, Stabilization of H number of pa-
tients call be obtained with repeat PTCA if the pro-
cedure can be accomplished immediately and the le-
sion can be crossed. Coexistent intracoronary throm-
bosis may be treated with intracoronary thrombolytic 
agents. Hemodynamic support by intraaortic balloon 
pumping may be mandatory.ll 
After provisional recanalization, different strate-
gies have been described to maintain vessel patency; 
balloon inflations of long duration 12 or newer treat-
ment modalities such as laser balloons,l:j various 
at herectomy devices,14 and intraCOl"Ollary endovas-
cular supporting prostheses or stents1~-HI have been 
mentioned as "hail~out" devices. Impiuntation of in-
tracol"Onary stents by skilled operator;; and in expe-
rienced centers is a promising technique to seal off 
intimal flaps after PTCA, to improve vessel geome-
try and flow, and to prevent. elastic recoil. In the 
present. report our experience during a learning phase 
is described with the Palmaz-Schatz stent, used in 
the treatment. of ob!!tructive dissection after PTCA. 
METHODS 
Percutaneous transfuminal coronary angloplasly. The 
x~ray imaging equipment used wa!! the Philips Poly Diag-
nost CI (Philips j\-ledical System!! International BV, DA 
Best, The Netherlands), powered by an Optimus M 200 
generator (Philips I\fedical SyBtems International BV) and 
equipped with a Digital Cardiac Imaging system (DCI). 
This system gives on-line video digitized images for opti-
mal angiogmphic assessment of coronary artery anatomy. 
PTCA was performed in all patients by means of a femoral 
approach, with the use of an over-the-wirc technique. In 
the persistence of a >50~·;. stenosis and coronary flow im~ 
pailment, caused by intimal dissection despite applicHtion 
of intracoronary nitroglyccrin and prolonged dilatations 
with conventional or perfusion catheters, it was decided to 
implant a Palmar.-Schatz stent. Contraindications for cor-
onar\' stenling were considered to be: excessive tortuosity 
of th'e segment proximal to the occlusion; vessel diameter 
less than 3.0 lllm; evident intrucoronary thrombus; con-
traindications for anticoagulation; and diffusely diseased 
coronary arteries with multiple significant le~ions. 
Stent implantation. The Palmaz-Schatz articulated stent 
consists of a balloon-expandable stainless steel meshwork, 
15 mill in unexpauded length and 1.6 mm in diameter in the 
collapsed state. The sten!. has two 7 !lUll segments con-
nected by a 1 mm bridging strut. The stent filaments are 
0.015 mm in thickness. The slent is crimped onto a stan-
dard PTCA halloon catheter. This slent-Ioaded balloon 
catheter is advanced over the guide wire to the obstructing 
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lesion. After careful positioning, the stent is delivered, fol-
lowed bv deflation and withdrawal of the PTCA catheter 
and the;} hy control {lngiography. Compared with the COI-
onary arte~v diameter, the stented segment is slightly 
overdilated . by repeal dilalations with higher inflation 
pressures or with a larger balloon to compensate for de-
crease of the stent diameter after delivery. Stenting was 
performed by four operators having difl·erent levels of ~x­
perience with this technique, with one operator coachlllg 
the others initially. 
Medical treatment, Immediately hefore and after stent 
deployment 200 pg of nitroglycerin was given via the intra-
COTOnary route. Further pharmacologic treatment was 
aimed at the prevention of thrombosis and spasm and con-
sisted of the following. (1) Dextran ,10, administered in 
duses of 100 cm3/hour to a total of 1 liter, started from the 
moment the decision was made to implant a stenL (2) 
Heparin, 10,000 IV, was administered through the femoral 
artery shl'ath after its insertion, followed by 5,000 IU for 
each 'hour the procedure lasted. A second 10,000 IU bolus 
of heparin was given after stent implantation. A heparin 
infusion wa~ continued for 24 hour;; and was adjusted 10 
maintain activated partial thromhoplastin time (APT'!') 
hetween 80 and 100 seconds. The arterial sheath was re-
moved after the heparin had been discontinued for more 
tban 3 hours at an APTT less than twice normal. This was 
fullowed after 1 hour by a holus of 5,000 IV of intravenous 
heparin and a heparin infusion titrated according to the 
APTT, measured at g·hour inlervals. 
(:1) Acellocoumarol (Sintrom, eiba-Geigy BV, Arnhem, 
The Netherlands) wa~ given for 3 months: G mg the first 
day, ·1 mg the second day, 2 mg the third day, followed 
by a dosage adjusted to maintain a '1"1' (thrombotest 
"QUICK", Phannachemie, Haarlem, 'rhe Netherlands) of 
5');. 10 10~'; .. Heparin was continued fOr a minimum of 5 
days and was stopped when the patient had a TI' in the 
therapeutic mnge, (4) Dipyridamole was given in a dose of 
225 mg/day for 6 months. (5) Acetylsalicylic acid, 300 
mg/day, wa.sgiven for6 months. (6) Diltiazem, 180 mg/day, 
was given for 3 months. This protocol was readjusted sev-
eral limes during the study according to new experience 
and insights. 
Postprocedural care. After the procedure, each patient 
was taken to the coronary care unit or to the cardiac ward, 
with the arterial sheath left in situ. InitialIy, the sheath wa~ 
removed after at least 24 hours of heparinization, with 
heparin temporarily being discontinued to obtain adequate 
local hemostasis. In a later phase of the study, heparin was 
di.<;colltillued immediately after the procedure. When the 
APIT was I£'ss than twice normal, the sheath was with-
drawn, followed by heparinization after 1 hour. After 
~heath re~oval the ,groin was compressed manually, until 
hemostasIs was achieved, followed by a compression ball-
dage for 8 hours and a 24-hour immobilization period. 
Data collection. Clinical, procedural, and postproce-
dural dala were prospectively coll£'cted in a data base file. 
Cineangiograms were judged for diameter stenosis using 
electronic calipers, Thrombolysis In Myocardial Infarction 
(TI!\Il) grade flow, and for the pr£'senCe of thrombus and 
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dissection before and after PTCA and after stent implan-
tation, Values are expressed as mean ± standard de\'ia-
tion. 
Definillons. Failed PTCA = unresolved or recurrent 
stenosis ?; 50~'i-, during or immediately after the procedure, 
caused by an obstructive intimal dissection. Obstructive 
intimal dissections = intraluminal linear filling defect 01' a 
luminal filling defect with irregular borders, causing coro-
nary flo\\' impairment. Intracoronary thrombus = discrete 
intraluminal filling defect surrounded by contrast material, 
visible in two orthogonal projections. Unslable angina 
= recurrent episodes of chest pain with documented ST 
segment changes, resistant to nitrates. Acute myocardial 
infarction = two or more of the following criteria: (1) 
development of new Q waves; (2) a total creatine kinase 
(myocardial band) elevation of more than twice the norlllal 
upper value; and (3) prolonged chest pain. Ste/lt occiuliioT! 
= angiographically proven stent occlusion with loss of 1 
grade of TIM! flow (acute: within 24 hours after delivery; 
subacute: beyond 24 hours after delivery during the initial 
hospitalization; late: after discharge). I.ate reMenosis = 
diameter stenosis 2": 50';';:, more than 1 month after stent 
implantation. Prophylactic coronary b)'pass surgery = by-
pass surgery i1wolving the previously stented vessel, with 
the vessel being patent and the patient in a nonischemic 
state. Inadequate (lind~'r)anticoagillatioll = more than 
two consecutive APTT values under 80 seconds with TT 
values over 10~7,. Major bleedill/{= hleeding leading to 
death, needing surgery or requiring hlood transfusion. Mi-
nor bleeding = bleeding without need for surgery or blood 
transfusion. 
RESULTS 
From January 1990 to ,June 1991, PTCA was per-
formed 011 961 patients at. our institution. Seventy-
five patients received an intracoronary Palmaz-
Schatz sten!. for varying indications (Fig. 1). In 52 
patients stent implantation was attempted for failed 
PTCA (5,4 % of PTCA; 69% of sten!. implantations) 
(Fig. 2.). Clinical baseline characteristics are SUlll-
marized in Table 1. Table II provides more detailed 
patient data. Patient. numbers in the text. are refer-
enced to Table II. Of 29 conservatively treated 
patients having successful stenl. implantation and an 
uncomplicated hospitalization phase, 22 patients 
were angiographically examined 6 months after dis-
charge (mean 6.0 ± 1.4; range 12 days to 8,3 months), 
Hospital course 
Failed stellt deliven'. A Palmaz-Schatz stent.could 
be successfully delh:ered in 46 patients. In five 
patients (9.6%) inabilit.y to delh'er the stent was 
caused by inability to reach or cross the stenosis. One 
female patient. (No. 22), had a total left. anterior de-
scending (LAD) artery occlusion after PTCA. After 
the guide wire had recrossed the occlusion, stent de-
livery was attempted. After stent. implantation no 
29 
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Fig, 1. Indications for stent implantation from January 
1990 to June 1991 in 75 patients. 
distal flO\v was visible from the sten!.. An effort was 
made to restore flow by multiple dilatations before 
subintimal delivery of the stent, advanced o\'er a 
subintimally positioned guide wire, was considered. 
Because the distal LAD was damaged by these sub-
intimal dilatations, the vessel was considered unsuit.-
able for bypass grafting, She had minor chest. pain, no 
elect.rocardiographic (ECG) changes, and a maximal 
creatine kinase (myocardial band) of 25 lUlL. Two 
patients (Nos, 12 and 41) were successfully managed 
with prolonged inflations with an oversized reperfu-
sion catheter, One patient. (No. 43) unsuitable for 
coronary bypass surgery with a residual significant. 
stenosis, was treated medically, and two patients 
(Nos, 16 and 29) had uncomplicated elective coro-
nary bypass surgery. 
Bridge to coronary artery bypass surgery. Of the 
remaining 46 patients (88W, of total attempts) with 
successful stent implantation, seven patients (15%) 
were sent for coronary bypass surgery in a stable 
condition and without signs of ischemia. In four pa-
tients (Nos. 8, 20, 46, and 52) surgery was indicated 
because of a persisting intraluminal filling defect 
caused by thrombus or dissection at. the stent im~ 
plantation site. Two patients (Nos. 21 and 38) had 
bypass surgery because of multiple and overlapping 
stents, which was considered a high risk for subacute 
thrombosis. One pat.ient. (No. 36) was operated upon 
because of an allergic reaction to aspirin. 
Stent occlusion. Acute stent occlusion was not en-
countered in this group of 39 medically treated 
patients after successful stentdelivery, Nine patients 
(23 %) had subacute stent. occlusion. Six patients 
(Nos. 7, 9, 17, 34, 50, and 51) were operated upon di-
rectly after successful recanalization by means of re-
peat. PTCA of t.he occluded stenL Two patients had 
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Fig. 2. A, Vef'.sel pre-PTCA. SignificfHlt stenosi:; in all\ewlaterai hranch (arruw). B, After PTCA. Dissec-
tion after repeated dilatations (arnml). C, After stent implantation. Optimal angiogrnphic result (arrows). 
a fluccessful repeat. PTCA, but were considered 
unsuitable for coronary bypass surgery because of 
malignant disem;e (No. 13) Or previous infarction in 
the stent-related myocardial region (No. 27), Re-
crossing an occluded LAD sleut failed in one patient 
(No. :~::J), resulting in an extension of a previous an-
terior infarction. Hetl'ospectively, two patients had 
inadequate anticoagulation (Nos. 1:3 and ~~8), three 
(Nos. 27, ;~'I, and l'i 1) had a pel'.,>isting obstruction near 
the stent, and one patient- (No. 27) had both. In four 
patients (Nos, 7,9, 17, and 50) no detectable cause for 
Rtent thrombosis was found, 
Bleeding complications . . Minor bleeding compli-
cations (21 1;;,) were puncture site-related (75~';',) in 
the majority of cases. t ... rajor bleeding complications 
were seen in three (8~';,) patients, one (No. 45) with 
vaginal bleeding requiring blood t.ransfusions and 
one (No. 21) with a false aneurysm in both groins re-
quiring surgery. The third patient (No. 14), whose 
condit-ioll was inoperable because of severe left ven-
tricular dysfunction, len the catheterization Iabora-
30 
tory with residual thrombus in the stent that. was 
treated with intracoronary and intravenous strep-
tokinase, One day later, this patient had fatal intra. 
cranial bleeding, 
Follow·up 
Late rel'o'lerwsis. Oflhe 29 patients without. cardiac 
complications after successful stent implantation at 
discharge, 22 (7fE'(») had control angiography 6 
months (mean 6.0 ± 1.4; runge 12 days toB.3 months) 
after stent implantation, One patient. (No, 10) was 
readmitted 12 days after stent implantation in a right 
coronary artery (RCA), with un extension of a previ-
ous inferior myocardial infarction. Recatheterizatiol1 
revealed total stent occlusion, Rliccessfully recana-
lized by repeat. PTCA. His '1'1' was 4% on the day of 
stent occlusion. Eight. patients (28%) had signific'ant. 
restenosis. Four patients (Nos. HI, 2fi, 37, and 39) had 
elective coronary artery bypass grafting (CABO). 
One patient (No, 42) had successful PTCA; however 
his condition was complicated by restenosh; within 2 
months, This patient underwent uncomplicated 
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CAHG electively. Two patients (Nos. 26 and 31) had 
successful PTCA G months after stent. implantation, 
and one patient. (No. 48) was treated conservatively 
because of absence of angina pectoris. 
Late mortality, Two patients (Nos. 10 and 45) died 
R months after stent. implantat.ion (7 %), One patient 
(No. 10) with traumatic bleeding in the groin after 
alcohol abuse was admitted in hypovolemic shock. 
After surgical repair, t.he clinical course was compli-
cated by pneumonia and a fatal cerebrovascular ac-
cident. The other patient (No. 45) died following an 
abdominal operation R months after successful stent 
implantation in the LAD, Warfarin was stopped pre-
operatively_ Postoperatively, this patient died in 
cardiogenic shock caused by an evolving anterior 
myocardial infarction. At. postmortem examination, 
the stent was found restenosed and a fresh thrombus 
was \'isible within the stent. 
DISCUSSION 
Bredlau et. al.:2il reported on 3500 patients under-
going elective PTCA. u'iajor ischemic complications 
were seen in 12%: lOAlJ;, showed angiographic signs 
ofilltimal dissection, compared with I.G'ir, of patients 
without evidence of dissection. By implantation of a 
coronary steut t.he intimal dissection can be sealed 
off, offering a solution for abrupt closure after PTCA. 
If it has been well delivered, a stent. maintains vessel 
patency and ischemia is alle\'iated, obviating the 
need for high-risk emergency bypass surgery in a pa-
tient with acute myocardial ischemia, Howe\,er, pa~ 
lients with acute or impending ischemia after subop-
t.imal PTCA also form a difficult population for 
emergency coronary stenting, Decisions have to be 
made ad hoc because of the emergency nature of the 
intervention, Patients with complex coronary anat-
omy and pathology may be subjected to this tech-
nique in the hope of restoring flow for at. least. some 
time, Stenl. implantation itself has to be performed 
rapidly in a patient. without. proper medical prepara-
tion. 
Emergency coronary stent ing is reported by Rou bin 
et. al,,15 using the Gianturco-Roubin stent. (Cook Inc., 
Bloomington, Ind.); by Sigwart et al. 16 and De Feyter 
et alP with the tVIedinvent. self-expanding wall stent 
(!\'ledinvellt. Inc., Englewood, N.J.) by Vrolix et al.,18 
llsing the balloon-expandable 1Jedtronic Wiktor cor-
onary stent (Medtronic, Inc" 1Hnneapolis, Minn,); 
and by Schatz et al. 19 with the ,Johnson & Johnson 
halloon-expandable Palmaz-Schatz stent (.Johnson 
& ,Johnson Intervent.ional Systems, Warren, N,.L). 
The present. study reports on the early experience in 
Our department. with the Palmaz-Schatz coronary 
stent in the treatment of failed PTCA. Several clin-
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Table I, Baseline characteristics of patient population 
No. Percent 
No. of patients [,2 
Male gender l2 81 ';; 
Ago 27-7-1 yr (,58 ± 10.5) 
Presentation 
NYHAI .1 6~,', 
NYHA I[ 0 O~ ;. 
NYHA III 17 :~2 ~ c. 
NYHAIV 2S 54:; 
Acute ,\II 4 w;:. 
Vessel of stented coronary artery 
LAD 32 02:; 
LeX 4 8',; 
AI, 4 ~, 
RCA 11 26~;, 
Type uf coronary lesion 
Type A 17 33',; 
Type B 1:1 25:,' 
'l'ypc C 22 ·j2~: 
Single· vessel di~e(l~e az 6:2';;, 
T\\'o-vessel diH'u.<;e ]a 25~, 
Three-vessel diseu.~c 7 1:1;; 
Prior myocardial infarctioll :1O 58~; 
Prior hYPi1"s surger~' 2'" 
H~'pertenRion 11 21 ',; 
Diabetes mellitus , I" 
Cholesterol ~6.5 mmol/L 12 2.1:; 
Cunl'nl cigarette ~moker IU a7',~ 
Family corOllary rulery di~c(lse 9 17:; 
AL, An((owlat~r,,1 hr,lnch; .icute Ml, HUJle my,'cardia1 illfllfdi"n: LAD, left 
ant~ri()r de,{tnding artery: LeX, ldt cir("H1l1~x arlery; NYHA, N~w y",k 
He;:u/ As_,nrLotitln: RL',1, right (c'tunar), rut~ry. 
ical and technical problems were encountered during 
this learning phase, and several solutions were intro-
duced over the course of time. 
In the present study, the sten1. could not. be deliv-
ered in six patients (i 1 %). Schatz et al.21 analyzed 
failed delivery in their report on the initial results of 
clinical experience in a llluiticenter study with the 
Palmaz-Schatz coronary stent. Successful delivery 
with the articulated stenL was more likely in the RCA 
and LAD coronary arteries compared with the cir-
cumflex artery, in proximal ven'lUS distalle!'.ions, and 
when there was no e\'idence of dissection after PTCA. 
The Stel1t. Delivery System (SDS) (Johnson and 
Johnson Interventional Systems) was developed to 
improve the safety and success rateR ofstent implan-
tation, with less chance of proximal deployment. and 
stent embolization.:2:2 This system consists of a fac-
tory preassembled unit, with an art.iculated stent 
crimped onto a balloon catheter of varying diameter 
between two radioopaque markers, covered by a 5F 
protecting Rheat.h. In our initial experience, however, 
the SDS was not available or in common use in 
emergency situations. This is partially explained by 
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Table II. Patient population: Clinical characteristics and outcome 
Patient 
No. Sex Age 
PTCA 
indo Vessel Success &wlt-/ree Bleeding SAC rePTCA CABU AMI Restenosis Death 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
3,' 
35 
36 
37 
3R 
39 
40 
41 
42 
,13 
44 
45 
46 
47 
48 
49 
50 
51 
52 
M 
M 
M 
M 
M 
M 
M 
M 
F 
M 
M 
M 
F 
M 
M 
M 
M 
M 
F 
M 
F 
F 
M 
M 
M 
F 
M 
M 
M 
M 
M 
M 
F 
M 
F 
M 
M 
M 
M 
M 
M 
M 
M 
M 
F 
M 
" M 
M 
M 
M 
M 
46 UAP 
65 SAP I 
72 SAP I 
54 UAP 
69 AMI 
65 SAP III 
66 SAP III 
72 SAP III 
69 UAP 
68 AMI 
·13 AMI 
48 UAP 
6-I UAP 
69 SAP I 
72 UAP 
50 SAP III 
62 SAP III 
46 UAP 
70 UAP 
37 SAP III 
6-I UAP 
61 UAP 
68 SAP III 
44 SAP III 
59 UAP 
52 SAP III 
69 UAP 
55 UAP 
63 HAP 
56 SAP III 
72 UAP 
27 UAP 
61 AMI 
54 SAP III 
72 SAP III 
45 UAP 
50 SAP III 
57 UAP 
70 SAP III 
54 UAP 
55 UAP 
46 UAP 
52 SAP III 
55 HAP 
69 UAP 
53 UAP 
74 UAP 
52 SAP III 
43 UAP 
55 UAP 
5S UAP 
6-I SAP III 
LAD 
LeX 
RCA 
AL 
LAD 
RCA 
RCA 
LAD 
RCA 
RCA 
RCA 
RCA 
LAD 
LAD 
LAD 
LAD 
LAD 
RCA 
LAD 
LCX 
LAD 
LAD 
LAD 
OM 
LAD 
LAD 
LAD 
LAD 
LAD 
RCA 
LAD 
RCA 
LAD 
RCA 
RCA 
LAD 
LAD 
RCA 
LAD 
LAD 
LAD 
LAD 
Lex 
LAD 
LAD 
LAD 
LAD 
LAD 
RCA 
LAD 
LAD 
AL 
Yo. 
Yo. 
Yo. 
Yo. 
Yo. 
y" 
Yes 
y" 
Yo. 
Yo. 
Yes 
No 
Yes 
y" 
Yes 
No 
Yes 
Yes 
Yes 
y" 
y" 
No 
y" 
y" 
y" 
y" 
Yes 
Yes 
No 
y" 
y" 
Yes 
Yes 
Yes 
Yes 
y" 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
No 
y" 
Yes 
Yes 
YeH 
y" 
y" 
y" 
Yes 
Yes 
No 
y" 
y" 
No 
Yes 
No 
No 
No 
No 
No 
Yes 
Yes 
No 
No 
No 
No 
No 
y" 
No 
No 
No 
No 
y" 
Yes 
No 
No 
No 
Yes 
No 
y" 
Yes 
No 
No 
No 
No 
Yes 
No 
No 
No 
Yes 
Yes 
No 
Yes 
No 
No 
No 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
Minor 
No 
Minor 
No 
No 
No 
Minor 
No 
No 
No 
Major 
Minor 
No 
No 
No 
No 
No 
Major 
No 
No 
No 
No 
Minor 
No 
No 
No 
No 
No 
Minor 
No 
No 
Minor 
No 
No 
No 
Minor 
No 
No 
No 
No 
Minor 
Major 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
y" 
No 
y" 
y" 
No 
Yes 
No 
No 
y" 
No 
No 
No 
No 
No 
No 
No 
No 
Yes 
No 
No 
No 
No 
Yes 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
y" 
Yes 
No 
No 
No 
No 
No 
No 
Yes 
No 
Yes 
Yes 
No 
No 
y" 
No 
No 
No 
y" 
No 
No 
No 
No 
No 
No 
No 
No 
Yes 
Yes 
No 
No 
No 
Yes 
No 
Yes 
Yes 
No 
No 
No 
No 
No 
No 
No 
y" 
No 
No 
No 
No 
No 
No 
No 
y" 
y" 
No 
y" 
No 
No 
No 
No 
No 
y" 
y" 
Yes 
No 
No 
No 
No 
No 
No 
y" 
Yes 
No 
y" 
y" 
y" 
No 
No 
No 
Yes 
No 
No 
No 
Yes 
No 
No 
No 
No 
Yes 
No 
Yes 
Yes 
Yes 
Yo. 
No 
No 
y" 
No 
No 
No 
Yes 
No 
No 
No 
Yes 
Yes 
Yes 
No 
No 
No 
No 
No 
No 
Yes 
No 
No 
Yes 
No 
No 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
Yes 
No 
No 
No 
No 
y" 
No 
No 
No 
No 
No 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
y" 
No 
No 
No 
No 
y" 
y" 
No 
No 
No 
y" 
No 
No 
No 
No 
No 
y" 
No 
y" 
No 
No 
y" 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
y" 
No 
No 
No 
y" 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
y" 
No 
No 
No 
No 
No 
No 
No 
AMI, Acute myOC<lloial infru-ction: CABG, coronary artery bypas.s grafting; F, female: M, male; OM, obtuse marginal branch; PTCA ind" PTCA indication; 
SAC, subacule slent closure: SAP, stable angina pedon;: flAP, unstable angina pectoris; other obbrevilltioll.i as in Table I. 
a reluctance to change the guiding catheter for one 
with a larger inner lumen diameter, necessary to en-
sure passage and adequate positioning of t.he SDS. 
This exchange procedure may be complicated by loss 
32 
of distal access of a damaged coronary artery. Start.-
ing PTCA with a large lumen guiding catheter (at 
least 0.82 inch inner luminal diameter) may have 
prevented this problem. 
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All patients wit h sllcce.';sful stent implantation had 
a patent. vessel, with relief of myocardial ischemia. 
Thus the immediate success rate was high (88%). 
However, 21 patient !'I (45~~.) needed bypass surgery 
either because of an anticipated high !'i!'lk for sub-
acute stent occlu!'Iion (15%) or for subacute stent. 
thrombosis or lale restenosis (30~(,). Only O,6~';, of 
anticoagulated patients suffered from subacute stent 
occlusion in the multicenter study of elective cases 
reported by Schatz et. a1.21 This complication rate 
compares favorably with the results achieved with 
the self-expanding wall stent. reported by Sigwart et 
al.,";l Puel et al.,"1 and Serruys et al."·) The results in 
favor of the Pahnaz-Schatz gtent may he a result. of 
the high concentration of metal in the self-expanding 
!'Itent, making the sten! more thrombogenic, as the 
open area of the expanded Pahnaz-Schatz stent. is 
90~'(" The subacute stent thrombogis rates after sub-
optimal angioplast.y, as reported by Schatz et al. 2B 
(5.3S;:,), Kimura et al.27 (9.3 ~'(,), Haude et a1.2;; (l2~(,), 
and Fajadet et. al. 2() (29,4 ~(,), are substantially higher 
compared with this complication rate in the elec-
tively Rtented patient group receiving warfarin 
(4,5~'(,), according to the mullicenter experience.21 
The subacute occlusion rate in Our group of medically 
treated patients with emergency implanted stentR is 
also high (23 ~7,), 
Several faclorg may contribute to the dift'erence in 
subacute occlusion rates in electively stented coro-
nary arteries. Fischman et al.:10 rep~rted on angio-
graphic predictors of Ruhacute stent. thromhosis in a 
group of 726 patients wilh a Palnw'l-Schatz coronary 
stenl. Intraprocedural thrombus and persistent di~­
section as well as suboptimal results after P'i'CA were 
associated with an increased risk for subacute throm-
bosis. Throm bus formation just. before, during, or af-
ter stent. implantation may have played an important 
role in our pat ient. population, Ril1ce a majorit.y of Oul' 
patients underwent PTCA for unstable i~cheI11ic 
heart. disease, thus having a higher tendency of 
intracol'Onary thrombosis than those having elective 
PTCA for stable angina pectoris. IO,:l1 
If active thromhosis is suspected, stenl implanta-
tion had better be avoided, prolonged local adminis-
tration of thrombolytic agentR being preferable, If 
this treatment fails to restore vessel patency, a stent 
may be implanted aR a bridge to immediate coronary 
artery bypass surgery, A second possible Cause may 
he suboptimal medical preparation for emergency 
stenting, the patients not hm'ing received anticoag-
Ulants and aspirin and lacking premedication with 
dextran before stent implantation, Although the role 
of dextran in the prevention of stent. thrombosis is a 
matter of debate,:l2 we now administer dextran to 
patients at. the start. of an elective PTCA. If a patient 
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had not used aspirin, itg intravenous form (Aspegic, 
Sem-Ie Farmuca, Wees}), The Netherlands) could be 
administered at the time of stent implantation, 
Finally, the treatment. of dissectionR \vith mult.iple 
dilatations of oversized bolloon catheters may in-
creasingly damage the vessel, creating a larger throm-
bogenic surface and thus enhancing the chance of 
Rubacute closure, Dissection extension beyond the 
stent. may contribute to inHoworoulflowobstruction, 
with increased risk for subacute occlusion."!} If the 
PTCA is complicated by an occlusive dissection, im-
plantation of a stent should not be postponed to the 
very last moment, Extension of t he dissect ion beyond 
the stent. must. be treated with one or more, not. over-
lapping, stents, 
iVIonitorillg of APTT and TT may be insufIicient to 
prevent. subacute stent- thrombosis even after train-
ing of medical, nursing, and laboratory statf. Erbel et 
atl:l reported on the determination of Fl + 2 pro-
thrombin fragments for monitoring of heparin (ther-
apeutic level <0,5 nmol/L) and of factor II for mon-
itoring warfarin treatment. (therapeutic level <42~';,). 
In a group of25 patients, no subacute thrombosis oc-
curred, compared wit h 16.9t;;, in a historical group of 
5,1 patients without. monitoring of these markers, In-
tmellict ion of monitoring of these parameters may im-
prove the outcome of patients with emergency im-
planted stents, In the multicenter study of Schatz et 
al.,21 8,5!,';-. of patients receiving anticoagulation had 
bleeding complications, In our group, 8% of patients 
developed major bleeding complications. The major-
ityofmil1or bleeding complications (21 %) were punc-
ture site-related. This may be related to an overRhoot. 
of heparin after stenl- implanlation and to sheath 
removal under some degree of anticoagulation. 
New vascular devices (VasoSeal, Datascope Corp., 
Montvale, N..J.) containing collagen for Rupraarterial 
application to enhance hemostasis, even under full 
heparinization, show promise in reducing this com-
plication. In an international registry reported by 
Ernst ef. al}4 100 fully anticoagulated patients had 
an 8F sheath removed and 180 mg of bovine collagen 
applied through an over-the-wire vascular hemoRta-
sis device. Hemogtasis was obtained i1194% within 5 
minutes, without device-related complications, An-
olher advantage of these devices may be the possi-
bility of continuing heparin infusion immediately af-
ter stellt implantation, obViating the necessity to 
withdraw heparin before sheath removal, with a pos-
sible reduction of subacute stent. closures. 
In conclusion, implantation of a Pahnaz-Schatz 
coronary stent· on an emergency basis after subopti-
mal PTCA proved to be feasible, with high primary 
success rates. However, during this early experience, 
nOllRurgical treatment of pat.ients with Ruccessfully 
30 Kiemeneij et af. 
implanted stents resulted in substantial subacute 
stent. occlusion and bleeding complication rates, 
Therefore patients with emergency implanted stents 
should be considered a high-risk population for sub-
acute stent. occlusion and should be monitored care-
fully during aggressive anticoagulant treatment. and 
careful ambulation, Keeping in mind the excellent. 
results of CABG in a patient. without ongoing cardiac 
ischemia, patients should be referred for CABG 
within 24 hours after emergency stent. implantation 
if additional risks for stent. occlusion are present. 
This applies especially for less experienced centers, 
With improving patient. selection, medical prepara-
tion, stent. implantation techniques, and hemostatic 
management, in combination with an opt.imal clini-
cal infrastructure, a more conservative treatment. af-
ter emergency stent. implantation Illay be advocated, 
\Ve thank Professor P. W. Serruys of Erasmus University, Hot-
terdam, The Netherlands, for his thoughtful and valuable review 
of the manuscript. 
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CHAPTER 2.3 
TWO MAJOR CLINICAL APPLICATIONS OF PALMAZ SCHATZ CORONARY 
STENTS 
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A COMPARISON OF BALLOON·EXPANDABLE-STENT IMPLANTATION WITH BALLOON 
ANGIOPLASTY IN PATIENTS WITH CORONARY ARTERY DISEASE 
PATRIUK \V. SERRUYS, 11.D., PETER DEJAEGERr., l\1.D., FERDINAND KID-IENEIj, M.D., 
CARLOS 1lACAYA, 11,D" \VOLFGANG RUTSCH, }'1.D., GIlY HI-:YNllRICKX, 11.D., IL\KAN E~IANIJELSSON, M.D., 
JEAN 1iARCO, "1.D., VICTOR LEGRAND, ,\1.D., PIF.RRE i\iATEl{NE, I\.1.D., JORGE llELARDI, i\LD., 
ULRiCH SIGWART, i\1.D., ANTUNIO CULOIl-IBO, 11.D., JEAN JACQUES GOY, 11.D., PAUL VA;.;' DEN" HEllVEL, M.D., 
JUAN DELe,\N, M,D., AND l\lARIE-ANGELE l\loREL, i\Uk:., FOR THE BENESTEXT STUDY GROupt 
Abstract Background. Balloon-expandable coronary· 
artery stenls were developed to prevent coronary reste-
nosis after coronary angioplasty. These devices hold cor-
onary vessels open at sites that have been dilated. 
However, it is unknown whether slanting improves long-
term angiographic and clinical outcomes as compared 
with slandard balloon angioplasty. 
Methods. A tolal of 520 patients wah stable angina 
and a single coronary-artery lesion were randomly as-
signed to either stent implantation (262 patients) or 
standard balloon angioplasty (25B patients). The primary 
clinical end poinls were death, the occurrence of a cer-
ebrovascular accident, myocardial Infarction, the need 
for coronary-artery bypass surgery, or a second per-
cutaneous intervention Involving the previously treated 
lesion, either at the time of the initial procedure or dur-
ing the subsequent seven months. The primary anglo-
graphic end point was the minimal luminal diameter at 
follow-up, as determined by quantitative coronary angiog-
raphy. 
Results. After exclusions, 52 patients in the stent 
group (20 percent) and 76 patients in the angioplasly 
group (30 percent) reached a primary clinical end point 
(relative risk, 0.6B; 95 percent confidence interval, 0.50 to 
I MPLANTATION of an inlracoronary stcnt in cOl~iuncti()n with balloon angioplasty is not ouly 
highlr efrective in treating acute \'{'sscl dosure due to 
balloon-induccd dissection, but it may also reduce the 
rate of restenosis. H Unfortunatclr, all slents currently 
available are metallic and thus thrombogenic, a prob-
lem that nrcessitates anticoagulation therapy.'i·r, This 
therapy exposes the patient 10 an increased risk of 
From lhe Uniw"ity H"'pitai R<>uemam Dijl..ngl. Thor.l-\ Cenler. Rotlwhm. 
th~ Netherlands (P.W.S., P.I., M.A.M.); Onz.: Lkw VwU\\.:Gasthuis, Amsler-
d.lIIl, the Netherlands WK.); Uniwrsil}' HOlpilJ..! San Cados, Madrid, Spain 
(C.:o..I.); Unil'er,iliilSlJini).um Rudolf Virchow, Cb.lrlol1cnburg, Berlin, GUTIl.lll).' 
IW.R.); Onle Ue\'e Vrouwe Klinick, Aal~l, Belgium (O.H.); Sahlgren,ka HOlpi· 
tal. Gotcborg. Slle,kn (H.E.); Cliniqu~ Pasleur, Touloule, fr"nc~ (J ,10.1.); Sart· 
Tilman Centre llolpit.'l.lier Uniwf;;it;lirc, Uege, neJgium (V.L.); Ilopital d~ l~ 
Citadelle, Liege. lIelgium (P.M.); In~tilut!) Cardio\'3!,cul:lJ de Buenos Aires. 
lIuenN Aire<, Argentina O.n.); Royal [Iwmpton Nati"naJ Heart and Lung In<ti· 
lute, London (U.S.); Centro CuweColumblll, Milan, Italy (A.C.); Centre lIospi· 
0.92; P = 0.02). The difference in ctinical·event rates was 
explained mainly by a reduced need for a second coronary 
angioplasty in the stent group (relative risk, 0.5B; 95 per-
cent confidence interval, 0.40 to 0.85; P = 0.005), The 
mean (±SD) minimal luminal diameters immediately after 
the procedure were 2.4B±O.39 mm in the stent group 
and 2.05±0.33 mm in the angioplasty group; at follow-
up, the diameters were 1.B2±0.64 mm in the stent group 
and 1.73±0.55 mm in the angiop!asty group (P = 0.09), 
which correspond to rates of restenosis (diameter of ste-
nosis, ~50 percent) of 22 and 32 percent, respectively 
(P = 0.02). Peripheral vascular complications necessitat-
ing surgery, blood transfUSion, or both were more frequent 
after stenting than after balloon angioplasty (13.5 vs. 3.1 
percent, P<0.001), The mean hospital stay was signifi-
cantly longer in the slent group than in the angioplasty 
group (B.5 vs. 3.1 days, P<0.001). 
Conclusions. Over seven months of follow-up, the 
clinical and angrographic outcomes were better in patients 
who received a stentlhan in Ihose who received standard 
coronary angiop!asty. However, thIs benefit was achieved 
al the cost of a significantly higher risk of vascular com-
plications at the access site and a longer hospital stay. 
IN Engl J Med 1994;331 :489·95.) 
major bleeding and vascular complications, which 
may prolong the hospital stay.7 Despite these draw~ 
backs and although the superiority of strut implanta-
tion o\'('r standard balloon angioplast}' has not yet 
been proycd, stenting has bccn used increasingly. 
There((Jrc, we conducted a multict'nter, randomized 
study comparing stent implantation and balloon an-
gioplasty with r('spect (0 their safety and effieacy 
talier UniHr;itaire Valid"i" Lau'annc, Sl\itz~rland O.I.G.); Midddhdm Z1, •• 
I..enhuis. Antwerp. Belgium (P.H.); and Gregorio Mar~non, Madrid, Spain 
(J.D.). AJJ""s reprinl reque'L' to Dr. Serruy, allhe Calh~teriIation bt"'IJtory, 
Thora.~ Cenl~r, Er.J.Smlh Uni--el'ily Rotterdam, P.O. Il(l~ I1~R, ~OOO DR Rotter· 
dam, the Ncthal:inds 
Sup""rted in pm by a gr.mt fwm Johm(ln and Joi1n;,'n Intuvention.ll S)S(I'ml, 
Warren, N.J.; Sc'hneiJer and Co., Ilub"h. S" i17elbnd; and LDln Phmna,:~ulit.l 
IlV, MllJ>'en, the Neth~rl.mill. 
'Tb~ r~m.:Uning inI61i!:dl<>" in th< Ileneltenl Stud)' Gwup are lilted in lll~ 
Apf'<.'odi •. 
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in palit'nls wilh stahle <lngina p<'cturis and a sin-
gle new lesion in a cOl"Onary artery. 
METHODS 
Selection of PatIents 
P.Hienb ,du,duJt"d I() und~!g" rUfflnary angioplasty bf("aus~ 01 
'I.lbk .Illgill.l due to a ,illgk lleW It·,inll iu .1 U)[(>llary drtef)" II"ne 
digihk j;,r !II'" 'IlHlr if th"): hJ.d no ullltr..tilldil.lli()ll to 'llllic().I.gu, 
I.lnt or .mtipl.lt('kt tl[('[,'I'}" .,,)(1 if tl)(')" were "I", ,uit"h!<- r"llllid"le.' 
f"r (""ronMY hn,.l~' ~llrgrry. Tht" Llrgd Inion rlt'nlrd lu l!l' k,~ thMl 
I.", llllll long and to 1)(" lo(.!tt"d in a vt"I~~1 mort" th.1ft :l mm in 
di.lllwln tiLl! 'Ul'pli"d n()[l)IJ.ll/· fUlltti()lling lllyoc.lrdium. P,ltients 
with ."1 o,li,,1 k,ioll, ..I Inioll «I « hifur<"olti()ll, ot .J Inioll in ,I pn" 
viou,ly gr.lf,,·;\ \T>wl \\"<,[<' tXt lurl~d from til<' 'ttl'\r, ,l~ w("n' p"linlh 
in whnm an intra{(,ron.u)· thrombu> W,l, ~Il~p("ft"d, 
The study II".J~ c.ltlied oul according to tht" principles of the 
J),'d.Jr.Jli()[j ()f Hehilll..i. Or.J] <or I"illen hlliJtJllrd Wllsrnt accord-
ing tu l()r.tI prMtirt' W.J~ o"t.Jin('11 fi,r ("I'cr}' p.l!leu\. 
Randomization 
P.lli~nh \\c'r" r,'ndomlr ;", .. ignrd br tr!ephoJH' f",m a c,'Il\r.JI 
ollirt' to tithn imp!.IIl1.ltion of a p,llmM-SI 11<111 ~t(,llt or 1'.I11ooll 
,lJlgi"pLI~!y. '1'" t'tlsurt" an t"qu'll distribution of tre.llml'llt\ in t.Hh 
(,'!lIn, w,' d"w!np,'J the IMld"mi2,ltion ~~qu~nrt" on ,; ~itt lJ.lsi, in 
hi", 1... .. "f 'IX IH','lmcni a~,,;g!ltll("nts. 
Balloon Angloplasty and Stent Implantation 
B.Jllool! aU,<.:iopl.l . ,ly and Sk,ll impLult.Jtilln wett' prri(,rmtd .\t"-
'"r,ling te, slcUI,laHI tlillie ,I! I,r..trlit" by till' kmOl.Ji "!,pre,ad .. TI,,' 
'knt 11".1., ,kl'l"ynl Ill' inn;lting.J 1000llOOll Ol"t'[ I,hidl til!' toUap""{j 
,knt W,l~ fil1~d. Inn.llion "f tht h,tllollll "'1'~l\Ckd llw ,Inll. Aftn 
tlw illll'l.ltll,ltion of tht" ,knl, Illr 'knl~d ;'n'.1 \\".,s ofttn dil.ltnl 
fUJ\lu'J by 'l.Jntl,ltd b"Il"ou <lllf(;"plasty. All p'lti~n1> rer~ivt{t 2.'10 to 
.'Jon IIlg or ,l'pidu d.lily .J1lt1 75 mg of dipl'ridamole Ihret' time;; a 
d.I)'; thi .. In·,,lnWlll I,.t.' ,1.J1I,·d tIl\' d"y I"'j'llt' tht pHJCt"dure and 
I'.l' lontinllnl I"r ,h month" During til!' I',occduu', patknt..<. IC-
(t"iving a ,knt wt'rt" In'.ltnt witit ,I ,"ontinlJolh i"lillioll of drXlr"lI 
([Ooo Ill!) ,\tid .1 hoill'> d",t" of lO,filili U of hq'.Jrin, n'llf.JIHt if 
nn,"'.I1Y, i'JnownllJY ,I ("<,mi,in.l1ion of htp"rin ;\tId or,,1 antito.lg-
UI~li"lIlll"'.J\,y (with II,ufJtin) .Iftn tilt'" rt"mov.l! of Ihe ~h~alh ;\tId 
litr,lt<"<ll,y IllC."udng Ihc plOtluollllJin tinl(" ,md ~ithf[ tht" artiv;ll~d 
p,lrti.d-thr"rnhopla'lillliul\' or til!' .It"lil',.il<,d tloning timt', The dose 
of it~p'lrin \\".I~ dn [(.,,,,'d prog[('"iwly .Jftcr tin' p"'lh"'Ulhill tlnl!' 
h"d ht .. n in th~ titn,IWllti!' r.trlg'· (inteTu"lioJlJl u"rJll.Jli~ed rolli .. , 
2 .. ",10 :l.5) li,r all~,lst :It, hnurs. \\'.Ht~lrin lher,lp)" w.t' IOJltillllfd fi'r 
till,'" Illomh,. TIle' p.\ti~nts who undtn\"~nl h,llIoon ;'ngiopl",ty ft·~ 
.. ciwd onl)' 1O,I)tl1) lJ "I' hrparin during IIt'lt proft"durt", follOll"td by 
. m ... I,litinllJ.I hohh do,r <It ~ (ontinuou> inlusion if dt"~m~d nt(t".>-
'-11')". III addition, I,,,tl, t'''''lmnll gJ<'up~ r,·rfln·d ("ldum ant.lgo-
ni>1, until di" h,n.~'· Irom lh!' 1""pil.J1. 
ClinIcal and Anglographlc Follow-up 
P.lti,'nh II"n,' H,'II in 111'" OlHpJtklll tlillie .Jhn "nt, thre,,, .Ind ~ix 
m,onth~ 1,,1' an in!n .... i('w, ph),it,,1 \"\arnjll~li"!l, .Illd elcd,o'J.rdin· 
gr.llll. LVf<i,t" It,ting 11".1' p~rl"rm,.d I,,'for{' til!' "',oud "lIdi.l" 
(",ltl"'h'l iL.Jtiou ,Itld I own.H)' ,111 . ::i"p;r.lphy at ,j" llIonth~, If ;; n'\',"~ 
,u).IriL.Jlinn p",,,'duu' illvoking the Ife.lted ~rgrllrnt Itdd htt"n pt'[-
I"r!!led h"I,,,,' tlH' ,L"'lll"llth .I!lgiog[.lphy, Ihe nll"t rfl"t"nt Mlgio-
.<.:r,u!\ "hl.,iw'd h,{o[<' lhi, jntnv..,lliou, if .I1·.JitJhlt', ".IS used.l, til(' 
1"II<lw-ul' ,mgiogr"m, [t'g,mll,'" of lhe lilllill.<.: or Ill<' ,"'com) imcr-
,""ulion. If tilt" lilllt 1" f"lIow-up ;mgin.gr,'pit)" II.J' jr" lh.lll IhnT 
lll"tld,~ .,nd U<l ,tUlud inlt"l"l"fntion W,I' pni',rm,'d, Ih" ll,ltl!-lIt W,I~ 
.t.,~,'d 10 lllHklg" .In.':ingr.lpity "g"in .11 ,j" monlll'. In Iht .lh,tfltt 
of .l.,,·,oud .Hlgiog[,un ,II ~i" Illnlltll.', the .Itlgingf.ltll "hlain~d llIost 
r~' frltly IlithiJl til!' p[tTioll' tll[tT !llOlllh~ W.I.' u",d, if .I1"'.IilJbh', 
pl,,\'id~d tit"l fl') ~nd I",int h.1(1 '" (un<"d. 
nu,'!' .Iugi".~r.Hn' \\trt" ohldin~d I;'r ""t'h IMli!'!lt - nil!' .il"t 
1"'Ii,[,' lilt· iut"1 \'t'uli"II, 'H'" illlmrdi.ltt"ll' .Inn, anrl ',nt" .,1 1',II""I·~np. 
All til<' .tll.d"gr.lln, IH'''' .Ju.tl) Led hy Ihe C.udiov.I" IIlar '\ngiogr,l-
phv ;\II.ti},j, S}'!<'III .<lul ,,'nt 10 til,· ,o,,·I.lhol.J10lY (Catdidly;h. 
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Rot\{"[(iJ.m, tht" i\'Hhn!and,). To '1.'nd'mli~\' IhO' 11\('lh"d of data 
"(qui,itiou .Ind 10 ensurt' tilt" t"X.lr\ rt'pnodllriloility of th!' angin-
gr,ml' pnformcd .Jfter tht" itlten'ention and at 1(,lIoll"-up, me,l>ur~­
ments II·t"rt" m"d!' ,l~ tle,;uih("d c.JJ!irr.H 
End PQlnts 
cnl!' plilll.llY dinir.ll ~nd points Weft" whkhtwr of the lo]Jo\ling 
<H (lIfr ... 1 fir:;!: dC.Jlh, a tef~bro\'ascul.lr a\ddenl, myoc.lldial infart'-
tion, b}"p.,,~ ~Jlr.<.:nr, or a ~rcotld percutaneous iUlnvention invok-
ing tilt" pr~\"iou~ly tU'.Ittd lesion helwtt'n lhe time of the initial 
procedure ;md til!' ;tlIgiogr.Jphy ]lflforlll!'d al <j tllUllIhs (±-I wt"~ks) 
(<or «17 months if no ;lngiogr,lplt)" " . .t' pnforrmd olt 1; UH>llIhs). The 
imlir..ttiOlI fi,r .I ~econd inten'~ntion or for hyp~', ,urger)' had 10 Ill' 
subslantiall'd IJl' ,ymptoms or by elel trn,",udingr,lpitk Of ,"illli-
graphic nidfrl<!, of JIl}·ocardi.l1 ischemia ,1t nest or during ~xnrht'. 
All n'ents w~re reviewed hI' Ilw uitic.JI-('vent committet", which was 
11I1.lW.JI<' of the tre,ltment ;,,>ignnH'Ilh, 
Dt,llh \\.IS defined to inrlllrie all d!'.Jlh" r<,g.Jrdk.~s of ('J.U'''. 
Cert"brov.t,(uiar J.ccidents occurring in p.;titnlS TI'fC;11I1g ;;n1iro,'g-
ulant thtrapl' \Wf<' considered to he intracranial heffiorrh;lges un-
less unequivot,llly d!'m'lllstr.Jtcd otherwise. ~1y()r'lrdia! inLlrdion 
\\".1., diagnosed if litn,' 11TH' II!'W 1'J.lhoioxic Q wal'es a(C<Jlding 10 
till' ~litlu .. so!a Code" or if thnt" ,,",'S an imT,'.Jsr in ,rrUIll (f"J.tillt' 
kin"~(> to mot,' thall twin' tht" nnrm,,1 v"lut, logdllfT "ilh" p.llllO' 
Ingic imTt".ts,' ill Ill/'ocardial isotflzymts. nnM~~ ~1lTgny w,t~ ,11'-
liut"d to inc!ndl' flllcrgCllCY or clrctil-e bypass surgery invoh1ng titr 
prn'iously tre,ltcd segmeut. Emt'lgfJlcy b)'pass surgery was defined 
;l~ involving .In imm~diat\' Ir.tulfn froJll tl'" .lngioplasty suitt III the 
nprr"ting lOtllll during Ih~ inili,,1 ph.Jlt, of tre.llltlfll\. "lhilout" 
Sitnt iml'1allt.tliou W,15 d~ftnt"d ,1S lh~ pl.l!tml'lll of a st,'lIt in Ihe 
t\'enl "I' 11lr''''II",iysis in :\1)'1,t ardi,lilnf.IH·tion (TI~n) gr.t(k (J "r 
! How ant"T ;lngiopia!.IY '" in th .. (.Ise of worsening ,,1' tht h;!~I'-!inl' 
TI~lIllo11" hr om' gr",I<,.I" III alt ins{.Jtl(es, prolongrd b;llInon all-
giopiasty h,ld to he atl\'ml*'d I,,'[ore bailout steHting was comid-
('[,'d. B)' design, stml impl.lnl.ltion ;II.J bailout pwn'du!',' was Hln-
sidtr,'d ("I]Uil'.Jlent In tmtrgtnq' h}lJ.l'1 ~llrgn)' hut W.Js u'muvcd 
rt"trnartiwlr fwm tile an,lJrsis of prim.try tnl! I'"inh, '>inn' it is 
t'ufrentl}' I'fTt rived as an itHegr,IJ p;ul (ll" an angiop!a,t)' slr,'lcgy. 
Only tilt" unhlw.Jrd rlill;(.11 HTHlS assodakd wilh sltth ~I<:'nling 
WI'''' c(lllnted as tnd points, ~k(mld inl('lwntions were Ihosr invok-
ing a previously trt',lkd h',ion tllal folJnw,'J Ih!' initial pwct"durt", 
whie II WJ.S (Omidt'Ted fomplde wlll'n Ihe guiding c.Jlhrlrf lIas re-
ffin\'r<1 from Ihe arleri;11 ~h~;llh, Rn'.i~,"IlI,lri'oltioll (surgleJ.I or pn-
cutanf<'u,) iuvoldug other ("(JT<mary arkrin did not t'(l[l'>tiWII' all 
end point. 
The primal')' ;"lgiogr.Jphk cnd point was tht" minim.,] Ilmlin.,] 
di.ltllet~r at fi,lIoll"-l1p. For <'.Jell I[<'~tfd segment, litis v.,hw W,l, 
Ldlcuiated Irom the n1('.tu \'"Iue, ,,1,{.Jinfd ill JIlultiplt' matI h~d pro-
j"f1i,ons . 
S", oudar}' flld p()int~ im luded (I) 111(' ;Jugin.-:raphic sucrns I .lIt, 
defint'd ,,~ lhe ralc "I' adtievfment ,,1' It" Ih,l!l .10 I,,'r{','ul Hruo,is 
on visual ;",n,lllCul; (2) tile' pwcedur'll sunt"'~ r,ltt, ,kftr[(',1 a., Iltt' 
1.11<' of arbin·t'ntl'1I1 of Irs, th.lll 50 !leHent stenolis on qll."ltil"ti\'(' 
,l'>"'"m~ut, I,ilh'nll till' onIHH'UU' 01 clinic,ll tvent~ during lh~ 
lu"pit.JI ~tJ.l'; (:l) the furHlioll,l1 <la.'1 aL(()ldiug 10 the dassiflta-
tion ,of lit!' CaJladi,\fl Card!",·,,,,"u).'r Sod!'t}';;t ,]x Illollth, or .It til(" 
timt" "f illtn, ullcnl angiography and ~r' <Inti illt('r .... "lIlion; (-I) the 
rt"sults of "MTti,,' \t',ling .It ~b: monlhs nr e.trlin, if dink..tlly iudi· 
t.lud; (.'i) lhe r~t" or r('\tcJlosi~ (steumis ;.50 percenl ;11 f"I!"w-up) 
.II ,ix month ... 
Power Calculations and Statistical Analysis 
AI tht" ouh,'t of th" slUdr, Ih!' ,il,' of tht r~quirt"d ,.Implt" (-1211 
p.Jlknts) ,,",lS b;,,~d <Ill all a."uttl('d [.II!' of dink,11 t"I·t"nts of :\0 
I'<'[\"t'llt ill the aogiopl",ty group ;.l!ld a n'du< tiou "I' tlhH r,ltc· hy -IO 
pennlt in till" stfnl group {lty a two-,idnt t,',t \,itll ;111 alph.i (,IIOT of 
O.H~ and a powt'r ofO.HU). To (ompen',ltt' I"r uno;lIU ,'"ful inter .... cn-
tiOllS and 10"", I" follow-up, tile .lamplr w~s tnl;lrgrd hy W plT(nlt 
(IO -I7tl p:ltit"nt.,), In .ttltliti'lll, 10 adjust 1;,r a loss of p"wn dut Itl a 
pl,lItucd intt'rim an;II}',i" lht' "unpil- WJ...' inut;ls"d by ;Hlothrr 10 
pnrclII, «'..Idling a lin.d ~i7(' of .')~O l"'tknh. 1I 
Th .. nt"in dink.ll ,11J.llysi., n,n,i,lt'd "f a 'ingit' ,ornjl.Jrj<,on he· 
Yol. :1'11 :":0. B IL\LLOO~ snxr \'J:RSUS HALI.OOX ,\L'\(;IUPL:\STY L\ COI{OX,\HY ,\RTf,RY IllsL\st: ,'II 
t"'''cn Ilw two ,llIdr poop, "ilh n"I"'" t,. Iht 1'" illl,UY diuir,,1 rlnl 
£loiut, rrgdrdl .. " "I' it~ lim .. "I' or< OIrrrlHr; lili, ,m"I) ,h i1)\'ol\'nl .tll 
r,uul"lllilcd £l.tdrnts Idlh llir ,':o.:<"<·pliol1' or IIInT p,ltiml'. Ii)und 
"fin r,lIl1lolllilJ.liollIlOII" I", di~i['r.- .wd or our p,lli .. nl II'ho "ith-
<irt'1I' jllli.nllrd nllllt'lll J')f fllTlhn tn',ltrrwnt and r"I!O\\"-up alrOld-
ing In tilt' inlt'ntion-«Hn'<lt prim-ipl ... 'nit ciinit.ll n-,'ul> ''''ft' 
l.lllled acwrding In tilt' highest (.!trgory oj "'\'('fi\~' <HI tilt" r"U'''ling 
sr,d\': d".llll, It"f(·hrol'.l'lULn .luid('lll, Ill)o'.lnli,d inl~lf('/i"n, emn-
gem y h)'l',h\ ~urg<'l)', ,,\e('li\"(' l.yp.!" ,"rgfry, and r .. pe.ll peauI.l· 
ITem» inttrv(,llliofl, 
'I he m,lin angiogr,lpliir anal}">i, ((Iusislt'd of.l ,il1g1P ,omp.ni'"n 
h('(wc{'u the 111'0 ~tudy group, "itl, 1\"'1"'( \ to minim,ll luminal di-
a111('I('[ ;llld \\'.1.\ jll'fl;mllCd a(c"rtliu,'-: 10 th .. intention-w-Ileal pJin-
.-ipk. 
Continuous v,ni"I)I", ar .... "presstd as me.lm ±SD "nd "Tn' 
compared by tht lIflp;;ired ~tudent's I-!e~t. 'Ill<" d,i-''1"J.!H" tnt \,ith 
Yatr_,' (",,<'(lion was med 10 comjl .. r,· proportion., Disrrete \'ari-
ahle, ;tn' c"jlrt's\t'u ilS (OUllb alld pCfrfnl",!;", and are {Ompah'J ill 
knns of n·I'IIiv{· ri,ks (Ii,r sIelllin,!; as (omp.ued with <lllgiopl.1.qyl. 
\,ith !J:, pa(t'nl ("nrid{'ill<' inlt'rv.tls r,llrulated by th .. formul .. or 
Greenland and Robin,.1l All statistical tests 1\,('1\' \lI'o-I.tilrd. 
RESULTS 
CharacterIstics of the Patients 
netw{'en June 1991 and 1Iarrh 1!:l!:l3, 520 patients 
were randomly ;lssigned to stenl implantation (262 
patil.'nts) Of balloon angioplasty (258 patients) at 2B 
participating ce)lters, Of these :'20 patients, 4 were 
excluded from fUrlhcr analysis, 3 in the stent group 
and 1 in tilt'" angiopiasty group. One patient withdrew 
his informed consent and lell the hospital without re-
ceiving treatment, two other patients did not under-
go Loronary revascularization bc('ause their ksions 
proved to be unimportant during- on-line quantitative 
coronar), angiography at the time of the intended in-
tervention, and one patient participated in another 
study with an investigational drug. There were no dif-
ferences in base-line chara{·teristics between the two 
study groups ('l';lules 1 and 2). 
In-Hospital Clinical Outcomes 
or the remaining 259 patients randomly assigned to 
receive stents, 14 (5.4 percent) did not receive a stent 
but were treater! successfully with balloon angio-
plasty. The reasons for this nossover were the with-
drawal of informed consent in Jive, the physician's 
preference bn'ausc of the patient's unfavorable anato-
my (e.g-., small vessel size) or angiographic evidence of 
thrombus in three, and failure to cross the lesion with 
the stenl in six. In addition, stent implantation was 
unsuccessful in 10 patients: 6 becallse the lesion was 
not dilated beforehand and 4 because the stenl muir! 
not he deployed. Of these 10 patients, 8 underwent 
bypass surgery that was urgent in :l and elective in 5. 
The remaining two patients, who unexpectedly had 
(otally occluded coronary arteries that could not be 
recanalized, were treated medically. 
Of the 257 remaining patients randomly assigncd to 
balloon angioplasty, 13 (.11.1 pen:ent) received stenl.<; 
Jar the following reasons: acute \'essd closure in I, 
flow-limiting dissection in II, and a suboptimal angio-
graphic result in I. Of these 13 patients, 2 \Vere re-
ferred for urgent bYP;lss surgery and I had a non-
41 
Table 1. Base-Une Clinical Charactorislics 01 the 516 Palients 
Included in the Intenlion·to-Treat Analysis. ~ 
l"H,-",rru'm< ,h'" ,l"" .~ -"-'i71 Sit ~I I~ - l'''J1 
Age ()l) S~± III 5"/:;:'1 
Wtil'hl (~g) 1')->: I.' 7~! II 
Height (.:m) 17L!-'1 171±.~ 
'" I'q '." I'(! 
,\.JJk ,,'X 212 (~2) 21)7 (~IJ) 
Eler <m,,~eJ 12.t (.tH) 11'1(46) 
Curr,'flt 'nI,.~.:r (>I) (2J) ('2 (2.1) 
[)i~t>.:I<' m<'lIitm ltl (6) 17 (7) 
Prni(>w'> ,,'ndiliol1' 
Myr"Jrd;al infa!di,'n 4H (I'l) 52 (21» 
(\>ronlf)-'·~rt<ry biPJ" gJ,lftirig 5 (2) 
" Aogi.)pl~"y 8 0) 5 (2) 
Il),porteo<i,'n .~9 (35) ~O (1) 
Ili rer,;nt>!e>tewlem;a 95 (J7) 1'9 (J4) 
Stf\\~e tl(2) tl (2) 
I'eripher,;! \,-<~uldf di<e,,-'e ~ (3) 10 (4) 
E\~r1j()I1~J angina (eCS d~,\)t 
I 9 (4) ') (3) 
" 
"IS (29) ~2 1.12) 
'" 
JJO (51) 125 (.tS) 
IV 20 (ll) !6 (tl) 
None 2J (9) 27 (10) 
Mi~eJ S\> (35) ~9 (.1--1) 
'ri\l'-,""l'~< ,~c,;< "" no"", -:,:sn 
t,\e<,'nl.og !.> tho ,h"ih~';,'" ')""" "f It~ n ___ ~,J' '" Cr.!:",."LW- S'''ld) lCCS) 
Q-wave myocardial inl~uclion. In addition, three oth-
er patients who har! complicated balloon <lng-iopiasty 
and in wholll no bailout stent implantation was at-
tempted underwent urgent bypass surgery. Tlwrciore, 
the <lngiographk succ{'ss rate was 9G,9 percrnt in tht' 
sten! group and 98.1 percent in the angioplasty group, 
whereas the procedural success rates were 9~.7 and 
91.1 percent, respectively. 
The ranking and the total number of dinieal events 
o('("llrring in the hospital are shown in Tahir 3. The 
composite rate 11)1' all in-hospital events was similar in 
both groups (16 events or 6.2 percent in the ang-io-
plasty group "s. 1H events or G,9 percent in the slmt 
group; relative risk, 1.12; 9S perrellt confidence inter-
val, 0.58 to 2.14). There were no in-hospital deaths in 
dther group; one patient treated with balloon angio-
plasty had all intracranial hemorrhage. There was 110 
difference between groups ill the incidenc{' of Q~wave 
and non-Q-w<lve infarction (:3.1 percent in the ang-io-
pIast)' group vs, 3.4 percent in the steHt group; relative 
risk, 1.12; 95 percent confidence interval, 0.4-4 to 2.H5) 
or in the nt'cd li)r urgent or elective cardiac surg-el), or 
second angioplasty during: the hospital stay (2.7 per-
cent in the angioplasty group vs, 3,,'j percent in the 
stent g-roup; relativ(, risk, 1.2B; 95 percent conlidenLt' 
inten'al, 0.48 to 3.37), 
Ang-iographkally documented stenl thrombosis 
during the hospital stay occurred in 3.5 percent of 
patients, an indrlence similar to thal of suhacute ves-
sel closure after hallooll angioplasty (2.7 percent). It is 
noteworthy that no stent thrombosis occurred in the 
13 patients treated with a bailout stellL However, the 
incidence of bleeding and vascular complications was 
1~1'l TIff. m;w Ei\UL\i\OJOURi\AL 01' :-'ll:DICINE Aug. 2\ l'I~Jj 
signilic<lntly higher after stent implantation than after 
balloun ang-ioplasty (13 . .1 \'s. 3.1 percent; relative risk, 
4.34; 95 percent confidence interval, 2.05 to 9.18; 
P<O.OOI). 
The mean hospital stay was R . .1 days in the stelll 
group and 3.1 days in the angioplasty group (P<O.OOI), 
Clinical Outcomes at Seven Months 
The numbers of various types of clinical events at 
seven months among all 51G patients are shown in 
Tahle 3. A primary clinical end point was re<ldlcd 
by 7G of the 257 patients randomly assigned to bal-
loon angioplasty (30 percent), as compared with 52 
of the 259 patients randomly assigned to stent im-
plantation (20 percent) (rdative risk, 0.68; 95 per-
cent confidence interval, 0.50 to 0.92; P = 0.02). 
This differencc in long-term clinical outwme is shown 
in the cumulative distrihution t:urves for the pri-
mary clinical end point in both treatment groups (Fig. 
ID). The favorable long-term outcome in the stellt 
group was also partly reflected in the difference be-
tween the two groups in functional class at the time 
of the second angiography (Tablc 4). The most 
striking difference in clinical outcomes was the signili-
Table 2. Angiographlc Characteristics of the 516 PaUents Includ-
ed in the Intention-to-Treat Analysis and Characteristics of the 
Procedures They Underwenl.· 
Arlay dilated 
Right (('woary 72 (2&) 60 (2]) 
Left anten(lr de'~eodin!! 159 (62) 165 (64) 
Left ciKum!k, 26 (10) J4 (D) 
Tn'" <,r ksi~nt 
Cooc~ntric 118 (46) 130 (50) 
Eccentric 
IA JJ (1.3) 34 (lJ) 
'" 
62 (24) 57 (22) 
IIA to (4) to (4) 
II. 13 (5) 10 (4) 
Tandem 0 I (OA) 
Multiple irrl'gularitie, 21 (8) 16 (6) 
o..:dud~d On-II 0 or 1)+ 5{2j 9(3) 
CakHkJ 27 01) 29 (II) 
Length (mm) 6,96±2,57 7.06±2.56 
l1uumbus after rrr'CedutC§ 10 (4) J (I) 
])i',e(ti"n~ 
No 145 (56) 215 (~J) 
T)'f"A 43 (17) 21 (~) 
T}f" il 57 (22) 16 (6) 
TnX' C 'J (4) 5 (2) 
T,f"E I ((1.4) I (OA) 
T)p..'F 2 (tU) 0 
N(lmilLll SiIC, It,'nl or balkxm (mm) 3.29±tU8 J.JI±O,J..\ 
Ihlloon"tent artery ratio 1.12±O.15 LlEO.15 
L1Ig~'t ballc-.)n ,ilC (rnm) II DO.tO.JH 3AO±OAO 
.\b,imal rre"ure (atmO'rhen:') 9±3 [(l.!.& 
Total inHati(ln time «ec) J9'1±J59 ISO±I'l& 
'Tb< init"'~.,,"'<r JnJ m!r~,'b'''''T \.rrllh~~) "I tbc,~ mMpb,>lc'l'iC rr"'"-'"",, h. r'" 
",,",1) N-<" "[,,,ud~) !r~ ,',w lJf"'"I".-,." PIo'-air,", ,.JL~' "''' mt-"l3 ±~D 
I'\",'r.bg I" lk d.i.\.lw,m"D ,)'t.;m "f Amb"", <I aj," 
tA"~rJ,";: I" tho: n!l.\1 StcJ:l G""",, ., 
~A<"'rd,og In tl;;, d<fi"i'i~" ~f fll" <1.1 " 
~A<,wJlo~ (,' lk d .. "i~wi('n ')''<10 "f LJ .. """ <I ,I," 
I.N"'miLlJ 'Jll 
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cantIl' reduced need fur an elective sccond rcvas-
cularization by means of perclitannllls intervention 
involving the target lesion. There was a 42 percent 
reduction favoring slenl implantation. 
During the ;;tud)" three patients died, one in the 
Table 3, Frequency of Primary Clinical End Points in the Hospital 
and at Seven Months in Descending Order of Severity, Tolal 
Number of Events, and Quantitative Comparison of Immediate 
and Long-Term Angiographlc Results.* 
0". 
In hospital 
At 7 rno 
AU eHots 
Cefl'bto\'JscuJar a~cident 
[0 hospital 
At 7 mo 
All event, 
Q·\\ave MI 
[n hOlrita! 
At 7 mo 
Allnents 
Non-Q-"al'e MI 
In h()lpital 
At 7 roo 
All e\'~nts 
Urgenl CABG 
In bmpitai 
AI 7 rno 
Alloents 
EIWiH' CABO 
In h05rital 
At 7 mo 
All e.-ent, 
Repeat ,'ICA 
In ho\pitai 
At7mo 
Allewnts 
Any C\'~n! 
In h<!spiuJ 
At 7 mo 
V"_'.HELd 
Referen(~ dtameta (min) 
Befor~ 
Art~r 
Fulloll',ur 
A.'GlG.Llin 
(N ~ 251) 
0 
I (OA) 
I (OA) 
I (OA) 
2 (0,8) 
2 (0,8) 
2 (0.8) 
4 (1.6) 
5 (1.9) 
6 (2.3) 
6 (2.3) 
7 (2.7) 
4 (1.6) 
4 (1.6) 
5 (1.9) 
0 
6 (2,3) 
6 (2,3) 
J(U) 
53 (20.6) 
60 (23.3) 
16 (6.2) 
76 (29.6) 
Snsr 
(N ~ 259) 
0 
2 (0.8) 
2 (0,8) 
0 
0 
0 
5 (1.9) 
7 (2.7) 
7 (2,7) 
4 (1.5) 
4 (1.5) 
4 (1.5) 
5 (1.9) 
5 (1.9) 
6 (2.3) 
3 (1,2) 
8 (3.0 
to (3,9) 
I (OA) 
26 (10.0) 
35 (13.5) 
18 (6.9) 
52 (20.1) 
A%i<H'l~H\ 
(N ~ 240) 
RHATIH R"K 
(~5~ U) 
1.98 (0.18 -21.75) 
1,98 (0, 18-21.75) 
2.48 (0.49-12.67) 
L74 (0.51-5.86) 
1.39 (0,45-4.32) 
0.66 (0.19-2.32) 
0.66 (0.19-2,32) 
0.57 (0.17-1.91) 
1.24 (0.3-4-4.57) 
1.24 (0.34-4.57) 
1.19 (0.37-3,85) 
1.32 (OA7-3.76) 
[,65 (0,61-4.48) 
0.33 (0,03-3.16) 
0.49 (0,32-0.75) 
0.58 (0.40-0.85) 
1.12 (0.58-2.14) 
0.68 (0.50--0.92) 
,=" (N = 2)1) P VAWI 
3.01±OA6 2.9'H0,45 NS 
3.09±0.4--I 3.16.!.0,4J 0.045 
3.05±OA9 2.96.!.0.48 0.0.> 
)..linimaJ luminal diameler (mm) 
ilef<!!e 1.0&±0.31 LOnO.J3 NS 
After 2.05±0.JJ 2AS:t0.39 <0.001 
f<!llow·ur 1.73.!.0.55 L82±O.6--t 0.09-J:-
Stenoli, ('t) 
Before 6--t.t to 64±to NS 
After JJ:t& 22±& <0.001 
Follrl\\"Up 43±16 3&±18 0.003 
Re,ten",;" mIt' (,X) 
-'2 22 0.02 
G~in (mm) 0.97.tO.J\l HO:tOA4 <0.001 
L"I,(mm) 0.J2!.OA7 O.65±O.57 <0.001 
N~t gain (mm) OAhO.59 O.75±0.66 U.09 
"AIl tltth" r<fm t,~ 1"< ("ta1 ,,,,,,,1 d <1<tl< 01 '''tn ",,'e,h, (i e,. if. r2t;<r,l ",~ui",J 
rep<.I,-ogi"rl"-<1)' "-oJ llli, c",,-'''''}'-M('f)' bH'''' p,flicg. tl;;, h'ta1 ,,,illll dI '~"n ""-'Olhl 
,,~uJJ ",ncd ,,-,Ih ",<~t;, ~.'I j\.<! Iho tim !l-.0.1 o,;;umd), CI Jc~ol<> wr:JiJen,·~ low»). MT 
1D)"",rduJ lcl"'I;"~. ,,\tlG «'n_ruIy_ark') b)p,-,-' ;:r.lfl. ['leA p<rc"-n", .. ,~, l"'-"!um;rill 
''''W"-'')' ~rli"rb.'l}, "",J:-'S 0,·1 'i~'''''l 
tRd<n:n,~ ,.Ju« " • .t,e i:''''T'-,I:>!<d d,,,-,,,,,:;',, ,)lc.,'lIIOll I(,,,,h, g..:n. Ih~ tr.lr.:n,1 b-
rrLr.:!l J,=<l<r ,f(<r Iho I"'><,J"", mb::", lk ,.!lee ,>bi.1ir-ci kIn" Iho rr;x,J'-'T<.10". ~ 
minirnallum;,.>J iliiT"'~I ..!l<r lk p",'cJete ",'r.", the fnl!.,,,."I' ,i[uo; ""J ,,-,I!"-'n. the 
n'TIirrc1l k"'-"'-'.l ili=<1<r;,t f"iI(,-.'-up In'ru<!!-< nbe IIbl.i.';,(d tdo", lh~ r<,><.d",~ 
:f:p = 0 I)~;rr,d P ~ 0 03 f,,, .t,~ d.ff",o,~ in Inlr.irni! lu:c:irul .iumd" t-<I~«'n I"~ (';\o 
,tuJ) Pl-'cp;'1 f~U"""-<Ir "~<n th~ r"''''--'-<IHoliC'~ lUIIl<n,,;J .. ,,,,I ,i7<, "'l".;ti"I). ",r< 
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Figure 1. Cumulative Frequency Distribution Curves for the Two Study Groups, Showing Minimal LumInal Diameters Measured before 
and after Intervention and al Follow-up, the Percentage of Stenosis al Follow-up, and the Percentage 01 Patients 
with Clinical End Points. 
Significant differences were apparenllhal consIstently favored the stent group over the angiopiasly group with respect to the Increased 
minimal luminal diameter at intervention (Panel A) and fottow·up (Panel B), the percentage of stenosis at follow-up (panel C), and the 
incidence of major clinical events (Panel 0). The vertical dashed line in Panel D indicates the end of the study. 
angioplasty group and two in the stenl group. One 
patient trealed with balloon angioplasty committed 
suicide four months after the intervention. T,vo other 
patients dicd two and three weeks after successful 
stellt implantations. In the first uf these patients, 
drath was preceded by chest pain associated with ST-
segment elevation and was therefore thought to he 
rdated to a subacute occlusion. In the second patient, 
the cause of death was hypovolemic shock during sur-
gical repair of an arteriovenous fistula. Although the 
stent was patent at the time of the pathological exami-
nation, the death was consider('d to be related 10 the 
stenl. 
Angiographfc Analysis 
AngiogJ'aphic ll.lllow-up data were ohtained for 93 
percent of the eligible patients (Table 3). The mini-
Illal luminal diameter at follow-up was greater afirr 
stent implantation than after balloon angioplasty 
(1.82±O.64 vs. 1.73±0.S5 mm, P = 0.09; median dif-
ference, 0.17 mm). The cumulative distribution of the 
minimal luminal diameter and percentage of stenosis 
arc shown in Figure lA, n, and C. The incidence of 
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restenosis (the criterion for which was ;::0..10 percent 
stenosis) was 22 percent after stent implantation as 
compared with 32 percmt after balloon angioplasty 
(P ~ 0.02). 
DISCUSSION 
\Ve found that implantation of coronar)' stents in 
patients with stable angina and a singlc new coronary-
artery lesion was associated with a rate of immediate 
clinical success similar to that of standard balloon 
angioplast}', but a significantly lower mtl' of resteno-
sis. This translated iuto it superior long-term clinical 
outcome, mainly due to a reduced need for additional 
percutaneous interwntion, at least according to the 
compositr analysis of clinical end points. The advan-
tage of this combincd clinical end point is that it leads 
to a simple estimate of the eflect of treatment. How-
ever, this analysis ignorf's the relative eflect of various 
eveuts (i.e., it considers death, it cerrbrovascuiar acd-
dent, myocardial infarction, and the like to be equally 
harmful to the patient) and docs not reflect the multi-
plicity of {'vents that may OLcur (e.g., in a patient 
undergoing second angioplasty and surgery and ulti-
1 ~ I t TIIf: :-':f,W EX{;LAXD.J0URXAL OF )'[ElJICIN"I: Aug. :13, 1~I~n 
Table 4. Functional Class at Seven Months 01 Fol-
low-up or at the TIme olthe Intercurrent Intervenlion 
for the 516 Patients Included in the Inlention-to-
Treat Analysis." 
,J,'fr""'·JI 
II (A,}mrt",ruticl 170 ((\(\) J'tO i7J) 
1-4 S.I (.11) ('7 (2(,1 
1 W(41 12 (5) 
2 Jl (12) 2~ 0 I) 
J 2l((l1) 15 (6) 
4 lJ (51 12 (5) 
lIn.l.n,)\\n 4 (21 2 (O,X) 
'r ~ 0 tI7 (,., tJ:,< c,,, r}Ji"" "I f,",ti ,""I d""" .""'rJlo~ I" ,,<>I. 
n",l1 gr,,"p lac.i,'pi"\)" 'ti;011 
In, .b;<> ,h.,," or. 'h"~ «'2~i,,~ •• l~; I~' Ca"l.l'l~ ""J ",~,,-"1l' 
lOf $e><i<\)' 
matd}' dying). To address this short{"Oming, a munt 
of all e\'ents is included in Table 3. 
One of the major drawbacks of studies on the pre-
vention or coronary restellosis is that at follow-up the 
angiographie knowledge of coronary anatomy may ill-
fluence the physician's therapeutic decision and artifi-
dally illLrease the number or second interveutions. 
This is especially true when the investigator is not kept 
unaware of the treatment assignments, as when a new 
devin' is tested. To circumvent this possible sourct' or 
bias, a second inten'ention was considered an end 
point in this study only when it was substantiatcd on 
the basis or anginal symptoms 01" objective evidence or 
ischemia (Table 5). Only two second interventions in 
the angioplasty group and one in the stellt grollp 
Illight not have been justified. I\ioreover, the J:1ct that 
the cumulative CUf\'es for the composite clinical end 
points (Fig. ID) diverged lwtw{'{'n day 75 and day l.'lO 
indicates that the dillerence in clinical outcome was 
not artifirially driv(,n hy the angiographic findings at 
th{' time of the second catheterization. 
Not unexpectedly, the incidence of m,yor bleeding 
romplkations was significantly higher in the stenl 
p;roup (13,5 percent) than in the angioplasty group 
(3.1 percent). The overall inddel1ce reported in the 
literature, expressed as a weighted average or groin 
Table 5. Presence 01 Clinical Symptoms, ischemic 
Signs, and Degree of Stenosis in Patients Who Un-
derwent a Second Intervention al Follow-up. 
'\"""I'l "" S""I 
V~'''"lf' (N ~ 157) (N ~ 159) 
NCl, "r p.11icnl' 59 J-It 
1'1", I,ilh .1Ilgill~ 5-1 31 
No, \\ilh [TO ch~n~e< al relt<:'r 14 8 
,lUling e,erd'e 
No. \\il0 neither angin3 n(lf 
fTG change_ 
:-:" "itil ErrJXrf('~,l 24 (4 
r~ro;ent 'ten",i, - mean ±SlJ 5'J±I-l M±2!* 
'l(U ,l.r"I" .I'''''';;'f~'''~f'rr,i'. ar·d FIT .""i«-{,'I."r',~ !~'1 
In" 1,\ltil< ri,\ l< "'~'~,lIeJ >lith t~< '",?"'ri"I)' ~"op "" I) 57 (95 
f""~('1 "·r,~,k,,,< i01o'HI. \l .19 I~ 0 &-I: P ~ (1 ( .. )~) 
If' ~ 006 f,·, \]",< ,o,np,1fil"n ~f ~,,"p;~) ""pJireJ SluJ.n.I', H<;! 
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hematomas and pst'udOalh:·UI YSIllS, was 7.5 percent 
(range, '2.7 to '2G percent) and '1.'2 peH"Cnt (range, () to 
\0.8 percent), respel'lively.11 
Another significant diHerence between the two 
treatment groups was in the duration of hospitaliza-
tion. However, Cohen et a!. recently showed that 
It'ngth of stay, consumption or resources, and total 
costs were still snbstantially greater 1'01' bypass surgery 
than for stenting and that the initially higher in-hospi-
tal costs of stent implantation as compared with bal-
loon angioplasty art' compensatt'd for by the reduction 
in subsequent interventions during follow'Up.lfI,19 The 
practitioner and the patient must, however, weigh a 
long hospital stay and it 13.5 percent risk or bleeding 
and vascular complications against the potential h{'ne-
fit or a reduction in the likelihood or clinical events 
rrom 30 percent to 20 percent. 
It may be argued that the difference in drug thcrapy 
between the two study groups accounts for the ob-
served differences in angiographic outcome and rate 
of restenosis, However, a number of clinical studies 
collectively rule Ollt any beneficial effect of anticoagu-
lant thcrap), on restenosis in humans,1'1-2'; 110reover, 
the degree of angiographically documented luminal 
loss was signifit'antly higher after stent implantation 
than ana halloon angioplasty (Table 3). Therefore, 
the benefidal angiographie and clinical effects or stent 
implantation are cxplained by the propensity of the 
slent to achieve a consistently greater increase in lu~ 
minal diameter immediately after the procedure than 
is the {'ase with balloon angioplasty, which is inherent-
ly limited by the well·described phenomenon or elastic 
recoil.3:1'; 
r t should be emphasized that in interpreting the 
favorahle results observed in this trial, the restrictive 
nature or the criteria ulr inclusion and exclusion must 
be kepI in mind, and thus the results may not be gen-
eralizahle to other patients, indications, and types of 
stents. Finally, hleeding and vascular complications 
and the prolonged hospitalization remain major draw-
hacks of stent implantation and continue to hamper 
its acceptance in clinical practice. 
ApPENDIX 
The fotto\\ing insliOHinn~ and inl·,'stig.liots participated ifl the 
lklltstent study. The numhn of p,\tirnh l'nroJlr<i at <'.lcli cellta is 
KiVell in p3remheses. 
Uni\'('r"il~' Hospital San Carlos, ;\Iadrid, Spain (76): F. Alf,m'lo, 
j. GniU,!t·.l, R. Huuandez, aud A Iniguez; University lIospila] 
Rotterd.lm Djjk~igt, 1110fax Center, Rotterdam, the Netherlands 
(57): l'.j. de Feytn and :.of. v..tn dw Br..tml; OUle Liel'e "rouwe 
G.lSlhuis, Amsterd.lm, Ih~ Ne\hnl,llllls (50): GJ. Laanllall and 
H. v.lndcr \\'ieken; Universit.ltsklinikllm Rudolf "irdH)w, Cilarlnt· 
t~nIHtrg, Brrlin, Germany (:i!J): W. Rutsrh; Gme Lie\'e "mu\\,,' 
Ziek~nhui" Aalst, Helgium (33): ll. de Bruyne; Sahlgremka Hospi-
tal, Gotenorg, Swrdfll (3fi): P. A!I'rIts;on; Cliniqne P,\steuf, Tou-
louse, france (32): J. raj,ldrt, S. Doucf\, and 0, Har; Salt-Tilman 
Cl'lltli." Hospitalier Univ{'fsitair<" Liege, Rdgiutn (32): V. Legrand; 
1MI'il.ll til' !a Citadelte, Liege, lltl!,'ium (19): j. Roland; Tn'itituto 
C;nlii.,v.ls(ul.lC de Huenos Aires, Buenos Aires, Argentin,\ (19): 
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CHAPTER 3.1 
TWO 1l'IAJOR CLINICAL PROBLEMS 
SUBACUTE STENT THROMBOSIS AND 1ll./i/iDTNG COMPLlCAI1ONS 
MULTIVARIATE ANALYSIS FOR PREDICTORS FOR SUBACUTE STENT THROMBO-
SIS AND BLEEDING COMPLICATIONS IN THE BENESTENT-I STUDY 
F. Kielllelle(i, A..I. Azm; M.iI. Morel, P.11( Ser/'llys, all heha(f 
of the Rencsten! - Study Group 
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IVlultival'iate analysis fur predictol's for subacute stent thrombosis and bleeding compli-
cations in the BENESTENT-I stndy. 
Ferdinand Kielllen~~, MD"', Aida J. Azar, MPH, PhD""', Marie-angele Morel, B.Se "', Patrick 
~erruys, MD, PhD , on behalf of the BENESTENT-Study Group 
,', Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands 
,~:" University Hospital Rotterdam Dijkzigt, Thorax Center, Rotterdam, the Netherlands 
ABSTRACT 
Backgrounds. In the BENESTENT-I study, a Palmaz Schatz stent was implanted in 227 
patients with stable angina and a de novo lesion in a native coronary artery and results were 
compared with balloon angioplasty in a randomized fashioll. To determine the risk for stent 
thrombosis and bleeding complications, a lllultivariate analysis was performed on the stentcd 
population lIsing the per-protocol analysis. 
IHethods. A lllultivariate regression analysis was performed controlling for age, gender, dia-
betes, smoker, hypertension, angina, prior myocardial infarction, left anterior descending arte-
ry disease, minimal lumen diameter and reference diameter (pre- and post procedure), lesion 
length, balloon diameter, inOation pressure, a post procedurnl dissection and a post procedural 
bleeding complication. 
Results. Subacute thrombosis was encoulltered ill 8 patients (3.5%). Vascular surgery and/or 
blood transfusion was required in 31 patients (13.7%). 1\1ultivariate analysis revealed that 
female patients had a 3 times higher risk of vascular bleeding complications than males (95% 
confidence interval: 1,2-7.7). Controlling for the same variables, a patient's probability of 
experiencing stent thrombosis was lowered when the patient had a large reference diameter 
pre-procedure, the prohability is increased when the patient had a prior myocardial infarction 
and if the patient had a postprocedural bleeding complication. 
Conclusion. Subacute stent thrombosis and bleeding complications form the achillesheel of 
implantation of metallic coronary stents. The chance for stent thrombosis lowers at large ves-
sel diameters and absence of a previolls myocardial infarction and of postprocedural bleeding 
complications. Female patients are more prone to bleeding complications than male patients. 
INTRODUCTION 
The purpose of the multicenter randomized BENES TENT 1- trial, was to compare safety and 
efficacy of coronary balloon angioplasty and Palmaz Schatz coronary stel1ling in patients with 
stable angina pectoris and a lesion in a native coronary artery (I). Although overall results in 
terms of restenosis and uneventful follow-up were more favourable in the stented patients, 
thrombotic stent occlusion (3.5%) and nwjor bleeding complications under intense anticoagu-
lation (13.7%) still remain the achillesheel orthis promising new technique (I). In the 
STRESS- trial, also exploring the differences of outcome of Palmaz Schatz stent implantation 
and balloon angioplasty, stent thrombosis was encountered in 3.4% and bleeding complica-
tions in 7.3% (2). Since no multivariate analysis on these stellt related complications has been 
carried out so far, a multivariate analysis was performed on the patient popUlation in the 
BENESTENT-I study undergoing a stent implantation. This was done in order to evaluate fac-
tors possibly associated with these two complications, 
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METHODS 
Patient population 
Subjects who took part in the BENESTENT-I trial, and who were randomized to stellt implan-
talion, comprised the study group. The study design has been described in detail elsewhere 
(1). In short, BENESTENT-I was a llluiticenter, prospective. randomized, controlled trial, 
which compared stellt placement to balloon angiopiasty 011 immediate angiographic results, 
incidence of re-stenosis and long-term clinical outcome. After randomization, angioplasty was 
performed according to the routine of the participating physician. Palmuz Schatz stellt implan-
tation was performed with either the SteIll Delivery System (3) or with bare stents, after pre-
dilatation of the stenosis, in patients with stable angina pectoris and a single de novo lesion in 
a native coronary artery. If necessary, implantation was followed by secondary stent dilata-
tions in order to improve stellt deployment and angiographical results. All patients received 
the "classical" regimen: heparin, dextran, 250-500 mg daily acetylsalicylic acid, dipyridamole 
75 mg tid and anticoagulants. Between June 1991 and rvlarch 1993, 259 patients were rando-
mized to stelll implantation and 257 to balloon angioplasty. 
Coronal'Y angiography 
Patients were seen at the outpatient clinic at 1,3 and 6 months for an interview, physical exa-
mination and electrocardiography. Qualitative and quantitative coronary analysis was perfor-
med on pre- and post-procedural angiograms, and those obtained at 6 months, by the automa-
ted Cardiovascular Angiography Analysis System (4) under standardized circumstances. If a 
revascularization procedure involving the treated segment had been performed before the 6 
month repeat angiography, the last angiogram obtained before this intervention, if available, 
was used as the follow-up angiogram, irrespective of the timing of repeat intervention (hours, 
days, weeks). If the time to follow-up angiography was less than 3 months and no repeat 
intervention was peit'ormed, the patient was asked to undergo another angiography at 6 
months. In the absence of a 6 month repeat angiogram, the last angiogram obtained within the 
previous 3 months, if available, was used provided that 110 end point had occurred. 
Definition of clinical events 
1. Bleeding complications 
All patients were considered to have a major bleeding complication in the event of 
blood transfusion and/or vascular surgery. 
2. Thrombotic stent occlusion 
\Vas defined to occur when a patient experienced a stent thrombosis within the 
hospital stny. 
3. Angiographic endpoints 
The allgiographic end point included 1) the minimal lumen diameter at follow-up as 
determined by quantitative angiography. For each dilated or stented segment, the mini-
mal lumen diameter was calculated from the mean values of mUltiple projections which 
had been identically matched pre and post intervention and at follow-up; 2) percent dia-
meter stenosis (after device) is the ratio of the minimal lumen diameter and reference 
diameter. 
Statistical analysis 
Patients in the trial randomized to balloon angioplasty \vere not included in this analysis for 
obvious reasons: patients randomized to the stellt group received anticoagulants and therefore 
were more prone to bleeding complications than the balloon angioplasty group who received 
no anticoagulants. 
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Analysis included patients who actually received a stent implantation, i.e. llsing the "per pro-
tocol" analysis. Continuolls variables were expressed as means and standard deviations. 
Discrete variables were expressed as counts and percentages. 
IHultivHl'iute analysis 
A multivariate logistic regression analysis was used to estimate the relative risks (RR) and 
95% confidence intervals (CI). The incidence rates obtained from the model maybe viewed as 
relative risks, i.e., the risk of event relative to the reference risk factor category controlling for 
the other risk factors. The precision of the relative risks were described by means of 95% con-
fidence intervals. 
RESULTS 
Study population 
From the 259 patients who were randomized to stent implantation, 14 patients did not receive 
a stent for several reasons (withdrawal of consent, physician's preference, evidence of throm-
bus or inabilaty to cross the lesion with a stent). In another 10 patients, stent implantation fail-
ecL Eight patients refused a 6-l11onths angiographic follow-up. In total 227 patients \vere sten-
ted according to the allocation. 
The baseline clinical characterisitics are given in Table 1, and the angiographical characteris-
tics are submitted in Table 2. 
Table 1. Baseline characteristics of 227 patients randomized to stellt implantation 
n % 
Age (years ± sdt 57± 9 
!vInie gender 189 83 
Current smoker 54 24 
Diabetes Mellitus 15 7 
Hypertension 70 31 
Hypercholesterolemia 80 36 
Prior myocardial infarction 43 19 
Prior CABG () () 
Prior PTCA 4 2 
Prior stroke 6 3 
History of peripheral vascular disease 8 4 
Exterional angina 
CCS I 7 4 
CCS II 66 33 
CCS III 112 56 
CCSIV 16 8 
Non exertional angina 994 
,~ ",leans and standard deviations are indkated 
CABG, Coronary Artery Bypas<; Graft; CCS, Canadian Cardiovascular Society angina classification; PTCA, 
Percutaneous Transluminal Corunary Angiography 
Clinical endpoints 
Table 3 shows the primary clinical end-points. Bleeding complications requiring blood trans-
fusions or vascular surgery were encountered in 31 patients (13.7%). Suba<.::utc stent thrombo-
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sis was angiographically demonstrated in 8 patients (3.5%). 
Results of multivariate analysis of predictors for bleeding complications is represented in 
Table 4. Controlling for all other extraneous variables, female patients had at least a 3 times 
higher risk of bleeding complications than male. The large conlldence interval (1.2-7.7) is 
explained by the small number of events involved in the analysis. 
In Table 5 the prediction of stent thrombosis is given. Controlling for all other extraneous 
variables, patients who had a post procedural bleeding complication were at 28 times higher 
risk for developing of stenl thrombosis. Patients with a prior myocardial infarction have more 
than 250 times a higher risk of stent thrombosis than patients with no history of myocardial 
infarction. However, although the risk is statistically significant, the large confidence interval 
(4.4;> 1000) indicates the small number of patients with subacute stellt thrombosis. 
Furthermore, the data indicate for every unit decrease in reference diameter pre prm.:cdure, the 
risk for stent thrombosis increases by 8.8* 10-7 i.e., the larger the pre-procedural reference 
diameter, the smaller is the probability for a stent thrombosis. 
Table 2. Angiographic and procedural characteristics of 227 stented patients 
LAD 
Lesion length 
TIMI flow 
() or I 
2or3 
Dissection 
No 
TypeAor B 
Type C or D or E or F 
Nominal stellt and balloon size (nUll ± sd) 
Balloonlstent artery ratio (± sd) 
Maximal pressure (atm ± sd) 
Total inflation (secs ± sci) 
Reference vessel diameter (mm ± sd) 
Pre-procedure 
After device 
Angiographic follow-up 
MLD (mm ± sd) 
Pre-procedure 
After device 
Angiographic follow-up 
DS (% ± sd) 
Pre-procedure 
After device 
Angiographic follow-up 
u % 
148 65 
7.0± 2.0 
7 3 
220 97 
195 86 
29 13 
3 1 
3.41± 0.40 
1.12± 0.15 
1O.1±7.8 
163± 144 
3.00± 0.44 
3.17± 0.42 
2.97± 0.48 
1.07± 0.33 
2.51± 0.36 
1.85± 0.64 
64± 10 
21±7 
38± 18 
DS, diameter ~Ienosis; LAD, left anterior descending coronary artery; LeX, left circumflex coronary artery; j\lLD, 
'" ** minimal luminal diameter; RCA, right coronary arlery; see reference 5; see reference 6 
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Table 3. Bleeding complications and thrombotic stent occlusion 
Bleeding Complications 
Vascular surgery 
Pseudoaneurysm 
Arteriovenous t1stula 
Major haematoma 
Gastro-intestinal bleeding 
Blood transfusion 
Pseudoaneurysm 
Arteriovenous fistula 
IvIajor haematoma 
Gastro-intestinal bleeding 
Thrombotic stent occlusion 
11 
31 
14 
I 
7 
o 
I 
I 
6 
I 
8 
Table 4. Prediction of bleeding complications 
Intercept 
Female 
Coefficient SEcoff. 
-2.1 
1.I 0.5 
% 
13.7 
3.5 
Ratc Ratio 95%, C.l. 
3.1 1.2-7.7 
SE, standard errur; cuff, coefficient; c.r., confidence interval; fin, myocardial infan.:tion; ref, reference. 
Table 5, Prediction of stenl thrombosis 
Intercept 
Bleeding complications 
Prior MI 
Ref. diameter (pre) 
Coefficient 
13.70 
3.33 
5.58 
-7.77 
SEcoff. 
1.35 
2.09 
3.15 
Rate Ratio 
28 
265 
4.2 x 10-4 
95%, c.1. 
2.0;394 
4.4;>1000 
8.8 x 10-7;0.20 
SR, :-,tamlard error; coff, l'Ocftldenl; C.I., confidence inlcrvu; ;"11, myocan.lial infarction; ref, reference. 
DISCUSSION 
Implantation of coronary stents for coronary artery disease aims at improvement and optimali-
zation of coronary geometry in order to reduce the incidence of restenosis of de novo lesions 
in native coronary arteries (1,2), in vcnous bypass grafts (7), refractory restenosis (8), and to 
treat dissections and sUboptimal results after balloon angioplasty (9, 10,11). 
The problems encountered after implantation of metallic stents are two-fold; risk for stellt 
thrombosis requiring aggressive anticoagulation and the associated risk for access site related 
bleeding complications, 
Only 0,6% of anticoagulated patients suffered from subacute stent- occlusion in the multicen-
ter study in elective cases reported by Schatz et al. (12), The highest subacute stellt occlusion 
rates are reported in early literature after stenting for suboptimal angio-plasty, as reported by 
Schatz et a!. (5.3%) 1131, Kimura et a!. (9.3%( [14], Haude et a!. (12%) [II], Kiemeneij et a!. 
(23%) [71 and by Fajadet et a!. (29.4%0 [15]. 
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The occlusion rates in the electively stented patient groups according to the BENESTENT-I 
(3.5%)[ I 1 and STRESS trials (3.4%)[2], takes an intermediate position between these two 
extremes, probably because during the course of this study, achievement of an optimal post 
procedural result was recognized to be associated with less thrombotic occlusions, 
Except [or bailout situations, in recent literature the following risk factors for stent thrombosis 
were recognized, Fischman et al. reported on angiographic predictors of subacute stent throm-
bosis in a group of 726 patients with a Palmaz Schatz coronary stent (16), lntraprocedural 
thrombus and persistent dissection as well as suboptimal results after PTCA were associated 
\vith an increased risk [or subacute thrombosis, Since presence of intracoronary thrombus was 
considered to be a contraindication for participation in the BENESTENT trial, this risk factor 
could not be studied in our trial. 
We found that small pre-procedural reference diameters « 3.0 mm) are associated with incre-
ased risk for stent thrombosis, Optimal stent expansion, under intravascular ultrasonic guidan-
ce, may further decrease the risk for stellt thrombosis (17). 
Erbel et al. (18) considered suboptimal monitoring of anticoagulation as a risk for stent 
thrombosis, By introducing monotoring of prothrombin factors FI +2, the incidence of stent 
thrombosis reduced in their experience. In the multivariate analysis of the BENESTENT 
study, the intensity of anticoagulation as risk factor for the thrombotic occlusions and blee-
ding complications could not be assessed, since there was a considerable difference in the 
laboratory tests lIsed to monitor treatment among institutions. Consequently, the thromboplas-
tin w..;ed to measure the prothrombin time were prepared by different methods and therefore 
their effect on the reduction of the vitamin K clotting factors varied significantly. In order to 
circlllllvent the problem of variability in the sensitivity of thromboplastin, the International 
Nomalized Ratio (lNR) should be introduced in subsequent trials (19). 
An infarcted area supplied by the target vessel formed a contraindication to participate in this 
study. However, the presence of a previolls myocardial infarction (19%) in other regions was 
associated with a higher risk for stent occlusion. Mechanisms such as deminished coronary 
perfusion caused by poor left ventricular function, irrespective the localization of the infarcted 
region, may have played a role. It should be emphasized however, that only 8 patient had sub-
acute stent thrombosis and that therefore the 95% confidence intervals are very wide. 
Of the 8 patients with stent thrombosis, 3 had a bleeding complication, before the stellt occlu-
ded. Since a bleeding complication forces the clinician towards less aggressive anticoagula-
tion or even to a strategy to reverse anticoagulation, a bleeding may be considered as a risk 
factor for stent occlusion. 
The incidence of puncture site related complications, has been reported to vary between 7.9% 
of 226 patients in the initial multicenter experience with the Palmaz Schatz stent (12) and 
16% of 220 patients in large single center experience (20). In the study of Piana et aI., repor-
ling on Palmaz Schatz stenting in vein grafts, vascular repair was necessmy in 8.5% ancl 
transfusions in an additional 14% (7). Bleeding complications requiring vaseular surgery or 
transfusions was reported in 13.5% of patients after stellt implantation in the BENESTENT 
study (I) and in 8.8% in the STRESS- study (2). 
Especially females were at risk for entry site related complications. Despite introduetion of 
new hemostasis techniques (21,22,23,24), the oceurence of vascular complications after coro-
nary stenting remains one of the major hazards of this technique. However, groin problems 
can be circumvented by performing stent implantation via the radial artery, as demonstrated 
by Kiemeneij et aL. (25,26). In a series of 100 patients, who had a transradial stellt procedure 
attempted, one patient developed a major radial artery related bleeding complication, requi-
ring vascular surgery. Another method to reduce the risk for bleeding complications is the 
simplification of the anticoagulation regimen after an optimal stellt implantation result (17), 
by eombining subcutaneous heparin with oral administration of ticlopidin and acetosalicylic 
acid (27,28). Although promising results have been reported, this approach requires careful 
patient selection, since suboptimal stellt results, not always appreciated with angiography, 
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may further increase the risk for stellt thrombosis if no adequate anticoagulation is administe-
red. Finally, the implantation of heparin coated stents, by reducing the thrombogenicity of the 
device, has the potential for a save reduction in systemic anticoagulation, without posing the 
patient at risk for stent thrombosis (29). 
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lHode of deployment of coronary Palmaz Schatz stents aftel' implantation with the Stent 
Delivery System! An intravascular ultrasound study. 
Ferdinand Kiemeneij, .MD, GertJan Laannan, MO, PhD, TOll Siagboom, IvID, 
ADIC - OLVG, Amsterdam, the Nederlands 
ABSTRACT 
Rationale: The Stent Delivery System (SDS) is a sheath covered, Palmaz Schatz stent, moun-
ted on a 3.0, 3.5 or 4.0 111m compliant polyethylene balloon catheter, resisting maximal infla-
tion pressures of 5.7,6.2 and 6.0 atmospheres respectively. It is postulated that these pres-
sures are too low to obtain optimal stent deployment. Since optimal stellt deployment is a pre-
requisite for optimal short- and longterm outcome, we performed an intravascular ultrasound 
study to the mode of stent deployment after delivery with the SDS and after high pressure 
dilatations with low compliant, oversized balloon catheters. 
IHethods! In 23 patients an intravascular ultrasound study (30 MHz, 4.3 French transducer) 
was performed to the geometry of 29 stents immediately after delivery with the SDS and after 
sllccessive high pressure intlations with low compliant balloons. 
Results: After delivery with the SDS (3.3 ± 0.4 mm), stent diameter was 3.0 ± 0.4 mIll. After 
high pressure dilatations (12.4 ± 1.4 atm), with low compliant balloons (3.9 ± 0.5 mm), stent 
diameter inereased to 3.4 ± 0.4 mm) (1'<0.001 J. 
Only 8 stents (28%) were completely and symmetrically expanded to the corresponding rete-
rence diameter, with good apposition, after delivery with the SDS. 
Diameter of incomplete deployed stents (n=16) was 2.8 ± 0.3 mm. After high pressure dilata-
tions with low compliant balloons (3.9 ± 0.5 111111), diameter increased to 3.4 ± 0.4 mm 
(1'<0.00 I). Now 20 stents (69%) (p=0.004} became completely and synllnetrieally expanded 
to a diameter corresponding to the reference diameter. 
Conclusion: Most stents are suboptimally deployed after delivery with the stent delivery sys-
tem. Stent expansion and geometry can be improved by dilatations with low compliant, high 
pressure, oversized balloons. 
INTRODUCTION 
In order to increase safety of Palmuz Schatz stent implantation, by reducing the risk for stent 
loss and stent embolization during attempts to reach and to cross the target lesion, a stellt deli-
very system (SDS) has been developed (Johnson & Johnson Interventional Systems Co, 
Warren, New Jersy). This system is a preassembled unit, containing a 5F sheath covered, 15 
mill Palmaz Schatz stellt, mounted on a polyethylene, compliant balloon catheter. The SOS 
comes in 3 balloon sizes; 3.0, 3.5 and 4.0 llllll, all 20 mIll in length. Recommended maximal 
inflation pressures are 5.7, 6.2 and 6.0 atmospheres, respectively. \Ve postulated that these 
pressures with compliant balloons are too low to obtain optimal stent deployment and geo-
metry. despite satisfactory angiographicaJ results. An example is given in Figure 1. 
Angiographical appearance improved markedly after stenting with the SDS, for this venous 
bypass graft stenosis. During intravascular ultrasound, however, the stent appeared to be oval 
shaped and incompletely deployed. After inflations with a low compliant, high pressure bal-
loon, stent geometry clearly improved ultrasonically, but angiography showed only a subtle 
change. The Palmaz Schatz stem has a poor radioopacity, so detailed information on the 
quality of stent deployment cannot be obtained by fluoroscopy and conventional angiography. 
Since intravascular ultrasound may provide complementary information to angiography, 
several techniques became guided by intravascular ultrasound; balloon angioplasty 0,2,3), 
directional (4,5,6) and rotational atherectomy (7) and coronary stellt implantation 
(8,9,10,11,12). Since optimal short- and longterm results of coronary stenting may be depen-
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Figure! il. Severe venous hypass graft ~tenosis 
Figure lb. Angiogrnphically markedly improved after ~tellt implantation by the SDS 
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Figure le. Oval shaped, incompletely deployed S!CIl!, with poor contact against the Vl'ssel waU C3.7x2.7 lllm) 
Figure Iti. Circular shaped sten! after high pressurc dilatation; sllU poor vessel wall contact at stent diameter of 4.4 
mill (no larger b.liloon available) 
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Figure Ie. Slight impruvement ;lIlgiographkally 
dent on optimal stent delivery and thus maximal acute gain in vessel lumen (7), we performed 
an intravascular ullrasound study to monitor stent deployment and geometry, nfter delivery 
with the SDS and after high pressure dilatations with low compliant balloon catheters. 
Mln'HODS 
Stud)' population 
This study was performed between september 1991 and november 1992. In 27 patients 
<L<;se.<;sment of stent diameters, by intravascular ultrasound, after delivery by the sheath protec-
ted system and after post stent dilatations was attempted. In 3 patients the ultrasound transdu-
cer could not cross the stent. From one patient (l stent), ultrasound data were not available for 
analysis due to technical problems with the imaging device as was the case in another patient, 
where data were lost from one of the 2 implanted stents. Thus from 23 patients, 29 stents 
were analysed. Intravascular ultrasound studies were performed after stellt implantation in 
venolls coronary bypass grafts (n:::9, 39%), the lett anterior descending coronary m1ery (n=6, 
26(l/c,), the left circumflex coronary artery (n:::6, 26%) and in the right coronary artery (n:::2, 
9%). Baseline characteristics are given in Table I. 
Angiograph,Y and percutaneous tl'anshlluinal coronary angioplasty 
The x-ray imaging equipment used at our catheterization laboratory is the Philips Poly 
Diagnost C2, powered by an Optimus M200 generator and equipped with a Digital Cardiac 
Imaging system (DCI). PTCA and stent implantation were performed in patients receiving 
acetylsalicylic acid 300 mg daily, nifedipine 30 lllg daily, Dextran 50 mUllr iv to a total of I 
liter. After introducing the arterial sheath 10.000 IU heparin was administered intraarterially, 
followed by 5.000 IU each hour during the procedure. Intracoronary nitroglycerin 100 micro-
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gram was given before the first coronary contrast injection and repeated aner stent implanta-
tion and before ultrasound analysis. 
PTCA was performed in all patients by means of the femoral approach. Super flow guiding 
catheters with an internal diameter of at least 0.079 inch, were used, in combination with a 
monorail dilatation system and a 0.014 inch guidewire. 
Stent-implantation 
Stellt implantation in elective cases was preceded by dilatation with an undersized halloon. 
The stent-loaded ballool1catheter was advanced over the guide\vire to the obstructing lesion. 
After careful positioning the protective sheath was withdrawn, followed by stent delivery with 
the recommended inflation pressures and control angiography. Compared to the coronary arte-
ry diameter, the stent was slightly oversized by high pressure dilatations with larger low com-
pliant balloons to compensate for some decrease of the stent-dimneter after delivel),. 
Intravascular ultrasound 
A 30-wIHz ultrasound transducer, housed in the tip of a 4.3F, 135 cm long rapi(? exchange 
catheter was llsed (Cardiovascular Imaging Systems). An angulated mirror (45 ) in the ultra-
sound transducer was connected to a motor-driven unit, rotating at I.SOO rpm. 
The reflected ultrasound beam creates a 360 degrees cross-sectional image, perpendicular to 
the vessel wall at a rate of 30 frames per second. No ultrasound studies were performed befo-
re the initial dilatation, because of expected catheter occlusion of the lumen. Ultrasonic stu-
dies were repeated after the last dilatation following stent implantation. The transducer was 
positioned under fluoroscopy during injections of contrast medium. Ultrasound gain and com-
pression settings were adjusted for optimal visualization of the stent filament reflections in 
relation to the arterial wall-lumen interface. Images were selected in end-diastole, with opti-
mal coaxial alignment of the ultrasound catheter, to prevent misinterpretation of stentgco-
metry. The calipers were diametrically placed central from two opposite leading edges of the 
vessel wall or at the inner surface of the stent filaments. Luminal diameters were recorded as 
minimal and maximal values. Images were obtained from different sites of the stented seg-
ment and from the immediate area from the stent in order to select the optimal balloon size, 
derived from manufacturer provided tables, plotting balloondiameter against intlation pres-
sures, The reference diameter was defined as the largest vessel diameter adjacent to the steno-
tic coronary segment. Referem::e- and stent diameters were determined on-line because it was 
felt critical to obtain data from real-time images, during cnreful manipulation of the transdu-
cer. Consensus-reading 011 rcferellce- and stent diameters was performed by at least 2 investi-
gators. The last passage of the ultrasonic catheter was followed by angiographic control of 
the vessel, to detect possible catheter induced damage. 
Definitiolls 
The stent was considered to be symmetrically deployed at a ratio of minimal and maximal 
stent diameters;:::': 0.9. After delivery with the SDS, complete stent deployment was defined as 
a stent diameter >90% of the refercnce diameter or >90<;~) of the nominal SDS balloon diame-
ter. After post stent dilatation a completely deployed stent was defined at a stent diameter 
>90% of reference diameter or >90% of the final balloondiamcter 
The stellt was considered to be well apposed if no free space between the stentfiiaments and 
the vessel wall was detectable. 
Statistics 
Values are expressed by mean ± SO. Differences in stent diameter before and after high pres-
sure balloon inflations were calculated with the {-test. A Chi-square analysis was performed 
on differences in mode of stellt expansion before and after post- stent dilatation. A p- value < 
0.05 was considered to be statistically ."ignificant. 
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RESULTS 
In all 23 pts good quality images from the slenl could be obtained before and after post stent 
dilatations, Diameters of target segments, ballooncatheters and stcnts arc given in Tahle II. 
Table I. Baseline characteristics (N=23) 
Male 
Age 
FUllctional class 
-Stable angina 
-Unstable angina 
-Acute myocardial infarction 
lw/ieafioll for corol/my stenting 
-Venous bypass graft stenosis 
-Restcnosis 
-Bailout 
-De novo, native 
14 61% 
61 ± 9.1 years (median 62; range 44-76) 
18 78% 
4 18% 
1 4% 
9 39% 
5 22% 
7 30% 
2 9% 
Diameter llllalysis for the total study population 
Reference diameter of stented segments was 3,6 ± 0.5 111m (median 3.5; range 2.8 - 5.2), The 
diameter (manufacturer specified) of the selected stent delivery systems (balloon length: 20 
111m) was 3.3 ± 0.4 mill (median 3.5; range 3.0 - 4.0) which came close to the reference dia-
meter. After deployment with the SDS, ~tent diameter \vas 3.0 ± 0.4 mm (median 2.9; range 
2.2 - 3.9). All stent~ were ~uccessively dilated wilh 20 mm long, high pressure balloons of 
lower compliance. At inflation pressures of 12.4 ± 1.4 atmospheres (median 12; range 8 - 14), 
manufacturer specified balloon diameter was 3.9 ± .5 mm (median 3.8~ range 3.2 - 4.4). Stenl 
diameter increased to 3.4 ± 0.4 ml11 (median 3.1; range 2.9 - 4.3) [p<o.on I}. 
Diameter analysis for improper deployed stellts. 
Of 29 ~tents, 16 (55%) stent~ were smaller in diameter compared to the diameter of the stent 
delivery system (3.3 ± O.4nlln [median 3.3; range 3.0 - 4.0)). For this subgroup, stent diame-
ter increased from 2.8 ± n.3 mm (median 2.8; range 2.2 - 3.5) to 3.4 ± 0.4 mm (median 3.3; 
range 3 - 4.3) [p<O.OOl} after post stent dilatations (balloon diameter 3.9 ± n.5 mm [median 
3.8; range 3.2 - 4.4)). 
lv/ode {~lsteflt deployment. 
Six mode~ of stenl deployment were encountered immediately after deployment with the deli-
very system (Table lI). Ten stents (35%) were incompletely, but symmetrically deployed with 
poor vessel wall contact (group 1). In group 2, 2 stents (7%) had the same mode of deploy-
ment, but were well apposed. Symmetric and complete deployment wa~ seen in 13 stent~ 
(45%). Three out of 5 completely deployed stents with poor apposition (group 3) were deli-
vered with an SDS ::;90% of the reference diameter. Only 8 stents (28%) showed initial com-
plete and symmetric expansion to the corresponding reference diameter (group 4). 
Asymmetric and incomplete deployment with and without appo~ilion (groups 5 and 6) was 
encountered in 3 (10%) and 1 (3%) instances, respectively. 
High pressure dilatations were performed in the 8 well deployed stents (group 4) in order to 
obtain maximal stellt deployment. However, these stents did not change significantly in dia-
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meter (3.1 ± 0.4 and 3.2 ± 0.4 mm respectively; p=O.5). After high pressure dilatations 20 
stcnts (69%) {p=O.004} were sYlllmetrically expanded to a diameter corresponding to the 
reference diameter. However, 8 stents (28%) were still smaller than the reference diameter, 
but in 2 cases this could be contributed to an undersized ballooncatheter (diameter :5:90% of 
reference diameter). One stent (3%) remained oval shaped, 
Table II. Initial and final stent diameters (SD) in relation to reference diameter (RD), SDS-
and post-slenl balloon (PSB) diameter. 
RD SDS Initial SD PSB Final SO 
Group J (11=10). Initial symmetric, but incomplete deployment, with poor apposition 
Mean 3.6 ± 0.4 3.2 ± 0.2 2.7 ± 0.3 3.7 ± 0.5 3.2 ± 0.3 
Median 3.5 3.0 2.7 3.5 3.1 
Range 3.n - 4.5 3.0 - 3.5 2.2 - 3.1 3.3 - 4.4 3.n - 3.8 
Group 2 (11::::2). Initial symmetric, but incomplete deployment, with good apposition 
Mean 3.5 ± 0.7 3.5 ± 0.7 3.1 ± 0.6 3.8 ± 0.9 3.6 ± 0.9 
Median 3.5 3.5 3.1 3.8 3.6 
Range 3.n - 4.0 3.0 - 4.0 2.7 - 3.5 3.2 - 4.4 3.0 - 4.2 
Gmup 3 (n=5), Initial sYlllmetric, complete deployment, with poor apposithm 
Mean 3.6 ± 0.4 3.3 ± 0.3 3.2 ± 0.3 4.0 ± 0.6 3.5 ± 0.6 
Median 3.9 3.5 3.2 3.8 3.6 
Range 3.1 - 4.0 3.0 - 3.5 2.8 - 3.5 3.4 - 4.4 2.7 - 4.1 
Group 4 (11::::8). Initial symmetric, complete deploymeflf, with good apposilioll 
Mean 3.2 ± 0.4 3.3 ± 0.4 3.1 ± 0.4 3.8 ± 0.5 3.2 ± 0.4 
Median 3.0 3.3 3.n 3.8 3.1 
Range 2.R - 3.9 3.0 - 4.0 2.8 - 3.9 3.3 - 4.4 2.9 - 3.9 
Group .'5 (n::::3). initial asymmetric, ;'lcomplete deployment, wilh poor apposilivlI 
Mean 4.4 ± n.s 3.8 ± 0.3 3.2 4.2 ± 0.4 3.9 ± 0.4 
Median 4.3 4.0 3.2 4.4 3.9 
Range 3.7 - 5.2 3.5 - 4.0 3.2 3.8 - 4.4 3.6 - 4.3 
Group 6 (11::::]) lnilial asymmetric, illcomplele deploymellf, lvill! good appositioll 
3.5 3.5 2.8 4.4 3.3 
Complications 
Control angiography following the final ultrasound examination revealed no visible damage 
to vessel wall or stent and no complications stich as distal embolization or spasm could be 
contributed to the use of the ultrasound transducer. 
Fo/low-lIp 
Subacute stent thrombosis was encountered in 2 patients (9%). One patient had a residual ste-
nosis bctween two stents, placed for a dissection in the LAD after PTCA. Sten! occlusion 
occured 7 days after the procedure. The other patient had a residual ± 40% stenosis distal 
from the stent. This patient developed stellt occlusion 3 days later. Both patients had success-
ful recanalization by repeat PTCA, followed by bypass surgery. Another patient had coronary 
bypass surgery the day of successful bailout stcnt implantation following PTCA of the right 
coronary artery complicated by an obstructive dissection, This patient required aClIte thoraco-
tomy for tamponade, caused by perforation of the right ventricle by a temporary pacing elec-
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trade. In order to prevent post-operative bleeding complications, the decision was made to 
bypass the stellt in the RCA, allowing a lower level of postoperative anticoagulation. Another 
patient died 2 weeks after a bailout stent implantation following PTCA of the LAD. This pro-
cedure was complicated by a severe groin bleeding, necessitating vascular surgery. In the 
post-operative phase this patient developed fatal multi-organ failure. Angiographical folIow-
up at 6.9 ± 4.0 months (range 0.5 to 13.5; median 7.5) after stellt implantation, was obtained 
from 13 of 19 patients (68%) who had an uneventful clinical course. Stent restenosis was 
encountered in I patient (8%), followed by successful repeat PTCA. From 5 out of 6 patients 
who did not have control- angiography, one year clinical follow-up was obtained from the 
referring physicians. All these patients were alive and were free of myocardial infarction, 
coronary bypass surgery, repeat PTCA, and angina. One patient was lost from follow-up. 
DISCUSSION 
Coronary Palmaz Schatz stent implantation has been shown to reduce rcstenosis in a selectcd 
group of patients with a de novo lesion in native coronary arteries (13,14) and to improve 
suboptimal results after balloon angioplasty (15,16,17,18,19). The underlying mechanisms 
may be improved vessel geometry and elimination of intimal flaps. In order to optimize pro-
cedural success and safety of the implantation technique, by reducing the risk for stellt loss 
and embolization during attempts to reach the corollary target lesion, a stellt delivery system 
has been introduced. This system, containing a compliant polyethylene ballooncatheter, comes 
in 3 baUoon sizes; 3.0, 3.5 and 4.0 mm. The recommended maximal inflation pressures (5.7, 
6.2 and 6.0 atmospheres, respectively) are expected to he too low, to achieve optimal stent 
deployment. Since optimal stent deployment or the maginitude of acute lumen gain may lead 
to improved short- and longterm success of this technique (7) additional balloon angioplasty 
after stellt implantation \vith high pressure oversized baUoons has been advocated. Based on 
careful quantitative coronary analysis (edge detection), de Jaegere et aI (20) demonstrated 
improved stellt deployment in patients who had post stent dilatations, when compared to 
patients who did not have additional balloon angioplasty. However, optimal angiographical 
results of stent implantation have been reported, where intravascular ultrasound demonstrated 
sUboptimal results (8,9,10, 11,12). 
In the study of Laskey et ai, angiographic quantitative analysis in 12 pts undergoing stent 
implantation revealed an increase of minimal stenosis diameter of 1.8 ± 0.6 mm after balloon 
angioplasty to 2.8 ± 0.3 mIll after Palmaz Schatz stent implantation. Determined by IVUS, 
fractional plaque area remained unchanged (30 ± 12% and 32 ± 11 % respectively). The aut-
Imrs conclude that considerably less improvement was found by IVUS compared to substan-
tial improvement if the residual luminal obstruction was assessed angiographically. Improved 
acute stent implantation results after oversized balloon angioplasty was demonstrated by intra-
vascular ultrasound in several studies (10,11,12). Tn the study of Nakamura et.al. (II) the fol-
100ving criteria for optimal stellt expansion were defined: I. Full apposition of the stellt 
against the vessel wall; 2. Lumen symmetry index (minimal diameter/maximal diameter) 2. 
0.7; 3. Stented lumen cross sectional area (CSA) 2. 60% of the reference vessel CSA. \Vith 
these 3 criteria applied, optimal stent expansion was obtained in 21 % after initial delivery and 
in 73% after post stent dilatations. In our study, criteria for optimal stent deployment were 
more rigid. Only 8 stents (28%) were completely and symmetrically expanded with good 
apposition against the vessel wall, after low pressure delivery with the SDS. 
The diameter of incompletely deployed stents increased from 2.8 ± 0.3 mm to 3.4 ± 0.4 mill 
(p<O.OOI) after post stent dilatations. Complete and symmetric stent expansion, corresponding 
to the target segment reference diameter increased to 20 stents (69%) {p:::O.004 \vhen compa-
red to initial expansion}. It remains uncertain if this optimal stent deployment has contributed 
to the low incidence of restenosis in those patients who had an uncomplicated clinical course 
(one of 13 patients {8%}) with angiographical follow-up and no clinical signs for restenosis 
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at I year in 5 other patients), since the study population was too small to allow such a conchl-
sion. Several other limitations of this study should be mentioned. Although information 011 
cross-sectional area and plaque area is more relevant than information on diameters, wc did 
not perform area measurements since on-line and off-line automated digitized border tracing 
was not available. Instead, diameters were assessed on-line by electronic calipers. Also, 110 
analysis was made on plaque- morphology and composition. Differences in plaque compo-
nents may have been present in patients in which optimal and suboptimal stent deployment. 
Another limitation of this study is the comparison between actuaiultrasonically assessed ves-
sel diameters and stent diameters on the one hand and manufacturer given balloon diameters 
on the other hand. Manufacturer specified balloon diameters are determined undcr in vitro 
conditions. Under circumstances, where vessel wall and obstructing plaque, as well as the 
stent itself, may considerably influence the extent of balloon expansion under given intlation 
pressures, real balloon diameters probably are significantly different from nominal diameters. 
However, the discrepancy between ultrasonically assessed stent diameter and reference dia-
meter after SDS delivery and the suboptimal mode of stent deployment could reliably be 
demonstrated ill our study, as well as the improvement after additional balloon angioplasty. 
These findings are noteworthy for several reasons. Based on this experience, we now routine-
ly perform additional balloon angioplasty after stent implantation with the SDS, because we 
expect initial stent deployment to be suboptimal. For clinical practice, this policy can be follo-
wed, even without ultrasound control, because of the anticipated improvement in stent 
deployment and geometry. However, a third balloon is required, when the under-over princip-
le is followed: one undersized balloon for prediIatation to allow easy passage of the second, 
stent- loaded Hnd sheath protected, balloon and the third balloon to obtain an optimal tlnal 
result. By replacing the current balloon, contained in the stent delivery system, by a nOll-com-
pliant, high pressure, adequately sized balloon, procedural costs and time call be reduced. 
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F. Kiemeneij, G.J. Laarman, H. Swart, K. Roozendaal 
Presented during the Scientific Sessions of the Amerkan Heart Association 1993 
73 

Practical valuc of prothrombin fragment Fl +2 assessment after coronary stcnling. 
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ABSTRACT 
Objectives. We conducted a prospective study of the relation between prothrombin fragment 
Fl+2 and the clinical course in patients under intense anticoagulation after Palmaz Schatz 
coronary stenting, 
Backgrounds. Monitoring of prothrombin fragment FI +2 (0,55- I, I nmolll) has been recom-
mended to de ted latent coagulation states and to prevent stent thrombosis by increasing 
heparin infusion at Fl+2 values over {),8 I1m01l1. However, this strategy also also may increa-
se the risk of bleeding complications. 
IVlcthuds. To avoid the clinical course being intluenced by information of the FI +2 results, 
daily Fl +2 samples were deep frozen and analyzed after discharge, in 38 consecutive 
patients, 276 FI +2 samples (7.3 ± 2, I; range 4-lO/patient) were analyzed, 
Results. Mean Fl+2 values under 0,55 nmolll were not encountered. However, from stent 
implantation lIntil discharge patients had therapeutic anticoagulation as determined by APTT 
and TT- measurements. One or more (3.4 ± 2.5; range 1-10, median 3) FI +2-values 21. I 
nllloVI were found in 26 patient:.; (68%). One of these patients (4%), with residual dissection 
between 2 stellts, had stellt thrombosis at day 9 (Fl +2:::: 1.3 nmoJlI, APTT::::90 seconds and 
TT=23%), Patients with a bleeding (n=ll, samples=88, mean FI+2=LlO ± 0,39nmolll) had 
higher mean Fl+2- values, compared to patients without a bleeding (n::::27, samples=188, 
mean FI +2=0,86 ± 0.37 nmol/l)! p<O,OOOI}, 
Conclusiun. Since the incidence of stent thrombosis was low even at elevated FI+2- levels 
(4%), we do not recommend additional FI+2 monitoring after coronary stenting. 
INTRODUCTION 
Coronary stenting may play an important role in the prevention of restenosis after balloon 
angioplasty (PTCA) in native coronary arteries (1,2) or in venous bypass grafts (3) and in the 
treatment of suboptimal PTCA results (4,5,6). Part of the management after implantation of 
metal1ic stellts consists of the treatment with a complex anticoagulant regimen, traditiona11y a 
combination of dextran, heparin, coumadin, acetosalicylic acid and dipyridamole, in order to 
prevent stellt thrombosis (7,8). During adjustment on coumadin, patients are treated with 
heparin, titrated on Acitivated Partial Thromboplastin Times (APTT), Monitoring of pro-
thrombin fragments FI +2 (normal range 0.55-1,1 nmolll), released at the conversion of inacti-
ve prothrombin into active thrombin, has been recommended to detect impending subacute 
stellt occlusion (9). Elevated Fl+2-levels can be encountered, even in the presence of 
Activated Partial Thromboplastin Times (APTT) in a therapeutic range (10), In order to pre-
vent subacute stent thrombosis, avoidance of dose reduction of heparin, even at therapeutic 
prothrombin time ratios (9) and additional heparinization at Fl+2levels > 0,8 nmolll (11) or 
1,2 microgr/l (12), has been advocated. Since puncture site related bleeding complications 
after coronary stenting in heparinized patients are frequently encountered, administration of 
extra heparin at therapeutic APTT's carries additional risk for bleeding complications. In this 
prospective study, the practical value of FI+2- assessments after coronary stenting is esta-
blished by the relation between Fl+2, APTT- and TT- values and the clinical course. 
PI +2 samples were stored at -20°C and were analysed after discharge of the patient, in order 
to prevent the clinical course being intluenced by knowledge of F12- values. 
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METHODS 
Stcnt M implantation 
All stent implantations were performed via the right femoral artery. The Palmaz Schatz stent 
was delivered with the steut delivery system, a preassembled unit, containing an articulated 
15 lTIm, two segment steIlt, crimped on a specified diameter balloon and prcloaded into a 
transparant sheath (13), Compared to the coronary artery diameter, the stented segment was 
slightly overdilated by repeat dilatations with a larger, non-compliant balloon. 
I\'Iedical treatment 
Pharmacologic treatment during the course of this study was aimed at the prevention of 
thrombosi:-; and coronary spasm and consisted of the following: 
Dextran 40, 100 cclhour to a total of 1000 ce, 1'Itarting 3 hours before stent implantation, or, 
in case of emergency stellt implantation, from the moment the decision was made to implant a 
stent. 
Heparin 10.000 IV was administered through the femoral artery sheath after its insertion, fol-
lowed by 5.000 IU if the procedure lasted longer then I hour. Hcparin infusion was disconti-
nued immediately after stellt implantation. The arterial sheath \vas removed when the 
Acticated Partial Tromboplastin Time (APTT) reached twice normal values (60-80 seconds). 
Two hours after hemostasis was achieved, a bolus of 5000 IU heparin was administered intra-
venously and heparin infusion was monitored with APIT measuremcnts. \Vhen a vascular 
hemostasis device was applied, the arterial sheath was removed immediately after stent 
implantation and heparin was titrated to therapeutic APTTs, without discontinuation. 
Heparin infusion was gradually decreased over 24 hours when therapeutic adjustment on 
coumadin was obtained. 
AcenOCOllmal'ol during 3 months: 6 mg the first day, 4 mg the second day, 2 mg the third day 
fol1owcd by a dosage adjusted to maintain a TT (Thrombotcst I Nycomed, Phannachemie, 
Haarlem, the Netherlands!) of 5 to 10%. Heparin was stopped when 3 consecutive TI's were 
in the therapeutic range. Additional medication consisted of dipyridamole 225 mg/day during 
3 months, acetylsalicylic acid 300 mg/day during 6 months and diltiazem 180 mg/day for 1 
month. 
~'IonHoring of anticoagulation 
Activated Pat·tial Thromboplastin Time (APIT; normal 30-40 seconds) 
APTT's were assessed every two hours after stent implantation to establish the optimal 
moment to remove the arterial introducer sheath (APTT;::::60-80 seconds). After readjustment 
on heparin, APTT was sampled 3 times a day, titrating heparin to APTI- values of 100 
seconds. The mean of APTT- values from multiple samples in the course of one day during 10 
days were calculated, to obtain an optimal reflection of the level of systemic heparinization. 
Thrombotest [Nycomed] (IT; normal> 40%) 
TIls were assessed once a day until patient discharge, when a stable adjustment 011 coumadin 
was established (TT::; 10%) during at least three consecutive measurements. 
Prothrombin fragments Fl+2 "Enzygnost® FI+2" (Behringwerke AG, Marburg, FRG) 
(F I +2; normal 0.55 - 1.1 nmol/l). Prothrombin li'agment F 1 +2 samples were collected daily 
lIntil patient discharge. Blood was drawn directly from a venous puncture and not from in-
dwelling venous catheters. Plasma samples were obtained by centrifugation and stored deep 
frozen (minus 200 Celcius) until analysis. Measurements were performed by enzyme immu-
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noassay technique, according to the sandwich principle (l4). Fl+2 samples were tested at 
room-temperature according to the instructions accompanying the assessment kits, 
Post pl'ocedul'ul care 
After sheath removal and manual compression or implantation of an vascular hemostasis 
device, a pressure dressing was applied overnight followed by 24 hours bed rest. 
Statisticul analysis 
Mean values of APTT were calculated from all available samples of one day. Mean values of 
TT and FI +2 were calculated from single daily samples. Values were expressed as mean ± 
standard deviation. Means of FI+2 from patients with and without a bleeding complication 
were compared by Student's t-test. A probability value <0,05 was considered to be statistical1y 
significant. 
RESULTS 
Between apr111991 and november 1992, Fl+2monitoring was performed in 38 patients after 
successful implantation of Palmaz Schatz coronary stents, 
Study population 
Baseline clinical characteristics of the study population and indications for coronary stenting 
are summarized in Tables 1 and II, respectively, Distribution of stented vessels is illustrated in 
figure 1. 
~nlble L Baseline clinical characteristics. 
Male 
Mean age (years) 
28 (74%) 
60±8(42-76) 
Risl< filetors 
Familiar 
Hypercholesterolaemia 
Smoking 
Hypertension 
Diabetes mellitus 
History 
Prior myocardial infarction 
Prior bypass surgery 
Prior PTCA 
13 (34%) 
13(34%) 
II (29%) 
10 (26%) 
6 (16%) 
15 (39%) 
12 (32%) 
10 (26%) 
PTCA= Percutaneuus Transluminal Coronary Angioplnsly 
Table 11. Indications for coronary stent implantation 
De novo lesions in native coronary arteries 
Saphenous vein bypass graft stenosis 
Failed PTCA 
Restenosis 
PTCA= Percutaneous Tnltls\uminai Curonary Angioplasty 
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12(32%) 
II (29%) 
10 (26%) 
5 (13%) 
RCX (16%) 
RCA (18%) 
Figure 1. Distribution of stcnled target \'esseis 
Clinical course 
One patient (3%) developed subacute stellt thrombosis. Bleeding complications, both access 
site related and systemic, were common in this population (11=11; 29%) {Table Ill}. 
Anticoagulation was not reversed in these patients. Four patients needed blood transfusions 
and 2 of them, also underwent vascular repair under anticoagulation (major bleeding; 11 %), 
Table III. Bleeding complications 
COMPLICATION TRANSFUSION SURGICAL REPAIR 
I Vaginal bleeding No No 
2 Groin hematoma, No No 
AV- fistula No 
3 Groin hematoma No No 
4 Brachial hematoma No No 
5 Groin hematoma Yes Yes 
6 Hematuria Yes No 
7 Retroperitoneal bleeding, Yes No 
Nose bleeding No 
8 Brachial hematoma No No 
9 Femoral pseudo aneurysm No No 
10 Femoral pseudo aneurysm, No No 
Hematuria 
II Groin hematoma Yes Yes 
Activated Partial Thromhoplastin Times 
In figure 2, the course of mean APTT- values per day are given. The mean of all APTT- valu-
es was 124 ± 20 seconds. The maximulll value was encountered at the day of stent implanta-
lion, retlecting therapeutic heparinization during the procedure and readjustment 011 heparin 
after removal of the arterial sheath. In the first week, APTT values could successfully be sta-
bilized near a level of 100 seconds. 
'I'hl'ombotests 
The course of TT- values is shown in figure 3. At the fifth day following stellt implantation, 
the mean IT reached therapeutic values. 
Prothrombin fragment Fl+2 
A total of 276 PI +2 samples were analyzed (7.3 ± 2.1 samples pcr patient; range 4-10). 
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An overview ofFI+2 values in the total study population is summarized in Table IV and the 
course of mean FI+2- values in the first 10 days is illustrated in figure 4. 
Table IV. FI+2 values (nmol/l) for the total study population. 
Day N Mean Median Range SD 
I 38 1.03 .91 .15-2.20.52 
2 38 .81 .74 .35-\.70 .35 
3 37 .88 .84 .34-2.65 .43 
4 38 .93 .85 .35-\.71 .34 
5 34 .98 .97 .54-1.52 .30 
6 31 .97 .93 .56-1.63 .33 
7 23 1.06 .95 .47-2.00.47 
8 15 .91 .85 .42-1.65 .35 
9 12 .92 .93 .42-1.95 .43 
10 10 .77 .73 .30-1.30 .32 
Mean Fl+2 values per day 
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Figure 4. ~kan FI+2 values for the total study populatiun and for patients with anti without a bleeding complication. 
Mean FI +2 concentrations under 0.55 nmolll were not found. In addition, one or more (3.4 ± 
2.5; range 1-10, median 3) FI+2-values <':1.1 nmo1l1 were found in 26 patients (68%). One of 
these patients, with a residual dissection between two stents, slistained subacute stent occlu-
sion at day 10. At day 9 , heparin infusion \vas decreased at a IT of 8%. The TT at day 10 
however was 23%, but the APTT was still within the therupeutic range (90 seconds). FI+2 
rose from 0.65 to 1.3 nmolll. When specified for patients with (u= II; #samples=88) and with-
out (n::::27; #samples= IS8) a bleeding complication, the Illean value of Fl+2 was significantly 
higher in the first group (1.10 t 0.39 nmolll and 0.86 to.37 nmolll respectively; p<O.OOO I) 
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(Table V and figure 4). In 5 of II patients with a bleeding complication (55%), the mean 
Fl+2 values exceeded the upper normal value (1.1111110111), whereas values in patients without 
a bleeding complication were within the normal range. In this group however, mean values 
did not fan lInder the lower normal vallie (0.55 nmolll). 
Table V. FI+2 values (nmol/l) for patients with and without bleeding complications. 
BLEEDING COMPLICATION NO BLEEDING COMPLICATION 
Day N Mean :r..'Iedian Range SD N IHean IVledian Range SD 
I II 1.19 .95 .42-2.20 .66 27 .97 .90 .15-1.90 .40 
2 II .97 .85 .35-1.71 .44 27 .75 .73 .35-1.32 .29 
3 II .94 .95 .35-1.30 .32 26 .85 .73 .34-2.65 .47 
4 II 1.06 1.10 .52-1.71 .33 27 .88 .82 .35-1.72 .33 
5 II 1.2 j'" 1.28 .70-1.52 .27 23 .86* .81 .54-1.45 .25 
6 9 1.27 1.30 .69-1.60 .31 22 .86* .78 .56-1.63 .26 
7 7 1.0S 1.10 .69-1.50 .31 16 1.04 .83 .47-2.00 .53 
8 6 l.Ii' 1.08 .77-1.60 .32 9 .73* .70 .42-1.10 .24 
9 6 1.20* .99 .90-1.95 .41 6 .64" .65 .42-1.00 .21 
10 5 ,85 ,75 ,68-1.27 .24 5 ,69 ,70 .30-1.30 .40 
* P < 0,05 
DISCUSSION 
Although suboplimal anticoagulation may be associated with increased risk for subacute slent 
thrombosis, optimal anticoagulation as measured by the APTT and TT, were not associated 
with a statistical11y signitlcant reduced risk of stent thrombosis (15). 
Daily measurements of prothrombin fragment FI+2 and coagulation factor II and subsequent 
adjustments of heparin infusion, has been advocated to reduce the incidence of subacute stent 
thrombosis. Haude et al demonstrated that monitoring of prothrombin fragment FI +2 could 
detect latent coagUlation states after implantation of Palmaz Schatz stents (II). F 1 +2 levels 
over 0.8 nmolll were associated with increased risk of subacute stent thrombosis. By giving 
extra heparin at elevated FI +2 values, even when APTT's were within the therapeutic range, 
stent thrombosis \vas retrospectively prevented in 39 patients of a consecutive group of 40 
patients with PI +2 monitoring. Tn 53 patients without monitoring of Fl +2, 9 subacute stent 
occlusions were reported. 
Gulha et al reported that 8 of 34 patients showed increased FI +2 values, which normalized 
after extra heparinization (12). None of these patients suffered from stent occlusions. 
Hafner et aL reported on 19 patients with Fl+2 monitoring after Palmaz Schatz stent implan-
tation (16). Fl+21evels were low (0.35 nmolll) immediately after stenting and a rise was seen 
to 0.44 nmolll in the first and second day. After a second peak to 0.44 nmolll at day 6, a con-
tinous decrease was observed to 0.29 nmoi/i. None of the patients developed stellt thrombosis. 
By analyzing daily collected Fl+2 samples after dis<.:harge of patients with coronary stents 
and thus by refraining from intervention in the anticoagulation regimen, we were able to <':01'-
relate the clinical outcome with FI+2 concentrations. Only one patient from the 26 patients 
with FI +2 levels above the normal value, who had a suboptimal stent result, developed sulnl-
cute stellt ocdusion. In a study of Strumpf et al. FI +2 was measured in 37 consecutive 
patients after elective stellt implantation (17). Five of these patients developed stellt thrombo-
sis. FI+2levels for patients with thrombosis did not significantly differ from patients without 
this complication; 1.046 ± 0, 156 ugrll and 1.009 ± 0.217 ugr/l respectively, The natural course 
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of patients with increased Fl+2- levels remained unknown in the studies of Haude (II), 
Gulba (12) and Hafner (16), because these patients received extra heparin. 
Surprisingly, in our study mean Fl+2 values were higher then the recommended 0.8 nl11oll1. 
This discrepancy in Fl+21evels can not be explained hy a difference in anticoagulant therapy, 
although in the study of Hafner et al (16) heparin is continued after angioplasty at an infusion 
rate of 1000-1800 IU/h. According to our protocol heparin is discontinued untill the introdu-
cer sheath can be removed aftcr at an APTT at 60 seconds, 2 hours later followed by readjust-
ment on heparin. Before and during readjustment, episodes of suboptimal anticoagulation 
were observed in individual patients. However, during heparinization, our patients were under' 
adequate anticoagulation as indicated by the APTT- values. Blood sampling <lmllaboratory 
assessment were performed strictly according to instructions from the manllfacurer 
(Enzygnost Fl+2, Behring, Marburg, Francc). A theoretical explanation for the elcvated 
FI+2-levels may be in vitro generation ofFl+2 in stored plasma samples at low temperatu-
res. Since we did not perform control analyses of FI +2 from fresh plasma and stored plasma 
from the same patient, this question will remain unresolved in this patient group. 
The higher FI +2 levels in patients with clinical evidence of bleeding, can be explained by the 
fact that any bleeding will be associated with activation of hemostatic processes. 
This hypothesis also explains the paradox of effective anticoagulation (therapeutic APTT 
from day 1-10 and IT from day 5-1 0) and bleeding complications on one hand, and hyperco-
agulability, represented by increased F 1 +2 levels on the other hand. 
Since activation of hemostatic processes by bleeding cannot be differentiated by means of 
FI+2-monitoring from impending stent occlusion, we do not perform FI+2-monitoring as a 
routine after Palmaz Schatz stent implantation and we consider APTT and TT- values ade-
quate parameters to monitor anticoagulant therapy follO\ving this intervention. 
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CHAPTER 4.3 
POTENTIAL SOLUTIONS 
IMPROVEMENT OF LOCAL HEMOSTASIS 
IMPROVED ANTICOAGULATION MANAGEMENT AFTER PALMAZ SCHATZ CORO-
NARY STENT IMPLANTATION BY SEALING THE ARTERIAL 
PUNCTURE SITE WITH A VASCULAR HEMOSTASIS DEVICE 
F. Kiemeneij, OJ. Laarmun 
Cathet Cardiovasc Diagn 1993;30:317-322 
Presented during the Scientific Sessions of the European Society of Cardiology 1992 and of 
the American Heart Association 1992 
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Catheterization and Cardiovascular Diagnosis 30:317-322 (1993) 
Improved Anticoagulation 
Management After Palmaz 
Schatz Coronary Stent 
Implantation by Sealing the 
Arterial Puncture Site With a 
Vascular Hemostasis Device 
Ferdinand Klemenelj, MD, and 
Gert Jan Laarman, MD, PhD 
Sealing the arterial puncture site with a vascular hemostasis 
device has the potential to maintain optimal anUcoagulalion af-
ter slent Implantallon, The level of heparinization during the 
first 3 days after successful slent Implantation was retrospec-
tively compared between 2 gtoupS of medically treated patients 
with (group Ai n = 18) and without {group B; n = 17} a Vaso-
5eal'-"- after sheath removal. The number of APTIs sampled in 
group A and B was 233 and 168, respecllvely. Respective mean 
values of APTT (seconds) In group A and B were 160 ± 79 and 
172 ± 91 al day 1 (p = NS), 132 ± 43 and 125 ± 61 at day 2 (p 
= NS)and 123 ± 36 and 116 ± 46 at day 3(p = NS). More APTIs 
were suboptimal « 80secs) In group B (3<1/168: 20%) compared 
10 group A (171233; 7%) [p < 0.001). More pallenls In group B 
compared 10 group A had 1 or more (14/17; 82% vs. 8118i 44%; 
P '" 0.04), 20r more(10!17j 59% versus 3/18; 17%j p '" 0.02) and 
3 or more (8/17i 47% vs. 2/18: 11%jp '" 0.03) suboptimal APTIs. 
Bleeding compllcalfons were seen In 4 pallents wlthoul and In 3 
paUents with a Vasoseal:Y • Thus appllcaUon of a vascular he· 
mostasls device resu1ls In a less variable anticoagulation alter 
coronary stenling, but 11 does nol abolish entry slte·related 
bleedIng complications. [1993 Woley·Uss, Inc. 
Key words: coronary slenl, bIodegradable collagen hemo-
stasis device 
INTRODUCTION 
After removal of the arterial introducer sheath in pa~ 
tients undergoing implantation of a metallic coronary 
stent, a careful balance between anticoagulation and he~ 
mostasis has to be maintained. Usually, immediately af~ 
ter stent implantation, heparin is temporarily discontin~ 
ued. When Activated Partial Thromboplastin Times 
(APIT) reaches twice the nonnal value (80 sec'~), the 
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sheath is withdrawn. Readjustment 011 heparine is started 
several hours after local hemostasis is achieved by giving 
a bolus intravenously resulting in a peak in the APIT 
cun'e, followed by continuous heparin infusion. APTIs 
are maintained at a stable level near 100 secs, until ef~ 
fective adjustment on coumarin is established (Fig. 1). In 
a clinical selling, however, monitoring and adjustment of 
anticoagulation can he less optimal. Episodes of sltbther~ 
,Ipeutic anticoagulation can occur not only during the 
initial discontinuation of heparin, but also during the 
readjustment phase, as there arc inevitible time lapses 
between blood sampling, laboratory assessment, and the 
final ,mnouncement of the APTr result. 
These episodes of suboptimal anticoagulation may 
subject the patient to an increased risk of stent thromho~ 
sis. Recently, local application of a collagen containing 
vascular hemostasis device (VasoscaFB') has been pro~ 
posed for a selected group of patients, as an alternative to 
prolonged femoral compression after sheath removal [I]. 
After insertion of such a device, heparin can be smoothly 
titrated to APIT levels ncar 100 secs, obviating early 
suboptimal heparinization and a fluctuating heparin rc~ 
adjustrnent~phase. In this retrospective study we report 
on our experience with this new device in relation to the 
quality of heparinization. 
METHODS 
Study Population 
The study group was derived from medically treated 
patients after successful stent implantation during the 
some period of stent experience, and after either success~ 
ful implantation of a vascular hemostasis device (group 
A) or after conventional sheath removal with prolonged 
local pressure application (group B), 
Stent Implantation 
The sten! delivery ,~ystem was used: a sheath protected 
unit, containing the articulated Palmaz Schatz stent, 
crimped on a specified diameter balloon calheter. Com-
pared to the coronary artcry diameter, the stented scg~ 
ment was slightly overdilated by repeat dilatations with a 
larger, noncompliant balloon. 
Insertion of a Vascular Hemostasis Device 
Percutaneous entry of the femoral artery was at~ 
tempted under an angle of 45-60"'. With the appearance 
of pulsatile blood from the needle, a clamp was placed at 
the needle at skin level to mark the distance between the 
skin and arterial wall, The ncedle was withdrawn and 
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Fig. 1. Ideal Acllvated Partial Thromboplastin Time (APTT) and 
Thrombolesl (TIl curves fOllowIng arterial shealh removal. 
APTT falls under 80 sees (arrow) before Ihe sheath Is removed 
from the femoral artery. After 2 hr the pallent Is heparinized, 
givIng rise to a peak in the APTT curve, followed by slabltlzallon 
around 100 secs. 
placed on the VasosealcpJ> color card. The color at the 
needle tip corresponds to a Vasoseal@' kit of the same 
color, containing 2 collagen plugs of a length detenllined 
by the arterial depth measurement. 
The artcrial sheath was removed over a guidewire un-
der occlusive compression 3-4 em above the puncture 
site. A blunt tissue dilator was advanced to a black 
marker line or until! resistance is felt. The Vasoseal® 
sheath was advanced over this dilator until the proximal 
opening was aligned with the colored band on the dilator. 
Tissue dilator and guidewire were removed and the first 
collagen ~.'artridge was inserted followed by delivery of 
the plug by advancing the plunger. After waiting 3-5 
sees, the plunger was removed and a second plug was 
inserted, followed by withdrawal of the sheath. Local 
pressure was applied for 5 min after collagen insertion, 
followed by application of a pressure dressing. 
Exclusion criteria for Vasoseal® application were ab-
sence or abundance of subcutaneous tissue, presence of a 
hematoma, no previous arterial depth measurcment, un-
controlled hypertension and known allergy to collagen or 
becf products. Both investigators had applied this tech-
nique routinely in patients after coronary artery balloon 
angioplasty, before using this device in patients after 
coronary stenting. 
Medical Treatment 
Phannacologic treatment was aimed at the prevention 
of thrombosis and spasm and consists of the following: 
Rbeomacrodex 40, 100 cc/hr to a total of I litre, startcd 
2 hr before the procedure or from the illoment the deci-
sion was made to implant a stent after failed PTCA. 
88 
Heparin 10,000 IU was administered through the femoral 
artery sheath after its insertion, followed by 5,000 lU for 
each hr during the procedure. When no Vasoseal® was 
applied, the arteriill sheath was removed when the Acti-
cated Partial Tromboplastin Time (APTl') reached twice 
normal values (80 secs). Two hr after obtaining local 
hemostasis, a bolus of 5,000 IU heparin was adminis-
tered intravenously and a heparin infusion was titrated to 
AP11's near 100 secs, measured with 8-hr interval." or 
more frequent if necessary. When a vascular hemostasis 
device was applied, the arterial sheath was removed im-
mediately after stent implantation and heparin was ti-
trated to APTfs of 100 sees, without discontinuation. 
Acenocoumarol during 3 mas: 6 mg the first day, 4 mg 
the second day, 2 mg the third day followed by a dosage 
adjusted to maintain a IT (thrombo-test "QUICK") of 
5-10%. Heparin was stopped when 3 consecutive TIs 
were in the therapeutic range. Additional medication 
consisted of dipyridamole 225 mg/day during 3 mos, 
acetylsalicylic acid 300 mg/day during 3 mos, and dilt-
iazcm 180 mg/day for 3 mos. 
Postprocedural Care 
After sheath removal and manual compression of the 
groin or implantation of an vascular hemostasis device, a 
pressure dressing was applied overnight followed by an 
24-hr immobilization period. 
Statistical Analysis 
Statistical analysis was performed with a commer-
cially available software program. Results are reported 
as mean value ± Ix standard deviation (SD). 
The number of total APTIs and suboptimal APTTs in 
group A ilnd I3 were compared by the Chi-square test. 
Haseline clinical characteristics and patients with morc 
then 1, 2, and 3 suboptimal AP'ITs in both groups was 
compared by the Fisher's exact test. Differcnces in mean 
ArTIs were compared by the Student's t-test. A p value 
< 0.05 was considered significant. 
RESULTS 
Baseline Clinical Characteristics 
Between l\'lay 1991 and May 1992, 36 consecutive 
patients were medically treated after succe~sful coronary 
stent implantation, 
One patient with a Vasoseal had an ischemic cerebro-
vascular accident the day of stent implantation. She de-
veloped a major puncture-site bleeding, caused by con-
fusion and extreme restlessness. Because heparin hlld to 
be discontinued for a prolonged period of time until a 
hemorrhagic stroke was excluded by computerized to-
mography, analysis of anticoagulation could not be in-
cluded in this study. Consequently, 35 patients were 
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Fig. 2. A. Level 01 APTTs in group A during the fIrst 72 hr after stenl Implantation (mean ± 1 
SO). B. level of APTIs In group B during the IIr5172 hr after slenl implanlallon (mean ± 1 SO). 
compared, 18 patients with (group A) and 17 patients 
without (gmup B) a Vasoseal@. 
Baseline clinical characteristics are summarized in Ta-
ble I. 
In group A, morc patients underwent elective stefl! 
implantation (6Ic/o) and venous bypass graft slcnting 
(33%) compared to group B (47% and 6c,{" respectively). 
This difference is explained by the fact that skin-femoral 
artery distance measurements for determination of the 
plug length were routinely perfomled prior to sheath in-
sertion in all elective and saphellous vene graft stellting 
procedures but not in all PTCA procedures leading to 
emergency stenling. Ignomnce of plug length was con-
sidered to be a contraindication for arterial sealing. 
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TABLE I. Baseline Clinical Characterisllcs of Pallents 
Treated With (group A) and Without a Vascular Hemostasis 
Device (group B) 
Group A Gwup B 
(n = l~) (n = I" '" 
M"le 14 
" 
NS 
Age (yr) 59 ±- ~ 57 ± 8 NS 
Pwc'edurt' 
Ekctive II 61~~· X 47'1 NS 
Ihilllut 7 -'9':l 9 53~(. NS 
V","c\' 
LAD (, -'-'':{ Y 53\(- NS 
LeX 5 28~~ 2 12'1 Ns 
RCA 1 6~{ 5 29(1 NS 
VIlG (, 33,:{ 1 6~,< NS 
'[.,\D·ldt anleri"r ,k,een(ling cnronJI)' arter),; LeX·lef! dn:ulnfln: l"j[· 
01l.ll)' arter),; RCA·right coroll.ll)· <irter)'; VUG·ven,lu, bypJ..'\ gr.lfl. 
'Fhha <,xact tc't. 
Level of Anticoagulation 
A sUboptimal APIT was det1ned as a value under 80 
sees, twice the upper value of the nonnal range. In the 
first 72 hr after stenl implantation, the number of APTIs 
sampled in group A and B was 233 and 168, rcspectively 
Crable II), \\olcan valucs of APTfs (sees) in group A and 
Bare illustratcd in Figure 2a,b. Although the level of 
APTIs at day 1,2, and 3 was higher in group A COIll-
pared to group B, the differcnces were not statistically 
significant. \\olore APTIs wcre suboptimal « SO sec-
onds) ill group B (341168; 20%) compared to group A 
(17/233; 7%) [p < 0.0011. r-,'Iore patients in group B 
compared to group A IHld I or more (14117; 82% Vs. 
~m8; 44%), 2 or more (10/17; SI)% vs. 3118; 17%) and 
3 or more (8117; 47% vs. 2/18; 11f'/p) suboptimal APTIs. 
Complications 
Four patients without <I henlO.~til~is device hild bleed-
ing complications, three related to the puncture site. All 
puncture-site-related complications in this group were 
arteriovenous l1 ... tulas. One patient also had macroscopic 
hematuria in the presence of a renal cyst. Another patient 
had macroscopic hematuria requiring blood tmnsfusioll. 
Surgical correction was necessary for olle patient with an 
AV fistula. 
One patient with a Vasoseal underwent vascular sur-
gery for a femoral artery pseudo<lneurysm aftcr a groin 
bleeding following an ischemic cerebrovascular accident 
as outlined above. Another patient developed puncture-
site bleeding imlllediately following insertion of a Vaso-
seal. This patient required blood transfusions and acute 
vascular surgery. 
The third complication after arterial scaling wus en-
countercd in a patient who developed a spontaneous 
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TABLE [I, Level of AnUcoagulallon In Patients With (group A) 
and Withoul (group B) a Vascular Hemostasis Device 
Gmup A 
(n = 18) 
,\PTF 1I~)' 0--' B-' 
APlT «HI) ~el') 17/233 (N.) 
:?l APlT «HO _,ee) 811H (4-1':-;') 
22 ArTf «HO ~ec) -'/11'1 (!7'.}.) 
2J APTr «80 ,~<:) 2/18 (ll~{-) 
'A(livalt'd PJrtial thrombopiallin time, 
tC1Ii·'quare Ie,\' 
* 'fi>her e~Jd Ie,\. 
Gmup Il 
(n = 171 P 
168 
J.fII68 (20~\.) <OJ)(lI' 
14117 (R2,:{) O.O-tH 
10.'17 (59~n ().()2*' 
8'17 (47~O (Ul~*' 
groin bleeding 2 days after stent implantation. Two mos 
later, the organized hematoma was surgically removed, 
because of femoral nerve compression. Subacute stent 
thrombosis occurred in one patient without a hemostasis 
device, at the third day after stent impiant.:lIion, .~uecess­
fully recanalized by rePTCA and subsequent coronary 
bypass surgery. This paticnt had 2 subtherapeutic APTf 
values before stellt occlusion occurred. 
DISCUSSION 
Coronary stent implantation has been proposed as a 
possible solution for 2 major limitations of conventional 
balloon angioplasty; abrupt closure during or late after 
the procedure [2-7) and late rcslcnosis in native coronary 
arteries [R,9] and saphenous vcin grafts [10]. Howcver, 
subacute stentthrombosis aftcr implantation of a Palmaz 
Schatz balloon expandable coronary stellt has been re-
ported to occur in 0.4% of 220 piS after both elective and 
bailout stcnt implantation 111] to 2S% of patients after 
emergcncy stent implantation for failed PTCA during 
early experience (7J. Risk factors for subacute stCllt 
thrombosis include: stenting for suboptimal PTCA, ves-
sel size smaller than 3.25 [Urn, multiple stellt implanta-
tion, poor LVEF 112], residual dissection (13], intracor-
onary thrombus [14], and suboptimal anticoagulation 
[R]. 
Implantation of metallic coronary stents requires in-
tense 1lIlticoagul.:ltion, which usually consists of a tom-
bination of Dextran, dipyridamole, acetosalicylic acid, 
and heparin [IS). Of 39 patients ill the multicenter study 
from Schatz et al. 18], anticoagulated without coumarin, 
7 patients suffered from stent thrombosis. Subacute 
thrombosis decreiL<;ed .significantly from 18% to 0.6% in 
those patients who also received couillarin. 
This aggressive anticoagulation regimen is associated 
with a high incidence of puncture-site-related bleeding 
complications, rt:'!ported to vary between 7.9% of 226 
pilticnts ill the initial Illulticenter experience with the Pal-
maz Schatz stent [~] and 16% of 220 patients in the 
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single ccnter experience of Carrozza et al. [11 J. A bleed-
ing complication aftcr ... tent implantation is a serious 
cvent, because this disturbes the anticoagulation regimen 
and subsequent risk for stent thrombosis. In order to 
prevent local bleeding complications, the arterial sheath 
is removed within 24 hr after Ment implantation under a 
low level of heparinization and prefcrably not during 
continued anticoagulation with heparin and coumarin. 
When the patient is subsequently readjusted on heparin, 
several short episodes of undercoagulation may still oc-
cur. These episodes of suboptimal heparinization can be 
prevented by immediate poslprocedural sealing of the 
arterial puncture site, obviating the need for early dis-
continuation of heparin and allowing titration of APITs 
to values near 100 secs. This study was perfonned to 
evaluate the quality of heparinization in patients treated 
with a vascular hemostasis device afler coronary stent 
implantation. The device used in our study was the bio-
degradable, collagen-containing, supraarterial plug (Va-
soseal\TH'), ftx'ommended as an alternative for prolonged 
local pressure application [1,16]. 
Although the level of heparinization, as delemlined by 
the mean of APIT- values in the first 72 hr, did not differ 
significantly in both groups, less APITs were in the 
subtherapeutic range in patients with a Vasoseal, signi-
fying an optimized adjustment on heparin. The clinical 
relevance of adequate heparinization inll11ediately after 
arterial sealing, however, remains theoretical at this 
time. Although stent occlusion within the first 24 hr is a 
rare phenomenon [121, early episodes of suboptimal he-
parinization may theoretically fonn the nidus for future 
subacute stenlthrombosis. In contrast, postponing read-
justment on heparin for 6 IIr after removal of the arterial 
sheath has presently been recommended in order 10 pre-
vent vascular complications. Since no studies are per-
fomled, evaluating the optimal heparinization regimcn 
postcoronary stenting, our policy to strive for therapeutic 
heparinization as soon as possible after stenl implanta-
tion and local hemostasis is legitimate. 
The role of vascular hemostasis devices in preventing 
local blceding complicatiollS also remains a matter of 
debate. The small number of patients and the non rall-
domized character of this study, where no corrections for 
baseline factors sllch as body size, hypertension, elective 
vs. emergency stentillg, wcrc made, docs not allow any 
conclusion concerning the differences in clinical end-
points such as blecding ,lIld cardiac complications. Only 
1I difference in laboratory valucs was found. In our ex-
perience, despite careful patient selection and optimal 
insertion and immobilization techniques, serious groin 
blccding could not be abolished in 3 patients after appli-
cation of a Vasoseal. Tn a randomizcd study comparing 
sheath removal and manual compression vs. insertion of 
a Vasoseal in 60 patients aftcr PTCA, Camenzind C.iI. 
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did not find a significant reduction in blecding compli-
cations [17J. 
However, techniqucs of coronary stenting and post-
procedural policies arc dynamically evolving. Efforts are 
directed toward the developmcnt of non thrombogenic 
stents, downsizing of PTCA equipment, allowing 
smaller vascular puncture holes [IHJ, alternative entry 
sites such as the radial artery [19] for stent implantation, 
improvement of local femoral pressure application by lin 
inflatable compression device [201, and several vascular 
hemostasis devices [21]. 
In order to determine the optimal strategy after im-
plantalion of the current Palmaz Schatz stent, aiming at 
a reduction of subacute slent thrombosis and of pUtletufC-
sitc bleeding complications, several studies need to be 
designed comparing these and future strategies in a ran-
domized fashion. 
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CHAPTER 4.4.1 
POTENTIAL SOLUTIONS 
RADIAL ARTERY AS ENTRY SITE 
Feasibility of bailout techniques with 6 French guiding catheters 
FIRST CLINICAL EXPERIENCE WITH A NEW LOW PROFILE CORONARY 
PERFUSION BALLOON CATHETER COMBINED WITH 6 FRENCH GUIDING 
CATHETERS 
F. Kiemeneij, GJ. Lnafman 
J Invas Cardiol 1993;5:219-224 
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First Clinical Experience With a New Low 
Profile Coronary Perfusion Balloon 
Catheter Combined With 6 French Guiding 
Catheters 
Ferdinand Kiemeneij, MD and Gert Jan Laarman, MD, PhD 
ABSTRAcn AI present, the use of 6 French (F) guiding catheters is limited by the inability 10 
accommodate large catheter systems, such as perfusion b.llloons, sten! delivery systems and 
catheters for intravascular ultrasound. In this study Ihe perfomtance of a new, low profile perfu-
sion balloon catheter, in combination with 6F guiding catheters, was evaluated in 12 consecutive 
patients undergoing coronary angioplasty (PTCA). In all patients the ACS® Flowlrack'>l40 perfu-
sion catheter, used as a primary device, was successfully adv.lflced towards and retrieved from 
the coronary artery. However, repositioning of the perfusion catheter was not possible in all 
cases, In 10 patients (83%) the catheter could be positioned across the coronary artery stenosis. 
Distal contrast op.lcification during balloon inflation was present in all these instances. Severe 
anginal complaints, necessitating extra antianginal treatment or cessation of balloon inflation 
and hemodynamic deterioration did not occur during inflations of 270 ± 136 seconds (range 105-
480; median 300). PTCA was successful in all patients. Diameter stenosis was reduced from 67 ± 
10% (range 42-79%) to 23 ± 12% (range 2-40%) and minimal luminal diameter increased from 0.8 
± 0.3 mm (range 0.4-1.4 mm) to 2.2 ± 0.6 mm (range 1.4-3.0 nun). The clinical course was unevent-
ful in all patients. These results demonstrate that this promising perfusion catheter furiller 
reduces the limitations of 6F guiding catheters. However, there is sHU need for improvement in 
the performance of this device. 
J INVAS CARDIOL 1993;5:219-224 
Key words: PTCA, perfusion balloon (.llheter, 6 French guiding catheter 
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New 6 French (F) guiding catheters for coronary 
angioplasty can accommodate low profile, rapid 
exchange balloon catheters.L2 Advantages of small 
sized guiding catheters are the ability to perform 
procedures with smaller arterial puncture holes, 
with the potential of less bleeding complications 
Vol. 5, No.6, July / August 1993 219 
KIEMENEIJ nlld LAARMAN 
Table 1. Crossing profiles for different balloon sizes 
Balloon size (mm) 2.0 2.5 
Crossing profile 
-inch .048 .049 
-mm 1.22 1.24 
and early ambulatioIl, the use of smaller arterial 
entry sites, such as the brachial3 and radial 
arteries2 and less pressure damping by the guiding 
catheter in the coronal)' ostitlifl, Performance of 6F 
guiding catheters with regard to contrast delivery, 
pressure monitoring and backup support is similar 
to 8 F guiding catheters.4 However, a potential lim-
itation of the use of 6F guiding catheters is the 
inability to accommodate large catheter systems, 
such as perfusion balloons, atherectorny catheters, 
slen! delivery systems and catheters for intravas-
cular ultrasOlmd. To evaluate the performance of a 
new I low profile, perfusion balloon catheter in 
combination with 6F guiding catheters, \ve select-
ed this catheter as a primary device in 12 consecu-
tive patients undergoing coronary angioplasty 
(PTeA). 
MATERIALS AND METHODS 
Patient selection. Twelve consecutive 
patients, undergoing elective coronary balloon 
angioplasty were included after having given 
informed consent. 
Guiding catheter. For this study, Scimed8 6F 
Triguide-Elite1" guiding catheters were used. 
These catheters are 100 cm long and have an 
inner diameter of 0.060 inch (1.53 mm). 
Perfusion balloon catheter. The perfusion bal-
loon catheter used was the ACSSl RX Flowtrack l "40 
3.0 3.5 4.0 
.050 .051 0.52 
1.27 1.30 1.32 
(Figure 1). Flow rate of this perfusion balloon is 
40 cc/min. This rapid exchange (20 cm 
"peel-away") catheter consists of a 135 cm long 
Dynacross p., shaft (proximal 2.3F and distal 3.5F). 
The shaft has 14 perfusion holes, 0.014 inch in 
diameter, 10 proximal and 4 distal from the bal-
loon. The balloon is made of PE-600. Rated burst 
pressure is 8 atmospheres. TIle distal 30 cm of this 
device is coated with Microglide"'. Crossing pro-
files for different balloon sizes are sLUnmarized in 
Table 1. 
Medical treatment. Through the arterial intro-
ducer sheath, 10,000 IV heparin was adminis-
tered. Prior to contmst injection (Hexabrix@ 320), 
nitroglycerin 100-200 micrograms was given 
intracoronary. For severe angina, intracoronary 
administration of nitroglycerin was repeated or 
nifedipine 10 mg was administered sublingually. 
A combination of fentanyl 0.05 mg and dropeddol 
0.25 mg (Thalamona10 ) 1-2 ml intravenously was 
given for refractory anginal complaints. 
Angioplasty. After crossing the obstructing 
coronary lesion, the balloon was inflated to 6-8 
atmospheres. Presence of distal flow, defined as 
distal contrast opacification of the coronalY artery 
during balloon inflation and the contrast agent 
disappearing after a few cardiac cycles, was 
angiographical1y assessed. The guiding catheter 
and guidewire were subsequently \vithdrawn 
towards the shaft marker in order to maximize 
RXP 46 lAX PERFUSION 46) DILATATION CATHFJ'ER 
10 pNdmLl j><rl ... k .. bolu 
(O,OU') 
MICRQOUDE$ c",.!l~. dliUJ:Mlaa 
Figure 1, Schematic represelltatiotJ of tile ACS0 FlowtmckT"40 petft/sioll baflooll catheter. 
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Table 2. Baseline clinical characteristics (N=12) 
N 
Male 11 (92%) 
Age (mean ± SO) 58.3 ± 8.6 years 
Angina 
Exertional 11 (92%) 
CCSI 0 
CCSII 2 (17%) 
CCS III 7 (58%) 
CCSIV 2 (17%) 
Non Exertional 2 (17%) 
Mixed 1 (8%) 
PreviousMI 7 (58%) 
Previous CABG 1 (8%) 
Previous PTCA 4 (33%) 
Diabetes mellitus (8%) 
Hypertension 3 (25%) 
Hypercholesterolemia 1 (8%) 
Familiar 2 (17%) 
Smoker 9 (75%) 
CCS '" Canadian Cardiovasculdr Society; 
11 I", myocardial infarction; 
CABG"" coronary artery bypass grafting; 
PTCA = percutaneous transluminal coronary angioplasty 
perfusion. 
Recording of events and performance of 
angioplasty equipment. Onset and severity of 
chest pain, hemodynamic deterioration (drop of 
blood pressure ~ 20 mmHg) and EKG changes 
were recorded, as well as the treatment required. 
Performance of the guiding catheter (backup sup-
port and opacification) and of the perfusion 
catheter (crossability and retrievability) were 
semiquantitatively scored in 3 categories; good, 
moderate (sufficient; no need to change guiding 
or balloon catheter) and poor (suboptimal; need 
to change guiding or balloon catheter). Pre-- and 
post-PTCA angiographic studies \vere performed 
with a computerized quantitative coronary analy-
sis system (DCI, Philips Medical Systems). 
RESULTS 
Study population (Table 2). Twelve patients 
underwent PTCA with a Flowtrack 40 perfusion 
balloon as the primary device. Baseline clinical 
characteristics and demographics are summa-
rized in Table 2. 
Al1giographical data (Table 3). Thirteen 
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Table 3. Angiographical data 
N 
Vessels 12 
Culprit lesion 13 
LAD 4 (31%) 
RCA 7 (53%) 
RCX 1 (8%) 
AL 1 (8%) 
Flow (TIM!) 
3 12 (100%) 
Type 
A 5 (39%) 
B 6 (46%) 
C 2 (15%) 
Quantitative angiography 
Mean± SD Range 
Reference diameter 2.6± 0.8 nun 1.3 -3.9mm 
Minimal luminal 
diameter 0.8±0.3mm 0.4 -1.4 rnm 
Diameter stenosis 67± 10% 42 -79% 
LAD = Left anterior descending coronary artery 
RCA = Right coronary artery 
LCX = Left circumflex coronary arlery 
AL = Anterolateral branch 
lesions were attempted in 12 coronary arteries. 
Entry sites and guiding catheter selection. 
Entry sites for PICA were the femoral (n=8; 67%), 
radial (n=3; 25%) and brachial (n=li 8%) arteries. 
Guiding catheter curves selected were FR4 (n=5), 
FL4 (n~4), FR 3.5 (n~I), El Gamal (n~l) and Voda 
(n=I). Cannulation of the coronary artery was 
successful in all patients. Opacification of the 
coronary artery and pressure monitoring was 
good in all patients. Backup support was good in 
10 patients and moderate in 2 patients. 
Dilatation catheters 
Number: Fourteen Flo\vtrack 40 catheters 
were used (2.5 mm; n=5: 3.0 mm; n=6: 3.5 mm; 
n=3). A second (3 patients) or third (2 patients) 
balloon catheter ·was required to further opti-
mize the result. 
CI'OSSillg, retrievalalld repositiollillg: (Patients; 
n=12, Flowtrack 40; n=14) Ability of the 
Flowtrack 40 to cross the stenosis was considered 
good in 8 (58%), moderate in 2 (21%) and poor in 
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2 (21%) instances. In one patient a Flowtrack 40 
2.5 mm could not cross a small anterolateral 
branch stenosis (RD 1.3, MLD 0.4 mm). The other 
patient had a 20 mm long stenosis in the right 
coronary artery (RD 2.2, MLD 0.8 mm), which 
could not be crossed by a 2.5 nun perfusion bal-
loon. These patients had successful PTCA with a 
Scimed® Express1'.1 balloon catheter. Eleven per-
fusion balloon catheters could be retrieved from 
the guiding catheter without noticeable friction 
(79%), ·while some friction was felt in 3 patients 
(21 %). In 5 patients repositioning of the balloon 
was attempted, to optimize the angioplasty 
result. In 3 patients it was impossible to recross 
the shaft of the guiding catheter after complete 
retrieval. All failed attempts were due to lack of 
stiffness of the distal shaft at the site of the 
peel-a-way slit. The lesions were successfully 
recrossed with Scimed Express balloon catheters. 
In the remaining 2 patients, repositioning the bal-
loon in the coronary artery 'was successful, after 
partial retrieval of the perfusion balloon to just 
proximal of the dilated segment. 
Balloon inflatiol1 arid clillical toler/mee: (Patients; 
n==-10, Flowtrack 40; n;=;12) Mean dmation of perfu-
sion balloon inflation was 270 ± 136 seconds 
(range 105-480; median 300). Distal perfusion dur-
ing balloon inflation could angiographically be 
demonstrated in all these patients. One patient 
(10%) had clear, but acceptable, anginal C011\-
plaints. Seven patients (70%) had mild angina dur-
ing inflation. Of the patients with angina, hvo had 
associated 1 mm ST -segment elevation and three 
had 1 mm ST-segment depression. Extra 
anti-anginal treatment was not given. No signifi-
cant blood pressure drop during balloon inflation 
was recorded. 
Angiographical and clinical results. (Patients; 
n=12) PTCA was successful in all patients. 
Diameter stenosis was reduced from 67 ± 10% 
(range 42-79%) to 23 ± 12% (range 2-40%); RD 
from 2.6 ± 0.8 (range 1.3-3.9 nun) to 2.8 ± 0.7 mm 
(range 1.7-4.2 mm); MLD from 0.8 ± 0.3 mm 
(range 0.4-1.4 nun) to 2.2 ± 0.6 mm (range 1.4-3.0 
mm). In three patients (25%) a small dissection 
(staining of some contrast medium parallel to the 
vessel wall, vanishing after a few cardiac cycles) 
\vas noted. No other angiographic complications 
were encountered. Clinical course was uneventful 
in all patients. 
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DISCUSSION 
Since the introduction of PTCA for treatment 
of coronary artery disease, angioplasty equip-
ment has been miniaturized. Low profile balloon 
catheters can now be used in association with 6F 
guiding catheters,!,2 and in selected cases even 
with 4F diagnostic catheters.s The major advan-
tage is the smaller arterial puncture hole, a key 
factor in preventing post procedural vascular 
complications. Another advantage is the possibil-
ity of selecting smaller arteries as entry sites, 
such as the brachial artery3 and radial artery,2 in 
order to reduce incidence and severity of vascu-
lar complications. Backup support and vessel 
opacification of 6F guiding catheters are compa-
rable with SF guiding catheters.4 However, one 
of the limitations of 6F guiding catheters is that 
they do not allow larger catheter systems, such 
as perfusion balloons, stent delivery systems, 
atherectomy catheters and catheters for intravas-
cular ultrasound. 
Perfusion balloons may be useful as primary 
tools if myocardial protection during inflatipn is 
required,6 (or example, if the patient does not tol-
erate inflations of normal duration because of 
severe angina or if hemodynamically dependent 
on the angioplasty vesse1.7 Prolonged dilatations 
may be required to improve acute suboptimal 
PTCA resultsR or to stabilize the patient before 
emergency coronary bypass surgery after failed 
PTCA, if stent implantation is impossible or con-
traindicated.9 The currently available perfusion 
balloons can only be used in combination with 
large bore guiding catheters. 
As demonstrated in this study, the low profile 
ACS Flowtrack 40 perfusion balloon catheter can 
be used in combination with 6F guiding catheters, 
allowing distal perfusion during balloon inflation 
(Figures 2A, B and C). Only recrossing the perfu-
sion catheter after complete retrieval from the 
guiding catheter turned out to be cumbersome or 
sometimes even impossible in some instances. To 
overcome friction between the perfusion catheter, 
now with a larger profile after initial inflations, 
and the guiding catheter, a considerable forward 
pushing force is applied at the proximal hypo-
tube catheter shaft. TIle flexible and relative weak 
part of the distal shaft, containing the peel away 
slit, easily kinks under these circumstances, 
resulting in prolapse of the guidewire through 
this slit. To overcome friction behveen the guid-
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Figure 2A. Right corollary aftcfY n'slel1osis. 
Figure 2B. Distal pe,jl/sioll durillg balloo" infJation 
at 6 atmospheres. 
ing catheter and the balloon, more stiffness of the 
distal part of the shaft is required, to propel for-
ward impulse towards the distal end of the bal-
loon catheter. By eliminating the 20 cm long 
peel-away slit and by increasing shaft stiffness by 
extra brading, this problem. may be overcome. 
With the current device, control angiography is 
better performed with the perfusion balloon 
retrieved to just proximal to the dilated segment, 
to allow recrossing and repeat dilatations if nec-
essary. In all but 2 cases the catheter could be 
advanced toward the obstructing lesion. In one 
patient, mismatch of the diameter of the coronary 
artery reference diameter, minimal luminal diam-
eter and catheter profile (1.3 mm, 0.4 mm and 
1.24 nun respectively) was responsible for failure. 
In the other patient, a 2.5 mm perfusion balloon 
Vol. 5, No.6, July! August 1993 
Figure 2C, Fillol fesult. 
(profile 1.24 mm) got obstructed in the center of a 
narrow lesion (0.8 mm) of excessive length (20 
mm), despite good backup support of the guiding 
catheter. In both instances conventional, large 
profile perfusion balloon catheters, probably also 
would have failed. Distal perfusion was demon-
strated to be present by contrast injection. 
Inflations were well tolerated and associated with 
no or minor EKG changes, absent or tolerable 
anginal complaints during prolonged inflations 
and absence of hemodynamic deterioration. 
These resuits demonstrate that this promising 
perfusion catheter further reduces the limitations 
of 6F guiding catheters. However, the perfor-
mance of this device can still be improved 
through advances in teclmology. 
SUMMARY AND CONCLUSIONS 
A new low profile perfusion balloon catheter 
was used as a primary device in combination ,,,,!th 
6F guiding catheters in 12 patients. It 'was dernon-
s,trated that these small sized guiding catheters do 
acconunodate the ACS Flowtrack 40 well and that 
distal coronary artery perfusion was present in all 
patients during balloon inflation. Although per-
formance of this device can still be improved, use 
of 6F guiding catheter no longer precludes the use 
of a perfusion balloon catheter. 
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POTENTIAL SOLUTIONS 
RADIAL ARTERY AS ENTRY SITE 
Feasibility of bailout techniques with 6 French guiding catheters 
BAILOUT TECHNIQUES FOR FAILED CORONARY ANGIOPLASTY USING 
6 FRENCH GUIDING CATHETERS 
F. Kicmeneij. GJ. Laannan 
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Bailout Techniques for Failed 
Coronary Angioplasty Using 6 
French Guiding Catheters 
Ferdinand KlemenelJ, MD, and 
Gert Jan Laarman, MD, PhD 
Coronary angloplasty (PTCA) through 6 French (F) guIdIng 
catheters Is feasIble, although acute or threatened closure fol· 
lowing coronary artery dissections may occur. This report de-
scrIbes our experience with the treatment of subopl1mal results 
In 13 pallents from a populallon of 144 pallents who had PlCA 
through 6F guIdIng catheters. Patients were treated with a new 
low profile autoperfuslon catheter (ACSE·, Flowtrack40~) or 
with Palmaz Schatz stents, advanced through 6F guIding cath-
eters, PTCA was performed via the radial artery In 11 pts (85%) 
or via the femoral artery In two patlenls (15%). In two patients, 
(15%) PTCA was complicated by an dlssecllon associated with 
complete loss of flow (TIMI 0) and a dlssecl/on was considered 
to lead to abrupt closure In the remaining 11 pallents (85%), 
despite the presence of normal flow. A Flow·track40s perfusion 
catheter was successfully applied In three of four patrents. In 
one pallent a persisting dissection after restoration of flow by a 
perfusion catheter was Ireated with three Palmaz Schatz stenls. 
Implantation of Palmaz Schatz stents was attempted as primary 
technique In nIne pallents. In one patient the stent could not 
cross a dIssection In the proximal LAD via the radial artery. With 
an 8F system via the femoral artery, two stents could success· 
fully be deployed with the stent delivery system. In another 
palient the stent could not be advanced across a subtotal reo 
sldual stenosIs In a tortuous left anlerlor descending coronary 
artery. OespUe normal antegrade ffow and emergency bypass 
surgery, this pallent developed a non-Q-myocardlallnfarcllon. 
In the remaining patients, the clinical course was uncomptf-
cated. With the limitations of the bare slent technique kept In 
mind, applying bailout techniques such as perfusion balloons 
and implantation of bare Palmaz Schatz coronary stents should 
be considered for Improvement of suboptimal angloplasty re-
sults In a selected group of patients afler PlCA with 6F guIding 
catheters. ~. 1994 Wlley-Uu, Inc. 
Key words: PlCA, dlssecUon, balloul, slentlng, perfusion 
balloons 
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INTRODUCTION 
Since the introduction of percutaneous transluminal 
coronary angioplasty (PTCA), a trend toward downsiz-
ing of balloon catheters was associated with considerable 
miniaturization of guiding catheters. PTCA through 6 
French guiding catheters can safely be perfonned [1-3]. 
However, despite improvement of material, PTCA still 
carries a risk for dissection and acute coronary artery 
occlusion [4,5]. 
The use of 6F guiding catheters was supposed to ex-
clude techniques such as perfusion balloon catheters and 
coronary stent implantation to improve suboptimal 
PTCA results. This report describes our experience in the 
management of suboptimal PTCA results and impending 
acute occlusion after PTCA through 6F guiding cathe-
ters, 
MATERIALS AND METHODS 
Deflnilion. 
A PTCA was considered to be suboptimal if the reo 
sidual diameter stenosis exceeded 40% or if dissections 
were visible with established or impending loss of flow. 
From the geometry of the coronary segment, reference 
diameter, minimal luminal diameter, and diameter ste-
nosis were derived (Quantitative Coronary Analysis by 
Philips DCI, Philips Medical Systems, Best, The Neth-
erlands). 
Dissections were classified according to the defini-
tions described by Dorros et a1. [4]. The perfusion status 
of the target vessel was classified according to the grad-
ing system of the Thrombolysis In Myocardial Infarction 
(TIMI) study [6]. Lesion morphology was classified ac-
cording to the definitions established by an American 
College of Cardiology/American Heart Association task 
force [7J. 
Study Population 
The study population was retrieved from 144 patients 
who underwent balloon angioplasty through 6F guiding 
catheters in our department between August 1992 and 
August 1993. This group comprised 13 subjects (9%), 
aged 64 ± 12 years, with a suboptimal PTCA result. A 
majority of patients (92%) \vere in CCS class III or IV, 
and one patient (8%) had nonexertional angina. Three 
patients had prior PTCA (23%) and one patient had prior 
coronary bypass surgery (8%). 
103 
360 Kiemenelj and Laarman 
Medical Treatment After Stent Implantation 
All patients received Heparin 5,000 IV after insertion 
of the arterial introducer sheath. This dose was repeated 
if the procedure lasted> 1 hr. Nifedipin 10 mg was 
administered sublingually. Before angiography and fol-
lowing PTCA, nitroglycerin 100-300 mgr intracoronary 
was administered and repeated if indicated. 
At the moment the decision of stent implantation was 
made, an additional bolus of Heparin 5,000 IV was given 
and Dextran 40 was administered, the first 500 ml at a 
rate of 100 mllhr, the second 500 ml at a rate of 50 mllhr. 
After stent implantation, dipirydamole 225 mg/d and ac-
etosalicylic acid 300 mg/d was started. The introducer 
sheath was removed immediately after the transradial 
procedure. After transfemoral stent implantation, the 
sheath was withdrawn at an Activated Partial Thrombo-
plastin Time (APTT) under 60 sec. 
At 3 hr after hemostasis was achieved, 3,000 IV hep-
arin was administered intravenously. Heparin was ti-
trated to APTTs of 80-100 sec until stable adjustment on 
oral anticoagulant drug therapy (3 consecutive therapeu-
tic Thrombotests) was obtained. Coumadin was given for 
3 rna and acetosalicylic acid and dipyridamole were 
given for 6 mo. 
Materials 
PTCA Catheters. For this study, Scimed@ 6F Tri-
guide-Elite@ guiding catheters were used. These cathe-
ters are 100 Col long and have an inner diameter of 
0.060" (1.53 mm). We used compliant rapid exchange 
balloon catheters (Scimed® Express@), the size being 
detennined by the reference diameter of the target seg-
ment and the inflation pressure applied. 
Perfusion balloon catheters. The perfusion balloon 
catheter used was the ACS® RX Flowtrack®40. Flow 
rate is 40 cc/min. This rapid exchange (20 em "peela-
way") catheter consists of a 135-cm-long Dynacross® 
shaft (proximal 2.3F and distal 3.5F). The shaft has 14 
perfusion holes, 0.014" in diameter, 10 proximal and 4 
distal from the balloon. The balloon is made of PE-600. 
Rated burst pressure is eight atmospheres. 
The balloon was inflated up to eight atmospheres. 
Presence of distal flow, defined as distal contrast opaci-
fication of the coronary artery during balloon inflation 
and the contrast agent disappearing after a few cardiac 
cycles, was angiographically assessed. The guiding cath-
eter and guidewire were subsequen'ly withdrawn proxi-
mal to the shaft marker in order to maximize perfusion. 
Balloon inflations of at least 300 sec were attempted. 
Stenls. A 15-mm Palmaz Schatz coronary stent 
(Johnson & Johnson Interventional Systems, Warren, 
NJ) was manually crimped on the balloon catheter, so 
that the balloon marker was positio,1ed in the middle of 
the stent and no free movement from the stent over the 
balloon was noted. The primary used balloon catheter 
was used as stent carrier, because its increased profile 
after the first inflations will allow better fixation for the 
stent, compared to a balloon, tightly wrapped on the 
catheter shaft. The balloon was cleaned with saline to 
remove contrast agent, possible blood clots, and lubri-
cating coating. The stent loaded balloon catheter was 
advanced over the guidewire toward the stenosis, under 
concomitant contrast medium delivery. After delivery, 
the stent diameter was optimized by successive dilata-
tions with higher inflation pressures or with larger bal-
loon catheters. 
strategies for Improvement of PTCA-Results 
Conventional means to obtain improvement of subop-
timal results comprised administration of nitrates, cal-
cium antagonists, additional heparin, or prolonged infla-
tion with the dilatation catheter. Stenting as first choice 
bailout technique W(l.S perfomled if the perfusion balloon 
was 100 short to cover the dissection, if the dissection 
persisted or extended under prolonged dilatations with 
the dilatation catheter, or in the initial phase of this study 
when no low profile perfusion balloons were available. 
Treatment with a perfusion balloon was attempted first if 
the vessel was not suitable for stenting or if contraindi-
cations for anticoagulation precluded stent implantation. 
Sten! implantation following the use of a perfusion bal-
loon was perfonned if the result of prolonged dilatations 
was considered suboptimal. 
RESULTS 
In II patients (85%), PTCA was performed via the 
radial artery after confirmation of collateral, ulnar blood 
supply to the hand, by performing the Allen test. 
PTCA was perfonned via the femoral artery in two 
patients (15%). Baseline quantitative coronary data and 
details on lesion severity and morphology before and 
after PTCA and after repair are shown in Table I. Com-
plex lesion morphology (Types Band C) was seen in 10 
patients (77%). In all patients, major dissections fomled 
the reason to to apply a bailout technique; 11 patients had 
nonnal coronary perfusion but a residual stenosis ~ 45% 
(85%) and 2 patients had an occlusive dissection (15%). 
Bailout Techniques 
The Flowtrack 40 perfusion catheter was used as pri-
mary device in four patients. The catheter could be po-
sitioned and retrieved without problems. 
Mean duration of balloon inflations (1-3 inflations per 
patient) was 450 sec (range 300-900 sec). During bal-
loon inflation, coronary flow distal to the balloon could 
angiographically be demonstrated in all patients. AI-
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TABLE I. Lesion Characteristics Before and After PlCA and After Intervention' 
Pre·PTCA Post-PTCA Final result 
No. eA %DSffThUlLesion" %DSrnMIIDissb Strategy %DSrnMIJDiss 
LAD 76 3 A 1()() 0 E PSS (I) 22 3 
LAD 72 3 e 55 B PSS (I) 22 
" LAD 60 A 45 A PSS (I) 20 
4 LAD 60 e 66 B Ff 900 se<: 35 B , LeX 73 B 
" 
3 A PSS (I) 19 A 
6 LAD 70 3 
" 
68 3 A PSSIUCABG 68 A 
7 LAD 
'" 
3 B 50 e PSS (2) 21 
8 LAD 75 B 45 B PSS (I) , 
9 LAD 57 e 50 3 B PSS (2) 21 3 B 
10 Lex 66 B 60 3 B PSS (2) 27 3 
11 RCA 72 3 C 1()() 0 e FfIPSS (3) 29 B 
12 LAD 79 J A 50 J A Ff 300 se<: 7 
!3 LAD 50 3 B 45 3 B IT 300 se<: 21 
Mean±ISD 67 ± 9% 60 ± 19% 24 ± 15% 
Median 70% 51% 21% 
• Abbreviations: CA = coronary artery; %DS = percent diameter stenosis; TIMI = Thrombolysis In M>'ocanlial Infan:tion flow grading; LAD = left 
anterior descending coronary artery; PSS = Palmaz Schatl stent: (n) number implanted; PI' = Flowtrad; perfusion catheter; UeABG = urgent coronary 
artery bypass grafting; LeX = left cin:umfle~ coronary artery; RCA = right coronary artery. 
'See ref. {7] for lesion morphology classification. 
bSee ref. [4] (or disse<:lion classification. 
though these patients had chest pain of moderate sever-
ity, no major EKG-changes and no hemodynamic dete-
rioration were recorded. 
Angiographical results were satisfactory in three pa-
tients (fable I). Clinical course was uneventful, and 
these patients were discharged the next day. 
In one patient with a total occlusion of the right cor-
onary artery, I hr after PTCA, flow could be restored 
with a Flowtrack catheter (Fig. I). After balloon defla-
tion, a large dissection persisted. Three IS-mm stents 
were successfully implanted to cover the dissection. Car-
diac enzymes remained nonnal and no electrocardio-
graphical signs of myocardial infarction were present. 
In nine patients implantation of a Palmaz Schatz stent 
was attempted as primary technique; in four patients, no 
Flowtrack was available, and in four patients the dissec-
tion was considered too long or too complex. In one 
patient, a stent was selected because no major change in 
morphology of a short dissection in the LAD was ob-
served despite two high pressure dilatations of I min 
duration with an adequate+size balloon (Fig. 2). In this 
patient, the stent·loaded balloon catheter could not be 
advanced across the lesion. During attempts to reach the 
stenosis, the stent partially slipped from the balloon. In-
stead of retrieving the stent from the LAD, with the risk 
of stent loss and embolization, the operator was forced to 
deploy the stent proximal from the lesion. Since attempts 
to recross the stenosis with other balloons also failed, the 
patient was referred for bypass surgery in a stable con-
dition. Postoperative course was complicated by a non-
Q-myocardial infarction (CKMB 79 lUll). 
Transradial artery stent implantation failed in another 
patient with a significant residual stenosis and type B 
dissection after PTCA for a proximal LAD restenosis 
(Fig. 3). Six guiding catheters were used before enough 
support was obtained to allow passage of the balloon 
catheter across the stenosis. Three attempts to cross the 
dissection with a stent-Ioaded balloon failed, due to in-
sufficient guiding catheter support and poor coaxial 
alignment of the guiding catheter. Through an 8F FL4 
guiding catheter via the right femoral artery, two stents 
were successfully implanted, with use of the sheath pro-
tected Stent Delivery System (Johnson & Johnson). In 
this patient, the clinical course was complicated by groin 
bleeding, necessitating a blood transfusion. Transradial 
artery stent implantation was successful in the remaining 
seven patients and clinical course was free of death, 
myocardial infarction, bypass surgery, rePTCA, and 
bleeding complications. 
DISCUSSION 
Since the introduction of PTCA for treatment of cor-
onary artery disease, angioplasty equipment has been 
miniaturized. Low profile balloon catheters can now be 
used in association with 6F guiding catheters [1-31 and 
in selected cases even with 4F diagnostic catheters [8]. 
The major advantage is the smaller arterial puncture 
hole, a key factor in preventing postprocedural vascular 
complications. Another advantage is the possibility to 
select smaller arteries as entry site, such as the brachial 
artery [9] and radial artery [3]. 
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Fig. 2. A, Type B lesion In a tortuous left anlerior descending coronary artery. B. Afler balloon 
dllatalfon, a significant residual stenosis and type A dlssecllon (arrow). C. Deployment of a 
15·mm Paimaz Schatz slent proximal from the stenosis. D, Final result after attempts to recross 
Ihe stenosis formed Indication for bypass surgery. 
Fig. 1. A. Type B lesion In the right coronary artery (arrow). B, 
Afler PTCA, a dissection type B was visible (arrow). C. RCA was 
totally occluded 1 hT laler. D. Flow was restored with a 
Fiowtrack 40 3.0 perfusion calheter, E. After balloon deflation, a 
residual slenosis and dissection type C were appreciated. F. 
Result following implanlallon 3 Palmaz Schatz slents was optl· 
mal (arrows). 
The radial approach is especially attractive because Ihe 
superficial course of this artery, together with the ab-
sence of major nerves and veins near the distal radial 
artery, allows effective hemostasis and is associated with 
low risk for puncture site-related complications, such as 
bleeding, arteriovenous fistula, and nerve damage, and 
with early patient ambulation. In 100 patients in whom a 
transradial PTCA was attempted. no major puncture site-
related bleeding complications were encountered (3). 
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Fig. 3. A. Dissection in the proximal LAD (arrow). S. Deployment of the distal stent w1th the 
stent delivery system. C. Deployment of the proximal stent with the stent delivery system. D. 
Final result. 
Early asymptomatic radial artery occlusion was present 
in 10 patients (10%), but in five patients (50%) sponta-
neous recanalization of this artery was encountered. Pro-
cedural success was 98% (92/94 pts via the radial artery 
and 6/6 piS via the femoral or brachial artery). However, 
the inner diameter of 6F guiding catheters may compro-
mise the use of large catheter systems, such as perfusion 
balloons, stent delivery systems, atherectomy catheters, 
and the current catheters for intravascular ultrasound. 
Prolonged dilatations with perfusion balloons may be 
required to improve acute suboptimal PTCA results [10] 
or to stabilize the patient before emergency coronary 
bypass surgery after failed PTCA [II], if stent implan-
tation is impossible or contraindicated. 
We recently reported on the successful use of the 
Flowtrack 40 perfusion catheter as a primary device 
through 6F guiding catheters [12]. The present study 
illustrates that the use of a low profile ACS® 
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FLowTrack@l40 perfusion balloon catheter can be at-
tempted to restore coronary geometry in the treatment of 
dissections after PTCA, with adequate distal perfusion 
during balloon inflation. Thus, 6 French guiding cathe-
ters no longer preclude the use of this bailout technique. 
Implantation of Palmaz Schatz stents is an effective 
technique to stabilize patients after suboptimal ?TeA 
results despite a reported higher incidence of subacute 
stent thrombosis, compared to elective stenting [13-17]. 
At suitable coronary anatomy, stenting may be the strat-
egy of choice if results of prolonged inf1ations are sub-
optimal, if these inflations are poorly tolerated by the 
patient or if the dissection is to long to be covered by the 
perfusion balloon. Sten! implantation through 6F guiding 
catheters has been reported by Urban et al. [18J and by 
our group [19J, which has the potential for a reduction of 
bleeding complications, compared to sten! implantation 
via 8F guiding catheters. We recently described 20 pa-
tients who underwent successful stentimplantation via 
the radial artery with 6F guiding catheters (ms. ac-
cepted). No subacute stent thrombosis and major local 
bleeding complications were encountered in this small 
series. 
During continued experience by our group (50 pa-
tients), 63 stents were successfully implanted (proce-
dural success; 96%) and no stent thrombosis or major 
entrysite bleeding complications were noted (unpub-
lished data). The procedural success of the trans radial 
technique is comparable with procedural results in the 
multicenter Benestent study where all patients received a 
stent via the femoral artery. Bare stents as well as sheath-
protected systems were used in this study. Of 251 pa-
tients in whom stent implantation was attcmpted, proce-
dural success was 92.3%. Inability to cross the lesion 
with a stent occurred in 16 patients, and in I patient a 
significant stenosis persisted [20]. The femoral, sheath-
protected stent technique as applied in the multicenter 
STRESS trial had a procedural success of 96. J % [21], 
However, two limitations of tile transradial, bare stent 
technique arc illustrated in the current report. Preshaped 
catheters (e.g., Amplatz, Judkins curves) are designed 
for the femoral approach, whereas the approach from the 
right arm often compromises the properties of these cath-
eters, such as adequate support for passage of unpro-
tected stent-loaded balloons over the target coronary le-
sion. This problem was encountered in one patient where 
6F Judkins Left and other catheters did not provide 
enough support and coaxial alignment. Via the femoral 
artery, enough support of an SF Judkins Left-curved 
catheter obtained to allow passage of a stent delivcry 
system. In the other patient where the stent failed to cross 
a mid-LAD dissection, an attempt with the SDS also 
would have failed since balloon catheters of lower profile 
could not be advanced over the dissected segment. 
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A limitation of both the bare stent teChnique as the 
sheath-protected technique is the inability to cross tortu-
ous coronary segments and tight lesions. Since only the 
bare stent technique can currently be applied in combi-
nation with 6F guiding catheters, stent displacement and 
embolization remain serious hazards during attempts to 
advance the system over curves and severe obstructions 
and during retrieval of the stent-Ioaded balloon in the 
guiding catheter, as was the case in one patient. In such 
a situation, both the stent-loaded balloon catheter and the 
guiding catheter need to be withdrawn, preferrably over 
the intracoronary guidewire. This maneuver carries con-
siderable risk for losing distal access by inadvertent loss 
of guidewire position. To circumvent this problem, the 
stent can be deployed proximal from the target lesion, 
provided that coronary anatomy is suitable for stenting. 
With these limitations in mind, applying bailout tech-
niques such as perfusion balloons and implantation of 
bare Palmaz Schatz coronary stents should be considered 
for improvement of suboptimal angioplasty results in a 
selected group of patients after PTCA with 6F guiding 
catheters. 
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POTENTIAL SOLUTIONS 
RADIAL ARTERY AS ENTRY SITE 
'fi'ansl'udial coronary angiopiasty 
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CLINICAL INVESTIGATIONS 
Transradial artery coronary angioplasty 
This study explored the feasibility and safety of percutaneous coronary balloon angloplasty 
(PTCA) with miniaturized PTCA equipment via the radial artery. Coronary angloplasty (PTCA) via 
the femoral or brachial arteries may be associated with rare vascular complications such as 
bleeding and damage to the artery and adjacent structures. It was postulated that PTCA via the 
radial artery with miniaturized angloplasty equipment Is feasible and thai no major puncture 
site-related compllcallons occur because hemostasis is obtained easily and because no major 
structures are near the radial artery. With double blood supply to the hand, radial artery 
occlusion is well tolerated. In 100 patients with collateral blood supply to the right hand, PTCA 
was attempted with 6F guIding catheters and rapid-exchange balloon catheters for exertional 
angina (87 patients) or nonexerUonal angina (13 patlenls). Angloplasty was attempted In 122 
lesions (type A n = 67 {55%], Type B n = 37 [30%], and type C n = 18 [15%]). Pre- and 
post-PTCA computerized quantitative coronary analysis was performed. Radial artery fUnction 
and structure were assessed clinIcally and with Doppler-and two-dimensional ultrasound on the 
day of discharge. Coronary catheterization vIa the radial artery was successful in 94 patients 
(94%). The 6 remaining patients had successful PTCA via the femoral artery (n = 5) or the 
brachial artery (n = 1). Procedural success (120 of 122 lesions) was achieved In 92 patients 
(98%) via the radial artery and In 98 patients of the lolal study population. Minimal luminal 
diameter Increased from 0.9 ± 0.3 (0 to 1.8) to 2.0 ± 0.5 (0.6 ± 3.6) mm, and diameter stenosis 
was reduced from 74% ± 11% to 24% ± 11%. In 3 pallents a coronary stent was Implanted via 
the radial artery because PTCA resulls were suboptimal. Of 98 patients with a successful PTCA, 
four (4%) had acute myocardial Ischemia 1 to 24 hours after the procedure. In these pailents an 
emergency second PTCA procedure via the femoral artery was performed successfully. but In 2 
patients a myocardiallnfarc!lon could not be prevented. No other major cardiac complications 
were encountered. No major entry site-related complicallons were seen, and no patient required 
vascular surgery or blood transfusions. In 10 patients radial artery pulsations were absent at 
discharge, and all 10 were asymptomatic. Of these 10 patients, lale recanalization was evldenl in 
5, and In 3 patients pulsations remained absent. PTCA via the radial artery Is effective and safe 
and minimizes major puncture sIte-related complications. (AM HEART J 1995j129:1-7.) 
Ferdinand Kiemeneij, MD, Gert Jan Laarman MD, PhD, and Edwin de Melker, MD 
Amsterdam, The Netherlands 
The external diameter of the guiding catheter used 
during the first percutaneous transluminal coronary 
angioplasty (PTCA) was 9.4F.l At present PTCA is 
most commonly performed with SF F guiding cat.he-
ters. The use of these large-bore guiding catheters in 
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conjunction with aggressive ant.icoagulation may con· 
tribute to uncommon but. severe entry sit.e-related 
complications such as bleeding, pseudoaneurysms, 
arteriovenous fistula, nerve damage, and arterial oc-
clusion. 
Low-profile rapid-exchange balJoon catheters per-
mit use of miniaturized guiding catheters while 
maintaining the advantages of over-the-wire sys-
tems: free guide wire movement and the ability to 
exchange balloons of different. diameters with main-
tenance of ·distal access. The performance of 6F 
guiding catheters wit.h regard to cont.rast delivery, 
pressure monitoring, and backup support is ade-
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Table I. Baseline characteristics 
Patients 
Gender 
Male 
Female 
Age (yr) 
Height (em) 
Weight (kg) 
Oral anticoagulation' 
Acetylsalicylic add 
DipyridlUnol 
Coumadin 
Angina (CeS class) 
Exertional 
I 
II 
III 
IV 
Nonexertional 
Previous myocardial infarction 
Previous bypa_',s surgery 
Hypertension 
Diabetes mellitus 
Cholesterol ;:::6.5 mmol/L 
Cigarette smoking 
Family history 
ees, Canadian Cardiovascular Society. 
'Not mutually exclU:5iv .... 
n (%) 
100 
77 
23 
62 ± 10 (34·82) 
172 ± 8 (154·190) 
78 ± 10 (5-4·100) 
80 
4 
10 
87 
1 
5 
67 
14 
13 
45 
14 
37 
11 
33 
58 
43 
quate,2 and pressure damping by the guiding cathe-
ter is encountered less frequently t.han with SF guid-
ing catheters. With these smaller guiding catheters, 
arterial puncture holes also become smaller, making 
possible fewer bleeding complications, shortened he-
mostasis time, and early ambulation. Another poten-
tial advantage of 6F guiding catheters is the possibil-
ity to select smaller arteries, such as the brachial or 
radial artery, as the entry site for PTCA. The safety 
of transradial corOllary angiopiasty is determined 
mainly by t.he favorable anatomic relations of the ra+ 
dial artery to its surrounding structures. No major 
veins or nerves are located near the radial artery, 
minimizing t.he chance of related injury to these 
structures. Because of the superficial course of the 
artery, hemostasis can be obtained easily by local 
compression. Thrombotic or traumatic artery occlu-
sion does not endanger the viability of the hand, if 
adequate collateral blood supply by the ulnar artery 
is present.. The purpose of this study was to explore 
t.he feasibility and safet.y of transradial artery PTCA 
with 6F guiding catheters and low-profile rapid-
exchange balloon catheters in 100 patients. 
METHODS 
Patient selection. f'rom six interventional practitioners 
in our group, first one and in a later phase two in\'estiga-
January 1995 
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tors performed this feasibility study. Suitability to partic-
ipate in this study with regard to local vascular and cardiac 
status was assessed at the arrival of the patient in the 
catheterization laboratory. The radial and ulnar artery 
pulsations were examined and the Allen test performed. 
The result of the Allen test was considered normal when 
after compression of both ulnar and radial arteries the 
normal color of the hand returned within 10 seconds after 
release ofthe ulnar artery. Because neither investigator was 
experienced with the transradial approach, a greater num-
ber of ideal candidates were selected in the early phase of 
this study. In a later phase, however, unstable angina, 
multi\'essel PTCA, complex lesion structure, and venous 
bypass graft stenosis formed no reason to exclude patients 
from this approach. Exclusion criteria were evident heart 
failure requiring right heart catheterization, expected he· 
modynamic deterioration during balloon inflation, the 
need for intraaortic balloon pumping (for example, during 
PTCA of the "last remaining vessel"), and PTCA for 
chronic total occlusions. 
Medical preparation. Before the procedure diazepam, 5 
mg was administered orally. Immediately after insertion of 
the arterial introducer sheath, heparin, 5000 IU was 
administered. The same dose was given for each hour dur-
ing the procedure. Activated partial thromboplastin time 
(APTT) was not monitored during the procedure. One to 
2 hours after immediate sheath removal and local hemo-
stasis, heparin infusion was begun and continued over-
night, titrated to APTT values of 60 to 80 seconds (normal 
30 to 40 seconds) in case of evidence of intracoronary 
thrombosis or dissection. Before initial and final angiogra-
phy (Hexabrix 320) intracoronary nitroglycerin, 100-300 Jig 
was administered and repeated on indication during the 
procedure. Nifedipin, 10 mg was given sublingually in case 
of radial or brachial artery spasm. 
Catheterizalion and ang!oplasty 
Radial artery catheterization. The right. arm, supported 
by a sideward extension of the catheterization t.able, was 
abducted to 70 degrees, and the wrist was hyperextended. 
After local anesthesia with lidocaine 2 %, the anterior wall 
of the radial artery was punctured with an arterial intro-
ducer needle or with a 22-gauge radial artery catheteriza-
tion needle (Arrow International, Reading, Pa.) set at 45 
degrees 1 cm proximal from the styloid process. After ap· 
pellIanCe of pulsatile flow from the Arrow needle, a 0.025· 
inch, 260 cm straight. guide wire (Allgiomed, Karlsruhe, 
Germany) was introduced; this set does not allow passage 
of a larger wire. An Angiomed O.035-inch, J-tipped guide 
wire was advanced if an arterial introducer needle was used. 
A small skin incision was made with a number 11 surgical 
blade, followed by insertion of a 6F 10 cm arterial intro-
ducer (Hemaquet. II, Bard, Billerica, 1>.lass.). 
Coronary artery cannulation. The position of the oper-
ator at the catheterization table was similar to that during 
the femoral approach. A guiding catheter (Scimed Life 
Systems, Maple Grove, Minn.; inner diameter 0.060 inch, 
shaft length 100 cm) was selected with au appropriate curve 
to provide maximal backup support during angioplasty. 
The guiding catheter was advanced over a long (260 em) 
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Q,025-inch guide wire positioned in the aortic root. The 
right coronary artery was cannulated with Judkins Right 
catheters and with multipurpose or EI Gamal catheters, 
Cannulation of the left coronary artery with a Judkins Left 
catheter requires special manipulation: over the guide wire, 
the catheter tip must be advanced and turned toward the 
coronary ostium. When the primary curve of the catheter 
reaches the aortic valve, withdrawal of the guide wire 
results in angulation of the secondary curve, which causes 
the tip of the catheter to be lifted toward the coronary os-
tium, We used the Judkins Left catheter as a first choice, 
followed by multipurpose and Amplatz catheters. 
Angi ograpliy. Computerized quantitative coronary anal-
ysis was performed with the DCI Polydiagnost C2 x-ray 
imaging system (Philips Medical Systems, Best, The Neth-
erlands). Pre- and post-PTCA single-plane digital coro-
nary angiography was performed under standard condi-
tions to permit quantitative analysis, We used automated 
edge·detection software to analyze digital radiographic 
images, with the guiding catheter as the calibration stan-
dard. From the shape of the coronary segment, the refer-
ence diameter, minimal luminal diameter, and diameter 
stenosis were derived. 'rhe perfusion status of the target 
vessel was classified according to the grading system of the 
Thrombolysis in Myocardial Infarction (TIM!) triaJ.3 The 
morphologic t.ypes of the lesions were determined accord-
ing to the definitions established by an American College 
of Cardiology-American Heart. Association Task Force.4 
Coronary artery dissections were defined according to the 
classifications described by Dorros et. aU' 
Angioplasty. After angiography a O.014-inch guide wire 
(High Torque Floppy, Advanced Cardiovascular Systems, 
Santa Clara, Calif,) was advanced across the lesion. Over 
this guide wire a rapid-exchange, low-profile, compliant 
balloon catheter (Scimed Express) was positioned at. the 
stenosis. Inflation pressures were adjusted according to 
balloon diameters given by the manufacturer and the ref-
erence diameters of the target segments. Performance of 
the guiding catheter (back-up support, opacification of the 
target vessel, and pressure monitoring) and of the balloon 
catheter (crossability and retrievability) were semiquanti-
tativelyscored as good,moderate (no need to change guid-
ing or balloon catheter), or poor (need to change guiding or 
balloon catheter), 
Introducer sheath removal and hemostasis. 'l'he arterial 
sheath was removed directly after withdrawal of the guid-
ing catheter, followed by application of a tourniquet. at the 
radial puncture site, The tourniquet was released gradually 
over a 15- to 30-minute period. After hemostasis had been 
achieved, a pressure bandage was applied over the punc-
tured artery for 6 hours. Patients were not restricted to bed 
rest but were advised to refrain from movements of the 
wrist joint. 
Predischarge examinations. The radial artery was eval-
uated for the presence of pulsations. The Allen test. was re-
peated. The reversed Allen test, the result of which is nor-
mal when after compression of ulnar and radial arteries the 
hand becomes normally colored <10 seconds after release 
of the radial artery, also was performed. Claudication of the 
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Table II. Allgiographic data 
n % 
Distribut.ion of lesions (n "" 122) 
LAD 51 41 
RCA 24 20 
Lex 22 18 
OM 16 13 
Diagonal 6 5 
VBG 2 2 
RDP 
TIMI grade 
0 3 2 
1 
2 5 4 
3 113 93 
Type of lesion (n = 122) 
A 67 55 
B 37 30 
C 18 15 
Calicified lesion 8 7 
Thrombus at lesion 2 2 
Dissection 1 
LAD, Left snterior deBcending cQIonruy artery; I.CX, left circumflex 00.0· 
nary aIterj~ OM, obtw<e marginal branch: RCA, right coronary artery; RDP, 
right descending posterior branch; TIMI, Thrombolysis in Myocardia! In-
farction trial: VBG, venous bypass graft. 
hand was tested by asking the patient to open and close the 
hand 50 times, A two-dimensional and Doppler ultrasound 
study was performed just- before discharge. If radial artery 
pulsations or flow were absent, an ultrasound study was 
repeated after 1 to 3 months. 
Definitions of success. Procedural success was defined 
as <50% Tesidual stenosis and normal flow without. proce-
dural major cardiac complications such as death, acute 
myocardial infarction, or coronary bypass surgery, Clinical 
success was defined as procedural success, absence of car-
diac complications, and no need for second PTCA from the 
moment the guiding catheter was withdrawn from the pa-
tient. 
RESULTS 
Study population. Between August 1992 and April 
1993, 660 patients underwent PTCA in our depart-
ment. From the 430 patients assigned to the two in-
vestigators, 100 patient-s were selected for transradial 
artery balloon angiopiasty. Clinical baseline charac-
terist.ics are summarized in Table I. 
Angiographlc data Distribution of angioplasty le-
sions, TIMI grade flow, and morphologiC types of le-
sions are presented in Table II. Reference diameter 
of target segments was 2.5 ± 0.5 (1.4 to 4.2) mm, 
minimal luminal diameter 0.9 ± 0.3 (0 to 1.8) mm, 
and diameter stenosis 74% ± 11% (30% to 100%). 
Procedure 
Radial artery cannulation. The radial artery was 
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Table iii. Balloon catheter selection and inflation char-
acteristics 
Total 
Balloon diameter (mm) 
2.0 
2.5 
3.0 
3.6 
No. of inflations 
Pressure (atm) 
Balloon size during inflation (mm) 
II % 
104 
14 13 
53 51 
34 33 
3 3 
2.9 ± 1.1 (1-7) 
10.6 ± 1.9 (6-15) 
3.0 ± 0.5 (1.9-4.1) 
successfully punctured and cannulated in 96 patients 
(85 % within 5 minutes). In 3 patients radial artery 
puncture failed, and in 1 patient the guide wire could 
not be advanced, leading to temporary staining of 
contrast medium in. the radial artery vessel wall. 
Three of these patients had successful PTCA via the 
femoral artery and 1 via the brachial artery. No pro-
cedural complications leading to functional disability 
of the hand or requiring vascular surgery were 
encountered. 
Guiding catheter selection and performance. 
Coronary artery cannulation with 6F guiding cathe-
ters was successful in 94 (98%) of 96 transradial ar-
tery procedures (89% within 5 minutes). In 1 patient 
the procedure had to be discontinued because of se-
vere spasm of the radial artery. In another patient the 
guiding cat.heter could not be advanced beyond a 
tortuous subclavian artery. Both patients had suc-
cessful PTCA via the femoral artery. One hundred 
fort.y-seven guiding catheters (1.47 catheters per 
procedure) were selected before the coronary artery 
was cannulated. For the left. coronary artery 
1.51 ± 1.09 and for the right coronary artery 
1.2 ± 0.65 guiding catheters were used (p not signif-
icant). Inability to engage the ostium of the coronary 
artery and kinking of the shaft after excessive ma-
nipUlations of the guiding catheter were t.he major 
reasons for failure. For PTCA 103 catheters were fi-
nally used. The left coronary artery was cannulated 
with t.he Judkins Left (49%), multipurpose (35%), 
Amplatz (11%), and El Gamal (5%) catheters and 
the right coronary artery with Judkins Right (40%), 
multipurpose (30%), and EI Gamal (30%) catheters. 
For these catheters, contrast opacification and pres-
sure monitoring were rated good in 97 % and 99 % of 
instances, respect.ively. Backup support was good in 
80% and moderate in 20% of cases. 
Balloon catheter selection and performance. For 
100 pat.ients, 104 balloon catheters (1.04 balloons per 
patient) were used. Details On balloon size and infta· 
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tions are given in Table III. Only 3 (3%) balloon 
catheters with a diameter of 3.5 mm were used 
because t.he compliant. 3.0 mm dilatation catheters 
reach a diameter >3.5 mm at inflation pressures> 11 
atm. Larger vessels were not encountered frequently 
in this study. Difficulty in vessel opacification and 
balloon retrieval did not playa role in selection of the 
smaller balloon cat.heters. Passage of the dilatation 
catheter through the guiding catheter and crossabil-
ity at the stenosis was rated good in 89% and mod-
erate in 9% of cases. All balloon catheters were suc-
cessfully retrieved, but 3 balloons were pulled back 
with noticeable friction. 
Angiographlc results. Procedural success was ob· 
tained in 92 (98 %) of 94 t.ransradial artery PTCAs 
and in the 6 PTCAs performed via the femoral or 
brachial arteries. Two (1.6%) lesions (reference di· 
ameter 1.9 and I.8mm, minimal luminal diameter 0.6 
and 0.9 mm) could not. be crossed with the dilatat.ion 
catheter. In both patients a second attempt via the 
femoral artery with 8F guiding catheters and lower-
profile balloon catheters also failed. Of 122 lesions, 
120 (98.4 %) were successfully crossed and dilated. 
Minimal luminal diameter increased to 2.0 ± 0.5 (0.6 
to 3.6), mm and diameter stenosis was reduced to 
24% ± 11% (0% t068%).Inthree (3%) patients the 
final result was considered suboptimal because of an 
obstructive dissection at the angioplasty site; in these 
cases a Palmaz-Schatz stent. (Johnson & Johnson In-
terventional Systems, Warren, N. J.) manually 
crimped on t.he same type balloon catheter was 
implanted, also via the radial artery, with an optimal 
result. At 10 (8 %) angioplast.y sites a type A 5 dissec-
tion and at 20 (16%) sites a type B dissection was 
visible. At 3 sites (2 %), a minor side branch was oc-
cluded without clinical or electrocardiographic signs 
of ischemia. No other procedural complicat.ions were 
encountered. The procedure lasted 15 to 120 (mean 
35 ± 17) minutes. 
Hemostasis. Hemostasis was obtained 29 ± 15 (16 
to 120) minutes after sheath removal. In one patient, 
collagen (Vasoseal) was applied subcutaneously near 
the puncture opening to stop prolonged leakage of 
blood. 
Clinical course. The 2 patients in whom t.he attempt 
to Cross the stenosis had failed had an uncomplicated 
clinical course. Of 98 patients with a successful 
PTCA,4 (4%) patient.s had acute myocardial ische-
mia. One patient had chest pain and electrocardio-
graphic changes 1 hour after PTCA of the left 
circumflex coronary artery (LCX) (11% residual 
stenosis, no dissection). At acute angiography the di-
lated segment showed no abnormalities, but a signif-
icant lesion was now visible more distally in the ves-
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sel. The patient had an uncomplicated course after 
successful PTCA of that lesion. One patient had un-
stable angina pectoris 1.5 hour after successful PTCA 
of t.he LCX (30% residual stenosis, type B dissec-
tion). During acute angiography, a significant steno-
sis caused by dissection and thrombus was visible; 
subsequent PTCA was successful. A small (creatine 
kinase MB isoenzyme [CK-MB] 35 lUlL) non-Q-
wave myocardial infarction developed in this patient. 
Another patient had a total occlusion 12 hours after 
PTCA of the left. anterior descending coronary artery 
(LAD) (24 % residual stenosis, type B dissection). 
Despite successful emergent second PTCA, the pa-
t.ient had a Q-wave anteroseptal infarction with a 
maximal CK-MB of 119 lUlL. One patient had three 
episodes of unstable angina, the first episode 24 hours 
after successful PTCA of the LAD for postinfarction 
angina pectoris (47% residual stenosis, type B dis-
section). 'I'his patient had three successful recanali-
zat.ions for reocclusions of the LAD. None of t.hese 
repeat PTCAs was followed by increases in CK-MB 
or development of new Q waves. All second PTCAs 
were performed via the right femoral artery. No 
emergent coronary artery bypass surgery was needed. 
No bleeding complications from the puncture site 
were recorded. Vascular surgery or blood transfu-
sions were not required. Patients were discharged 
1.6 ± 2.0 (0 to 14) days after angioplasty. 
Radial artery assessments. Two-dimensional and 
Doppler ultrasound examination of the radial artery 
was performed in 97 patients (97%). An intimal le-
sion was seen in 11 (11 %) patients. Two patients had 
a pseudoaneurysm at the puncture site. At follow-up 
one pseudoaneurysm spontaneously disappeared, 
and t.he other remained stable. In 10 (10%) patients 
the radial artery pulsations were absent at. discharge, 
and the result of the reversed Allen test. was negative 
(abnormal). These patients also had absent. (n = 8) or 
diminished (n = 2) Doppler flow patterns. None of 
these patients had claudication or functional disabil-
ity of the hand, Late recanalization at, follow-up was 
clinically evident in 5 patients. In 3 patients, radial 
artery pulsations remained absent. Two pat.ients 
with early radial artery deficit were not available for 
late follow-up. 
DISCUSSION 
At present there is a trend toward the downsizing 
of PTCA guiding cat.heters, from the 9AF catheter in 
early experience with PTCA to the commonly used 
8F catheters and the newer 7F,6 6F,7 5F,s and even 
4F9 guiding catheters. This evolution toward minia-
ture equipment makes a small artery, such as the ra-
dial artery, suitable as an access site for PTCA. 
Kiemeneij, I.Alarman, and de Melker 5 
CampeaulO performed transradial diagnostic heart 
catheterization in 100 patients with 5F catheters. In 
this series the coronary arteries were successfully 
reached in 88 patient.s; in 10 patients puncture or 
cannulation failed; and in 2 patients the coronary 
catheterization failed. Early and late pulse deficit 
occurred in 22 and 6 patients, respectively. Signifi-
cant complications were arterial dissection in 1 
patient and radial artery occlusion in another, both 
without signs of ischemia in the hand. 
Our study was performed with 6F introducer 
sheaths and with a new 6F guiding catheter (Scimed 
Triguide). For the total study population, procedural 
success was 98% (98 of 100) and clinical success 94 % 
(94 of 100). In patients in whom transradial artery 
angioplasty was completed, procedural success was 
98% (92 of 94) and clinical success 95% (89 of 94). 
These results compare favorably with the literature 
on t.he conventional femoral approach.a In this early 
experience, we used only 0.025- or 0.035-inch An-
giomed® guide wires for guiding catheter advance-
ment. Although the 0.035·inch guide wire allowed 
more support, friction between this wire and t.he ra-
dial artery is felt by the operator more commonly, 
Ideally a more slippery guide wire of appropriate 
stiffness should be used. Because guiding catheters 
are changed more frequent.ly, the use of 260 em ex-
change wires also facilitates the procedure. The per-
formance of guiding catheters with regard to backup 
support .• passage of dilatation catheters, and visual-
ization of coronary anatomy was satisfactory. 
A large number (147) of guiding catheters were 
used because several catheters had to be replaced 
because prolonged manipUlation caused kinking of 
the thin shaft. Preshaped catheters (e.g., Amplatz 
and Judkins) are designed for the femoral approach, 
whereas the approach from the right arm may com-
promise the properties of these catheters. A reason 
for not using the left radial artery to cope with this 
problem is a change of the position of the operator 
toward t.he left side of the catheterization table. This 
change requires major rearrangement. of the cathe-
terization table and laboratory especially if the mOIl-
itors cannot be moved toward t.he right side of the 
table. The number of balloon catheters per procedure 
(1.04) was low as a result of the inflation pressure-
dependent. diameter of this compliant balloon, so 
t.hat. the final result could be obtained by a single 
balloon catheter. The High Torque Floppy guide wire 
performed well with regard to support. for the balloon 
catheters and with regard to abilit.y to cross the 
lesion. However, recanalization of chronic total oc-
clusions was not attempted in this study, Stiffer 
guide wires may be more appropriate for this indica-
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tion. The use of 6F guiding catheters has been ques-
tioned for inappropriateness for use with bailout de-
vices such as coronary stents and perfusion balloon 
catheters. 
In the present. study, no stent. was primarily 
implanted in patients with a type B dissection 
because residual stenosis was <50% and flow was not 
impaired. However, in three of these patients a post-
procedure coronary artery occlusion developed. 
Three other patients in whom PTCA resu1t.s were 
subopt.imal because of an occlusive dissection were 
successfully treated by transradial artery implanta-
tion of a Palmaz-Schatz stent. The stent was manu-
ally crimped on the balloon catheter used. Palmaz-
Schatz stent implantation via 6F guiding catheters 
has been reported by Urban et a1. 11 The transradial 
artery approach for stent. implantation t.hrough 6F 
guiding catheters has recently been studied by our 
group12 in a series of 20 patients. No attempt to op-
timize suboptimal results with long inflations by us-
ing a perfusion balloon was made because during this 
study no low-profile perfusion balloon catheters were 
available. In another recent. report, however, we13 
described satisfactory results of angioplast.y through 
6F guiding catheters with a new perfusion balloon 
(ACS Flowtrack 40) as primary device in 14 patients. 
An important finding in the present study is the 
absence of major vascular complications such as sig-
nificant bleeding, need for vascular surgery, and 
functional disability of the hand. Radial artery oc-
clusion after the procedure (10 patients) and at, fol-
low-up (3 patients) was higher than would be ex-
pected at. the femoral or brachial artery sites but was 
surprisingly low when compared with the 30% and 
38 % incidences of radial artery occlusion reported by 
Davis and Stewart 14 and by Bedforl and Wallman,I5 
respectively after prolonged cannuiations of the 
radial artery for blood pressure monitoring. Early 
withdrawal of the sheath, immediately after angio-
plasty, may be an important. factor in the prevention 
of radial artery thrombosis. However, an 2% inci-
dence of pseudoaneurysm formation may be related 
to sheath removal during anticoagulation. 
Symptoms of radial artery occlusion were absent in 
our study because only patients wit.h collateral blood 
supply to the hand were selected. In the series by 
Bedfort. and Walhnan15 105 radial artery canl1ula-
Hons were prospectively studied in 100 patients. 
Forty (38%) radial arteries were occluded. No major 
ischemic complications were detected in these pa-
tients, but 4 patient.s had signs of distal vascular in-
sufficiency in the form of a pale, cold thenar emi-
nence. Mandel and Dauchot16 reviewed 1000 radial 
artery cannulations. The cannulas were removed af-
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ter 5 hours to 5 days. Distal ischemia requiring em-
bolectomy or vascular reconstruction was encoun-
tered in only 2 (0.2%) patients. Slogoff et a1. 17 exam-
ined 1699 patient.s who had prolonged radial artery 
cannulation for monitoring purposes after cardiac 
surgery. Although flow was diminished or absent in 
25% of patients during Doppler examination, no is-
chemic damage or disabilit.y of the hand occurred. 
Based on our experience and on these reports, we 
consider radial artery cannulation as a low-risk ent.ry 
site even if postprocedural radial artery patency is 
absent.. The absence of puncture-related complica-
tions reduces the costs of coronary interventions by 
reducing the need for diagnostic procedures, the need 
for vascular surgery, and hospital stay (1.6 days in 
t.his study). 
The high procedural and clinical success rate, t.he 
possibility of using bailout. techniques such as perfu-
sion balloons and coronary stents for treatment. of 
suboptimal PTCA results, and the absence of major 
puncture site-related complications makes the radial 
artery an promising entry site for coronary angio-
plasty. To compare the safet.y and efficacy of this ap-
proach with those of the percutaneous femoral and 
brachial approach a randomized study is being per-
formed in our department. 
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A randomized comparison uf' coronary angiuplasty by the transradial, transbrachial and 
transfcmol'al appruach: Interim analysis of U1e ACCESS~ study 
Ferdinand Kiemeneij, Gert Jan Laanllan, Diego Odekerken, Rein Schuilcnburg, Ton 
SlagboOlll, Jo Suwarganda, Ron van der \Vieken 
ADIC - OLVG, Amsterdam, the Nederlands 
ABSTRACT 
Bucl<gronnd. :Miniaturization of angioplasty material has made coronary angioplasty (PTCA) 
via the radial artery feasible. 
No randomized data are available on procedural and clinical outcome of PTCA with 6F gui-
ding catheters, introduced via the radial, brachial or femoral arteries. 
J\·lcthods. To compare the mutual relation between access-failure rates and vascular complica-
tions, under the assumption that PTCA- results are equal, a randomized comparison is perfor-
med in our center between elective transradial, transbrachial and transfemoral PTCA with 6 
French guiding catheters in 900 pts. Primary endpoints are entrysite related (necessity to 
puncture 2nd access-site, Hb-loss>2 nml01!1, transfusions, vascular interventions) and angio-
plasty related (death, CABG, rePTCA, MI, unstable angina, residual stenosis>50%). 
Secondary endpoints are QCA- pre and postPTCA, vascular ultrasound findings, procedural 
and fluoroscopy time and hospitalization. An interim analysis at 450 pts was performed. 
Baseline characteristics were balanced in all groups. 
Results. A successful corouary cannulation was achieved in 140 (92.1%),141 (96.6%) and in 
152 (100%) of patients, randomized to the radial, brachial and femoral artery respectively. In 
this order a sllccessful PTCA procedure (with or without stenling) was achieved in 93.4%, 
95.1 % and 96.0% of patients (p=ns). 
Procedural time (and as a consequence fluoroscopy time) of transradial PTCA was longer 
(43.7 ± 26.4; median 37 minutes) compared to transbrachial PTCA (40.6 ± 26.9; median 33) 
[p=ns) and trans femoral PTCA (36.6 ± 24.3; median 30) [p(radial-femoral}=O.02). Cardiac 
events during hospital stay shO\ved no significant differences in the three groups. 
No ischemic complications of the hand were recorded following transradial PTCA, even in 
patients with absent radial artery pulsations (n=12; 7.8%) at discharge. No major entrysite 
related bleeding complications were encountered in this group, whereas 2 patients (t.3%) 
(p=ns} in the femoral group and 6 patients (4.1%) in the brachial group (p=O.03) had an 
access complication, requiring intervention. The mean hospital stay in the radial group was 
1.5 ± 1.8 days (median 1; range 0-15) in the brachial group 1.6 ± 1.8 (median 1; range 1-12) 
ancl in the femoral group 1.7 ± 3.4 (median 1; range 0-39) [p=NSj. 
Conclusion: Procedural and clinical outcome of PTCA with 6F guiding catheters are favora-
ble and similar for the three subgroups, but access- failure is more common during transradial 
PTCA. Bleeding complications are more frequently encountered after transbrachial angiopla-
sty. The ACCESS-study will be continued to an enrollment of 900 patients. 
INTRODUCTION 
Safety of transradial coronary catheterization is mainly determined by the favourable anatomi-
cal relations of the radial,artery to its surrounding structures. No major veins or nerves are 
located near the radial artery, exduding the chance of relevant injury of these structures. 
Because of the superficial course of the artery, hemostasis easily can be obtained by local 
compression, Thrombotic or traumatic artery occlusion does not endanger the viability of the 
hand, if adequate collateral blood supply from the ulnar artery is present. We modified the 
technique of trallsradial coronary catheterization as described by Campeau in 1989 (1), to per-
form transradial coronary angioplasty (PTCA), with 6 French (F) guiding catheters and minia-
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turized ballooncatheters. In 1992, when these catheters became commercially available, we 
initiated a feasibility study towards transradial artery coronary angioplasty (PTCA). In a 
series of 100 patients, PTCA could be performed via the radial artery in 94 patients; procedur-
al success in this group was 98% (2). No major bleeding complications were encountered. 
Since little is known about the incidence of access failure and vascular complications after 
insertion of 6F guiding catheters in the femoral and brachial artery and since no randomized 
data are available comparing these three approaches, we designed the ACCESS-study: (A ran-
domized Comparison of perCutaneous Entry SiteS for coronary angioplasty). This is an open, 
randomized, single center study, to establish the mutual relation of access-failure rates and 
vascular complications of transradial, transbrachial and transfemoral PTCA with miniaturized 
(6F) PTCA equipment under the assumption that PICA results are equal in the three treat-
ment groups. The total study will include 900 patients. 
We describe the results of the interim analysis of procedural and clinical outcome, performed 
after enrollment of 450 patients. 
METHODS 
Patient selection 
Patients were included with both stable and unstable angina, selected for single or multi vessel 
PTCA of lesions in native coronary arteries and venous bypass grafts. 
Suitability to participate in this study, concerning cardiac status, was assessed by one of the 
investigators. At arrival of the patient in the catheterization laboratory, femoral, brachial, 
radial and ulnar mtery pulsations were examined and the Allen- test was performed. Informed 
consent of the patient to participate in this study was obtained if the patient fullfilled the 
enrollment criteria. Exclusion criteria are represented in Table 1. 
If no exclusion criteria were encountered, the patients were randomized to the radial, brachial 
or femoral artery approach. 
lVIedical preparation 
At the start of the procedure patients received Diazepam 5 mg orally and Aspegic 900 mg 
intravenously. The puncture site was infiltrated with Xylocaine 2%, 2-IOcc. Heparin 5.000 IU 
was administered via the introducer sheath at the start of the procedure. 
After sheath removal and local hemostasis, heparin infusion was continued "overnight" in 
case of angiographical evidence of intracoronary thrombosis or dissection. 
Nitroglycerin 100-300 microgram was administered before the first coronary angiogram and 
before the final angiogram and repeated if necessary. 
Femoral and brachial cannulation 
In all patients the percutaneous transluminal technique was used. After appearance of p111satiJe 
blood from the arterial needle, an 0.035 inch guidewire was advanced, followed by insertion 
of a 6F arterial introducer, 10 em in length. 
Radial artery cannulation 
The right ann, supported by an extension of the catheterization table is abducted (approxima-
tely 450 ) and the wrist is hyperextended. 
After local anesthesia with Xylocaine 2%, the radial artery is punctured with an Arrow®, 22 
OA Radial artery catheterization set or with an 180 arterial needle at I cm proximal from the 
styloid process. After appearance of pulsatile flow from the needle an Angiomed® 0.025 inch, 
260 cm long guidewire is introduced through this system, followed by insertion of a 6 French, 
23 cm long arterial introducer, after having made a small skin incision with a #11 surgical 
blade. 
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Table 1. Exclusion criteria 
A. Vascular status. 
Absence of pulsating femoral, brachial or radial arteries 
Absence of collaterals between radial and ulnar arteries (Negative Allen-test) 
Previous surgery at a potential entry site 
Failed previous attempts 
B. Cardiac status 
Chronic total occlusion 
Acute myocardial infarction 
Expected severe hemodynamic deterioration during balloon inflation or after 
PTCA- failure, leading to intraa0I1ic balloon pumping or right heart 
catheterization for haemodynamic monitoring. 
Expected need for insertion of a temporary pacemaker 
C. Procedural 
Ad-hoc PTCA, following diagnostic coronary angiography 
Ind\ve1ling sheath from previous arterial pUllction 
Planned stent implantation 
Planned rotational or directional coronary atherectomy 
C. General 
No consent 
Coronary artery cannulation 
Six French guiding catheters were available from Scimed® (Inner diameter 0.060 inch), 
Schneider® (ID 0.061 inch) and from Cordis®(ID 0.062 inch). A 6 French guiding catheter 
was selected with an appropriate curve, providing maximal backup support during angiopla-
sty. In all patients compliant rapid exchange balloon catheters were used (Scimed Express TM) 
in comhinationwith an ACS® 0.014 inch High Torque Floppy guidewire. 
Access failure 
After a failed attempt to cannulate the coronary artery, because of an access- site related pro-
blem, the operator was free to select any other entry- site. This could be the same artery at the 
contralateral side or any other artery. Selection of a second entry site to achieve a successfuI1 
angioplasty was considered to be a primary endpoint (Table 2). 
Sheath removal, immobilization and discharge 
In all instances, the arterial sheath was removed, directly after withdrawal of the guiding 
catheter, followed by application of a tourniquet at the radial puncture site or by manual com-
pression of the brachial and femoral punture sites. A pressure bandage over the punctured 
m1ery was applied for 4 hours. After femoral entry. patients had bed rest for 6 hours. 
Following brachial and radial entry patients were not restricted to bed rest, but the patients 
were advised to restrict movements of elbow and wrist joint respectively. If no complications 
were encountered, the patient was discharged the day following PTCA. 
Qualitative coronary analysis 
PreproceduraJ lesion morphology was classified according to the definitions established by an 
American College of Cardiology/American Heart Association task force (3). Post- procedural 
coronary artery dissections were described according to the classification described by DOlTOS 
et. al.(4). 
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Quantitatiye coronary analysis 
The x-ray imaging equipment used was the Philips Poly Diagnost C2, equipped with a Digital 
Cardiac Imaging system (DCI) (Philips Medical Systems, Eindhoven, the Netherlands). This 
system gives on-line video digitized images, for optimal angiographic assessment of coronary 
artery anatomy. 
Quantitative analysis of coronary segments was performed with this system before and angio-
plasty and after the final balloon inflation under standardized conditions. 
Assessments and examinations 
An ECG was made before and after the procedure and at 1 month follow-up. 
Laboratory assessments were hemoglohin and hematocrit before PTCA and at discharge and 
creatine phosphokinase (included MB- fraction) prior to discharge. 
At discharge physical examination of the puncture site was performed on the presence of a 
complication (occlusion, hematoma, arteriovenous fisllla, psellc!oaneurysm) followed by a 2D 
and Doppler ultrasound examination. 
FolloW-UIJ evaluation 
One month after the procedure patients were examined at the outpatient clinic and screened 
for the presence of any access-site related and cardiac complication. 
Endpoints 
Primary access- site and PTCA related endpoints and secondary endpoints are shown in 
Table 2. 
Table 2. Primary and secundary endpoints 
A. PRIMARY ENDPOINTS 
I. Access-site failure defined as either one of the following: 
1. Necessity to puncture second access-site for any failure. 
2. Access- site complication with: hemoglobin-Ioss:::::-: 2 points and/or 
blood transfusions and/or 
vascular repair 
II. PTCA- failure 
1. Residual stenosis> 50% after (perfusion-) balloon angioplasty or stellt implantation 
2. Death 
3. Myocardial infarction 
4. Unstable angina pectoris 
5. Need for coronary artery bypass grafting 
6. Need for repeat PTCA 
B. SECONDARY ENDPOINTS 
1. Change in Minimal Lumen Diameter (and %diameter stenosis) pre- and post PTCA 
2. Ultrasound findings: pseudoancurysm, arteriovenous- fistula, occlusion, hematoma 
3. Duration of the procedure 
4. Fluoroscopy time 
5. Consumption of angioplasty material 
6. Hospital stay 
Statistical analysis 
Randomization was performed by opening of a closed envelope, containing a code for either 
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transradial (R), transbrachial (B) or lransfemorai (F) angioplasty. These envelopes were orde-
red at random and provided of a registration Humber, running from I to 900. 
Continuous variables are expressed as means ± SD and were compared by the unpaired two-
tailed Student's t test. Proportions were compared with the Chi square test. 
Statistical signifance was defIned as p < 0.05. An interim analysis on an intention to treat 
basis was made aftcr enrollment of 450 patients. 
DEFINITIONS 
Allell- tcst 
Positive (normal) when after compression of both radial and ulnar arteries, a return of the nor-
mal colour of the hand occurs within 10 seconds after release of pressure over the ulnar arte-
ry. 
Rel'ersed Allell- tcst 
Positive (normal) when after compression of both radial and ulnar arteries, a return of thc nor-
mal colour of the hand occurs \vithin 10 seconds after release of pressure over the radial arte-
ry. 
Canadian Cardiovascular Society Classification 
Class 0= Free of exertional angina 
Class I:::: No angina at ordinary physical activity 
Class 2= Slight limitation of ordinary activity 
Class 3:::: lvlurked limitation of ordinary activity 
Class 4= Inability to carryon any physical activity without discomfort 
SuccessFul PTCA 
Residual diameter stenosis postPTCA less than 50%, as assessed by QCA, irrespective the 
technique or dcvice used after a having obtained a suhoptimal result with conventional bal-
loon angioplasty. 
~IIajor bleeding/catheter site complication 
Any bleeding associated with a Hb- loss of 2 m111ol/l or leading to blood transfusion, vascular 
repair or any complication leading to functional disability 
l\1yocardial infarction 
The presence of at least 1 wo of the following: I. Occlusion of a previously patent coronary 
artery; 2. prolonged chest pain; 3. serial enzyme pattern typical for myocardial infarction, 
with at least one enzyme raised to more than t\vice the upper limit of normal; 4. the develop-
ment of new Q- waves. 
RepcntPTCA 
PTCA after the guiding catheter has been removed out of the arterial sheath, 
Bypass surgery 
Emergency or elective coronary bypass surgery involving the previously dilated segment. 
Cardiac dcath 
All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. 
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RESULTS 
Study group 
Between November 1993 and September 1994, 450 patients were included at our department; 
Radial artery group (R): n=152, Brachial attery group (B): n=146 and Femoral artery group 
(F): n;::;-152. One patient included in the brachial and one in the femoral artery group was 
excluded from furher analysis, since at the time of the procedure, no significant lesion was 
present. Baseline clinical characteristics arc displayed in Table 3. Angiographical and QCA-
data are given in Tables 4 and 5. No significant differences were encountered between prcpro-
cedural variables in the three study subgroups. 
Table 3. Baseline clinical characteristics 
RADIAL BRACHIAL FEMORAL P 
n (%) 11 (%) n (%) 
Male 1I4 (7S.0) lOS (71.9) liS (7S.7) NS 
Age (year) S9.9 ± 10.9 60.8 ± 9,4 61.7 ± ILl NS 
Height (em) 174 ± 8 171 ± 8 173 ±9 NS 
Weight (kg) 79 ± II 77 ± II 79 ± 13 NS 
CCS I 2 ( 1.3) 3 (2.1) 4 (2.6) NS 
CCS II 2S (16,4) 16 (11.0) 18 (12.0) NS 
CCS III 71 (46.7) 66 (4S.2) 68 (44.7) NS 
CCSIV 40 (26.3) 46 (3I.S) 49 (32.2) NS 
MI 60 (39.S) 63 (43.2) 70 (46.0) NS 
CABO 13 (8.S) 7 (4.8) 3 (3.3) NS 
PTCA 40 (26.3) 36 (24.7) 35 (23.0) NS 
Aspirin 129 (84.9) 110 (7S.3) 119 (78.3) NS 
COllmadin 4 (2.6) 4 (2.7) 8 (5.3) NS 
Persantin I (0.7) 0 (0) 2 (1.3) NS 
Hypertension 46 (30.3) SI (34.9) 45 (30.2) NS 
Diabetes 10 (6.6) 12 (8.2) 21 (13.8) NS 
Cholesterol 45 (29.6) 46 (31.5) SO (32.9) NS 
Smoking 104 (68,4) 89 (61.0) 104 (68,4) NS 
Family SI (33.6) 55 (37.7) 42 (27.6) NS 
CCS Canadian Cardiovascular Society- angina pectoris c\a~sincalion 
MI I\lyocardial infarction 
CABO Coronary Artery Bypass Grafting 
PTCA PercutaneOllS Transluminal Coronary Angiography 
NS Not Si!:,'nifico1llt 
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Table 4. Angiographical characteristics 
RADIAL BRACHIAL FEMORAL P 
11 (%) 11 (%) 11 (%) 
No. Vessels 170 (100) 155 (100) 181 (100) NS 
LAD 76 (44.7) 73 (47.1) 74 (40.8) NS 
LCX 44 (25.9) 35 (22.6) 57 (31.5) NS 
RCA 45 (26.5) 42 (27.1) 46 (25.4) NS 
Olher 5 (2.9) 5 (3.2) 4 (2.2) NS 
No. lesions 192 (100) 176 (100) 193 (100) NS 
Type * 
A 86 (44.8) 79 (44.9) 82 (42.5) NS 
B 70 (36.4) 55 (31.3) 64 (32.2) NS 
C 36 (18.8) 42 (23.S) 47 (24.3) NS 
LAD Left anterior descending coronary artery '~Rcference #3 
LCX Left circumilex coronUl)' artery 
RCA Right coronary 1111ery 
Table 5. Quantitative and qualitative coronary analysis 
RADIAL BRACHIAL FEMORAL P 
QCA- pre 
RD (mm) 2.66 ±0.65 2.73 ± 0.67 2.66 ±0.64 NS 
MLD (mm) 0.80 ± 0.38 0.82 ± 0.45 0.77 ± 0.36 NS 
DS(%) 69.8 ± 12.8 69.4 ± 15.5 71.0± 12.7 NS 
QCA- post 
RD (mm) 2.76 ± 0.62 2.80 ± 0.58 2.77 ± 0.58 NS 
MLD (mm) 2.09 ± 0.63 2.15 ± 0.69 2.12 ± 0.69 NS 
DS (%) 24.0 ± 18.5 23.0 ± 16.0 23.9 ± IS.6 NS 
Dissection 
Type * N (%) N (%) N (%) 
A 19 (12.5) II (7.6) 2S ( IS.5) 0'(J09 
B 24 (15.8) 30 (20.7) 29 (19.2) NS 
C 4 (2.6) 3 (2.1 ) 3 (2'cJ) NS 
D 0 (0) 0 (0) 3 (2.0) NS 
E 0 (0) 0 (0) I (0.7) NS 
F 4 (2.6) I (0.7) I (0.7) NS 
Total 51 (33.5) 45 (31.0) 65 (43.0) 0.04** 
QCA Quantitative coronary analysis * Reference #4 
RD Reference diameter *,~ Femoral-Drachial 
J'dLD IVlinililalluminal diameter 
DS Diameter stenmis 
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Procedural l"l-'Sults 
COJVnwy caNnulation 
A successful coronary cannulation was achieved in 140 (92.1 %), 141 (96.6%) and in 152 
(100%) of patients, randomized to the radial, brachial and femoral artery respectively. In 12 
patients from the radial group coronary cannulation failed versus none of the patients in the 
femoral group (p=O.OOI). In 5 pts froJll the brachial group, the coronary artery could not be 
reached (p::::ns) because of a puncture failure (n::::2), inability to advance the guidewire (n::::l) 
or the guiding catheter (n::::I), Most failures in the radial group were due to a puncture failure, 
whereas in 1 patient the sheath and in another the guidewire could not he advanced. During 
the same session, 11 patients crossed over to the femoral artery and 1 to the left radial artery, 
followed by a successful procedure, In the brachial artery group, 4 patients crossed over to the 
femoral artery and I to the radial artery, also with successful outcome. 
j1;laterial consumption 
In the radial and the brachial group, more guiding catheters (1.4 ± 1.0 and 1,3 ± 0.8 respecli-
vely) were uscd, cOJllpared to the femoral group (1.2 ± 0.5) [p=O.007 and 1'=0.03 respective-
lyJ, No differences were fOllnd in the number of guidewires and ballooncatheters consumed 
(Table 6). 
Table 6 .. Material consumption 
RADIAL 
mean ± SO 
Guiding catheters 1.4± 1.0* 
Guidewires 1.3 ± 0.7 
Ballooncatheters 1.2 ± 0.6 
CorollalY llngioplasty 
BRACHIAL 
mean ± SD 
1.3 ± O.S 
1.2 ± 0.6 
1.2 ± 0.6 
FEMORAL 
mean ± SD 
1.2 ± 0.5**1* 
l.3 ± 0.9 
1.2 ± 0.5 
P 
"0.007 
*"'0.03 
NS 
NS 
In the radial group 5 patients (3,3%) received a stent during the procedure to improve subop-
timal balloonangioplasty results, in the brachial group 6 patients (4.3%) and in the femoral 
group 2 patients (1.3%) [p=nsl. A successful PTCA procedure (with or without stenting) was 
achieved in 93.4%, 95,1 % and 96,0% of patients randomized to the radial, brachial und 
femoral approach, respectively (p=ns). Reasons for failed PTCA's (radial n=IO [6.6%]; 
brachialn::::7 [4.9%] and femoral n=6 [4.0%]) and ensuing strategy are shown in Table 7, 
Results of final quantitative and qualitative coronary analysis post PTCA are given in Table 5, 
Compared to the patients in the brachial group, more dissections were seen in the femoral 
group. Thus 33.5%, 31.0% and 43,0% of patients in the radial, brachial and femoral groups 
were treated with a heparin infusion untill the next day, 
Procedural time 
Procedural time (moment from first attempt to puncture the artery to moment of sheath withd-
rawal) of transradial PTCA was longer (43.7 ± 26.4; median 37 minutes) compared to trans-
brachial PTCA (40.6 ± 26.9; median 33) [p=ns] and transfemoral PTCA (36.6 ± 24.3; median 
30) [pi radial-femoral }=O.02]. 
Also, fluoroscopy time was longer; 13.7 ± 10.5: median 9.6,13.0 ± 11.3: medianS.9 and 11.0 
± 10.2: median 6.9 minutes in the 3 groups respcctively (p{radial-femoral}=(1.02) 
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Table 7. Procedural outcome (intention to treat) 
RADIAL BRACHIAL FEMORAL P 
n (%) n (%) n (%) 
Unable to cross with 
-guidewire 5 (3.3) 4 (2.x) 3 (2.0) NS 
-balloon 3 (2.0) () (0) I (0.7) NS 
Final DS ::'50% 2 (1.3) 2 (1.4) 2 ( 1.3) NS 
Total 10 (6.6) 6 (4.2) 6 (4.0) NS 
Treatment 
-medically 6 (3.9) 3 (2.1) 3 (2.0) NS 
-rePTCA 2 (1.3) 0 (0) 1''' (0.7) NS 
-elective CABG I (0.7) 2 (1.4) I (0.7) NS 
-emergent CABG 0 (0) 1 (0.7) I (0.7) NS 
Procedural Success 142 (93.4) 138 (95.1) 145 (96.0) NS 
'" SllccessfullASER procedure fora total occlusion 
DS Diameter stenosis 
~H Mym:arJiai infarction 
CABO Coronary nrtcry bypass grafting 
PTCA PercutaneOllS transiuminal coronary <lngiopiasty 
C011lpressiml-ti Ille 
Since no manual compression was applied over the radial artery, no man-power time was 
required to obtain hemostasis. No differences were recorded in manual compression time in 
the brachial artery (14.1 ± 8.3; median 12.2; range 3-55 minutes) and femoral artery group 
(12.8 ± 8.6; median 10.0; range 5-60 minutes). 
Clinical course 
Cardiac events 
Cardiac events Juring hospital stay are shown in Table 8. No significant differences in the 
three groups were found. One patient died (Brachial group) from a intracerebral hemorrhage, 
during anticoagulation after bailout stent implantation. In the radial artery group, 2 patients 
underwent a second attempt via the femoral artery after a failure to cross the lesion; these 
were counted as a cardiac event. 
ElItl)'site complications 
No ischemic complications of the hand were recorded following transradial PTCA, even in 
patients \vith absent radial artery pulsations (n=12; 7.8%) at discharge. Spontaneous recanali-
sation was found in 4 of these patients, at I month follow-up. No major entrysite relatcd 
bleeding complications \vere encountcred in this group, whereas 6 patients (4.1%) in the 
brachial group (p=O.03) had an access complication, requiring intervention. Surgery was 
required in 3 patients (2 pseuaneurysms, 1 bleeding). One patient required hloodtransfusion. 
In one patient a pscudoaneurysm could sllccessfully be obliterated by prolonged compression 
under ultrasonic guidance. One patient required local infiltration of analgetics for the treat-
ment of nerve compression by a hematoma. In the femoral group, 2 patients (1.3%) required 
vascular surgery, one for a major bleeding and one for a pscuJoaneurysm (p=ns). 
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Table g, Cardiac events during hospital stay '" 
RADIAL BRACHIAL FEMORAL P 
n (%) n (%) n (%) NS 
Death 0 (0) I (0.7) 0 (0) NS 
Q-wave MI I (0.7) 0 (0) 0 (0) NS 
Non-Q lVave MI 2 (1.3) I (0.7) 1 (0.7) NS 
Emergent CABO 2 ( 1.3) I (0.7) 2 ( 1.3) NS 
Elective CABO 1 (0.7) 4 (2.8) I (0.7) NS 
Repeat PTCA 5 (3.3) 2 (1.4 ) 3 (2.0) NS 
Total 11 (7.2) 9 (6.4) 7 (4.7) NS 
In the first collum, all events are taken into account, also multiple events in 1 patient (e.g. repeat PTCA, followed 
by emergent coronary bypass surgery and a non-Q wave myocardial infarction arc counted as 3 separate events). 
MI 
CABO 
PTCA 
Hospitalization 
Myocardial infarction 
Coronary artery bypass grafting 
Pen':lltaneOliS translllminal coronary angioplasty 
The mean hospital stay in the radial group was 1.5 ± 1.8 days (median 1; range 0-15) in the 
brachial gronp 1.6 ± 1.8 (median I; range 1-12) and in the femoral group 1.7 ± 3.4 (median 1; 
range 0-39) [p=NSJ. 
DISCUSSION 
In this first half of the study, success rate of coronary cannulation via the radial artery was 
acceptable (92.1 %). Most failures (n= 10; 83.2%) were due to inability to puncture the radial 
artery. With better equipment selection and with improved experience, a better success rate 
can be achieved. Coronary cannulation was successful in 100% of the patients in the femoral 
group. This favorable outcome does not only renect the operator's experience. Since patients 
with a previous failed catheterization, due to an entry-site problem, were excluded and since 
almost an patients had their diagnostic catheterization via the femoral artery, a bias towards a 
successful transfemoral catheterization was present. Once the radial artery was punctured, 
coronary catheterization was successful in 9S.6%. More guiding catheters were llsed in the 
radial group and to a lesser extent in the brachial group, when compared to the femoral 
approach. This is explained by the fact that most guiding catheters are designed for the femor-
al approach; via the right arm the curves may have less adequate properties, Caused by a 
more difficult radial artery cannulation procedure and by problems with proper catheterselcc-
tion and coronary cannulation, median procedural time and fluoroscopy time were longer 
compared to the femoral approach (7 and 2,7 minutes respectively; p=O.02). On the other 
hand, with the hemostasis techniques applied, no personel was involved to compress the 
radial artery, while manllal compression of the hrachial and femoral artery lasted 14, I and 
12.2 minutes, respectively. 
No ditTerences in procedural and clinical outcome of PTCA were present between the three 
groups. Procedural Sllccess rates with 6F guiding catheters were high; 93.4%, 95.1 % and 
96.0% for transradial, -brachial and -femoral PTCA, respectively, Only in 2 cases (0.4%) an 
attempt with SF systems had to be undertaken, because lack of guiding catheter support was 
considered to he the main reason for failure; in 1 patient success was achieved. Since corona-
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ry stenting has become an essential part of the PTCA- technique to improve suboptimal 
PTCA results (in this study 13 patients; 2.9%), it is important to notice 6F guiding catheters 
do not preclude the use of Palmaz Schatz coronary stents. The applicability of stents through 
6F catheters has recently been reported (5,6,7,8,9). \Ve also reported on the feasibility of 
applying perfusionballoons through 6F catheters in elective and in bailout situations (7, I 0). 
The main reason to start the percutaneous transradial PTCA program (2) was to abolish cntry-
site complications. Indeed, no major bleeding complications were encountered after transra-
dial PTCA. 
Early radial artery occlusion was encountered in 12 (7.8%) patients; spontaneous recanalisa-
tion was found in 4 patients. In the feasibility studies on tmnsmdial PTCA (100 pts) and on 
transradial stenting (100 pts), incidence of radial artery occlusion was also low (2, II) when 
compared to a 30% and 38% incidence of radial artery occlusion reported by Davis et al (12) 
and by Bcdt(Jrt et al. (13), respectively, after prolonged cannulations of the radial artery for 
blood pressure monitoring. Symptoms and signs of radial artery occlusion were absent. In the 
series of Bedfort e.a. 105 radial artery cannulations were prospectively studied in 100 
patients. Radial artery thrombosis was found in 40 patients (38%). No major ischemic compli-
cations were detected in these patients, but 4 patients had signs of distal vascular insufficien-
cy, in the form of a pale, cold thenar eminence. Mandel e.a. reviewed 1.000 radial artery cal1-
nulations (14). The cannulas were removed after 5 hours to 5 days. Distal ischemia, requiring 
embolectomy or vascular reconstruction was encountered in only 2 patients (0.2%). Slogoff 
et.aL analysed 1.699 patients who had prolonged radial artery cannulation for monitoring pur-
poses after cardiac surgery (15). Although 25% of patients had deminished or absent flow 
during Doppler examination, no ischemic damage or disability of the hand occurred in any 
patient. Thus the radial artery can be considered as a low risk entry site, even if post proced-
ural radial artery patency is absent. Most complications were seen after trans brachial angio-
plnsty. This may be due to the overlying tendon of the biceps muscle and to the relation of the 
brachial artery to its surrounding structures. Artery, vein and nerve are located near eachother. 
Thus arteriovenous tlstula and nerve damage can result during attempts to puncture the artery. 
The brachial artery is more difficult to compress, especially if the upper ann is very muscular 
or obese. Finally, the elbow is more difficult to immobilize. 
Study limitations. The bias towards a more favorable transfemoral catheterization success 
has been mentioned: exclusion of previous failures and the use of catheters, designed for the 
femoral approach. This partially explains the longer procedural and fluoroscopy times for the 
transradial- and brachial approaches. By using the left radial or brachial artery, the guiding 
catheter problem is solved. However, working from the left side of the patient, may be cum-
bersome. \Ve have only limited experience with left radial procedures, performed at the right 
side of the patient. A suitable guiding catheter, specifically designed for the right radial appro-
ach may offer a solution. 
The study will be continued to an inclusion of 900 patients. 
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CHAPTER 4.6.1 
POTENTIAL SOLUTIONS 
RlIDiI\LlIRTERY liS ENTRY SITE 
Transradial artcry corona1'Y stent implantation 
PERCUTANEOUS TRANSRADIAL ARTERY APPROACH FOR CORONARY STENT 
IMPLANTATION 
F. Kiemcllcij, GJ. Laarman 
Cathet CarJiovasc Diagn 1993;30:173·178 
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Catheterization and Cardiovascular Diagnosis 30:173-178 (1993) 
Percutaneous Transradial 
Artery Approach for Coronary 
Stent Implantation 
Ferdinand Klemenelj, MD, and 
Gert Jan laarman, MD, PhD 
A new approach for Implanlallon of Palmaz Schatz coronary 
stents Is reported. We describe the technIque and rationale of 
coronary stenling with miniaturized angloplasly equipment via 
the radial artery. 
This technique is illustrated In three patients. One pallent 
underwent Palmaz Schatz stent implantation for a saphenous 
vene coronary bypass graft stenosis, the second patient for a 
reslenosls In the anterior descending coronary artery after ath-
ereclomy, and the thIrd patient for a second restenosls after 
balloon angioplasly In the cIrcumflex coronary srtery, 
<, 1993 Wil<lY'Uss, Inc. 
Key words: Percutaneous translumlnal coronary angloplasty, 
coronary stent 
INTRODUCTION 
Coronary stenting has been developed to overcome 
two major limitations of coronary balloon angioplasly 
(PTCA): nbrupt closure and late reslenosis. Agressive 
anticongulant therapy is mandatory 10 prevent thrombotic 
occlusion of the stent. 
Coronary stenling by the femoral artery approach 
carries a substantial risk for bleeding complkrltions, es-
pecially if large-bore guiding catheters and arterinl intro-
ducer shenths are used. A possible solution for prevent-
ing severe puncture site-related events may be found in 
the combination of a smaller puncture opening with se-
lection of another entry site. With the introduction of 6 
French guiding catheters allowing passage of low-profile 
monorail balloon catheters, PTCA via the radial artery 
became possible. In an ongoing study exploring the fea-
sibility of transradial artery coronary angioplasty, PTCA 
success via the radial artery was 90% in 50 patients (sub-
mitted). No vascular complications urged to bloodlrans-
fusion or vascular surgery. Even in case of Doppler-
From the Amsterdam Department of Intervenlional Cardiology-
OlVG, Onze Ueve Vrouwe Gasthuls, Amsterdam, The Netherlands. 
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Netherlands. 
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proven radial artery occlusion (6%), no functional 
disability of the hand was reported. Encouraged by these 
results, we perfonned transradial artery Palmaz Schatz 
coronary sten! implantation through 6F guiding cathe-
ters. This report describes the technique in three patients. 
TECHNIQUE 
Patient Selection 
In an ongoing study, patients undergoing stent implan-
tation and having a good pulsating radial artery and a 
positive Allen test were selected for the transradial artery 
approach, irrespective of sex, weight, and size. The 
Allen test was considered positive when, after compres-
sion of both ulnar and radial arteries, a return of the 
normal colour of the hand occurred within 10 sec after 
release of the ulnar artery. 
Medical Treatment 
Patients arc treated with Dextran 40, the first 500 Illi at 
a rate of 100 mllhr, the second 500 ml at a rate of 50 
mlihr. The infusion is started 2 hr before elective sten! 
implantation or from the moment the decision is made to 
implant a stent in acute situations. 
At the day of stent implantation, dipirydamole 225 
mg/day and acetosalicylic acid 300 mgld are started. Af-
ter sheath insertion, 10.000 IV heparin is administercd 
intra-arterially, followed by 5.000 lU for each hr the 
procedure lasts. Thrce hI' after hemostasis is achieved, 
3.000 IV heparin is administered intravenously. Heparin 
is titrated to Activated Partial Thromboplastin Times 
(APITs) of 80-100 secs until stable adjustment on oral 
anticoagulant drug therapy (3 consccutive therapeutic 
Thrombotests). Coumadin is given for 3 1110 and aceto-
salicylic acid and dipyridamole arc given for 6 mos. 
In order to prevent radial and coronary artery spasm, 
10 mg nifedipine are administcred sublingually. 
Radial Artery Catheterization 
The right aml is abducted to an angle of 700 , and the 
wrist is hyperextended. 
After local anaesthesia with lidocaine 2%, the radial 
artery is punctured with an Arrow®, 22 GA Radial ar-
tery catheterization set at an angle of 450 at 1 cm prox-
imal from the styloid process. After appearance of pul-
satile flow from the needle an Angiomed® 0.025", 260-
cm-Iong guidewirc is introduced through this system, 
followed by insertion of a Bard® Hemaquet II, 6 French 
IO-cm arterial introducer, after having made a small skin 
incision with a # 11 surgical blade. 
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Coronary Artery Cannulation 
A Scimcd® 6 French guiding cathetcr (inner diameter 
0.060", shaft length 100 cm) is selccted with an appro-
priate curve, providing maximal backup support during 
angioplasty and stcnt implantation. 
Angioplasty 
After angiography an ACS® High Torque Floppy 
0.014" guidewirc is advanced across the lesion. Over this 
guidewire a rapid cxchange, low profile, compliant bal-
loon catheter (Scimed® Express) is positioned at the 
stcnosis. This dilatation catheter can easily be advanccd 
through 6 French guiding catheters, is easy to exchange, 
and has variable diameters, dependent on inflation pres-
sures. 
This inflation pressure-dependcnt variation of balloon 
diameter makes a single balloon approach for thc com-
pletc procedure possible. The balloon size during predi-
latation corresponds to the reference diameter of the cor-
onary artery. The stenosis is prcdilated in order to reduce 
friction between stent and lesion. 
Stent Preparation 
The predilating balloon catheter is used as stent car-
rier, because its increased profile after the first inflations 
will allow better support for the stenl, compared to a 
balloon, tightly wrapped on the catheter shaft. The bal-
loon is cleaned with saline to remove contrast agent, 
possible blood clots, and lubricating coating. A 7.3 mm 
(prefabricated) or 15 mm Palmaz Schatz coronary stent 
(Johnson and Johnson) is manually crimped on the bal-
loon catheter, such that the balloon marker is positioned 
at the articulation site from the stent (15 mm) or in the 
middlc of the sten! (7 mm). No free movement from thc 
stcnt ovcr the balloon is allowcd to persist. 
Stent Delivery 
The stent-loaded balloon catheter is advanccd over the 
guidewirc toward the stenosis, undcr concomitant con-
trast dclivery. The articulation site of the Palmaz Schatz 
stent, the weakest portion of the stent, is positioned just 
ecccntric from the narrowest part of the stenosis. After 
delivery, thc stent diamcter is optimized by successive 
dilatations with larger balloon catheters or highcr infla-
tion pressures, 
Introducer Sheath Removal) Hemostasis) 
and Heparinization 
The arterial sheath is removed immediately after thc 
procedure. Hcmostasis is achieved by progressively de-
creasing compression with a tourniquct over the puncture 
site during 30-45 mins. This is followed by application 
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of a pressure dressing during 6 hr. Thc patient is free to 
mobilize. 
RESULTS 
Patient 1 
A 71-ycar-old male with a history of coronary artery 
bypass surgery in 199B for stable angina pectoris and 
triple coronary artery disease was admitted to our depart-
me-nt for recent onset anginal attacks. Cardiac cathetcr-
ization revealed severe triple vessel disease and a signif-
icant stenosis proximal in a saphenous vene jump graft, 
with anastomoses on the first diagonal, obtuse marginal, 
and on the posterolateral and descending posterior 
branches of the right coronary artery (Fig. IA), This 
culprit lesion was considered suitable for angioplasty and 
primary implantation of a Palmaz Schatz coronary stent. 
Thc presence of collaterals between a well-developed 
right radial artery and ulnar artery, as demonstrated by 
thc Allen test, allowed a transradial artery approach. 
Over the guidewire a Scimed® 6 French multipurpose 11 
guidingcatheter was advanced to the ostium of the 
venous bypass graft, followed by visualization of the 
lesion. Quantitative coronary analysis (Philips Digital 
Coronary Imaging; Philips Medical Systems, Best, The 
Nethcrlands) revealed a stenosis> 8 mm in length, ex-
tending from the ostium of the bypass graft (minimal 
luminal diameter [MLD] 1.04 mill, reference diameter 
[RD] 3.05 mm, diameter stenosis [DSJ 66%). Predilata-
tion with 2 inflations at 6 atmospheres during 120 sec 
with a Scimcd® Express 2.5 mOl balloon catheter re-
duced the stenosis to < 50%. After adequate positioning, 
a IS mm long stent was delivcred with the same dilata-
tion catheter bcing inflated with 12 atmospheres during 
30 sec (Fig. IB). 
The result was optimized by repeat dilatations with 3.0 
and 3.5 mm Scimed® Exprcss balloons, resulting in an 
17% residual stenosis (MLD 2.7 mm, RD 3.26 mm) 
(Fig. Ie). The clinical course was uncomplicated. Phys-
ical, 2-dimensional and Doppler ultrasound examina-
tions of the right radial artery were normal. Patient was 
dischargcd 6 days after stellt implantation. 
Patient 2 
A 48-year-old man was admitted for unstable angina 
pectoris and ST-segment elevation in the precordial 
Icads. Cardiac enzymes did not rise and a diagnostic 
catheterization, 1 d after admission, showed a normal 
left ventricular function and a significant stcnosis prox-
imal in thc left anterior descending coronary artery 
(LAD) (Fig. 2A). One wk later we perfomlcd a success-
ful directional atherectomy with a 7 French Simpson 
Coronary Athetcrocath (DVT) (Fig. 2B,C). Two 1110 
later, the patient was readmitted with unstable angina. A 
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significant restenosis in the proximal LAD (Fig. 20) was 
considered suitable for Palmaz Schatz stent implantation. 
A patent radial artery and collateral blood supply of the 
hand allowed a transradial artery approach. A Scimed® 
Amplatz Left II 6 French guiding catheter provided op-
timal support for angioplasty~ With quantitative coronary 
angiography the lesion showed to be 10 mm in length 
(MLD 0.58 mOl, RO 2.79 mm, DS 71%). Predilatation 
with a 3,0 mm balloon at 4 atmospheres during 45 sees 
significantly reduced the stenosis. The stent was crimped 
on the same balloon and successfully delivered at 10 
atmospheres during 40 sec (Fig. 2E). The angiographical 
result was optimized with one dilatation at 12 alnlO-
spheres. Quantitative angiography revealed an 11 % ste-
nosis at the articulation site (MLD 2.98 mm, RD 3.34 
mm) (Fig. 2F). 
The sheath was removed directly after the last contrast 
injection, and hemostasis was obtained after 45 mins. 
Physical, 2-dimensional, and Doppler ultrasound exam-
ination of the radial artery revealed no abnonnalities. 
The subsequent clinical course was uneventful, and pa-
lient \vas discharged 7 dafter stent implantation. 
Patient 3 
A 63-year-old man with previous successful PTCA of 
the LAD (1989) and firsl diagonal branch of the LAD 
(1991) was admitted in October 1992 with unstable an-
gina. Coronary angiography showed good long-term 
PTCA result of the LAD and first diagonal branch and a 
significant stenosis in the proximal segment of the ramus 
circumflexus (RCX), which was successfully reduced by 
balloon angioplasty. Because of progressive anginal 
complaints, patient underwent repeat PTCA of a signif-
icant restenosis in the RCX 3 mos later. After I mo, the 
patient was readmitted for unstable angina. Because a 
second restenosis in the RCX was suspected to be re-
sponsible for the patient's complaints, stent implantation 
was planned directly after diagnostic angiography. 
After medical preparation for coronary stenting, cor-
onary angiography was perfomled via the right radial 
artery with a 6 French Scimed® Amplatz Left I guiding 
catheter. This indeed revealed a 77% restenosis in the 
RCX (MLO 0.74 mOl, RD 3.17 mm) (Fig. 3A). The 
lesion was predilated with a Scimed® Express 2.5 mm 
balloon catheter at 12 atmospheres during 120 sees. On 
a 3.0 mm balloon catheter, a 15 mOl Palmaz Schatz stent 
was manually fixed. The stent was delivered with 13 
atmospheres. Despite one more dilatation with a 3.5 mm 
Fig. 1. A. Proximal stenosis (arrow) extending from ostium 01 
the venous bypass graft. B. Slent delivery with a Sclmed~ Ex-
press 2.5 mm balloon catheter at12 atmospheres. C. Final re-
sult. 
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Fig. 2, A. Proximal stenosis (arrow) In the lett anterior descending coronary artery. B. Direc-
tional atherectomy with a 7 French Simpson Coronary AtheroCalh. C. Immediate result alter 
directional atherectomy, D. Proximal reslenosls In the LAD. E. Stent delivery with Sclmeds: 
Express 3.0 mm balloon catheter at 10 atmospheres. F. Final result. 
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balloon at 10 atmospheres (Fig. 3B), a 33% stenosis 
persisted (MLD 2.47 mm, RD 3.65 mm) (Fig. 3C). The 
sheath was removed immediately after the procedure, 
and hemostasis was obtained after 30 minutes. 
The hospital course was uneventful and patient was 
discharged I wk after the procedure. 
DISCUSSION 
The main concern after implantation of metallic cor-
onary stents is to find an optimal balance between he-
mostasis and anticoagulation. The incidence of puncture 
site-related bleeding complications after coronary stent-
ing has been reported to vary between 7.9% of 226 pa-
tients in the initial multicenter experience with the Pal-
maz Schatz stent [IJ and 16% of 220 patients in single 
center experience with the Gianturco-Roubin stent [2J. A 
bleeding complication docs not only have serious local 
sequelae, but it may also force this balance toward sub-
optimal heparinization, with increased risk of stellt oc-
clusion. 
A possible solution for prevcnting severe puncture 
site-related events may be found in the combination of a 
smaller puncture opening with selection of another entry 
site, In recent years development of miniaturized PTCA 
equipment allowed the use of 7 French (3), 6 French 
[4,5], and even 4 French [6] guiding catheters for coro-
nary angioplasty. 
Transfemoral artery stent implantation through 6 
French guiding catheters has been reported in 3 patients 
by Urban et al. [7J. 
Dorms et al. [8J described an alternative route for 
perfomling percutaneous transluminal coronill)' angio-
plasty by performing arteriotomy of the brachial artery. 
At present there is extensive experience with percutanc-
ous transbrachial coronary catheterization and angio-
plasty, showing to be an effective and sale alternative to 
the Sones- technique and the Seldinger- technique of the 
femoral artery [9-11). 
Complications after brachial artery puncture are rare, 
but if present, they oftell require surgical repair [121. 
Complications described are arteriovenous fistulae, 
nerve injury, thrombotic artery obstruction, dissection, 
and false aneurysm. 
Campeau 112J reported on percutaneous entry of the 
radial artery for cardiac catheterization in 100 pts with a 
collateral blood supply to the hand. An arterial sheath, 
with an internal diameter of 5 French was used [I2J. 
Only 2 symptomless, vascular complications were ob-
Fig. 3. A. Proximal reslenosls (arrow) In the left circumflex 
coronary artery, B. Stent dllataUon with Sclmed" Express 3.5 
mm balloon catheter at 10 atmospheres, C. Final result. Note 
residual stenosis (arrow). 
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served. Safety of transradial artery coronary catheteriza-
tion is mainly detemlined by the favourable anatomical 
relations of the radial artery to its surrounding structures 
and the double blood supply to the hand. The sequelae of 
radial artery obstruction are frequently mild even in pa-
tients not selected for good collateral circulation. Slogoff 
et al. [13] reported on a series of 1,699 patients under-
going heart surgery, with perioperative radial artery can-
nulation. No ischemic damage to the hand was observed, 
even in 25% of patients with abnormal Doppler flow 
patterns, compatible with partial or complete radial ar-
tery occlusion [13J. No major veins or nerves are located 
near the radial artery, excluding relevant injury of these 
structures. Because of the superficial course of the ar-
tery, haemostasis easily can be obtained by local com-
pression, which is of major importance. An additional 
advantage is the immediate ambulation of the patient, 
increasing comfort of the procedure, We recently ex-
plored the feasibility of transradial artery coronary an-
gioplasty (submitted). PTCA success via the radial artery 
was 90% in 50 patients and no vascular complications 
urged to bloodtransfusion or vascular surgery, Radial 
artery occlusion (3 patients; 6%) was not associated with 
functional disability of the hand. 
As illustrated in these cases, transradial artery stent 
implantation is feasible through 6 French guiding cathe-
ters. However, several theoretical limitations of this ap-
proach should be emphasized, As prefabricated, sheath-
protected sten! delivery systems cannot be advanced 
through 6 French guiding catheters, some risk for stent 
dislodgement and embolization exists, when the stent-
loaded balloon passes the catheter lumen. Friction may 
shear the bare stent from the balloon, possibly leading to 
stent embolization. 111erefore it is advised to crimp the 
stent on a balloon after it has been inflated several times 
in order to increase balloon profile, allowing beller sup-
port to carry the stent. Removing the lubricating coating 
from the balloon may also help to keep the stent fixed to 
the balloon. 
Small guiding catheters may provide less support than 
large ones, Adequate backup support is needed to allow 
passage of a metallic stent on an unlubricated balloon 
catheter beyond a coronary stenosis. For this reason, a 
guiding catheter curve has to be selected, which gives 
optimal support. We recommend to predilate a tight ste-
nosis, because this will allow easier passage of the sten!. 
Visualization by contrast injection was satisfactory in 
these patients, allowing precise positioning of the stent 
in relation to the vascular segment of interest. However, 
in those situations requiring additional visualization 
techniques, such as angioscopy or intravascular ultra-
sound, large bore catheters arc preferred, 
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Despite these limitations, when appropriate precau-
tions arc takcn, transradial artery stent implantation may 
be a promising approach for a careful selected group of 
patients. 
To explore the feasibility, safety, and efficacy of elec-
tive percutaneous transradial coronary Palmaz Schatz 
stent implantation with miniature angioplasty equipment 
in patients wilh symptomatic coronary artery disease, a 
prospective study is presently perfomled in our depart-
ment. 
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Percutaneous trans radial artery approach for 
coronary Palmaz-Schatz stent implantation 
Ferdinand Kiemelleij, MD, and Gert Jan Laarman MD, PhD 
Amsterdam, The Netherlands 
The first metallic coronary stents were implanted in 
human beings in 1986 to overcome t.w~ major limita-
tions of percutaneous transluminal coronary balloon 
angiopiast.y (PTCA): abrupt closure and late rest-
enosis,l Rigorous anticoagulant therapy is manda-
tory to prevent thrombotic occlusion of metallic 
stents.2 Coronary stenting by the femoral artery ap-
proach carries a substantial risk of bleeding compli-
cations, especially if large-bore guiding catheters are 
used. A possible prevention of severe puncture site--
related events is the combination of a smaller punc-
ture opening with selection of another entry site. 
With the introduction of 6F guiding cat.heters that 
allow passage of low-profile balloon catheters, percu-
taneous balloon angioplasty via the radial artery be-
came possible as demonstrated by our group in 100 
consecutive pat.ients.3 This report. describes the tech-
nique, procedural results, and clinical course in 20 
consecutive patient.s who underwent. Palmaz Schatz 
coronary stent. implantation via the radial artery. 
METHODOLOGY 
Patient selectfon. In an ongoing st.udy, patients se-
lected for coronary stent. implantation who had a 
good pulsating right or left. radial artery and a posi-
tive Allen test result. were selected for transradial ar-
tery approach, irrespective of t.he patient's sex, 
weight., and size. The Allen test result. was considered 
normal when, after compression of both ulnar and 
radial arteries, hand color returned to normal within 
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10 seconds after release of the ulnar artery. Patients 
were included in our study after giving informed 
consent. 
Medical treatment. Patients were treated with Dex-
tran40, the first. 500 ml at. a rate of 100 ml/hr and the 
second 500 ml at 50 ml/hr. The infusion was started 
2 hours before elective stentimplantation or from the 
moment. the decision was made to implant a stent. in 
acute situations. At. the day of stent implantation, 
dipyridamole 225 mg/day and acetosalicylic acid 300 
mg/day was started. After sheath insert.ion, 10,000 IU 
of heparin was administered intraarterially, followed 
by 5,000 IV for each hour the procedure lasted, Three 
hours after hemostasis was achieved, 3,000 IU hepa-
rin was administered intravenously. Heparin was t.i-
trated to Activated Part.ial Thromboplastin Times 
(APTTs) of80 to 100 seconds until stable adjustment. 
on oral anticoagulant. drug t.herapy (three consecu-
tive therapeuticThrombotests). Coumadin was given 
for 3 mont.hs and acetosalicylic acid and dipyrida-
mole were given for 6 months, To prevent. radial and 
coronary artery spasm, 10 mg nifedipine was admin-
istered sublingually before radial artery puncture. 
Radial artery catheterization. The right ann was ab-
ducted to an angle of 70 degrees, and the wrist was 
hyperextended. After local anesthesia wit.h lidocaine 
2%, t.he radial artery was punctured with an Arrow 
(Arrow International, Reading, Pa.) 22-gauge radial 
artery catheterization set or an 18 gauge introducer 
needle at. a 45-degree angle 1 cm proximal from t.he 
st.yloid process, After appearance of pulsatile flow 
from the needle, and Angiomed (Angiomed, Karl-
sruhe, Germany) 0.025-inch, 260 em long guide wire 
was introduced through this system, followed by in-
sertion of a Bard Hemaquef. (Bard, Billerica, Mass.) 
II 6F 10 cm arterial introducer after a small skin in-
cision was made with a No, 11 surgical blade. 
Coronary artery cannulation, A Scimed Triguide 
(Scimed Life Systems, Maple Grove, Minn.) 6F 
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guiding catheter (inner diameter 0.060 inch, shaft 
lengt.h 100 cm) was selected with an appropriate 
curve, providing maximal back-up support. during 
angiophlsty and stent implantat.ion. 
Angioplasty. After angiography an ACS (Advanced 
Cardiovascular Systems, Santa Clara, Calif.) High-
Torque Floppy 0.014-inch guide wire was advanced 
across the lesion. Over t.his guide wire a rapid-
exchange, low-profile, compliant balloon catheter 
(Scimed Express) was positioned at the stenosis. This 
dilatation catheter can easily be advanced through 
6F guiding catheters, is easy to exchange, and has 
variable diameters depending on inflation pressures. 
This inflation pressure-dependent variation of bal-
loon diameter makes'a single-baUoon approach pos-
sible for the complete procedure. The stenosis was 
predilated to facilitate positioning of the stent-
loaded balloon at the lesion. Performance of the 
guiding catheter (back-up support, opacification, 
and pressure monitoring) and of the balloon catheter 
(crossability and retrievabilit.y) were semiquantita-
tively scored in three categories; good, moderate 
(sufficient.; no need to change guiding or balloon 
catheter), and poor (suboptimal; need to change 
guiding or balloon catheter). 
Stent preparation. The predilating balloon catheter 
was preferably used as sten1. carrier, because its 
increased profile after the first. inflat.ions allow better 
fixation for the stent. compared to a balloon tightly 
wrapped on the catheter shaft. The balloon was 
cleaned with saline solution to remove cont.rast. agent., 
possible blood clots, and lubricating coating. A 7.3 
mm or 15 mm Palmaz-Schatzcoronarystent (Johnson 
and Johnson Interventional Systems, Warren, N. J.) 
was manually crimped on the balloon catheter so that 
the balloon marker was positioned in the middle of 
the stent and no free movement. from the stent over 
the balloon was noted. 
Stent delivery. The stent.·loaded balloon catheter 
was advanced over the guide wire toward t.he steno-
sis under concomitant contrast. medium delivery. 
The articulation site of the 15 mm Palmaz-Schatz 
stent, the weakest portion of the stent, was posi-
tioned just, eccentric from the site with t.he minimal 
luminal diameter. After delivery the stent. diameter 
was optimized by successive dilatations with higher 
inflation pressures or larger balloon catheters. 
Introducer sheath removal and hemostasis. In all in-
stances the arterial sheath was removed immediately 
after withdrawal of the guiding catheter, followed by 
application of an occlusive tourniquet at the radial 
puncture site for a minimum of 30 minutes. Pressure 
was gradually released until hemostasis was ob-
tained. A pressure bandage over the punctured artery 
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was applied for 6 hours. Patients were not restricted 
to bed rest, and were advised to rest.rict movement of 
the wrist joint. 
Quantitative coronary analysis. The x-ray imaging 
equipment. used was the Philips Poly Diagllost. C2, 
equipped with a digital cardiac imaging (DCI) system 
(Philips Medical Systems, Eindhoven, The Nether-
lands). This system gives on-line video digitized 
images, for optimal angiographic assessment. of cor-
onary artery anatomy. Quantitative analysis of coro· 
nary segments was performed with this system before 
angioplasty and after t.he stent. implantation or after 
the last. balloon inflation within the coronary stent. 
Predischarge examinations. The radial artery was 
controlled for the presence of pulsations, and the 
Allen test and reversed Allen test were repeated. 
Claudication of the hand was tested by having the 
patients open and close their hand 50 times. A two-
dimensional and Doppler ultrasound study was per~ 
formed before discharge. 
Statistics. All values are expressed as mean ± SD. 
OBSERVATIONS 
Study population. Bet.ween March and June 1993 in 
20 consecutive patients transradial artery implanta~ 
Hon of a Palmaz Schatz stent. was attempted for 
saphenous vein coronary bypass stenosis (n = 9, 
45 %), native coronary artery restenosis after previ-
Ous angioplasty (n := 7, 35%) and for suboptimal 
PTCA results (n := 4, 20%). Twenty-five stents were 
implanted for 24 lesions in 20 vessels. During this 
episode t.wo patients underwent coronary stent. im-
plantation via the femoral artery because this ap-
proach was required to participate in a multicenter 
randomized study in which stent, implantation and 
balloon angioplast.y (Benestent st.udy) were com~ 
pared. One patient, had a transfemoral stent. implan-
tation immediately after transfemoral artery PTCA 
complicated by a coronary dissection. Patient base-
line clinical characteristics are shown in Table I. 
Anglographic data. Vessel distribution, TIM! grade 
flow, and t.ype of lesion are summarized in Table II. 
Quantitative coronary angiographic data are listed in 
Table III. 
Procedure 
Radial artery carumlation. The radial artery was 
successfully punctured and cannulated within 15 
minutes in all patients (85% within 5 minutes). No 
complications were encountered. 
Guiding-catheter selection and performance. Cor~ 
onary artery cannulation with 6F guiding catheters 
was successful within 15 minutes in 85% of the pro-
cedures (65% within 6 minutes). Thirty~nine guiding 
catheters were used (1.95 catheters/procedure). An 
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Table I. Baseline characteristics 
No. of patients 
Gender 
Male 
Female 
Age (yr) 
Mean ± SD 
Range 
Height (em) 
Mean ± SD 
Range 
Weight (kg) 
Melin ± SD 
Range 
Oral anticoagulation 
Acetyl salicylic acid 
No. 
% 
Dipyridamol 
No. 
Coumadin 
No. 
Exertional angina 
CCS III 
No. 
CCS IV 
No. 
7<. 
NOneXCllional angina 
No. 
Mixed angina 
No. 
u 
" 
20 
16 (80%) 
4 (20%) 
63 ± 12 
40·82 
175 ± 7 
165-187 
86 ± 11 
70·106 
19 
95 
5 
25 
11 
55 
9 
45 
8 
40 
3 
15 
8 
40 
overview of guiding catheters used for stent implan-
tation is given in Table IV. For these catheters, con-
trast opacificaHon and pressure monitoring were 
rated as being good in all instances. Back-up support 
was moderate in 6 (30%) cases. Seven patients (35%) 
had discomfort in the arm during catheter manipu-
lation. Additional application of nifedipin and local 
warm compresses was necessary in 4 (20%) patients. 
Balloon-catheter selection and performance. 
Thirty-eight baUoon catheters were used for 20 
patients (1.9 balloons per patient). Details on predi-
latation, stent delivery, and oversizing are summa-
rized in Table V. 
Predilatation. In all but one elective procedure the 
lesions were predilated. Crossability through the 
guiding catheter and the target vessel was rated as 
being good in 89% and moderate in 11 % of cases, but 
all balloons could be successfully positioned across 
the stenosis. All balloon catheters were easy to 
retract After predilatation of a stenosis in t.he LAD, 
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Table I. Cont'd 
Prior myocardial infarction 
No. 
Prior bypass surgery 
No. 
Hypertension 
No. 
Diabetes mellitus 
No. 
Cholesterol 2':6.5 mmo!/L 
No. 
% 
Cigarette smoker 
No. 
Family history 
No. 
Disease 
Single-vessel 
No. 
% 
Two-vessel 
No. 
Three-vessel 
No. 
9 
45 
10 
50 
6 
30 
5 
15 
35 
7 
35 
10 
50 
5 
9 
45 
a major diagonal branch occluded in one patient.; it. 
remained occluded during the procedure and after 
stent implantation and resulted in a non-Q myocar-
dial infarction (creatine phosphokinase-MB 64 
mmol/L). 
Stent delivery. Twenty-five stents (4 stents of 7.3 
mm and 21 stents of 15 mm in length) were success-
fully implanted (1.25 stents per patient). Crossabil-
ity through the guiding cat-heter and coronary artery 
was good during 21 implantations. Noticeable fric-
tion between the stent and the tip of Amplatz-shaped 
(left and right) guiding catheters was noticed in two 
patients, but. the friction did not lead to stent 
dislodgement.. 
In one pat.ient the guiding catheter (Judkins Left 
4) did not provide enough support to advance a 7.3 
mm stent at the target lesion in the LAD. In our at-
tempt to withdraw the stent within the guiding cath-
eter, we noticed displacement of the stent toward the 
distal end of the balloon. This stent was partially de-
ployed in the LAD proximal from the target lesion 
and could not· be crossed by the same stent delivery 
catheter. With a 2.0 mm balloon catheter, this stent 
could be expanded, followed by optimal deployment 
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Table 11. Angiographic data. 
No. of stents placed (n =' 2ft) 
LAD 
No. 
RCA 
No. 
';}. 
Lex 
No. 
,. 
VBG 
No. 
TIMl grade (20 vessels) 
o 
2 
3 
No. 
<:;. 
No. 
" .. 
No. 
No. 
Type (24 lesions) 
A 
B 
c 
No. 
,. 
.. -
No. 
,. 
" 
No. 
10 
40 
3 
12 
2 
8 
10 
40 
5 
5 
17 
85 
13 
54 
6 
25 
5 
21 
J.AD, Ldt anterior deocending ("Nnary artery; LeX, left circumflex ((IN-
runy artery; RCA, right (\JT\lnary artery; TIMl, thrombo\pis In Myocardial 
Infllrction study; \/BG, \'tnous byp.'l.i;s graft. 
with a 3.5 mill balloon catheter. With the use of an 
Amplatz Left. II guiding catheter, the target-lesions 
were successfully stented. In anot.her pat.ient friction 
was noticed between the stent and the target lesion 
(LAD dissection). However, two stents were success-
fully implanted to cover the entire lesion. AU other 
procedures were uncomplicated. 
Opacification of the vessel containing the deflated, 
stent-Ioaded balloon easily allowed adequate posi-
tioning of the stent in relaHon to the cUlprit lesion. 
In eight patients no additional dilatations were 
applied after stent delivery because the angiographic 
result. was considered opt imal. 
Oversizing. In four patients the stent was dilated 
at higher inflation pressures with the same balloon 
catheter to optimize the angiographic result. In eight 
patients stent. deployment. was improved by dilata-
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Table III. Quantitative coronary angiography 
Baseline A/ter stenting 
Mean ± SD Range Mean ± SD Range 
Reference diametfr 3.2 ± 0.5 2,2-4.2 3,4-0.5 2.3·4.5 
(mm) 
Minimal lumen 0.9 ± 0.4 0-1.7 3.1 ± 0.4 2.4-4.1 
diameter (mm) 
Diameter stfnosis 71 ± 12 52-100 13 ± 10 0-32 
(~) 
Table IV. Selected guiding catheters (11 =' 20) 
Cun'e 
Judkins left 
El gamal 
Multipurpose 
Amplatz left 
Amplatz right 
Judkins right 
" 
5 
5 
5 
3 
" " 
25 
25 
25 
15 
5 
Hons wit.h a larger balloon. In one patient. undergo-
ing stent. implantation for an obst.ructive dissection 
of the circumflex coronary artery after PTCA, three 
balloon catheters could not. cross a well-deployed 
stent in the LCX to improve a residual dissection 
distal from the stent.. With aggressive anticoagula-
tion, this patient- had an uncomplicated clinical 
course. Oversizing the stented segment. wit.h a larger 
balloon catheter was associated with the appearance 
of a dissection distal from a tandem stent. in t.he LAD 
in the patient. described earlier. In this segment a 
fourth stent. was successfully implanted. 
Anglographlc results. All stents were angiographi-
cally well deployed (stent/coronary artery reference 
diameter ~1 and no filling defects within the stent.). 
Quantitative analysis data are summarized in Table 
V. In 2 (10%) patients some contast- medium re-
mained visible parallel to the vessel outside t.he stent. 
The patient. with a small filling defect in t.he LCXjust 
beyond the stent and the patient. with sidehranch 
occlusion were described earlier. 
Hemostasis. The arterial sheath was removed im-
mediately after the last. control angiogram. Hemo-
stasis was obtained after 32 ± 11 minutes (range 20 
to 60). In one patient. some coliagen (Vasoseal) was 
successfully applied subcutaneously near the punc-
ture opening to stop prolonged bleeding. 
Clinical course. AU patients were free from acute or 
subacute stent- thrombosis. Except for the patient 
with a non-Q myocardial infarction caused by occlu-
Volume 12a, Numbe, 1 
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Table V, Inflation characteristics during predilatation, 
stent delivery, and oversizing 
Stent 
Predilatation delivery Otwsizing 
n 19 
" 
18 
Balloon diameter (mm) 
2.0 
No. 
% 5 
2.5 
No. 2 
'ii:. 16 8 
3.0 
No. 9 13 5 
W. 47 52 33 
3.5 
No. B 10 7 
% 32 40 47 
4.0 
No. 3 
'i~. 20 
Inflations (No.) 
Mean ± SD 1.5 ± .8 l.l± .3 1.2 ± .6 
Range 1·4 1·2 1·3 
Pressure (atm) 
Mean ± SD 8.4 ± 3.1 11.2 ± 1.7 10.2 ± 1.4 
Runge 4-13 8-14 8-12 
Duration (sec) 
Mean ± SD 89 ± 50 55 ± 29 62 ± 30 
Range 30·240 15·140 15-130 
Size (mm)* 
.Mean ± SD 3.2 ± .4 3.6 ±.3 3.7 ± .3 
Range 2.3·4.1 3.0·4.1 3.2·4.2 
·Mllnufncturer·~p",dfied balloon diameters at variable inllation pr~s.smes. 
sion of a diagonal branch, no cardiac events were re-
corded. No bleeding complications leading to pro-
longed hospitalization, blood transfusion, vascular 
surgery, or functional disability were encountered. In 
five patients removal of the pressure dressing was 
followed by prolonged oozing of blood from the 
puncture site. When a new pressure dressing was ap-
plied bleeding could be stopped. Blood loss was min-
imal and did not require transfusion or surgical 
intervention. 
No other clinical catheter site-related complica-
tions were encountered. One patient had temporary 
macroscopic hematuria during heparinization and 
adjustment on coumadin, No underlying caUse could 
be detected, and blood t.ransfusion was not required, 
Hospitalization was prolonged by 1 month in one pa-
tient requiring int.ravenous antibiotic treatment. of a 
fever and Staphylococcus aureus bacteremia related 
to a contaminated intravenous cannula. The other 
patients were hospitalized for 6.1 ± 2,3 days (range 
1 to 10, median 6 days) after stent implantation. 
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Doppler and physical radial artery studies. In all pa-
tients the radial artery was palpable at. discharge. 
The reversed Allen test results were normal (after 
compression of both radial and ulnar arteries, hand 
color returned to normal within 10 seconds after re-
lease of the radial artery) in all patients. Claudication 
of the hand could not be provoked. Doppler ultra-
sound examination proved the presence offtow at the 
puncture site in all patients. In one patient. a small 
hematoma and intima defect was visible on two-
dimensional echography. 
COMMENTS 
Coronary stent implantation is currently used as a 
modality to improve results of percutaneous translu-
minal coronary balloon angioplasty (PTCA), The 
main concern after implantation of metallic coronary 
stents is prevention of stent thrombosis. The inci-
dence of stent thrombosis is high, especially after 
stent implantat.ion for abrupt. coronary closure after 
PTCA:I-7 A poststenting regimen of a combination of 
coumadin, heparin, dextran, acetosalycilic acid, and 
dipyridamole is usually advised to prevent stent 
thrombosis. Monitoring of prothrombin fragments 
1 + 28 and application of vascular hemostasis devices 
after coronary stenting9 are reported as possible 
means of optimizing heparin therapy during adjust-
ment on coumadin. It. is not. surprising that entry 
site-related bleeding complications are frequently 
encountered in the days after stent. implantation. 
The incidence of puncture site-related complications 
has been reported to vary between 7.9% of 226 pa-
tients in the initial multicenter experience with the 
Palmaz-Schatz stent.2 and 16% of 220 patients in a 
large single-center experience. to A bleeding compli-
cation has serious local sequelae and may force 
the clinician toward suboptimal heparinization and 
increased risk of stent. occlusion. One possible solu-
tion for prevention of severe puncture site-related 
events may be found in the combination of a smaller 
puncture opening with selection of another entry 
site. 
Stent implantation through 6F guidIng catheters. In 
recent. years development of miniaturized PTCA 
equipment allowed the use of 7F,1l 6F,3, 12, 13 and 
even 4F14 guiding catheters for coronary angioplasty. 
Transfemoral artery stent· implantation through 6F 
guiding catheters has been reported in three patients 
by Urban et al. IS Our results also show that. 6F guid-
ing catheters accomodate stent.-Ioaded, low-profile 
balloon catheters well. 
Adequate back-up support allows passage of a me-
tallic stent. on an unlubricated balloon catheter 
across a coronary stenosis, For this reason a guiding 
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catheter curve that provides optimal support has to 
be selected. Pressure damping in the coronary ostia 
by these guiding catheters was not. encountered. Ac-
curate positioning of the stent in relation to the 
stenosis was feasible as a result of adequate opacifi-
cation of the vessel with contrast. medium. Balloon 
retrieval after stent delivery and balloon exchange 
for stent oversizing were also easily accomplished. 
However, a hazardous limitation of this approach 
should be emphasized. Because prefabricated shealh-
protected stent delivery systems cannot be advanced 
through 6F guiding catheters, friction between the 
stent and the guiding catheter tip (friction was 
noticed in two of four patients in whom an Amplatz-
shaped catheter was used) or vessel wall may shear 
the bare stent.from the balloon, potentially leading to 
stent embolization. To minimize this risk, optimal 
coaxial alignment between the guiding catheter and 
coronary artery should be obtained before steut im-
plantation is attempted. We crimp the stent on the 
balloon after it has been inflated several times to in-
crease balloon profile and allow better fixation to 
carry the stent. Removal of the lubricating coating 
from t.he balloon also helps to keep the stent fixed to 
the balloon. We recommend predilat.ing a tight 
stenosis because this will fascilitate stent passage. 
Despite these precautions, displacement of the stenl 
from the balloon catheter occurred in one patient 
during an attempt. to retrieve the stent.-Ioaded bal-
loon within the guiding catheter. Another limitation 
at present is the inability to use int.ravascular ultra-
sound or angioscopy to assess obstructions distal to 
a stent. or suspected suboptimal stent. deployment.. In 
these instances large bore catheters are preferred. 
Because 6F guiding catheters accomodate low-profile 
ACS Flowtrack 40 M perfusion balloon catheters, 
prolonged dilatations with preservation of distal flow 
are no longer precluded after a 6F guiding catheter is 
selected.16 
Stent Implantation via the radial artery. Dorros et. al. 17 
described an alternative route for PTCA by perform-
ing arteriotomy of the brachial artery. At. present. ex-
tensive experience with percutaneous trans brachial 
coronary cat heterization and angioplasty shows them 
to be effective and safe alternatives to the Sones 
technique and the percutaneous technique of the 
femoral artery.18.20 Complications after brachial ar-
tery puncture are rare, but. if present they often re-
quire surgical repair. Complications are arterio-
venous fistulae, nerve injury, thrombotic artery ob-
struction, dissection, and false aneurysm.21 
Campeau21 reported percutaneous entry of the ra-
dial artery for cardiac catheterization in 100 patients 
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with a collateral blood supply to the hand. An arte-
rial sheath with an internal diameter of 6F was used. 
Only two symptomless vascular complications were 
observed. Safety of transradial artery coronary cath-
eterization is mainly determined by the favorable 
anatomic relations of the radial artery to its sur-
rounding structures and the double blood supply to 
the hand. The sequelae of radial artery obstruction 
are frequently mild even in pat.ients not selected for 
good collateral circulation. Slogolf et al.22 reported a 
series of 1699 pat.ients who underwent heart surgery 
with perioperative radial artery cannulation. No 
ischemic damage to the hand was observed, even in 
26% of patients with abnormal Doppler flow pat-
terns, compatible with partial or complete radial ar-
tery occlusion. No major veins or nerves are located 
near the radial artery excluding injury of these 
structures. Because of t.he superficial course of the 
artery, hemostasis can be easily obtained with local 
compression. Feasibility and safety of transradial ar-
tery PTCA was demonst.rated by our group in 100 
consecutive patients, with a procedural success rate 
of 98% (92% via the radial artery) and absence of 
major puncture site-related complicat.ions, leading 
to functional disability of the hand, vascular surgery, 
or need for blood transfusions.3 
We attempted a transradial artery stent implanta-
tion irrespective of gender, age, body weight, and 
height. of patient. All patients selected for stenting 
had successful radial artery puncture and cannula-
tion. Our results indicate that transradial artery 
catheterization with 6F guiding catheters can be 
performed within acceptable time limits and without. 
major discomfort for the patient. Immediate ambu-
lation of the patient after stenting is associated with 
increased patient. comfort. The sheath was removed 
immediately after the procedure to reduce the risk of 
radial artery thrombosis.23 Even in heparinized pa-
t.ients, hemosta'lis was obtained at a mean interval of 
31 minutes. 
No clinical puncture site-related complications 
were encountered that. required blood transfusions or 
vascular surgery. The absence of post.procedural ra-
dial artery occlusion compares favorably with re-
ported incidences of 6% in the series of Campeau,21 
30% of 333 radial artery cannulations in the series of 
Davis and Stewart,24 and 38% described by Bedfort 
and Walhnan.23 Early sheath removal and combined 
anticoagulat.ion may have contributed to this favor-
able outcome. 
Potential benefit. By using one dilatation catheter 
for predilatation, stent delivery, and oversizing and 
by using a bare stent, considerable reduction in ma-
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terial COSt. can be achieved. We used 1.9 dilatation 
catheters per procedure including bail-out. proce-
dures where multiple balloon catheters were used 
before stent. implantation. Reduction of vascular 
complications and subsequent treatments also con-
tribute to reduced cost. A potential advantage of the 
transradial artery approach is early discharge of the 
patient after stent. implantation. The mean duration 
of hospital stay after stent implantation in this st.udy 
was 6 days. However, if the elective stent. candidate 
is adjusted on coumadin before hospital admission, 
there is no other argument for prolonged hospital-
ization if the stent. result. is optimal. 
Conclusions. When appropriate precautions are 
taken, transradial artery coronary stent. implantation 
with miniaturized angiopiast.y equipment is feasible 
and safe, although the limitations of the "bare-stent 
technique" remain a concern. A major benefit of this 
approach is a reduction in clinical puncture site-re-
lated complications and patient. comfort. 'l'o estab-
lish the potential superiorit.y of this approach over 
the t.ransfemoral approach, a larger sample size 
, should be st.udied, ideally in a prospective random-
ized fashion, 
SUMMARY 
The purpose of this study was to evaluate feasibil-
it.y, safet.y, and efficacy of implantation of unsheat hed 
Palmaz-Schatz coronary stents via the radial artery, 
Anticoagulation after coronary stenting has the haz-
ard of vascular complications if large-bore guiding 
catheters are introduced via the femoral artery. Such 
complications have serious local sequelae, are associ-
ated with suboptimal anticoagulation, and prolong 
hospitalization. By combining 6F guiding cat.heters 
and low-profile dilatation catheters with bare Pal· 
maz-Schatz stents, smaller vessels such as the radial 
artery can be selected as the entry site. It is postu-
lated that. no major puncture site-related complica-
tions occur because hemostasis is easily achieved and 
no veins and nerves are near the radial artery, With 
double blood supply to the hand, radial artery occlu-
sion is well tolerated. Twent.y-five bare Palmaz-
Schatz stents were implanted via the radial artery 
through 6F guiding catheters in 20 consecutive pa· 
tients for venous bypass graft stenosis (n =: 9; 45%), 
native coronary artery restenosis (n =: 7; 35%) and 
suboptimal transradial artery PTCA (11 "" 4; 20%), 
Immediately after stent. implantation and assess-
ment. of the result. by means of computerized quan-
titative coronary analysis, the arterial sheath was 
withdrawn followed by intense anticoagulation and 
free ambulation of the patient. Radial artery function 
IS! 
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and anatomy were assessed by two-dimensional and 
Doppler ultrasound examination. Lesions (n = 24) 
were oft.ype A (n = 13; 54%), B (n = 6; 25%) and C 
(n = 5; 21 %), The reference diameter of the stented 
segments was 3,2 ± 0.5 mm (2.2 to 4,2 mm). Proce-
dural success via the radial artery was 100%, How-
ever, one patient. had a non-Q myocardial infarction 
as a result of occlusion of a diagonal branch after 
predilatat.ion of a stenosis in the left anterior de-
scending coronary artery. In the same patient., over-
sizing the distal of three stents resulted in a distal 
antegrade dissection, for which a fourth stent was 
successfully implanted, Minimal luminal diameter 
increased from 0.9 ± 0.4 nun (0 to 1.7 mIll) to 3.1 
± 0.4 mm (2,4 to 4,1 Hun), and diameter stenosis was 
reduced from 71% ± 12% (52% to 100%) to 
13% ± 10% (0% t032%),Hemostasiswasobtained 
within 32 ± 11 minutes (20 to 60 miuutes) after the 
procedure, No puncture site-related complications 
were encountered. One patient had macroscopic he· 
maturia, which subsided spontaneously, No blood 
transfusions were required, No patient, suffered from 
stent. occlusion. In all patients the radial artery was 
patent. at discharge. Coronary stenting via the radial 
artery is feasible and safe, excludes major entry site--
related complications, and facilitates postprocedural 
patient management.. 
We thank Dr, Richard A. Schatz, Research Director, Cardiovas· 
cular Interventions, Scripps Clinic, La Jollo, Calif., for his critical 
review of this paper. 
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ABSTRACT 
Objectiycs. The purpose of this study was to evaluate feasibility and safety of implantation of 
unsheathed Palmaz Schatz coronary stents via the radial artery. 
Backgrounds. Anticoagulation after coronary stenting carries the risk of vascular complica-
tions if large bore guiding catheters are introduced via the femoral artery. Such a complication 
has serious local sequelae and leads to suboptimal anticoagulation and prolonged hospitaliza-
tion. By combining 6 French (F) guiding catheters and 10\'1 profile dilatation catheters, moun-
ted with Palmaz Schatz stents, smaller vessels such as the radial artery, can he selected as 
entry site. It is postulated that major puncture site related complications rarely occur because 
hemostasis is easily achieved and no veins and nerves are near this artery, 'With double blood 
supply to the hand, radial artery occlusion is well tolerated. 
lVIethods. In 100 consecutive patients, stent implantation wus attempted for 122 lesions, dis-
tributed in 104 vessels. Immediately after stent implantation and final angiography, the intro-
ducer sheath was withdrawn, followed by intense anticoagulation and mobilization. The radial 
artery puncture site was studied by two-dimensional and Doppler ultrasound. 
Results. Successful stent implantation via the radial artery was achieved in 96 patients. In 2 
patients, arterial puncture failed, followed by sllccessful stenling via another entry site. In 1 
patient, stent implantation was achieved with a stent delivery system via the femoral artery, 
after a failed attempt to cross the lesion with a bare stent via the radial approach, complicated 
by a groin bleeding requiring transfusions and vascular surgery, One patient was referred for 
coronary bypass surgery, because the stent could not reach a dissection in a tortuolls LAD. 
Lesions were of type A (n=43 [35%]), B (n=30 [25%]) and C (n=49 [40%]). Reference dia-
meter of the stented segments was 3.3 ± 0.5 mill (1.2 - 5.0 mm) .. Minimalluminal diameter 
increased from 1.1 ± 0.4 mm (0 - 2.1 l1un) to 3.1 ± 0.5 111m (1.0 - 4.2 mm). Diameter stenosis 
was reduced from 67 ± 11% (37 - 100%) to 13 ± 10% (0 - 68%). Procedural success and an 
uncomplicated clinical course \vas achieved in 93 patients (93%). One patient (1%) had sub-
acute stent thrombosis, followed by sllccessful PTCA and coronary bypass surgery. Another 
patient died 2 days after stenting for unstable angina and a poor left ventricular function, wit-
hout signs of stent occlusion. One patient developed a radial artery bleeding, requiring surgi-
cal repair. None of the 4 pts with a post procedural radial artery occlusion showed signs of 
ischemia of the hand. Hospital stay was 5.2 ± 4.1 days. Patients (n:::64) using coumadin at 
admission, were hospitalized for 4. I ± 4.2 days. or this population, 22 patients (34%) were 
discharged within 24 hours after stenting. 
Conclusion. Transradial artery Palmaz Schatz coronary stenting is feasible and safe. Under 
intense anticoagulation early m~tior entry site related complications are rarely encountered. 
INTRODUCTION 
Implantation of metallic coronary stents via the femoral artery, under complex anticoagulation 
regimens (1), carries a substantial risk for bleeding complications, especially if large bore gui-
ding catheters are used (2,3,4,5). A possible solution to prevent severe puncture site related 
events may be fOllnd in the combination of a smaller puncture opening with selection of an 
other entry site. With the introduction of 6 French guiding catheters that allow passage of low 
profile balloon catheters, percutaneous balloon angioplasty via the radial artery became possi-
ble, as demonstrated by our group in 100 consecutive patients (6). 
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This report describes the technique, procedural results and clinical course in 100 consecutive 
patients who underwent Palmaz Schatz coronary stent implantation via the radial artery. 
METHODS 
Pnti~nt selection 
From March 1993 to May 1994, 100 patients were selected for coronary stent implantation 
via the radial artery. Excluded for this approach were patients with absence of collaterals from 
the ulnar artery, as assessed by the Allen- test. The Allen- test was considered normal when 
after compression of both ulnar and radial arteries, a return of the normal colour of the hand 
occurred within 10 seconds after release of occlusion of the ulnar artery. Included were also 
patients with a suboptimal result after transradial artery PTCA. 
Medical treatment 
.Medical treatment has been described previously by our group (7,8). In the course of this 
study, however, more elective patients were pretreated with coumadin, in order to reduce the 
hospitalization time. The INR was assessed just prior to the procedure. At an INR > 2.7, the 
patient received 10.000 IU heparin after sheath insertion, together v.lith Dextran 40 (a total of 
I liter) and Acetylsalicylic acid 500 mg intravenously. No heparin was given after the proce-
dure. At an INR < 2.7, heparin was titrated to an APTT of 80 seconds after a 3.01l0 IV holliS, 
three hours after hemostasis was achieved. Heparin was gradually stopped at an adequate INR 
> 2.7. 
TranSl'adial PTCA technique 
The technique for radial artery catheterization, coronary cannulation, angioplasty, stent 
implantation and quantitative coronary analysis, has been described previollsly (7,8). 
In brief; The right arm was abducted and the wrist hyperextended. After local anaesthesia, the 
radial artery was punctured with an Arrow®, 22 gauge radial artery catheterization set or with 
a Kimmal® needle. After appearance of pulsatile flow from the needle an 0.025 inch, 260 cm 
long, J shaped guidcwire (Schncider®) was introduced through this system, followed by 
insertion of a 6 French arterial introducer. During ongoing experience, we preferrably used 23 
em, instead of 10 em long Tel'lUllO® 6F introducer sheaths, to prevent radial artery spasm and 
to facilitate gukling c<'ltheter manipulations. 
Meticulous care was directed towards optimal selection of the puiding catheter, with respect 
to backup support and coaxial alignment. The Cordis@ Petite n 6F guiding catheter was pre-
ferrably selected because of its large inner diameter (0.062 inch). For len coronary artery pro-
cedures, the Scimed® Triguide HI 6F Voda- curve was selected because of optimal support and 
alignment, despite 1.1 smaller inner diameter (0.060 inch). Later in the study, this curve also 
. • Dl • Bl became avmlable from Cordls® (Extra Backup ). We selected SClll1ed® Express balloon 
catheters for predilatation and stent delivery, because of it's low profile, ease of advancement 
over the guidewire and through the guiding catheter and because of the proper fixation of the 
stent, once crimped on the balloon. 
One or more 7 mm, 10 mm or 15 mm Pnlmaz Schatz coronary stents (Johnson and Johnson 
Interventional Systems, \Varren, NJ) were used. After delivery, the stellt diameter was optimi-
zed by successive dilatations with higher inflation pressures or with larger balloon catheters 
of intermediate compliance (Schneider® Magical Specdyn.l). 
Prevention of stellt embolization 
After a failed attempt to advance the stent into the coronary artery or across the tnrget lesion, 
two strategies were applied to prevent stent loss or embolization. If intracofOnary withdrawal 
of the stent loaded balloon, back into the guiding catheter, was considered to result in dislod-
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gement of the stellt, the stent was deployed proximal from the target lesion, if that coronary 
segment was suitable for stent implantation. In other instances, the stent loaded balloon was 
retrieved to a position just outside the guiding catheter. Preferrably over the intracoronary 
guide v.lire, the entire system was withdrawn into the brachial or radial artery, without a chan-
ge of the mutual position of guiding catheter and balloon catheter. Only in the brachial or 
radial artery, an attempt was made to withdraw the balloon catheter into the guiding catheter. 
If the stent became detached from the balloon, the balloon and guiding catheter were removed 
and a looped snare, madc of an intracoronary guidewire, was advanced through the sheath and 
over the guide wire towards the lost stent. After capture of the stenl, the loop was closed allo-
wing stellt retrieval into introducer sheath. 
Intl'oducer sheath removal and hemostasis 
The arterial sheath was removed, immediately after withdrawal of the guiding catheter, follo-
wed by application of an occlusive tourniquet at the radial pUllcture site for a minimum of 30 
minutes. Pressure was gradually released until hemostasis was obtained. A pressure dressing 
over the punctured artery was applied for 6 hours. Patients were encouraged to mobilize, and 
advised to restrict movements of the wrist joint. 
Predischarge examinations 
The radial artery was control1ed for the presence of pulsations, the Allen test and the reversed 
Allen test. Claudication of the hand was tested by opening and closing the hand 50 times. A 
two-dimensional ancl Doppler ultrasound study was performed prior to discharge. 
Statistical Methods 
All values are expressed as mean ± standard deviation. 
RESULTS 
Stltdy populatioll 
Between March 1993 and May 1994, in 100 consecutive patients transradial arlery implanta-
tion of a Palmaz Schatz stellt was attcmpted for native coronary artery restenosis after pre-
vious angioplasty (n::::33, 33%), saphenous vein coronary bypass stenosis (n::::31, 31 %), for de 
novo native coronary artery lesions (11=27, 27%) and for a suboptimal PTCA result (n::::9, 9%). 
For 122 lesions, 146 stents were implanted in 104 vessels. During the course of this study, 
stellt implantation via the femoral or brachial artery was only attempted in those patients, par-
ticipating in other stent- studies or undergoing emergency stenting after failed PTCA via the 
femoral or brachial route. Table I displays baseline clinical characteristics. 
Allgiogfaphical data 
Vessel distribution and lesion morphology are displayed in Table II. 
Quantitative coronary angiographical data are listed in Table 111. 
Procedllre 
Overall, a sllccessful stellt implantation via the radial artery was achieved in 96 patients 
(96%). A successful transradial stent implantation, together with an uncomplicated clinical 
course (no death, coronary artery bypass surgery, Q- wave myocardial infarction, sterlt occlu-
sion, repeat PTCA, vascular surgery or blood transfusions) was achieved in 93 patients 
(93%). 
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Table 1. Baseline characteristics 
No. patients 
Male gender 
Age (years) 
Height (em) 
Weight (kg) 
Oral anticoagulation 
Acetyl salicylic acid 
Dipyriclamol 
Coumadin 
Exertional angina; 
Non exertional angina 
Mixed angina 
CCS I 
CCS II 
CCS III 
CCSIV 
Prior myocardial infarction 
Prior bypass surgery 
Hypertension 
Diabetes mellitus 
Cholesterol;' 6.5 nnnolli 
Smoking history 
Fami Iy history 
Table II. Angiographieal data. 
Stented vessels (n~104) 
LM 
LAD 
LCX 
RCA 
VBG 
* Lesion morphology (n~ 122) 
Type A 
Type B 
Type C 
N 
100 
82 
64 ± II 
174 ± 8 
81 ± 10 
75 
16 
64 
I 
11 
45 
38 
43 
38 
35 
49 
24 
27 
30 
48 
16 
N (%) 
2 
34 
14 
23 
31 
43 
30 
49 
(2%) 
(34%) 
(13%) 
(24%) 
(27%) 
(35%) 
(25%) 
(40%) 
LAD Left anterior descending coronal)' artery 
LeX Left circl1mllex coronal)' artery 
UtI Left lllllinstem 
RCA R;ght conm",), ,,,<cry 
VBG Venous bypass graft 
,~ 
Reference 2:-:. 
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(range 35 . 89) 
(range 149 . 193) 
(range 58 . 112) 
Table III. Quantitative coronary angiography 
Reference diameter (mm) 
Minimal lumen diameter (mm) 
Diameter stenosis (%) 
Baseline 
Mean ± SD 
3.3 ± 0.5 
1.1 ± 0.4 
67 ± 11 
Range 
1.2'" - 5.0 
o -2.1 
37 - lOa 
"Inadvertent depluyment of II stent, distal from an LAD- disset:tion after PTCA 
Radial art cry cannulation 
Post stenting 
Mean±SD 
3.5 ± 0.5 
3.1 ± 0.5 
13 ± 10 
Range 
2.2 - 5.1 
1.0 - 4.2 
0-68 
The radial artery was successfully punctured and cannulated in 98 patients (98%). 
1n one 89 year old patient the radial artery, weak at palpation, could not be punctured, follo-
wed by successful transfemoral stellt implantation via 6F guiding catheters of the mainstem 
(LM) of the left coronary artery (LCA) and of the ostiulll of the right coronary artery (RCA). 
The other patient underwent stenting via the brachial artery of a venous bypass graft (VBO) 
and of a restenosis in the left circumflex coronary artery (LCX), immediately following a fail-
ed attempt to puncture the radial artery. 
Guiding catheter selection and performance 
For 104 vessels, 170 guiding catheters were used (1.7 catheter per procedure). Venous bypass 
grafts and the RCA were usually cannulated with EI Gamat or Multipurpose- type guiding 
catheters (81 % and 65%, respectively). The most frequently lIsed catheter for the LCA had a 
Voda-Ieft curve (52%). An ovcrvie\v of guiding cathcters used for stent implantation is given 
in Table TV. For these catheters, contrast opacification and pressure monitoring were rated 
good in all instances. Good back-up support was obtained during stellt implantation in 88 can-
nulated vessels (85%). Backup support was moderate to poor in 16 instances (15% of cannu-
lated vessels), but with these catheters, the procedure could be successfully completed in 13 
patients. Tn I patient the procedure had to be continued via the femoral artery with an 8F gui-
ding catheter to allow passage of a sheath protected stent delivery system across a proximal 
LAD dissection. In anothcr patient, a stent could not cross a proximal insignificant stenosis in 
a venous bypass graft, due to poor coaxial alignment. \Vith another guiding catheter, the pro-
cedure could sllccessfully be continued. Tn a third patient the guiding catheter did not provide 
enough support to advance a 7 mm stent at the target lesion in the LAD. In an attcmpt to 
withdraw the stent within the guiding catheter, displacement of the stent towards the distal 
end of the balloon was noticed. This stellt was incompletely deployed in the LAD, proximal 
from the target lcsion, and could not be crossed by the same balloon cathetcr. 'Vith a 2.0 mm 
balloon catheter, this stent could be expanded, followed by optimal deployment with a 3.5 
mm balloon catheter. 'Vith the use of another guiding catheter, the target Icsions were succes-
sfully stented. 
Balloon catheter selection and pel'fol'mance 
A total of 156 balloon catheters were used (1.6 balloon per patient and 1.0 balloon per stent). 
Pl'edi/lI(lI(ioll 
During elective procedures the lesions were predilatcd, except in 2 patients. Predilatation was 
performed at low inflation pressures with adequately sized balloons, also suitable for stellt 
delivery and secondary dilatations if necessary. After selection of the optimal guiding cathe-
ter, the halloons could successfully be positioned and retrieved across the stenosis. However, 
in one patient the balloon could not cross a tight stenosis in the LAD. After several passes 
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with a rotablalor (burr-size 1.25 mm) the procedure could be continued sllccessfully. 
Following predilatation of a stenosis in the LAD, a major diagonal branch ocduded in one 
patient. This branch remained occluded during the procedure and after stellt implantation and 
resulted in a non-Q myocardial infarction (CPK-MB 64 mmolll). In one patient selected for 
elective stenting of a restenosis in the RCA, predilatation resulted in a local dissection and 
subtotal oed us ion, well managed after implantation of one slent. In another patient, predilata-
tion of a restenosis in the LAD, was complicated by a distally progressing dissection, succes-
sfully stabilized after implantation of 4 stents. 
Predilatation did not result in complications in the other patients, although one patient with a 
membrane-like stenosis in the LAD did not show any improvement after predilatation with an 
adequately sized balloon . 
• Went delil'ery 
Opacitlcation of the vessel containing the detlated, stent loaded balloon, easily allowed ade-
quate positioning of the stellt in relation to the culprit lesion. 
For 122 lesions, 146 stcnts (15 mm: n=121; 7 mm: n=20; 10 nUll: n= 5) \Vere successfully 
implanted (1.5 stent per patient {range 1-5}), Mnltiple stents \Vere implanted for multiple 
lesions (15 patients) or to cover residual obstructions or dissections near the stenl (10 
patients). In two of these 10 patients a stenl was inadvertently deployed too distally. In one 
patient a second stent was deployed at the proper site in patient. In the other patient a third 
stent had to be implanted distal from the misplaced stent, in order to correct an acute transi-
tion in diameter between the stent and the small distal segment (RD 1.2 mm). Outcome of 
these patients was uneventful. In one patient it was not possible to stent a dissection half-way 
in a tortuous LAD, despite adequate backup support from the guiding catheter, because the 
stent loaded balloon could not reach the lesion. This stent was deployed proximally from the 
target lesion in order to prevent stent loss or embolization during attempts to retrieve the bal-
loon. This patient was referred for emergent coronary bypass surgery in a stable condition. 
The post-operative course was complicated by a non-Q- wave myocardial infarction (CKMB 
79 JUlI), 
In one patient the stent, mounted Oil a 3.5 mm balloon catheter used for predilatation, could 
not enter a venous bypass graft. A successful attempt was performed with a 3.0 balloon 
catheter as stent carrier. In another patient, a stent, crimped on a 3.5 mm balloon catheter, 
could not cross a proximal stellt, implanted in the RCA. With a new balloon catheter the pro-
cedure could be completed. In these patients the dispatched slents were retrieved successfully 
from the radial artery. No stents were lost. 
Secoudary stenl dilatations 
In 29 patients the result was considered to be optimal after stenl delivery. In the remaining 70 
patients the stents were dilated at higher inflation pressures with the same balloon catheter 01' 
with semi-compliant balloon catheters, to optimize stellt deployment. 
Tn one patient, undergoing stelll implantation for an obstructive dissection of the circumflex 
coronal), artery after PTCA, three balloon catheters could not cross n well deployed stent in 
the LCX, in order to improve a residual dissection distal from the stent. 'Vith aggressive anti-
coagulation, this patient had an uncomplicated clinical course. 
High pressure dilatation of the stcnted segment with a larger balloon catheter wus associated 
with the appearance of a dissection near the stent in 3 patients, requiring additional stent 
implantation. 
AlIgiographiclil results 
All stents Were angiographically well deployed. Quantitative analysis data are summarized in 
Table 3, A small tilling defect within the stent was visible in 5 stents (3,4%), 
At 11 stented sHes (7,4%) some contrast medium remained visible parallel to the vessel, outs-
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ide the stent. 
Hemostasis 
The arterial sheath was removed immediately after the last control angiogram, except in the 
patient who had bypass surgery after a failed attempt to implant a stent in a dissected LAD-
segment after PTCA. The tourniquet was replaced by a pressure dressing after 33 ± 17 minu-
tes (range 0 - 120). Tn two patients some collagen (Vasoseal®) \vas sllccessfully applied sub-
cutaneously ncar the puncture opening to stop prolonged bleeding. 
Clinical course 
Cardiac complications 
One patient developed subacute stellt thrombosis, 5 days after a double stenl implantation, 
following PTCA of the LAD, which resulted in a long dissection, 
Allthough a small residual dissection remained visible in between both stents, this result was 
considered acceptable, The patient WftS adequately adjusted on cOlll11adin at the time of stent 
occlusion, After successful recanalization by immediate PTCA, this patient was referred for 
emergent coronary bypass surgery. The patient developed a non-Q myocardial infarction, 
One 73 year old male patient died in cardiogenic shock, the day after stent implantion proxi-
mal in a subtotally occluded LCX, for unstable angina pectoris, This patient had a poor left 
ventricular function caused by an old anterior infarction, An optimal result was obtained 
during an uncomplicated stent procedure, At autopsy, the stellt was patent without signs of 
thrombus, The left ventricle showed extensive fibrosis by old myocardial infarction, with evi-
dence of more recent necrosis, Another patient had temporary anginal complaints without 
EKG- changes, 2 hours after successful stent implantation of a lesion in the Lex, Because of 
a rise in the cardiac enzymes (CKMB 42 lUll), a control angiogram was made the following 
day, Normal now was visible, with a dissection in the LCX, extending from the distal part of 
the stent into a marginal branch. No other stent related t:ardiac complications were registred, 
Bleeding cOlllplications 
One patient developed a subcutaneous bleeding of the hand and forearm 2 hours after the pro-
cedure, requiring acute vascular repair and decompression of the hematoma. During hospitali-
zation, no other vascular surgery or blood transfusions in relation to the radial approach were 
indicated, Four patients had transient hematuria, without need for additional treatment. 
Another patient had temporary oculomotoric dysfunction due to a transient ischemic attack, A 
CT- scan of the brain was normal, 
HO,\lJifal izafiOlI 
Hospitalization was prolonged to 29 days in one patient requiring intravenous antibiotic treat-
ment for fever caused by a StaphylococclIs aureus bacteremia, related to a contaminated intra-
venous cannula, Patients were discharged 5.2 ± 4, I days (range 0-29) aftcr stent implantation. 
From the 64 patients, llsing coumadin on admission, 22 patients (34%) with all INR > 2.7, 
could he discharged the day following stent implantation .. Mean duration of hospital stay of 
all patients using cOllmadin was 4, I ± 4,2 days (0-29). 
Doppler and physical radial arlef), studies 
In 96 patients normal radial artery pulsations were palpable at discharge. Doppler ultrasound 
examination proved the presence of tlow at the puncture site in these patients. None of the 4 
patients with absent pulsations had symptoms or complaints of ischemia of the forearm and 
hand. During follow-up, a pseudoaneurysm was encountered in 3 patients, In I of these 
patients the pseudoaneurysm disappeared spontaneously, Because of associated discomfort, 
the 2 other patients underwent elective local surgical repair one and 3 months following stent 
implantation and after discontinuation of coumadin, 
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Table IV. Guiding catheters used for stent implantation (n=104) 
RCA LM LAD LCX VBG Total 
EI Gamal 8 0 5 0 21 34 
MUltipurpose 7 0 0 0 4 II 
Voda Left 0 2 14 10 2 28 
Judkins Left 0 0 13 2 0 15 
Judkins Right 5 0 0 0 0 5 
Amplatz Left 0 0 2 2 3 7 
Ampl"tz Right 3 0 0 0 4 
Total 23 2 34 14 31 104 
LAD Left [Interior dest'cndillg coronary artery 
LCX Left dn:umtlex CorOlla!)' artery 
U\'I r-,'Iainstcm left c{lfonary artery 
RCA Right coronary artery 
VBG Venous hypn.;s graft 
DISCUSSION 
Implantation of coronary stcnts for coronary artery disease aims at improvement and optilllati~ 
zatioll of coronary geometry in order to reduce the incidence of restenosi1'l of de novo lesions 
in native coronary arteries (2,3), in venous bypass grafts (5), refractory restenosis (9), and to 
treat dissections and suboptimal results aftcr balloon angioplasty (10,11,12), The problems 
encountered after implantation of metallic stents are two-fold; risk of stellt thrombosis requi-
ring aggressive anticoagulation and as a consequence the risk of access site related bleeding 
complications. Although new insights may have resulted in a lower incidence of stent throm-
bosis, bleeding complications still remains a matter of concern, not only because of associated 
morbidity and mortality, but also because of patient comfort, prolonged hospitalization and 
cost effectiveness. 
Several strategies have been developed in order to reduce the incidence of bleeding complica-
tions. A number of hemostasis devices have been recommended in order to obtain fast, stable 
and save hemostasis after coronary catheterization or angioplasty, such as collagen plugs 
(l3,14), the Kensey device (15) and mechanical compression devices (16). The role of these 
devices still remains a matter of debate, since safety and efficacy are not cOllvincingly repor-
ted and since its application increases the costs of the technique. 
Reduction of the anticoagulation regimen lllay be associated with less bleeding complication. 
This may be only be possible after introduction of heparin coated stents (17) or after optimal 
deployment of the stent as assessed by intravascular ultrasound (18,19,20,21), 
At this moment there are promising reports on the treatment with only platelet aggregation 
inhibitors together with subcutaneous heparin (22,23) after an optimal stent result. 
Another lllodaUly is the lise of less traumatic, 6F guiding catheters for transfemoral stent 
implantation. Although the sheath protected slent technique has to be abandoned for this 
approach, Palmaz Schatz stents can he implanted successfully (24). 
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lVIiniaturizatioll of angiopJasty equipment made selection of smaller arteries as entry sHes 
such as the radial artery, possible. Campeau reported on transradial coronary angiography 
with SF catheters (2S). Major advantages of this approach are the superficial course of the 
radial artery, the absence of major veins and nerves close to the radial artery and the presence 
of collaterals between the radial and ulnar arteries. As a consequence, hemostasis Can be 
obtained easily and safely, nerve damage and arteriovenolls fistula occur rarely and ischemia 
of the hand is prevented, in case the radial artery becomes occluded. In a previous study from 
our institution, of 100 patients who had PTCA via the radial artery, a procedural success was 
obtained in 92% of patients and 110 major vascular complications, requiring vascular surgery 
or blood transfusions were encollntered (6). 
Bailout techniques such as the use of perfusion balloons (26,27) and stents (27) can success-
fully be applied atier PTCA by Ihe 6 French transradial approach, increasing safety of this 
technique. 
In the current study, success rate of stenl implantation via the radial artery was 96%, which 
compares favorably with results of stenting via RF guiding catheters, Procedural success in 
the Benestent study was 93.2% (slent implantation failed in 17 of251 aHempts; 6.8%) (2). 
Procedural success in the STRESS- study was 92.3% (3). The high successratc and a low 
incidence of stent occlusion (1%) contributed to the favorable clinical outcome in 93% of the 
cllrrent study population, despite the fact that patients were included with more complex coro-
nary anatomy such as ostial lesions and type C lesions (28), saphenous vein graft disease, res-
tcnosis and suboptimal PTCA- results, 
The incidence of puncture site related complications, has been reported to vary between 7.9% 
of 226 patients in the initial multicenter experience with the Palmtlz Schatz stellt (I) and 16% 
of 220 patients in large single center experience (4). In the study of Piana et aI, reporting on 
Palmaz Schatz stenting in vein grafts, vascular repair was necessary in 8.5% and tWllsfusions 
in an additional 14% (S), Bleeding complications requiring vascular surgery or transfusions 
was reported in 13.7% of patients after stent implantation in the Bencstcnt study (2) and in 
6.8% in the STRESS- stndy (3). 
The major advantage of the transradial approach for coronary stenting is illustrated by the low 
incidence of radial artery related early bleeding complications (1 %). The promise of this tech-
nique in prevention of local bleeding complications is even morc pronolillced, since the 
sheath \vas \vithdrawn immediately after the procedure in fully heparinized patients, most of 
them under a partial or complete preprocedurallevel of oral anticoagulation. The indidence of 
chronic radial artery occlusion was 3 to S% in our PTCA experience (6) and 4% in our stellt 
experience, This is in contrast with high radial artery occlusion rates after perioperative 
intraUl1eriai monitoring; 30% and 38% as reported by Davis et al. (29) and by Bedfort et aI. 
(30) respectively. Ischemic symptoms after radial artery occlusion were absent in ollr study, 
because only patients with collateral blood supply to the hand were selected, In the series of 
Bedfort et al. lOS radial artery cannulations \vere prospectively studied in 100 patients. Radial 
artery thrombosis was found in 40 patients (38%) without major ischemic complications . 
. ~vlandel e.a, reviewed 1.000 radial artery cannulations (31). The cannulas were removed after 
S hours to S days, Distal ischemia, requiring cmbolectomy or vascular reconstruction was 
necessary ill 2 patienls (0.2%). Slogoff et al. analysed 1.699 patients who had prolonged 
radial artery cannulation for monitoring purposes after cardiac surgery (32). Although 25% of 
patients had dcminished or absent flow during Doppler examination, no ischemic damage or 
disability of the hand occurred in any patient. Based on our experience and on these reports, 
we consider radial artcry cannulation as a low risk entry site, even if post procedural radial 
artery patency is absent. Immediate withdrawal of the sheath under anticoagulation may have 
contributed to both this low occlusion rate, as well as the 3% incidencc of late pseudoaneu-
rysm formation. 
Early mobilization of the paticnt, a low incidence of bleeding complications, and preprocedur-
al adjustment on oral anticoagulation, resulted in a hospital stay of S.2 ± 4, I days for the total 
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population and of 4.1 ± 4.2 days for patients using coumadin before admission. From these 64 
patients receiving coumadin before the procedure, only 22 patients (34%) had an INR > 2.7 
and these patients could be discharged the day following stent implantation. This shorter hos-
pitalization time may reduce cost of this technique, since Cohen et al. found hospital charges 
after stenting 35-45% higher than for other interventions, due to a longer hospital stay and 
more expensive utilization of resources (33). Costs Illay further be reduced by a reduced use 
of angioplasty material (I halloon per stellt), despite the higher consumption of guiding cathe-
ters, and by less costs for diagnosis and therapy for bleeding complications. 
Certain limitations of this approach should be mentioned. Although most patients have a col-
lateral connection with the ulnar artery, some patients have to he excluded if the radial artery 
is the only artery supplying the hand. In that case a transradial procedure via the left ann can 
be considered if the Allen- test is normal at that site, Protected angioplasty by intraaortic bal-
loon pumping also is evidently incompatible with the transradial approach. Should this sup-
port he necessary during a transradial PTCA, the balloon has to be inserted via the femoral 
artery. For this reason and for a potential failed transradial attempt, we routinely prepare one 
of the groins for a transfemoral continuation of the procedure. 
Stent implantation through 6P guiding catheters, requires optimal back-up amI coaxial align-
ment in order to facilitate advancement of the stent loaded balloon and to prevent stent loss 
and embolization, Since most guiding catheters are produccd for application via the femoral 
artery, optimal cannulation via the right radial artcry may be difficult to achieve, resulting in a 
high numher of guiding catheters used. Frequent guiding catheter exchanges, may induce 
spasm of the radial artery. Therefore, we recommend the use of long (23 cm) sheaths and of 
exchangc wircs. Although no scrious sequelae of stent cmbolization has been described, the 
potential for life-threatening complication remains, such as stent emholization to the cerebro-
vascular circulation. After a failed attempt to cross a stenosis with a stellt, retrieval of the 
stellt into the guiding catheter should not be attempted in the ascending aorta, but in the bra-
chial or radial artery. If the stellt detaches from the balloon, the stent can he captured by the 
technique initially described by Pan ct al.(34) and modified for the radial artery approach, as 
described in the "Methods"- section, 
Despite these limitations we consider the transradial stent implantation techniquc as a safe 
approach with high succcss rates and a low incidence of bleeding complications, even under 
aggressive anticoagulation. It is associated with increased patient comfort and this approach 
has the potential for short hospitalization times and for significant cost reduction. 
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Percutaneous Transradial Coronary Palmaz-Schatz Stent 
Implantation, Guided by Intravascular Ultrasound 
Ferdinand Klemenel], MD, Ger! Jan Laarman,MD, PhD, and Ton Siagboom, MD 
INTRODUCTION 
Intravascular ultrasound (IVUS) allows accurate assessment of slent deployment, Its use 
being confined to the use of 8 French (F) guiding catheters. We evaluated the leaslb1f1ty 
of combining transradlal artery Palmaz·Schatz stent Implantallon through 6F guiding 
catheters with IVUS lor assessment of stent diameter after delivery at moderate Inflallon 
pressures (10-12 atmospheres (atm)) with compliant balloons and aHer high pressure 
dilatations with balloons of Intermediate compliance. In 8 consecutive pallents, 12 stents 
were delivered wilh Sclmed~ Express'" balloon catheters at 10-12 atm followed by IVUS 
(EndoSonlcsll, CathScanner; Visions:': FX 3.5F 20 MHz transducer). An ultrasound study 
was repeated after high pressure dilatations (16-20 atm) wllh Schnelder3 Magical 
Speedy'" balloon catheters. The balloon diameters were derived from manufacturer pro· 
vlded specifications. In all pallents the transducer could easily be advanced through the 
guiding catheters. Reference diameter of the stented segment was 3.7 ± 0.5 mm (2.7-4.5) 
and the diameter of Sclmed'" Express'" balloons during InfJaUon was 4.0 ± 0.3 mm 
(3.6-4.7). Stent diameter was 3.0 ± 0.1 mm (2.8-3.2) (P < 0.001 compared to the reference 
and the balloon diameter). The diameter of the Schneider"" Magical Speedy'" balloons at 
secondary dilatations with 16 ± 3 aim (14-20) was 4.1 ± 0.4 mm (3.3-4.5) (P = 0.50 
compared to the Inlllal balloon diameter). Final slent diameter was 3.3 ± 0.4 mm (2.9-4.1) 
(P == 0.02 compared to the Initial stent diameter). All stenls were symmetrically deployed 
and well apposed. No damage to vessel or slenls was detected after passage of the 
transducer. Thus ultrasound guided slentlng via 6F guiding catheters Is feasible, and 
high pressure dllatallons with balloons of Intermediate compliance results In better stent 
expansIon than after 10-12 aim Inllatlons with compliant balloon catheters. 
t, 1995 Wlley·Un, Int:. 
Key words: transradlal angloplasty, stenls, Intravascular ultrasound 
Intravascular ultrasound (IVUS) plays an important 
role in optimizing coronary stent techniques. Compared 
to coronary angiography, IVUS provides superior assess-
ment of stent deployment and geometry [1-6 J. The ap-
plication of IVUS has been limited to the use of 8 French 
(F) or larger guiding catheters. However, 6F guiding 
catheters are of value in reducing the incidence of bleed· 
ing complications after coronary stenting by creation of 
smaller puncture holes [7] or by selection of a safer entry 
site, such as the radial artery {8,9J, This feasibility study 
was performed to evaluate the possibility of combining 
transradial stent implantation through 6F guiding cathe-
ters and IVUS with a low profile ultrasound transducer. 
equately sizcd balloons. Additionally, we looked for a 
possible improvement after secondary high pressure di-
latations (14-20 aIm) with stronger balloon catheters of 
inlennediate compliance. 
METHOOS 
Patient Selection 
In an ongoing study, patients arc selected for elective 
coronary stent implantation via the right or left radial 
artery, irrespective of patient's sex, weight, and size or 
From the Amsterdam Department of Inlerventiona) Cardiology 
(ADIC)· OlVG, Onze Ueve Vrouwe Gasthu\s, Amsterdam, The 
Netherlands. For stent delivery via 6F guiding catheters, we use the 
compliant Scimedj) Express'" balloon catheter. During 
ongoing experience we noticed that this .'lIen! loaded bal· 
loon can be maximally inflated to 10-12 atmospheres 
(atm), before the balloon ruptures. Therefore, we were 
interested in the stcnt diameter and apposition after de· 
ployment at these inflation pressures with compliant ad-
© 1995 Wlley-Liss, Inc. 
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clinical status. An abnormal Allen-test was considered to 
be a contraindication. The Allen-test is considered nor-
mal when after 'compression of both ulnar and radial 
arteries, a return of the nomlal colour of the hand oc-
curred within 10 sec after release of the ulnar artery. 
Medical Treatment 
Patients were treated with Dextran 40, the first SOD ml 
at a rate of 100 mllhr, the second 500 ml at a rate of 50 
mllhr. The infusion was started 2 hr before elective stent 
implantation or from the moment the decision was made 
to implant a stent in acute situations. At the day of stent 
implantation, dipirydamole 225 mg/day and acetosali-
cylic acid 300 mg/day was started. After sheath inser-
tion, 10.000 IV heparin was administered intra-arteri-
ally, followed by 5.000 IU for each hour the procedure 
lasls. Three hours after hemostasis is achieved, 3.000 IU 
heparin was administered intravenously. Heparin was 
titrated to Activated Partial Thromboplastin Times 
(APITs) of 80-100 sec until stable adjustment on oral 
anticoagulant drug therapy (3 consecutive therapeutic 
Thrombolests). Coumadin was given for 3 months and 
acetosalicylic acid and dipyridamole were given for 6 
months. In order to prevent radial and coronary artery 
spasm, 10 mg nifedipine was administered sublingually, 
prior to radial artery puncture. 
Quantitative Coronary Analysis 
The X-ray imaging equipment used was the Philips 
Poly Diagnost C2, equipped with a Digital Cardiac Im-
aging system (DCI) (Philips Medical Systems, Eind-
hoven, The Netherlands). Quantitative analysis of coro-
nary segments was performed witb this system before 
angioplasty and after the final ultrasound examination 
following stent implantation or after the last balloon in-
flation within the coronary stent. 
Transradlal Artery Stent Implantation 
Tbe technique of transradial artery stent implantation 
and the medical treatment has been previously described 
in detail by our group (8]. For the purpose of this study, 
Cordis'lY Petite '" 6F guiding catheters were used (inner 
diameter 0.062 inch, shaft length 100 em). In all patients 
the lesions were predilated in order to reduce friction 
between the stent and the lesion, followed by stent im-
plantation and secondary dilatations. 
Palmaz-Schatz stents (Johnson and Johnson Interven-
tional Systems, Warren, NJ) were manually crimped on 
the balloon catheter. The stents were delivered with 
Scimed lY Express BJ compliant rapid exchange balloon 
catheters. Balloons were selected with a manufacturer 
specified diameter (at 10-12 atm) at least corresponding 
to the angiographically assessed reference diameter of 
the target segment. After delivery, the stell! diameter was 
optimized by secondary dilatations at higher inflation 
pressures with balloon catheters of intermediate compli-
ance (Schneider® Magical Speedynl). 
Intravascular Ultrasound 
For this study the EndoSonics CathScanner l4 Intracor-
onary Ultrasonic Imaging System was used, combined 
with the Visions® FX H' 3,5F, 20 MHz monorail ultra-
sound transducer, containing 64 Piezoelectric ultrasonic 
elements, circumferentially mounted in the proximal 
neck of the catheter. The transducer was positioned un-
der fluoroscopy during injections of contrast medium. 
Ultrasound studies were performed after stent implanta-
tion and after successive post stell! dilatations to assess 
any difference in stent diameters. No ultrasound studies 
were performed before the initial dilatation, because of 
anticipated catheter occlusion of the lumen. Reference 
and stent diameters were detemlincd on-line from real 
time images, selected in end-diastole. The calipers were 
diametrically placed at two opposite leading edges of the 
vessel wall or at the inner surface of the stent filaments. 
Luminal diameters were recorded as minimal and maxi-
mal values. Consensus reading on reference and stent 
diameters was performed by at least 2 investigators. The 
last passage of the ultrasonic catheter was followed by 
angiographic control of the vessel, to detect possible 
catheter induced damage. 
Definitions 
The stent was considered to be symmetrically de-
ployed at a ratio of minimal and maximal stent diameters 
2:: 0.9. After secondary dilatations a completely de-
ployed stent was defined at a stent diameter >90% of 
reference diameter or >90% of the final balloon diame-
ter. The stent was considered to be well apposed if no 
free space between the stent filaments and the vessel wall 
was detectable. 
Statistical Methods 
All values arc expressed as mean ± standard devia-
tion. Reference and stent diameters were calculated from 
the mean of minimal and maximal diameters. Differ-
ences in diameters were calculated with the I-test. A P 
value < 0.05 was considered to be statistically signifi-
cant. 
RESULTS 
Between October and November 1993 12 stents were 
implanted in 8 consecutive male patients (61 ± 13 years) 
who underwent transradial artery ultrasound guided cor-
onary stent implantation for venous bypass graft stenosis 
(n = 3), native vessel restenosis (n = 3), and native 
vessel de novo lesions (n = 2). Angiogmphical and 
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TABLE I. Anglographlcal Data' 
N (%) 
No. s!enls pla,ed (n = 12) 
LAD (8) 
RCA (17) 
LeX (17) 
VIlO (58) 
TIM I-grade (8 ve,sels) 
2 (13) 
3 (87) 
Type (12 lesions) 
A 6 (50) 
B (25) 
C (25) 
'LAD, left anterior de,cending ~omn:ll}' artCfY; 
LCX, Idt drcumfle:o;: coronary artelY; RCA, right 
coron:ll}' artery; TlMI, thrombolysis in lllyocardia! 
infan:lion; VIlG, vcnons bypass grafl. 
quantitative coronary analysis data are given in Tables I 
and II, respectively, 
Procedure 
Radial artery cannulation, coronary angioplasty, stent 
positioning, and stent delivery were stlccessful in all pa-
tients. In all patients, the ultrasound transducer could 
easily be advanced through the guiding catheter, No 
problems were encountered during advancement of the 
transducer towards the stented segment. The position of 
the transducer-marker in relation to the region of interest 
was well visualized by contrast agent injections. r-..-Iarked 
pressure damping and flow impaimlent were not encoun-
tered. Angiography following ultrasound examinations 
revealed no signs of transducer caused damage to the 
stents or vessel wall. 
Quantitative Ultrasound Assessments 
The manufacturer specified diameters of the Scimed~ 
balloon catheters at 12 atm exceeded reference diameters 
during 10 of 11 stent implantations. In I patient the 
balloon ruptured during a lO-see inflation up to 10 atm, 
rcsulting in an undersized balloon during stent delivery. 
Reference diameter of the stented segments was 3.7 ± 
0.5 mm (2.7-4.5 mm) and the balloon diameter was 4.0 
± 0.3 mm (3.6-4.7) (P = 0.09). Sten! diameter how-
ever was 3.0 ± 0.1 mm (2.8-3.2) (P < 0.001 compared 
to the reference diameter and balloon diameter). The 
diameter of balloons used for secondary stent dilatations 
at 16 ± 3 atmospheres (14-20) was 4.1 ± 0.4 mm 
(3.3-4.5) (P = 0.50 when compared to stent delivery 
balloon diameter). Although this difference is not signif~ 
icant, stent diameter increased significantly to 3,3 ± 0.4 
mOl (2.9-4.1) (P = 0.02 when compared to initial stent 
diameter). All stents were symmetrically deployed and 
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TABLE II. Quantllatlve Coronary Angiography 
Baseline Poststenting 
Mean ± SD Range Mean ± SD Range 
Reference diameter 
(~) 3.2 ± 0.6 2.4-4.5 3.5 ± 0.8 2.4-4.6 
Minimal lumen 
diametcr (mm) 1.1 ± 0.2 0.8-1.5 3.2 ± OA 2.7-4.2 
DiamNer stenosis 
('?o) 60 + 9 39-71 12 + 9 0-26 
well apposed Jgainst the vessel wall, although the final 
stent diameter was smaller than the reference diameter 
(P ~ 0.04). 
DISCUSSION 
The transradial artery approach for coronary stenting 
through 6F guiding catheters is an attractive technique 
since it is associated with high procedural success rates, 
a very low incidence of access-site related bleeding com-
plications, and increased patient comfort, as patients are 
not restricted to prolonged immobilization [8,9J. Most 
ultrasound transducers arc not compatible with 6F guid-
ing catheters and no studies have been reported of the usc 
of IVUS combined with miniaturized angioplasty equip-
ment. J n the present study we could demonstrate the 
feasibility of ultrasound guided stent implantation 
through 6F guiding catheters, using the EndoSonics 
CathScanner'" Intracoronary Ultrasonic Imaging System 
combined with the Visions® FX'" 3,5F, 20 MHz mono-
rail ultrasound transducer. Transducer manipulations, 
contrast agent delivery, and pressure monitoring were 
not compromised by guiding catheters with an inner di-
ameter of 0.062 inches. 
The low profile of the stent loaded Scimed:& Express '" 
balloon catheter, makes this combination suitable for 
passage through 6F guiding catheters. However, this 
stent loaded compliant balloon, does not resist inflation 
pressures over 10-12 atm. We previously demonstrated 
that low pressure inflations of compliant stellt delivery 
balloons, results in improperly deployed steflts [10]. 
Therefore, we performed secondary high pressure infla-
tions with a less compliant balloon in order to improve 
stent geometry. It was a surprising finding that the stenl 
diameter improved after secondary dilatations despite the 
fact that manufacturer specified balloon diameters did 
not differ significantly from the initial stent delivering 
compliant balloon. Therefore, the ideal balloon catheter 
to predilate the lesion and to deliver and to deploy stents 
should have a low profile, be of intemlediate compli-
ance, since some inflation pressure dependent increase in 
diameter is useful in order to oversize the stent, and 
should resist high inflation pressures. Such a balloon 
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makes a single-balloon stent procedure possible and will 
further reduce costs of coronary stenting, 
Except for the small number of stents studied, another 
limitation of this study is the comparison between ultra-
sonically assessed reference and stent diameters on the 
one hand and manufacturer specified balloon diameters 
on the other hand, since manufacturer specil1ed balloon 
diameters are determined under in vitro conditions, Un-
der in vivo circumstances, where vessel wall and ob-
structing plaque, as well as the sten! itself, may influence 
balloon expansion under given inflation pressures, real 
balloon diameters probably are signit1cantly different 
from the specified diameters, 
However, these limitations do not aIter the practical 
consequences of the findings of this study: ultrasound 
guided stent implantation via 6F guiding catheters is fea-
sible, and high pressure dilatations with balloons of in-
termediate compliance result in better stent expansion 
than after inflations to burst-pressure with compliant bal-
loon catheters, 
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Comparison of costs between two modes of implantation of Palmaz Schatz coronary 
stents: The tl'ansradial bare stent technique versus the transfemoral sheath protected 
stent technique. 
Ferdinand K)emeneij MD, Jan Hon~Dd ~"lD, Gert Jan Laannan, MD, PhD, Danielle Hupkens 
van del' Elst"', Harry van cler Lubbe ' '," 
," Manager Health Care OLVG 
*'" Economical Director OLVG 
ABSTRACT 
Rationale. Coronary Palmaz Schatz stellt implantation is usually performed by using the 
sheath protected stent delivery system (SDS) via the percutHneous transfemoral route. 
However, downsizing of PTCA equipment made transradial coronary stenting feasible. Bare 
stent implantation, 6F technique, increased patient mobility, reduced vascular complications 
and reduced hospital stay Illay increase cost effectiveness of this novel technique. 
lVIethods. T\vo well documented patient groups selected for elective single vessel and single 
lesion Palmaz Schatz stent implantation were retrospectively compared, Group A (transradial 
stenting; n::::35) was compared to Group B (transfemoral stenting; n::::25) derived from the 
Benestent population, included in our hospital. A comparison was made for 3 areas of interest: 
I. Procedural consumption of material (the number of guidingcatheters, guidewires, balloon~ 
catheters and stents); fI. Post procedural need for diagnostic and therapeutic procedures for 
stent related complications; III. Duration of hospital stay. Differences between these subjects 
in Group A and B were translated to hospital costs. 
Results. Although more guidingcatheters were used in group A (1.69 ± 0.87 versus 1.08 ± 
0.28; p=O.OO I), the use of the SDS contributed importautly to higher material costs in group 
B (cost reduction in group A; 13%). Less patients in group A required diagnostic (2 versus 7; 
p=0.027) and therapeutic (0 versus 5; 1'=0.01) procedures for bleeding complications (cost 
reduction; 93%). Hospitalization in Group A was shortcr (6.4 ± 4.7 versus 11.6 ± 9.9 days; 
p=0.005), caused by early and safe mobilization, lcss vascular complications ancl prcproce~ 
dural adjustment on coul11adin (cost reduction; 45%). Overall, the mean cost per patient in 
group A was 67% of these costs in group B. 
Conclusion. Significant savings were realized with the transradial bare stell! tcchnique, by 
reduction of costs for angioplasty material, diagnostic and therapeutic procedures for stellt 
related complications and hospital stay. 
INTRODUCTION 
Tnmsfemoral artery coronary stent implantation with a sheath protected stent delivery system 
(Johnson & Johnson Interventional Systems, \Varren, NJ) requires the use of large bore (8 or 
9 French) guiding catheters. In combination with intense anticoagulation regimcns this 
approach is associated with a high incidence of access-site related bleeding complications, 
often requiring additional diagnostic and therapeutic procedures and prolonged hospitalization 
(1,2,3,4), Miniaturization of balloon catheters made coronary angioplasty (PTCA) possible 
through 6 French (F) guiding catheters, \vith maintenance of means to improve suboptimal 
PTCA- resuits with perfusion balloons (5,6) and with coronary stents (6,7). Additionally, 
smaller arteries became suitable as entrysite for coronary angioplasty. Successful coronary 
angiography via the radial artery has been reported by Campeau in 1989 (8), wlore recently 
we described techniques for percutaneous transradial coronary angioplasty (9,10) and corona-
ry bare steHt implantation (1 J, 12, 13), with high procedural success rates and low vascular 
complication rates. The major advantages of the 6F transradial artery approach for stent 
implantation are the superficial course of the radial artery, allowing easy hemostasis and the 
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ahsence of major veins and nerves, excluding damage to these structures. These factors con-
tribute to a low incidence of major entrysite complications and to increased patient comfort 
by immediate postproccdural mobilization. Additionally, the "under-over" principle Crill be 
applied with the bare stent technique by using one to two balloons; the first one serving for 
predilatation, stent delivery and secondary dilatations, and if necessary, a second one to opti-
mize deployment. The traditional sheath protected technique usually requires three balloons: 
one for predilatation making passage of the delivery system possible, one for stent delivery 
(incorporated in the delivery unit) and an additional one for secondary dilatations. These basic 
differences in the two approm::hes should translate in a reduction of cost, in favor of the trans-
radial technique. This study compares the procedural and inhospital costs of the generally 
applied trans femoral sheath protected stent technique and the transradial bare stent technique, 
in patients selected for elective single vessel, single lesion stenting. 
Both study populations are compared in a non-randomized fa.shion. However, the study 
groups are derived from two prospectively studied and wen documented populations: the 
transfemoral treated patients afe derived from the Benestent study population (4), randomized 
to stent implrllltation in our center and the transradial treated patient.s from a prospective feasi-
bility study to tnmsradial coronary stenting. 
METHODS 
Study population 
From March to November 1993, 35 consecutive patients underwent elective single stent 
implantation via the radial artery (Group A). These patients \vere compared with 25 patients 
\VI1O were randomized to stellt implantation for the Benestent study in our department from 
June 1991 to I'vlay 1993 (Group B). Data concerning areas of interest were prospectively col-
lected in both groups. Comparison between the groups however, was made retrospectively. 
Areas of interest 
A comparison was made for 3 areas of interest: (1) Procedural consumption of material (the 
number of guidingcathcters, guidewires, ballooncathcters and stents). (II) Postprocedurai need 
for diagnostic and therapeutic procedures for stent related complications. (TIl) Hospitalization-
time for both groups. Differences between these areas were translated to hospital costs in 
Dutch guilders (10Ft: ± 0.6 US $). Cost of any procedure, includes material costs and utili-
zation charges for personnel and equipment. The totnl cost for the procedure was determined 
by adding these costs to the charges for each hospital-day. No datu on procedural time \vere 
available of the Benestent population, thus a comparison of catheterization laboratory resour-
ce utilization could not be macie. Also, laboratory assessments after the procedure were not 
taken into account, because protocols for both groups showed marked differences; a less 
extensive pre- and postprocedural analysis was performed in group A. 
Stent implantation 
A. Transradial artery protocol 
Catheterization, angioplasty and stent implantation 
After local anesthesia of the skin with Xylocaine 2%, the radial artery was punctured with an 
Arrow® (Arrow International Inc. Reading, PA), 22 gauge radial artery catheterization set or 
with an 18 gauge arterial puncture needle. An O'()25 inch, 260 em long guidewire was intro-
duced through this system, followed by insertion of a 6 French, 10 em long arterial introdu-
nl 
eel'. A 6 French guiding catheter with an inner diameter of 0.060" (Scimed® Triguide ; 
Scimed Life Systems, Ine., Mineapolis, MN) or of 0.062" (Cordis@ Petite"'; Cordis Corp., 
Miami, FL) was selected with an appropriate curve, providing maximal backup support and 
coaxiality during angioplasty and stent implantation. Over a 0.014 inch intracoronary guide-
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wire, a rapid exchange, low profile, compliant balloon catheter (Scimed® Expressn.l; Scimed 
Life Systems, Inc., Mineapolis, IvIN) was positioned at the stenosis. The inflation pressure 
dependent variation of balloon diameter made a single balloon approach for predilntation and 
stent delivery possible. The stenosis was predilated in order to facilitate positioning of the 
stent loaded balloon at the lesion. The predilating balloon catheter was preferably lIsed as 
stent carrier. A 7.3 nun or 15 rllm Palmaz Schatz coronary stent was manually crimped on the 
balloon catheter. After delivery, the stent diameter was optimized by successive dilatations 
with higher inflation pressures or with larger balloon catheters. 
Introducer sheath removal and hemostasis 
In all instances, the arterial sheath was removed, immediately after withdrawal of the guiding 
catheter, followed by application of an occlusive tourniquet at the radial artery puncture site 
for a minimum of 30 minutes. Pressure was gradually released until hemostasis was obtained. 
A pressure bandage over the punctured artery \vas applied for 6 hours. Patients were not res-
tricted to bed rest. 
B. Trallsfemoral artery protocol 
Catheterization, angioplasty and stent implantation 
PTCA was performed via an 8F, 20 cm long introducer sheath. Super flow guiding catheters 
with an internal diameter of at least 0.079", were used in combination with a rapid exchange 
dilatation system and a 0.01411 intracoronary guidewire. The lesion was predilated with an 
undersized balloon to facilitate passage of the stellt delivery system. This system is a preas-
sembled unit, containing a 5F sheath covered, 15 111111 Palmaz Schatz stent, mounted on a 
polyethylene, compliant balloon catheter (balloon sizes; 3.0, 3.5 01' 4.0 nUll). The recommen-
ded maximal inflation pressures are 5.7, 6.2 and 6.0 atmospheres, respectively. The system 
was advanced over the extended guidewire to the obstructing lesion followed by stent deli-
very. Compared to the coronary artery diameter, the stent was slightly oversized by high pres-
sure dilatations with larger balloons to optimize stent deployment. 
Introducer' sheath removal and hemostasis 
After the procedure the arterial sheath was left in situ until the Activated Partial 
Thromboplastin Time (APTT) was less than 60 seconds. After sheath removal the groin was 
compressed manually, until hemostasis was achieved, followed by an compression bandage 
for 8 hours and an 24 hour immobilization period. In some patients hemostasis was achieved 
by insertion of collagen plugs (Vasoseal®). 
IHedical treatment 
Immcdiately before and aftcr stent deployment 200 microgram nitroglycerin \vas given intra-
coronary. Additional pharmacologic treatment was aimed at the prevention of thrombosis and 
spasm. Rheomacrodex 40, 100 cc/hour to a total of 1 litre, was started t\VO hours before the 
procedure. Heparin 10.000 IV was adminislered through the arterial sheath after its insertion, 
followed by 5.000 IV for each hour the procedure lasts. According to the protocol, a second 
10.000 IV bolus of heparin was given after stent- implantation in group B. In this group the 
heparin infusion was discontinued untill the APTT was under 60 seconds, before the sheath 
was removed. After 2 hours, heparinization was restarted by an intravenous loading dose of 
5000 IV, follmved by a heparin infusion, titrated to APTT's of 80-100 seconds, measured al 8 
hours intervals. In group A the sheath was removed immediately after the procedure. A hepar-
in infusion was started 3 hours following hemostasis after a loading dose of 3.000 IV. 
Acenocoumarol (Sintrom) was administered during 3 months, the dosage adjusted to maintain 
a TT (Thrombotest "QUICK") of 5 to 10% (INR;;> 2.7). Heparin was stopped when the 
patient had 3 consecutive TT's in the therapeutic range. In group A, 5 patients (14%) were 
adjusted on coumadin, prior to admission. Additional treatment consisted of Dipyridamole 
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225 mg/day during 6 months, Acetosalicylic acid 300 mg/day during 6 months and Diltiazem 
180 mg/day for 3 months. 
Statistical methods 
Values are exprcs!\ed as mean ± standard deviation, Nlean values in both groups \vere compa-
red by the unpaired, two-tailed t- test. Incidence of complications, as well as the need for 
diagnostic and therapeutic procedures were compared by the Fisher's exact test. Differences 
with p-value less then 0,05 were considered to be significant. 
RESUI:rS 
Baseline clinical characteristics and vessel distribution are given in Table I. 
In group A significantly more patients received a stent for venous bypass graft S'tenosis, which 
\vas considered to be an exclusion- criterium for group B, 
In Group B, 2 patients did not receive a stent. In one patient it was not possible to predilate 
the stenosis. In another patient, cannulation of the right coronary artery resulted in an extensi-
ve dissection, which was treated conservatively. Both patients underwent elective coronary 
bypass surgery. seventl months after discharge. Two additional patients in group B developed 
subacute stellt thrombosis, treated by acute repeat PTCA, followed by coronary bypass surge-
ry, In group B, bleeding complications, requiring additional diagnostic or therapeutic procedu-
res was encountered in 9 patients (360/0) {vascular; 11=7, hematuria; n=2} versus one patient 
with hematuria (3%) in group A (p=0.001). In this group however. I patient underwent a CT-
scan of the brain for a transient ischemic attack. Another patient was treated for fever of 
unknown origin. prolonging hospitnl stay to 29 dn),s. No patients in group A had an access-
site related complication, Tn Table II the lise of angioplasty equipment. need of additional 
diagnostic and therapeutic procedures for stellt related complications and hospital stay per 
patient are disp1ayed, These differences are translated to mean costs per patient in Table Ill. 
Table 1. Baseline clinical characteristics of patients with transradial bare stent implantation 
(group A) and \vith transfemoral sheath protected stent implantation (group B). 
Group A (11=35) GrollI' B (11=25) P 
Age 62±1O (44-83) 57±9 (38-69) NS 
Male 30 (86%) 21 (84%) NS 
CCS- class 
I o (0%) o (0%) NS 
II 2 (6%) 6 (24%) NS 
III 16(46%) 13 (52%) NS 
IV 14 (40%) 4 (16%) NS 
Non-exertional 3 (8%) 2 (8%) NS 
Vessel 
VBG 11 (31%) o (0%) 0.002 
LAD II (31%) II (44%) NS 
cx 4 (12%) 9 (36%) 0.03 
RCA 9 (26%) 5 (20%) NS 
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Table 1, continued 
LAD I.eft Anterior descending coronary artery 
CX Circumtlex coronary artery 
RCA Right coronary artery 
VBG Saphenous vein coronary bypass graft 
~n-lble II. Use of angioplasty equipment, incidence of complications, diagnostic and therapeu-
tic procedures and hospital stay after transradial (group A) and transfemoral (group B) coro-
nary :-;tenting, 
Group A (n=35) 
Matel'i"l 
- Guiding catheters 59 (1.69±.87; range IA) 
- Guidewircs 43 (1.23±.69; range 1-4) 
- Extensionwires o (0.00) 
- Ballool1catheters 62 (1.77±.65; range 1-2) 
- Bare stents 37 (I.06±.34; range 1-3) 
-SDS o (0.00) 
Cardiac complications 
- Patients 0 
rePTCA 0 
CABG 0 
Bleeding complications 
- Patients 
Other complications 
- Patients 
TIA 
Fever 
2 
I 
I 
Group B (n=25) 
27 (I.08±.28; range 1-2) 
26 (1.04±.20; range 1-2) 
23 (O.92±.28; range 0-1) 
48 (1.92±.49; range 0-3) 
o (0.00) 
24 (0.96±.35; muge 0-2) 
2 
2 (O.08±0.28; rnnge 0-1) 
2 (0.08±0.28; range 0-1) 
9 
o 
o 
o 
Diagnostic procedures for non~ cardiac complications 
- Patients 2 7 
- Total procedures 4 (O.II±O.53; range 0-3) 21 (0.88±1.72; range 0-6) 
Ultrasound I (0.03±0.17; range 0-1) 14 (0.56±1.04; range 0-4) 
Venous DSA 0 3 (0.16±0,47; range 0-2) 
IVP I (0.03±0.17; range 0-1) 2 (0.08±O.28; range 0-1) 
Cystoscopy I (O.03±0.17; range 0-1) 2 (0.08±O.28; range 0-1) 
CT- brain I (0.03±0.17; range 0-1) 0 
Thel'apeutic procedures 
- Patients o 
o 
o 
o 
o 
5 
- Total 
Surgery 
Collagen 
Compression 
lliood transfusions for bleeding complications 
7 (0.28±0.61; range 0-2) 
5 (O.20±0.58; range 0-2) 
I (0.04±0.2 ; range 0-1) 
I (0.04±0.2 ; range 0-1) 
P 
0.001 
NS 
<0.001 
NS 
<0.001 
<0.001 
NS 
NS 
NS 
0.001 
NS 
NS 
NS 
0.027 
0.015 
0.005 
0.049 
NS 
NS 
NS 
0.01 
0.009 
0.D45 
NS 
NS 
- Patients 0 4 0.026 
- Units 0 17 (0.68±1.84; range 0-8) 0.032 
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Table II, continued 
Hospitalization 
- Days 
- Median 
CABG 
CT 
DSA 
IVP 
PTCA 
SDS 
TIA 
223 (6.4±4.7; range 1-29) 291 (l1.6±9.0; range 2-45) 0.005 
6~ 8~ 
Coronary Artery Bypass Grafting 
Computerized Tomography 
Digital Subtraction Angiography 
Intravenous Pyelography 
Pen.':lItancous Transluminal Coronary Angioplasty 
Stent Delivery System 
Tran~icJlt Ischemic Attack 
Aren of interest I: Consumption of angioplasty equipment. 
Tn group A more guidingcatheters were used (1.69 ± 0.87; range 1-4) compared to group B 
(1.08 ± 0.28; range 1-2) {p=O.OOI}, which reflects the difficulty to engage the coronmy arte-
ries in a stable and coaxial fashion with Judkins-type catheters via the right radial artery. 
Since in group A rapid exchange balloon catheters were used, no extension wires were requi-
red, versus 0.92 ± 0.28 in group B (1'<0.001). The number of balloon catheters (1.77 ± 0.65 
and 1.92 ± 0.49) and stents (1.06 ± 0.34 and 0.96 ± 0.35) did not differ significantly. 
However, in group A only bare stents were used, whereas the more expensive stellt delivery 
system in group B was used, which can be considered as a stent with an additional balloon. 
If the SDS is considered in this way, in group B 2.88 ± 0.67 balloons were used (1'<0.00 I). 
Material costs in group A were reduced by 13% of the costs made in group B. 
Area of interest II: Diagnosis and therapy for stent related complications. 
In group B, 2 patients needed emergency repeat PTCA followed by coronary bypass surgery 
for subacute stent thrombosis, whereas no patients had a cardiac complication in group A 
(p::::NS). More patients in group B (n::::7) required a diagnostic procedure (total number of pro-
cedures 21; 0.88 ± 1.72; range 0-8) compared to group A (n=2) (total procedures 4; 0.11 ± 
0.53; range 0-3) {p=0.027}. More patients in group B required bloodtransfusions (17 units) 
compared to group A (4 versus 0 patients; p::::0.026). In group B, 7 vascular interventions were 
required versus none in group A (p::::O.009). In the fonner group, 2 patients required 2 vascular 
operations and one patient a single operation. Another patient underwent percutaneous treat-
ment of a pseudoaneurysm by transcatheter application of collagen and one patient underwent 
successful ultrasound guided closure of a pseudoaneurysm by prolonged compression. \Vith 
respect to periproccdurat diagnostic and therapeutic interventions for complications, cost 
reduction in group A was 93%, when repeat PTCA and coronary bypass surgery are not taken 
into account. 
Arc" of' interest III: Hopsitalization. 
Patients in group A were discharged earlier (6.4 ± 4.7; range 1-29) compared to group B 
(11.6 ± 9.0; range 2-45) {p=O.005}. Cost reduction in group A by shorter hospitalization Was 
45%. In group A more patients Were OIl coumadin before admission (n::::5) and could he dis-
charged after 1 or 2 days. In group B no patients were adjusted on coumadin prior to admis-
sion (NS). 
Overall, the savings achieved (OF! 4.636,72) by the transradial bare stent technique was 33% 
of the total costs for the trans femoral sheath protected stent technique. If costs for repeat 
PTCA and emergent bypass surgery in group B are not taken into account, mean cost per 
patient in group A was still 011 2.631,54 less than in group B (cost reduction; 22%). 
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Table III. iVlean hospital costs per patient of transradial (Group A) versus trans[emoraI (Group 
B) coronary stenting. 
Gronp A (11=35) Gronp B (11=25) 
Price Mean price per patient Mean price per patient 
Material IHean ±SD Mean ±SD 
- Guidingcathetcrs D/I 323,00 545,87 28 I ,01 348,84 90,44 
- Guiucwires Dfl 335,00 412,05 231,15 348,40 67,00 
- Extensionwires l~f! 46,00 0,00 0,00 42,32 12,88 
- Bal100ncatheters D111809,50 3202,82 1176,18 3474,24 886,66 
- Bare stents DJ! 2780,00 2946,00 945,20 0,00 0,00 
-5DS DjI 4350,00 0,00 0,00 4176,00 1461,60 
----------------- -------------------
7106,74 2633,54 8389,80 2518,58 
PTCA utility costs DjI 1117,36 1117,36 0,00 1117,36 0,00 
----------------- -------------------
8224,10 2633,54 9507,16 2518,58 
Treatment for cardiac complicatiuns 
- rePTCA 1)11 5064,81 0,00 0,00 405,18 1418,14 
- CABG (saIlle pIs) DI120000,- 0,00 0,00 1600,00 5600,00 
----------------- -------------------
8224,10 2633,54 11512,34 9536,72 
Diagnostic procedures for complications 
- Ultrasound Pf! 122,50 3,68 19,13 68,60 127 ,40 
- Venons DSA DII 286,29 0,00 0,00 45,81 134,56 
- IVP PII 286,29 8,59 48,67 22,90 80,16 
- Cystoscopy DII 250,00 7,50 42,50 20,00 0,00 
- CT- brain Df! 444,00 13,32 75,48 0,00 0,00 
----------------- -------------------
8257,19 2819,32 11669,65 9948,84 
Therapeutic procedures 
- Surgery Dr/llOO,- 0,00 0,00 220,00 638,00 
- Collagen D.f7 785,- 0,00 0,00 31,40 157,00 
- Compression DII 122,50 0,00 0,00 4,90 24,50 
----------------- -------------------
8257,19 2819,32 11925,95 819,50 
Blood transfusions for bleeding complications 
- Units DII 47,00 0,00 0,00 31,96 58,81 
----------------- -------------------
8257,19 2819,32 1957,91 878,31 
Hospitalization 
- Days DII 180,00 1152,00 846,00 2088,00 1620,00 
------------------ -------------------
Total 9409,19 3665,32 14045,91 2498,31 
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Table III, continued 
CABO 
CT 
DSA 
rvp 
PTCA 
SOS 
TIA 
DISCUSSION 
Coronary Artcry Bypass Grafting 
Computerized Tomugraphy 
Digital Subtraction Angiography 
In!nlvcnous Pyelography 
Percutaneous Transllllllinni Coronary Angioplas!y 
Stent Dclivcl)' System 
Transient Ischemic Aunck 
In previous studies costs of inhospital stay have been analyzed for patients who underwent 
elective angioplasty, directional angioplasty and coronary Palmaz Schatz stellt implantation. 
Cost of coronary stenting turned out to be 103% higher when compared to conventional 
angioplasty (14). Caused by a longer hospital stay and increased utilization of resources, 
Cohen et. a!. found total hospital charges 35-45% higher than for other interventional proce-
dures (15). In this study costs for stenting were higher than for alherectomy due 
to the more frequent adjunctive lise of conventional balloons. Additionally, the device itself 
was the largest single component of procedural cost. However, the stent technique applied 
was the conventional transfemoral, sheath protected approach, where large hore guiding 
catheters were used. No cost comparison has currently been made between this approach and 
the transradial stent technique. During a properly appJied conventional technique, the target 
lesion is predilated, before the stent is delivered with the stent delivery system. In order to 
maximize the stent diameter, a secondary dilatation with high pressure oversized balloons is 
lIsually performed. By the transradial approach, only the bare stellt technique can be applied, 
because the sheath protected stellt delivery system and 6F guidingcatheters are not compati-
ble. By using the predilatation balloon as the stellt carrier, one balloon is saved. Oversizing 
can he performed by the same balloon or by a larger balloon if necessary. 
fvlore guidingcatheters were used in the patients treated via the radial artery. This is explained 
by the fact that most commonly used catheters are preshaped far the femoral approach. Since 
optimal backup support and coaxial alignment is required in order to achieve a successful 
stent implantation, meticulous care was addressed towards proper guiding catheter selection. 
Also, sharp primary and secondary angles in the guidingcatheter, may cause excessive friction 
between the stent-Ioaded balloon and the inner surface of the guklingcatheter. Al1though this 
has not resulted in stent dislodgement in our experience, sharp angled guidingcatheters (e.g. 
Amplatz- shapes) are avoided. For the right coronary artery and for venous bypass grafts, 
l11ultipmpose shaped guiding catheters were most frequently used and for the left coronary 
artery the Voda- shape was selected. 
At present it is known that coronary stenting by the conventional approach is associated with 
an important incidence of access-site related bleeding complications (1,2,3,4). In the 
Benestent study, a randomized trial comparing safety and efficacy of coronary stenting versus 
balloon angioplasty, the incidence of bleeding and vascular complications was 13.5%. In the 
patient popUlation randomized to stenting in our department, a 20% incidence of major blee-
ding complications, requiring surgery or blaadtransfusions, was encountered. These complica-
tions, prolonged immohilization of the patient and the time it takes to adjust patients on 
coumadin, contribute significantly to a longer admission time. 
The transradial technique 011 the other hand was not associated with major bleeding complica-
tions and immediate mobilization of the patient, together with preprocedural adjustment on 
coumadin made earlier hospital discharge possible. 
The present study compares both techniques in two well documented patient populations. 'We 
demonstrated an important reduction in costs of angioplasty material (13%) in favor of the 
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transrndial technique, despite the high Humber of guiding catheters used in this group. As 
expected, postprocedural cost reduction (93%) was established in the transradially stented 
patients, due to less diagnosic and therapeutic procedures for bleeding complications. A shor-
ter hospital stay in group A resuHed in an additional 45% cost reduction. Overall, the costs for 
transradial bare stent implantation were 67% of the costs for the conventional transfemoral 
technique. \Vhen eliminating extra costs associated \vith repeat PTCA and emergent bypass 
surgery (2 patients in group B), the transradial technique was still 22% cheaper than the she-
ath protected, transfetlloral technique. 
Study limitations. 
The two study populations were compared in a non-randomized fashion, however, the study 
groups are derived from two prospectively studied and carefully documented populations: the 
transfcmoral treated patients are derived from the Benestent study population (4), randomized 
to stent implantation in our center and the transradial treated patients from a prospective feasi-
bility study to transradial coronary stenting. 
This retrospective study shows differences in some haseline characteristics between the two 
different populations. The "ideal" character of the Bcnestent patients (de novo lesions in nati-
ve coronary arteries in patients with stable angina) is in contrast ,vith the more unfavorable 
baseline characteristics of the transradial group (unstable angina, venous bypass graft steno-
sis). Procedural success however was not significantly different in both groups. With 2 failed 
stent procedures, 2 subacute occlusions requiring repeat PTCA and bypass surgery and with 8 
bleeding complications (5 major complications) out of 25 Benestent patients, we had a higher 
incidence of complications compared to the total Benestent study population. This means that 
for larger study populations the differences in costs between both techniques may be less out-
spoken. The lower incidence of complications in group A is not only determined by the radial 
artery approach. The transradial stent experience is from a later date, when more details on 
the pitfalls of coronary stenting were recognized and more attention was focused 011 optimali-
zation of the final results and on the optimal timing of heparinization after sheath removal. 
Also, a reduction of costs, associated with the transfemoral approach, can be expected if bare 
stents would have been implanted via 6F transfemoral guiding catheters and if patients would 
have been adjusted on coumadin prior to the procedure. It can also be expected that stenting 
via the femoral artery, on minimized anticoagulation regimens with the conventional stellt 
(16,17,18) or with heparin-coated stents (19) will also be associated with less bleeding com-
plications. The impact of different hemostasis devices on the safety of transfemoral stenting, 
remains unclear. In our experience, we coulcillot prevent bleeding complications with the 
Vasoseal, after coronary stenting (20). Carerc et a!. reported 011 a 18-33% of complications, 
associated with the use of this device after transfemoral coronary angiography and PTCA, 
including stents (21). These devices, and others such as pneumatic compression devices (22) 
and percutaneous suture devices (23), are having their price and will also add to the costs of 
coronary stenting. Hmvever, it was not the purpose of this study to compare costs of stenting 
via two different entry sites, but to compare two strategies; the traditional transfemoral sheath 
protected technique versus the novel transradial, bare stellt approach. Another limitation is the 
incomplete analysis of true costs. Not all elements were taken into account such as laboratory 
costs, pharmacological costs, intensity of nursing care and physician charges. However, by 
analyzing the most important items with expected largest differences (angioplasty equipment, 
diagnostic and therapeutic procedures for complications and hospital stay) we were able to 
establish a realistic comparison bet\veen the techniques. Finally, we did not perform an analy-
sis of costs for postdischarge complications, hut no major differences are expected between 
both groups after successful stenting. Despite these short-comings, it can be concluded that, 
compared to the traditional stellt technique, transradial coronary bare stent implantation redu-
ces costs by a lower consumption of balloon catheters, a reduced incidence of entry site rela-
ted complications and by a shorter hospitalization. 
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CHAPTER 4.6.6 
POTENTIAL SOLUTIONS 
RADIAL ARTERY AS ENTRY SITE 
Tl'ansradial m'ter), coronary stent implantation 
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Transradial Palmaz-Schatz Coronary 
Stenting on an Outpatient Basis: Results of 
a Prospective Pilot Study 
Ferdinand Kienleneij, MD, Gert Jan Laannan, MDt PhD, 
Ton Slagboom, MD, Pieter Stella, MD 
ABSTRACT: Background: The applicability of Palmaz Schatz coronary slenl intplanlalion is lim-
ited by bleeding complications and prolonged hospitalization. Coronary stenting on an outpa-
tient basis, may be the ultimate means to reduce costs of this treatment. Since bleeding and stenl 
occlusion were infrequent complications in a group of 100 ambulatory patients who undenvent 
sten! implantation via the radial artery in our department, we performed a pilot study 10 deter-
mine lhe feasibility of using coronary stenling on an outpatient basis. 
Methods: Patients selected for l'almaz Schatz slen! implantation, were adequately adjusted on 
coumadin. At an INR > 2.5, stenting was performed via the radial approach. Based on pre-, posl-
and procedural criteria, considering clinical status, procedural COllrse and outcome, absence of 
predictors for stenl occlusion and of events during 4 to 6 hours observation, patients were con-
sidered candidates for same-day discharge. Heparin was administered only during the proce-
dure. Immediately after the procedure, Ihe arterial sheath was removed. Patients were mobilized 
and were discharged wHit a pressure dressing over the puncture site, Follow-up was performed 
on the next day, at 2 weeks and at one month. 
Results: Between May and September 1994, 47 patients underwent Palmaz Schatz stenl implan-
lation via Ihe radial artery. Of these, 27 remained hospitalized for reasons, considered to be 
incompatible with outpatient treatment, Twenty patients (CCS-class III and IV; n=17 {85%)) 
received 29 stents for 23 lesions, distributed in 21 vessels and were discharged the day of treat-
ment. No cardiac or bleeding events were encountered within 24 hours. At 2 weeks follow-up, 
one patient was readmitted (day 4) because of a bleeding abdominal aortic aneurysm, requiring 
surgery. At 1 month follow-up, no bleeding, entry-site and cardiac complications wefe noted. 
Conclusion: Since no complications were encountered (95% confidence interval; 0-17%) in the 
first 24 hours after optimal coronary stent implantation in patients with an adequate preprocedur-
alleveJ of anticoagulation, a larger feasibility study of outpatient coronary slenting will be under-
taken. 
J INVAS CARDIOL 1995;7:5A-llA 
Elective implantation of Palmaz-Schatz coro-
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nary stents is vcry rarely associated with acutc « 
24 hours) coronary incidents provided the stent is 
optimally expanded and is not placed in the pres-
ence of angiographic predictors of stcnt occlu-
sion, This phenomenon may alIo,"" coronary 
stenting to be performed on an outpatient basis if 
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the patient can he mobilized immediately after 
the procedure and if the risk for bleeding compli-
cations from anticoagulation is minimized. 
Transfemoral artery impiuotation of metallic 
coronary stents has the hazard of bleeding com-
plications during the postoperative course when 
the patient is receiving intense anticoagulation!-3, 
even during prolonged bcd-rest. 
Stent implantation through 6 French guiding 
catheters via the radial artery has been demon-
strated to be an effective mml1s of reducing the 
risk of major bleeding complications4-6 in 
patients who arc not restricted to prolonged 
immobilization. 
No ischemic complications of the hand ·were 
encountered, even in 3 patients (3%) ·with a 
post-procedural radial artery occlusion. During a 
feasibility study on transradial stenting, conduct-
ed in our department, hospital stay 'was limited to 
one day in 22 patients who were on a therapeutic 
level of anticoagulation. None of these patients 
developed major complications following the 
procedure and early after discharge. Thus with 
the transradial artery approach it is possible to 
implant a Palmaz-Schatz stent on an outpatient 
basis, 'which reduces costs and which increases 
patient comfort. We conducted a non-random-
ized, prospective, single center pilot study to 
explore the feasibility of transradial Palmaz· 
Schatz coronary stenling on an outpatient basis. 
METHODS 
Study population. Patients referred for elec-
tive stent implantation were pretreated on 
Coumadin0 prior to admission. Most of these 
patients came directly from home or, in some 
instances, from the referring hospital, to the 
catheterization laboratory. At the start of the pro-
cedure, an INR was assessed. If an INR > 2.5 was 
achieved, the patient was. asked to participate in 
this study. Patients were excluded who under-
went stenting via the femoral artery. 
Study population. In our department, stent 
implantation is performed by the radial approach 
if the Allen-test is normal in the right or left 
hand. Reasons to implant stents via the femoral 
artery are: requirement of SF systems (Benestent 
study), bailout stent procedure for a failed trans-
femoral PTCA or a failed (previous) transradial 
attempt. 
6A 
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Also, stenting as bail-out procedure and stent-
ing in patients who were in poor clinical condi-
tion were reasons to exclude patients from the 
outpatient protocol. 
Outpatient triage. Based on preprocedural, 
procedural and post-procedural variables, a deci-
sions 'was made to keep the patient hospitalized 
or to discharge the same day (Table 1). 
Transradial stent implantation technique. 
Technique of transradial angioplasty and stent 
implantation4,5 has been described in detail 
before. In brief, the right arm \vas abducted and 
the wrist hyperextended. After local anesthesia, 
the radial artery was punctured with an Arrow1'> 
22-gauge radial artery catheterization set or with 
a KimmaP needle. After appearance of pulsatile 
flow from the needle, an 0.025 inch, 260 CIll long, 
J-shaped guidewire (Schneider0) was introduced 
through this system, followed by insertion of a 6 
French arterial introducer. During ongoing expe-
Table 1. Arguments for prolonged hospitalized 
following stent implantation. 
A. Preprocedural 
1. Unstable angina (last attack and ECG-
changes within 24 hours despite in nitro-
glycerin) 
2. Suboptimal adjustment on c()umadin (INR < 
2.5) 
3. Poor clinical condition 
4. Urgent non-PTCA related indications for 
hospitalization, e.g., social circumstances. 
B. Procedural 
1. Transient closure 
2. Resuscitation 
3. Prolonged chest-pain 
4. Persistent ECG-clHU1ges 
5. Suboptimal result: distal stenosis or obstruct-
ing dissection, thrombus 
6. Major side branch occlusion 
7. Entry site complication 
8. Failed transradial attempt 
C. 6 hours observational period 
1. All cardiac events 
2. Bleeding: complications 
3. Non stent-related complications 
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rience, ·we preferred using a 23 cm, instead of 10 
cm long Terumo® 6F introducer sheaths, to pre-
vent radial artery spasm and to facilitate guiding 
catheter manipulations. 
Meticulous care ·was directed towards optimal 
selection of the guiding catheter with respect to 
backup support and coaxial alignment. The 
Cordls0 Petite"l 6F guiding catheter ,vas pre-
ferred because of its large inner diameter (0.062 
inch). For left coronary artery procedures, the 
Scimed® Triguide1'! 6F Voda curve was frequently 
selected because of optimal support and align-
l11ent, despite a smaller inner diameter (0.060 
inch). Later in the study, this curve also became 
available from Cordi SO (Extra Backup''!). We 
selected Scimed~ Express'" balloon catheters for 
predilatation and stent delivery because of their 
low profile, ease of advancement over the 
guidewire and through the guiding catheter and 
because of the proper fixation of the stent, once 
crimped on the balloon. One or more 7 mm, 10 
mm or 15 mOl Palmaz Schatz coronary stents 
(Johnson and Johnson Interventional Systems, 
Warren, Nev,,' Jersey) were used. After delivery, 
the stent diameter was optimized by successive 
dilatations with higher inflation pressures or with 
larger balloon catheters of intermediate compli-
ance [Schneider9 Magical Speedi'! (20 mm) or 
ChubbyT'1 /10 nun)]. Procedures were performed 
by two operators (FK and GJL). 
Medical treatment. Elective patients were pre-
treated ·with coumadin, at least one week before 
the procedure. The INR was assessed just prior to 
the procedure. At an JNR > 2.5, the patient 
received 10,000 ill heparin after sheath insertion 
and Acetosalicylic acid SOD mg intravenously. No 
heparin was given after the procedure. 
Introducer sheath removal and hemostasis. 
The arterial sheath was removed immediately 
after withdrawal of the guiding catheter, fol-
lowed by application of an occlusive tourniquet 
at the radial puncture site for a minimum of 30 
minutes. Pressure was gradually released until 
hemostasis was obtained. A pressure dressing 
over the punctured artery was applied for 6 
hours. Patients were encouraged to mobilize, and 
advised to restrict movements of the wrist joint. 
Predischarge examinations. TI1e clinical status 
of the patient was monitored by a physician and 
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the radial artery was examined for adequate 
hemostasis and the presence of pulsations. 
A new pressure dressing was applied, fol-
Im\'ed by application of a sling supporting the 
forearm. Written instructions were given to the 
patient, followed by oral explanations. The 
patient ·was advised to remove the pressure ban-
dage the next day. Prior to discharge the patient 
was instructed on the method fOf achieving 
hemostasis by applying local pressure, in case of 
a punchlre site bleeding. In case of uncontrollable 
bleeding or other emergency situations, patients 
,vere instructed to contact the general practition-
er, the cardiologist, the first aid department of 
our hospital, the 24~hour service of our cardiolo-
gy department or one of the available alarm tele-
phone numbers. 
Endpoints. A sllccessful outpatient treatment 
was defined as an uncomplicated course within 
the first 24 hoUl's after the stent procedure. A suc-
cessful short~term outcome after coronary stent-
ing was defined as an uncomplicated course in 
the first month after discharge. Follow-up was 
considered uncomplicated if none of the follow-
ing endpoints occurred': death, acute myocardial 
infarction, need for coronary artery bypass graft-
ing, need for PTCA of the stented coronary 
artery, angina caused by stent rcstenosis or occlu-
sion and any bleeding requiring hospitalization. 
Occlusion of the radial artery was considered to 
Table 2. Baseline characteristics 
N % 
No. patients 20 
Male gender 18 (90%) 
Age (years) 63 ±9 (range 45-76) 
Exertional angina: 
CCS II 3 (15%) 
CCS III HI (50%) 
CCSN 7 (35%) 
Prior myocardial infarction II (55%) 
Prior bypass surgery 7 (35%) 
Prior PTCA 8 (40%) 
Hypertension 5 (25%) 
Diabetes mellitus 3 (15%) 
Cholesterol ~ 6.5 I1lmol/ 1 3 (15%) 
Smoking history 10 (50%) 
Family history 9 (18%) 
7A 
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Table 3. Angiographical data 
N 
Stented vessels (n=21) 
LAD 4 
LCX 4 
RCA 7 
VBC 5 
Intermediate branch 
lesion morphology N=23)7 
Type A 5 
Type B 10 
Type C 8 
% 
(19%) 
(19%) 
(33%) 
(24%) 
(5%) 
(22%) 
(43%) 
(35%) 
LAD = left anterior descending coronary .utery; Lex"," left 
circumflex coronary artery; L1\I = Left mains\cm; RCA = 
Right coron<1ry artery; VBC =' Venous bypass gr,ut. 
be a major event if the forearm or hand shO'wed 
signs of ischemia (e.g., functional disability by 
claudication, necrosis, surgical recanalization). 
Follow-up. The day following discharge and 
after 2 weeks, the patient was interviewed by 
telephone. Patients were questioned about the 
occurrence of any complications or discomfort. 
Questions from the patient were addressed dur-
ing this same interview, 
At one month follow-up, the patient was seen 
and screened for entry-site--relatcd complications 
and cardiac complications. Radial pulse was also 
examined by palpation. 
St,ltistical analysis. Values were expressed as 
mean ± standard deviation. 
RESULTS 
Between May and September 1994,47 patients 
underwent Palmaz Schatz coronary stent implan-
tation via the radial artery. Of these, 27 patients 
Table 4. Quantitative coronary angiography 
were considered to be unsuitable for treatment on 
an outpatient basis because of one or more of the 
following reasons: suboptimal adjustment on oral 
anticoagulation (n = 16; 59%), prolonged angina 
andlor persisting ECG changes during the proce-
dure (n ;;: 3; 11 %), stenling after failed PTCA (n =; 
3; 11%), residual dissection (n = 2; 7%), unstable 
angina immediately prior to stent implantation (n 
;;: 1; 4%). The remaining 20 patients, treated on an 
outpatient basis underwent stenling for de novo 
lesions in native coronary arteries (n ::;; 10; 50%), 
native coronary artery restenosis after previous 
PTCA (n = 5; 25%) and venous coronary bypass 
graft stenosis (n =; 5; 25%). Baseline clinical char-
acteristics, angiographical data and quantitative 
angiographical data of Ihis group are shown in 
Tables 2, 3 and 4, respectively. 
Procedural results. Stenl implantation was 
successful in all patients. In 6 patients, multiple 
stents were implanted for long lesions (n :::; 3), 
multiple lesions (n =; 2) and for a dissection after 
predilatation of the stenosis (n "" 1). Diameter 
stenosis improved from 70 ± 16% to 9 ±·7%. In 
one patient a type B dissection, parallel to the 
stent was visible. No residual obstructions could 
be detected by digitized coronary angiography. 
Clinical observation. Effective hemostasis 
was obtained within 1 hour in all patients. All 
patients were discharged before the evening of 
the day of coronary stent implantation, after an 
lIneventful observation period. However, 4 
patients coming directly from a referring hospital 
were not discharged home, but to their clinics for 
various reasons. For 3 of these patients, 
same--day-discharge had not been arranged with 
relatives. These patients remained for 1 night in 
their referring clinic. One patient needed further 
evaluation of mild renal failure. Since these 
patients, according to our criteria were suitable 
for outpatient tre<ltinent but were not admitted to 
OUI' clinic, they were included in this study. 
Baseline Post stenling 
Mean ± SD Range 
Reference diameter (mm) 3.4 ± 0,4 
Minimal lumen diameter (mm) 1.0 ± 0.5 
Diameter stenosis (%) 70 ± 16 
SA 
2,8-4,4 
0,3-2,4 
32-92 
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Mean±SD Range 
3.7 ± 0.5 2,9-4,8 
3.4 ±OA 2,9-4.4 
9±7 0-20 
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24-Hour follow-up. None of the 20 patients 
had bleeding from the radial artery puncture site. 
No cardiac complications were encountered. 
14-Day follow-up. Two patients were read-
mitted to our hospital. One patient had an 
aneurysm of the abdominal aorta requiring vas-
cular surgery and was admitted 4 days after stent 
implantation with signs of bleeding from this 
aneurysm. This was successfully operated on the 
saille day. TI1is patient underwent stent implanta-
tion for severe anginal complaints caused by a 
stenosis in the circumflex coronary artery. Since 
the right coronary artery was occluded and left 
ventricular function (and anterior wall motion) 
was severely compromised, the LeX was consid-
ered to be the last remaining vessel. Coronary 
angioplasty was required before any operation 
for the aortic aneurysm could be lmdel'taken. TIle 
patient was given COllmadin for 2 months. No 
additional anticoagulants, except for dipyri-
damole, were added to his medication. Therefore, 
this condition was not considered to be related to 
the stent implantation. The second readmitted 
patient had anginal complaints on the 11 th day 
following stenting. Coronary angiography 
reveall:'d a patent stent and no significant stenosb 
in other coronary arteries. The other patients 
were free of bleeding and cardiac complications. 
One-month follow-up. At one month fol-
100\'-up, no bleeding or cardiac complications 
were noted. One patient with si,b'Tlificant coronary 
adery disease in non-treated and inoperable coro-
nary arteries still had angina, but was ftmctionally 
improved. None of the patients had complaints of 
disability of the hand. No signs of ischemia were 
noted. In all patients the radial artery was palpa-
ble at phy~ical examination. 
DISCUSSION 
Coronary angioplasty is usually pedormed 
based on clinical indications. A major reason to 
keep the patient lmder clinical obsen'ation is the 
risk for acuie reocclusion of the treated coronary 
vessel. The incidence for acute closure after bal-
loon angioplasty \vas 7.S'Yo in the early NHLBI 
PTCA registry (1977-1981)1'\ and 6.S');, in the sec-
ond NHLBI PTCA registry (1985-1986).'" In a 
more recent survey from Myler et al., the inci-
dence ·was 4.9%.10 This complication usually 
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requires an immediate attempt to obtain restora-
tion of flow by repeat PTCA, coronary stenting or 
emergency bypass surgery. TIw other major rea-
son to keep the patient hospitalized is to limit 
mobility in order to reduce the fisk for an access 
site related bleeding complication. 
Since the number of patients lmdergoing coro-
nary angioplasty is still increasing, there is a need 
to reduce costs since resources are limited. In cen-
ters with high case loads, the restricted number of 
available hospital beds may pose a problem. 
Coronary angioplasty on an outpatient basis may 
offer a solution to this problem. II Early mobiliza-
tion after sheath removal may additionally be 
associated with increased patient comfort. 
The ideal combination of requirements for out-
patient coron<uy angioplasty should contain the 
following elements; probability of high procedur-
al s'uccess rates, no risk for acute coronary artery 
closure, minimal risk for access site related bleed-
ing complications and the ability to immediately 
mobilize the patient. 
Implantation of Palmaz Schatz coronary stents 
is very rarely associated with acute stent occlusion 
(lNithin 24 hams) if the sten! is optimally delivered 
and if no predictors of sten! thrombosis are pre-
sent. From several early single center and multi-
center series, no acute stent thromboses were 
reported. I ,12.13 Acute slent occlusion was not 
observed in an angiographic follow-up study of 
Kimura et al)4 Stenosis diameter in the stent group 
was stable in the interval bet\veen stent implanta-
tion and the following day. No acute }iten! occlu-
sion was encountered in the more recent 
Benestent3 and the STRESS2 studies, where 
patients. were randomized 10 either balloon angio-
plastyor to stenl implantation. However, subacute 
sten! occlusion is a complication that usually 
occurs in the first week after stenting. With 
improved patient selection and by optimizing 
stent implantation techniques, the complication 
rate has fallen from high rates in the early experi-
ence after bailout stentingl5 to low rates in a later 
series. In a recent report on Palmaz-Schatz stent 
implantation in venous bypass grafts13 no stent 
thrombosis was encountered. Low incidences of 
subacute stent thrombosis are reported after ulh'a-
sound controlled ::Itent implantation (0%)1(, and 
even after stenting with subcutaneous heparin, 
combined with platelet inhibitors (0I>k)P,18 
In om recent experience with 100 patients after 
transradial stent implantation, no stent occlusion 
9A 
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·was encountered in electively treated patients (in 
press, American Heart TOllrl/al). Since an optimal 
result after stent implantation may help minimize 
the risk of acute vessel occlusion, a major prereq-
uisite for outpatient angioplasty is to place 
patients. on adequate levels of oml anticoagula-
tion prior to the procedure. 
Access site-related bleeding complications arc 
the main hazard of coronary stenting in patients 
receiving complex anticoagulation regimens. By 
using smaller guiding catheters, ·we have demon-
strated the feasibility of coronary stenting via the 
radial artery with dmvl1sized PTCA equipment. 
In 100 patients, one patient developed subcuta-
neous bleeding of the radial artery requiring sur-
gical decompression of the hematoma. By inuno-
bilizing the hand ·with a supporting sling, risk for 
bleeding can further be reduced. With appropri-
ate instructions, most patients are able to address 
a bleeding radial artery themselves. If after an 
observation period of 6 hours, no access 
site-related bleeding occurred, we consider 
hemostasis to be safely established. Together lNith 
the immediate mobilization of the patient after 
the procedure, the second and third requirements 
for outpatient coronary angioplasty are also met. 
A careful patient selection, based on a triage, 
was performed before the decision was made to 
discharge the p<uticipating patients on the same 
day. This triage contained general criteria, mak-
ing outpatient treatment after successful stent 
implantation impossible (e.g., poor clinical status, 
social circumstances, patient compliance, pro-
longed chest-pain with a good stent results, etc.) 
and generally accepted risk factors for stent 
thrombosis such as the presence of a distal 
obstructing lesion l9, intracoronary thrombus}':! 
and suboptimal anticoagulation.1 
If this tri<lge resulted in no reason for hospital-
ization, we used any complication during a 
post-procedural observation period as a final rea-
son to keep the patient under clinical observation. 
In the case of same-day-discharge, extensive 
information was given to the patient to optimize 
the safety of this new approach. It should be 
acknowledged that a minor bleeding in a hospital 
may turn into a major problem when the patient 
is at home. TIlerefore, we have kept the pressure 
dressing in place for 24 hours. No entry site 
bleeding and no cardiac complications were 
encountered early after discharge. rVfajor concern 
on a stent thrombosis is addressed beyond the 
lOA 
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first 24 hours. Although stent thrombosis is a seri-
ous event frequently leading to myocardial 
infarction, the low incidence of this complication 
in patients on an adequate level of anticoagula-
tion after an optimal stent result does not justify 
keeping ambulatory patients under prolonged 
clinical observation. 
Study limitations. Only a small number of 
patients are described in this study. Of the 47 
patients selected for transradial stenting, a minor-
ity were considered suitable for this outpatient 
protocol. Since no experience on outpatient stent-
ing is currently available, we carefully defined 
exclusion criteria based on current literature on 
increased risk for occurrence of stent thrombosis. 
However, the most common reason to exclude 
patients was an inadequate level of oral anticoag-
ulation. This policy may be changed in the neal' 
future by treating patients ·with potent 
antiplatelet medication only. 
The small number of patients studied does not 
allow outpatient stenting to be recommended on 
a large scale. With a sample size of 20 patients 
without a bleeding or cardiac complication with-
in the first 24 hours, the 95'-'/0 confidence interval 
for the absence of complications runs from 0 to 
16.8'1<,. By expanding this experience, we will be 
able to report on the results of a larger study in 
the near future. 
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CHAPTER 4.7 
POTENTIAL SOLUTIONS 
HEPARIN COATED PALMAZ SCHATZ CORONARY S1ENTS 
IMPLANTATION OF HEPARIN COATED PALMAZ SCHATZ STENTS IN HUMAN 
CORONARY ARTERIES: PROCEDURAL AND CLINICAL RESULTS OF THE 
BENESTENT-II PILOT STUDY 
The Benestent-II study group 
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Implantation of Heparin coated Palmaz Schatz stellts in human coronary al'tel'ies: 
Procedural and Clinical Results of' the Benestent- II pilot study 
The Benestent- II study group 
INTRODUCTION 
The Benestent-I trial, a multicenter randomized study comparing the safety and efficacy of 
primary Palmaz Schatz stent implantation with balloon angiopasty (PTCA) in patients with 
stable angina and a de novo lesion in a native coronary artery, demonstrated that eventfree 
survival in patients who received a stent was higher compared to patients who underwent 
PTCA (80% versus 70%)(1), This was largely due to a reduction in repeat revascularization in 
patients who were treated \vith a stellt by significantly reduced restenosis rates in this group 
(22% versus 32%), However, the incidence of bleeding complications (13,5%) and subacute 
thrombosis (3.5%) after stenting resulted in considerable longer hospitalization (8.5 days) 
than following balloon angioplasty (3.1 days). 
A heparin coated stent has been developed, in order to improve the clinical results of coronary 
stenting by minimizing the risk for thrombotic stent occlusion and by reducing anticoagulant 
therapy. The Benestent-Il pilot study is an open, multicenter, non-randomized, prospective 
registry, designed to evaluate the safety of elective implantation of a heparin-coated Palmaz 
Schatz stent in a patient population comparable to that enrolled in the Benestent-I study. 
J\IETHODS 
Stud), design 
Following stellt implantation, heparin was reinstituted in a step-wise fashion. The study con-
sisted of four phases in which a total of 202 patients were treated with a single stent (51, 50, 
5l and 50 patients in each of the 4 phases), Heparin infusion was started 6, 12 and 36 hours 
after sheath removal in the first 3 respective phases. In phase 4, no heparin or coumadin was 
given, hut patients were treated with aspirin and ticlopidine. 
The decision to proceed with the study from the one phase to the next was made 011 the basis 
of a predetermined incidence of (sub-)acute thrombotic stent occlusion. If there were 3 or 
more incidents of subacute stent thrombosis in phase I (based on a 3.5% angiographically 
demonstrated subacute thrombosis ratc in Benestent-I), the study had to be abandoned. \Vere 
there less then 3 subacute occlusions, phase II was started, and so on to phase IV. 
Objectives 
Primary endpoinls included incidence of (sub-)acute stent occlusion, location and severity of 
bleeding complications during hospital stay and within 30 days of implantation. The occur-
rence of all cardiac and non-cardiac events during the same period (death of all causes, myo-
cal'dial infarction, repeat revascularization procedures) was recorded. 
Secondary oiJjecli\'('s were the efficacy of the procedure (symptom-free and event-free sUl-vi-
val at 6 months, freedom of death, myocardial inf~lrction or repeat interventions) and changes 
in stenosis geometry, assessed by quantitative coronary angiography immediately after stent 
implantation and at 6 months. 
Patient selection 
Patients with stable angina, caused by a de novo lesion in a native coronary artery, were 
recruited for this study if there were no contraindications for anticoagulation or anti platelet 
therapy or coronary bypass surgery. The lesion had to be located in a vessel of at least 3 111m 
in diameter and the lesion length was required to he less than 15 111111. Other anatomical COIl-
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traindicatiolls were lesions in or distal from a sharp bend, or at a bifurcation of an important 
side branch C~2.5 mm), ostiallesiolls and the presence of intra(;oronary thrombus. Also a 
lesion in a grafted coronary artery was an exclusion criterion. 
The study was performed according to the principles of the Declaration of Helsinki. Oral or 
written informed (;onsent was obtained from al1 patients. 
Stellt implantation technique 
Stent implantation was performed via the femoral approa(;h. The stellt was delivered by the 
Stent Delivery System (SDS), a preassell1bled unit, containing a, 5F sheath covered, 15 mm 
heparin-(;oated Palmaz Schatz stcnt, mounted on a 3,0, 3,5 or 4,0 111m compliant polyethylene 
balloon catheter, 
IHcdical l'egimen 
Commencing the day before the procedure, all patients received 250-500 mg of aspirin daily 
and dipyridatpole 75 mg 3 times a day, This medication was (;ontinued for 6 months. 
Diltiazem 120 mg bid was continued until hospital discharge. An infusion of Dextran (1000 
ml) was given, the first 500 Ill] at 100 ml/hr, the second 500 ml at SO ml/hr. 
In the first 3 phases, coumadin was given from the day of stellt impantation for a period of 3 
months. Heparin was administered as a holus dose of IO,OOD IU at the start of the procedure 
and reinstituted as continued infusion 6 h (phase I), 12 h (phase 2) and 36 h (phase 3) after 
removal or the arterial sheath. Sheath removal took place when the aPTT had fallen to below 
twice the norIllal value (normal range 30-40 sees), Heparinization was gradually decreased 
when the INR (international normalized ratio) was within the therapeutic range (2,5 - 3.0) for 
at least 36 hI'S. 
In phase 4, patients received ticlopine 250 mg bid for 1 month, starting the day before the 
procedure. In this phase coumadin was not given and heparin 10,000 IU was administered 
only during the procedure. 
Quantitatiyc Coronal'Y Analysis 
The angiograms were analyzed at the core laboratory (Cardialysis, Rotterdam, the 
Netherlands) by the Cardiovascular Angiography Analysis System, To standardize the method 
of data acquisition and to ensure reproducibility of the angiograms performed after the inter-
vention and at follow-up, measurements were made according to previously described 
methods, 
Statistical analysis 
Continuolls variahles are expressed by means ± SO. A p-valuc of < 0.05 \vas considered signi-
ficant. 
RESUJ;fS 
Between February and Decemher 1994, 207 patients were included in the Bcnestent-H pilot 
study. Fifty-one, 55, 51 and 50 patients were enrolled in phases I-IV respectively. 
In phase I, 2 patients received 2 stents in order to optimize the angiographical result. In phase 
II, 5 patients were excluded [rom further analysis, as they did not receive a slenL In 4 patients 
the SDS could not cross the lesion. In one of these patients, the ostium of the right coronary 
artery dissected, followed by acute surgery. This patient died postoperatively by intractable 
arrhythmias. In 2 other patients there was a problem with removal of the SDS- sheath, One 
patient could not be stented and in the other, a "bare" heparin coated stellt was implanted, In 
phases III and IV, all allocated patients were evaluable. In phase IV, however, one "bare" 
heparin-coated sten! was implanted, as the lesion was unable to he crossed with the SDS, 
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Four patients received 2 stents. Baseline clinical characteristics and lesion characteristics are 
displayed in Tables 1 and 2 respectively. For comparison, data on stented patients, participa-
ting in the Benestcnt- 1 study, are displayed in both tables. 
Table 1. Baseline characteristics 
Benestent-I Phase I Phase II Phase III Phase IV 
(n=225) (n=51) (n=50) (n=51) (n=50) 
foliale 80% 88% 71% 82% 88% 
Age (yrs) 57±9 59±10 58±1O 59±10 58±1O 
% % % % % 
CCSI 4 4 9 6 5 
CCS II 32 45 37 30 42 
CCS III 48 33 41 9 23 
CCSIV 6 2 0 4 II 
Mixed 34 20 31 32 28 
MI 20 10 23 34 23 
CABG 0 6 2 4 2 
PTCA 2 6 6 6 5 
Diabetes 7 8 10 6 7 
Hypertension 31 24 35 26 30 
Cholesterol 35 31 46 34 30 
Smoker 
-previous 46 39 33 23 51 
-current 24 20 29 38 26 
CABO Coronary artery bypass grafting 
CCS Canadian Canliovascular Society 
MI 1Jyocardial infarction 
PTe" Percutaneous transluminal coronary angioplasty 
Procedural data 
During the course of the study, on line quantitative coronary angiography (QCA) became 
increasingly used, with 45%,63%,67% and 67% of cases during the 4 phases respectively. Tn 
phases I-IV, 10%, 8%, 20% and 8% of clinics respectively, used intravscular ultrasound to 
guide the stent procedure. Post stellt dilatation in order to optimize final results were applied 
in 80%, 88%, 86% and 94% in the 4 phases respectively. Normal inflation pressure was used 
in 37%, 12%,22% and 22% whereas pressures over 12 atmospheres were applied in 43%, 
76%, 65% and 78% (Figure I). In all groups, a mean of 2.8 devices (stent included) were 
used in order to come to achieve an acceptable final result. Maximum balloon diameter incre-
ased from 3.45 ± 0.40 mill to 3.54 ± 0.37 mm, 3.62 ± 0.43 illl11 and 3.64 ± 0.42mm in Lhe 4 
respective phases. In Benestent- I, mean maximum balloon diameter was 3.40 ± 0040 mm. 
Acute angiogl'aphic results 
In table 3 data on pre- and post procedural reference diameter (RD), minimal luminal diameter 
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Table 2. Lesion characteristics 
Concentric 
Eccentric 
Tandem 
Multiple 
irregularities 
Calcified 
LAD 
LCX 
RCA 
TIMIO 
TIMII 
TIMI " 
TIMIIII 
LAD 
LCX 
RCA 
TlMI 
Bellestellt·I Phase I 
(11=225) (11=51) 
% % 
49 27 
51 63 
I 6 
7 4 
11 8 
65 51 
14 8 
21 41 
I 0 
I 4 
II 10 
86 86 
Phase II 
(11=50) 
% 
41 
53 
4 
2 
2 
55 
16 
29 
0 
2 
8 
90 
Left anterior descending coronary artery 
Left circllmtlcx coronary ;tn~try 
Right coronary artery 
Thrombolysis in rvfyocardiailnfarction 
Benestent-II Pilot Study 
Phase III 
(11=51 ) 
% 
22 
74 
0 
4 
II 
61 
IO 
29 
0 
2 
9 
89 
Maximal pressure Post-stent balloon 
Phase IV 
(11=50) 
% 
19 
75 
2 
4 
11 
62 
IO 
28 
0 
2 
9 
89 
I_ Phase 1 D Phase 2 ~ Phase 3 § Phase 41 
% pts 
50 
40 
30 
20 
10 
o~~~~~~~~~~~~~~~~ 
No swk 4-8 9-12 
(Atm) 
Figure 1. Distribution of m;Lximai pressure during post stent dilatations. 
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13-16 >17 
(MLD) and diameter stenosis (DS) are given. \Vhen compared to Benestent-I, a trend 
towards selection of patients with a larger RD was detectable (3.00, 3.17, 3.06, 3.22 and 
3. I 7 III III respectively) as well as an increase in MLD post- stenting (2.51, 2.76, 2.75, 2.79 and 
2.74mm). From phases I-IV, RD increased from a preprocedural value of 3.16 ± 0.41 111m to 
3.38 ± 0.37 mm. (figure 2). A preprocedural RD less than 3.0 mill was encountered in 39% 
of thc 202 patients, and a RD<2.75 nun in 16% and a RD<2.5 lllm in 4%. A final RD of < 
3.0 and < 2.75 111m was accepted in 12% and 5% of patients respectively. 
In figure 3 and 4 cumulative frequency curves of MLD and RD arc represented for Benestent-
I and the 4 phases of Bel1estcnt-11. The final.MLD was larger in Benestent-H and an improved 
final DS was obtained. 
Table 3. Acute angiogl'aphic results 
Benestellt-I Phase I Phase II Phase III Phase IV 
(11=225) (11=51) (11=50) (11=51) (11=50) 
Pre Post Pre Post Pre Post Pre Post Pre Post 
RD (tlllll) 3.00 3.17 3.17 3.41 3.06 3.32 3.22 3.42 3.17 3.36 
MLD (mill) 1.07 2.51 1.11 2.76 l.()9 2.75 1.13 2.79 1.07 2.74 
DS ('Yo) 64 21 65 19 65 17 65 18 66 18 
DS Diamctcr Stcnmis 
ft'fLD Minimal Luminal Dimlleter 
RD Reference Diameter 
BENESTENT II Pilot Study 
Cumulative frequency of Reference Diameter 
% 
100 
80 
60 -
40 - 39% 
20 16% 
4% 
o 
PRE 
3.16 ± .41 
POST 
3.38 ± .37 
Benestent II 
Phase 1 t/m4 (202) 
2 2.25 2.5 2.75 3 3.25 3.5 3.75 4 4.25 4.5 4.75 5 
RefDiam (mm) 
Figure 2. Cumulative frequency of RD in Benestellt- If Pilot Study 
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Figure 3. Cumulative frequency of IvlLD in Bencstent-J aOtI II 
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Figure 4. Cumulative frequency of OS in Beneslent I and II 
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Clinical outcome during the in-hospital phase 
Stent thrombosis was not encountered in this pilot study. Table 4 summarizes clinical events 
ranked in the following order; death, intracranial hemorrhage or CVA, Q- wave and non Q 
wave myocardial infarction, urgent CABG, elective CABG and rePTCA. In phase 2, I patient 
died after a failed attempt to deploy a stent, as mentioned above. A cardiac enzyme rise 
(CPK:349 In=25-190]) was detected in one phase I patient, without signs of myocardial ische-
mia. In phase I and II, an additional bailout stent had to be implanted in 2 patients in order to 
cover a distal dissection. All patients were free of cardiac events during hospilalization, 
except for 2% in phase II. Major bleeding complications showed a trend to decrease in the 
respective phases (figure 5), Bleeding complications requiring therapy fell from 13,6% in 
Bencstent-I to 7.9%, 4.1, 4.0% anci 0% in the respective 4 phases of the pilot study. 
Hospital stay was 8.5, 7,4, 6, I, 7.0 and 3.n days in the different study groups. 
Table 4. Ranking of clinical events for Benestent- I and II 
Benestent-I Phase I 
(11=225) (11=51) 
% % 
Death 0.0 0.0 
ICHlCVA 0.0 0.0 
QMI 1.9 0.0 
non QMI 1.5 0.0 
Urgent CABO 1.9 0.0 
Elective CABG 1.2 0.0 
Re-PTCA 0.4 0.0 
None 93 100 
Subacute occlusion 3.5 0.0 
Coronary artery bypass grafting 
Ccrebrova<;cular accident 
Intracranial hcmorrhage 
Phase II 
(11=50) 
% 
1.8 
n.n 
0.0 
n.o 
0.0 
0.0 
0.0 
98 
0.0 
CABO 
CVA 
ICH 
PTCA 
QMI 
Percutaneous tfUnsluminal coronary angiography 
Q- wave myocardial infarction 
DISCUSSION 
Phase III Phase IV 
(11=51) (11=50) 
% % 
n.o 0.0 
0.0 0.0 
n.n 0.0 
0.0 0.0 
0.0 0.0 
0.0 0.0 
0.0 0.0 
100 100 
0.0 0.0 
The most important problems associated with the use of metallic coronary stents are mechani-
cal rigidity and thromhogenicity, requiring complex anticoagulant treatment (2,3). Nlulti-drug 
anticoagulation is associated with unacceptable high access-site related rate of bleeding COlll-
plications, if the femoral approach is used (1,4). 
From the Bcnestent-I study it was learned that the positive effects, in terms of event-free sur-
vival were partially negated by costs of the stent itself, a prolonged hospital stay and addition-
al costs related to the bleeding complications. 
In order to further improve the clinical results of coronary stenting, attention is directed to 
coating the stent with material which would minimize the risk of abrupt stent closure and the-
reby allow a reduction in anticoagulant therapy, To that purpose a heparin-coated stent has 
been developed. 
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Figure S. Incidence of bleeding complications requiring therapy. 
Principles of heparin-coating. 
Blood compatibility is a critical requirement for intravascular devices, since contact of blood 
\vith a foreign surface will commonly result in deposition and activation of piasmaproteins, 
platelets and other cellular elements, leading to thrombus formation. Over the last decades. 
there has been intensive research in the area of blood-compatible materials for non-coronary 
purposes (5), Instead of introducing a foreign mateial directly into a blood vessel, material 
surface modifications with improved properties with regard to blood and tissue compatihiility 
appears to be a promising approach. It has been shown that heparin-like molecules with anti-
coagulant activity are synthesized on the luminal surface of endothelial cells (6,7). Indeed the 
endothelium plays an important part in the activation of thrombin and possibly other coagula-
tion factors. Not unexpectedly therefore, heparin has been one of the most extensively explo-
red substances for adsorbtion or binding to the surfaces of biomaterials. Heparin-coated sur-
faces have been evaluated in various types of devices where thromboresistance might be of 
particular clinkal value, e.g. arteriovenous shunts, catheters, arterial filters, oxygenators, car-
diopulmonary bypass circuits and vascular endoprosteses (8-12). 
The principal anticoagulant mechanism of heparin is its interaction with antithrombin-III, 
accelarating the inactivation of thrombin and other coagulation factors. It has been shown that 
the active site of heparin contains a specific carbohydrate sequence (13-15). Obviollsly, when 
the heparin molecule is modified by the process of surface coating, it is essential that the acti-
ve sequence responsible for anticoagulation remains unaltered. The simplest solution for bin-
ding heparin to a surface is adsorbing a heparin solution to the biomaterial surface (16). A 
problem with this type of coating is the lack of control of the rate of release. The heparin 
molecule contains a large number of negatively charged groups and may therefore be ionical-
ly or electrostatically bound to surfaces with positive charges (17-19). Another principle is to 
incorporate heparin molecules into a polymer, either to make heparin a permanent component 
of the polymer, "surface-grafter" heparin (20), or to provide a controlled release of heparin 
upon introduction into the blood stream (21,22). Since heparin is a higly charged and hydrop-
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hillic polymer, the binding has to prepared by pretreatment of the surface to be coated with 
reactive groups ("fullctionalising"). In the early development of heparin-coatings, a reduction 
of heparin activity was frequently observed when the molecules were covalently attached to 
the surface, probably due to aHeration of the active carbohydrate sequence during the linking 
pro<.:ess (23). This problem was circumvented if heparin was coupled by end-point attachment 
(24,27). The first step in this procedure is partial degradation of heparin with nitrous acid, 
creating reactive aldehyde groups in the reducing terminal residues. In 1983 it was shown by 
Lann et a1. that heparin fragments could be immobilized by end-point attachment on materials 
coated with polyethylenimil1e (24). The aldehyde group was subsequently coupled to the ani-
mated surface by reductive animation. By this method, the active carbohydrate sequence of 
the heparin molecule can be preserved functionally intact throughout the coupling reaction. 
In addition to being compatible with the plasma coagulation system, a thromboresistant sur-
face should not promote adhesion and activation of platelets and leucocytes. Since heparin 
has been reported to induce platelet activation (26), this consequen<.:e might be expected wilh 
surface immobilized heparin as \velL However, it has been shown that in comparison with 
uncoated material the surface with end-point attached heparin on a high molecular weight 
polyamine stabilized wilh glutaraldehyde, was highly compatible with platelets as well as gra-
nulocytes and macrophages (27,28). 
The principle of perpendicularly oriented, end-attached, covalently bound and immobilized 
heparin molecules on a polymer surface (Canncda Bioactive Surface, Canneda AB, 
Stockholm) was considered to be the best technique for coating of coronary stents. A new 
"CH5" coating, a special form of the Canned a Bioactive Surface, was used, allowing higher 
heparin activity on the stent surface. 
Tn an in vilro model, Il1lndium labeled platelet attachment to uncoated and heparin-coated 
stents was measured. Platelet attachment to the coated stents was reduced by ahout 95%. 
Tn an animal study, heparin-coated and uncoated Palmaz Schatz stents were implanted in the 
left anterior descending coronary artery of 40 non-atherosclerotic pigs (29). In the 20 pigs 
who received a coated stent, no thrombotic events were recorded at the time of sacrifice 4 
weeks or 12 weeks after implantation. Of the 19 pigs, with a non-coated stent, 7 thrombotic 
events were recorded (p<O.OI). 
These in vitro and in vivo studies of thromhoresistance of the heparin coated stellt formed the 
basis for the iIlllantation in humans, in the Bencstent-II pilot study. In this study, no subacute 
thrombotic occlusion occurred in any of the patients. In phase lone patient received a bailout 
stent and in phase II one patient died. Neither event was related to the heparin coating of the 
stenL In the respective four phases there was a trend to a decreasing incidence of bleeding 
complications, resulting in a shorter hospitalization time. 
Factors other than the heparin-coating may also have contributed to this improved outcome 
when compared to the Benestent-I study. There may have been better patient selection (larger 
RD and i\1LD), bctter stent implantation technique (more frequent use of on-line QCA- on-
line, larger balloon size and higher post stent dilatation inflation pressures) and achievement 
of a better stent result (larger RD and MLD post stenting and reduced diameter stenosis). The 
new antiplatelet treatment (Ticlopidine) may have contributed to improved outcome, when 
compared to the Bcnestent-I study results. 
It is thus concluded that postponement of heparin treatment, 6, 12 and 36 hI'S after sheath 
removal has not resulted in (sub-)acute occlusions in these patients treated with antivitamin 
K. A trend towards less bleeding and peripheral vascular complications is observed. 
Substitution of heparin and coumadin with the antiplatelet agents, aspirin and ticlopiciine, did 
not result in stellt thrombosis and bleeding complications. Heparin coated stents are well tole-
rated, as no thrombogenic, al1ergic, toxic or immunologic side effects were encountered. 
However, the profile of the SDS should be improved, since this \vas the factor, limiting pro-
cedural success. 
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The absence of (sub)acllte occlusion as well as the virtual disappearance of bleeding and 
peripheral vascular complications in phase IV (ticlopidine and aspirin only), confirm the 
feasibility of a randomized trial testing the clinical value of this new stellt, as well as the 
innm.::uous nature of the new post treatment regimen. 
Based on the data of the Benestent-ll pilot study, the Benestent-ll trial has been deigned. In 
this multicenter randomized study, the hypthesis is tested that the use of a heparin-coated 
Palmaz Schatz stent in conjunction with acetyl salicylic acid and ticlopidine in patients with 
stable and classes I and II unstable angina will: 
- reduce hospital slay, risk of bleeding and vascular complications resulting in similar rates to 
that following ball loon angioplasty, without increasing the risk of (sub)acute stellt thrombosis; 
-further reduce the restenosis rate resulting in a further reduction in the need for repeat revas-
cularization when compared to PTCA. 
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SUMMARY 
Implantation of metallic coronary stents is a promising strategy to obtain improvement of sub-
optimal results and for prevention of restenosis after percutaneous transluminal coronary bal-
loon angioplasty (PTCA). However, dinicaI studies revealed two major problems, associated 
with this technique .. Metallic coronary stenls arc prone to thrombotic occlusion, which is usu-
ally prevented by using complex anticoagulation regimens. Intense anticoagulation after a 
transarterial coronary intervention in turn is associated with a high risk for access- site related 
bleeding complications. Both complications may affect the overall applicability of the techni-
que, since they arc potentially life threatening and because they arc associated with patient 
discomfort, prolonged hospitalization times and increased costs. 
This thesis gives an inventory of our efforts to overcome the problems associated with 
implantation of Palmaz Schatz coronary stellts, in order to optimize dinical outcome of this 
intervention. 
SUMMARY OF FINDINGS 
First the results and problems associated with implantation of Palmaz Schatz coronary slents 
for two major indications are disclIssed in chapters 2 and 3. 
\Ve described our results of Palmaz Schatz stenting for failed PTCA, during very early stent 
experience (chapter 2.1 and 2.2). Tn the larger series, procedural success was achieved in 
89%. Hmvever, 23% of 39 conservatively treated patients sustained subacute stent occlusion 
and a major bleeding was encountered in 3 patients (8%). 
Although Pahnaz Schatz stent implantation was associated with a more favorable short and 
long term outcome compared to banoon angioplasty in selected patients with stable angina 
and a de novo lesion in native coronary arteries (Benestent-I study; chapter 2.3), the results 
were partially offset by a 3.5% subacute stent occlusion rate and a 13.5% incidence of ml.Uor 
bleeding complications, requiring vascular surgery and/or bloodtransfusions. 
In a multivariate analysis performed Oil patients randomized to stellt implantation in the 
Benestent study (chapter 3. I), risk for subacute stent thrombosis appeared to he a small pre-
procedural vessel size, prior myocardial infarction and the occurrence of bleeding complica-
tions. Female patients were at higher risk for bleeding complications. 
In chapter 4, solutions for stent thrombosis and bleeding complications are explored in 5 
directions: [a] improvement of stent deployment, [b] improvement of anticoagulation monito-
ring, [c] improvement of local hemostasis, [dl selection of safer entry sites and [e] decreased 
thrombogenicity of the stellt. 
[a] Intravascular ultrasound plays an important role in the proper assessment of stellt deploy-
ment (chapter 4.1). It was round that 21 of 29 stents (72%) were suboptimally deployed after 
implantation with the sheath protected stent delivery system. Improvement was achieved by 
high pressure dilatations with less compliant balloon material. Since we expected that early 
and long term outcome improves with improved stent deployment, we routinely perform high 
pressure stent dilatations with adequate sized balloons. 
[b] A second prerequisite for a successful outcome was considered to be optimal anticoagula-
tion. Since an optimal level of anticoagulation depends on optimal monitoring, assessments of 
prothrombin fragment (PTF) Fl+2 \vas recommended by several investigators. Despite con-
vincing reports, we were not able to demonstrate a relation between elevated levels of PTF 
FI+2 and stent thrombosis in a prospective study (chapter 4.2). Bloud sampling and analysis 
have been performed correctly. The variability of laboratory results may be due to storage 
techniques. However, in the patients with a bleeding complication, levels were higher, compa-
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red to patients \vithout a bleeding, whk:h is not surprising, since formation of thrombin is the 
natural answer on any bleeding and hemostasis process. Because of this variability in results 
and since thrombus formation secondary to a bleeding can not be differentiated from throm-
bus formation due to impending stent thrombosis, we decided not to perform this costly and 
time-consuming monitoring of PTF FI+2 after Palmaz Schatz stent implantation. 
Ie I \Vith enthollsiasm, a new hemostasis device, a collagen plug (Vasoscal®) was wellcomcd 
in our department, \vith the expectation that safe and early mohilization of patients under full 
heparinization would become feasihle. Immediate sheath removal followed by stable local 
hemostasis, would allow the clinician to maintain heparinization on a high level, without 
interruption of the heparin infusion. In a retrospective study, comparing patients with and \vit-
hout a Vasoseal® after stenting, we were able to demonstrate a better level of heparinization, 
with less suboptimal APTT- values in patients treated with a Vasoseal®; 7% of 233 APTT 
samples, versus 20% of 168 samples in patients without a hemostasis device (chapter 4.3). 
Early and late punctllresite bleeding complications, however, could not be prevented, limiting 
the applicability of this costly device, 
[d] Another possible means to obtain improved local hemostasis is the use of smaller guiding 
catheters and introducer sheaths, which became possible since miniaturized angiopiasty mate-
rial became compatible with 6 French (F) guiding catheters. 
Instcad of using these catheters by the traditional transfemoral technique, we explored the 
feasibiIty of transradial coronary angiopiasty, since several advantages of this approach are 
evident: the superficial course allows safe and effective hemostasis, the absence of major ner-
ves and veins ncar the radial artery excludes damage to these stmctures, and collateral blood 
supply from the ulnar artery prevents the hand from becoming ischemic if the radial artery 
occludes . 
. Maintenance of the possibility to treat suboptimal results such as ocdusive coronary dissec-
tions with autoperfusion balloons or coronary stents, may currently be considered as a prere-
quisite for any new PTCA- technique. New low profile perfusion balloon catheters proved to 
be compatible with 6F guiding catheters (inner diameter 0.060 inch) for primary use (chapter 
4.4. I), although friction was noticed during introduction and removal of the balloon catheter 
from the guiding catheter. Re-introduction after removal \vas impossible in 3 of 5 patients. 
Applicahility of perfusion balloons or coronary steIlts via 6F guiding catheters for suboptimal 
PTCA- results is reported in 13 patients (chapter 4.4.2). Thus 6F transradial coronary angio-
pia sty can be performed, without losing the possibility to optimize poor immediate PTCA 
results with the two most commonly applied techniques. 
In order to study the feasibility of transradial balloon angioplasty, we performed an open pro-
spective study in 100 patients (chapter 4.5. I .). Coronary catheterization via the radial artery 
was successful in 94 patients. Of these patients a procedural succcss was achieved in 92 
patients (98%). Radial artery occlusion occurcd in 10% of patients. Spontaneous recanalisa-
tion was evident in 5%. No patient had signs of ischcmia of the hand and forearm and no 
major bleeding complications werc encountered. 
Encouraged by these promising results we designed a randomized study, the ACCESS- study, 
to establish the mutual relation of access-failurc rates and vascular complications of PTCA 
with 6F guiding catheters via the percutaneous femoral, brachial or radial artery. 
The interim analysis (450 patients) is described in chapter 4,5,2, 
During this first part of the study, coronary cannulation was successfully achieved in 92. I % 
of patients, randomized to the transradial artery approach, versus 96.6% (p=0.03) and 100% 
(p=O.OO I) in the patients who underwent PTCA via the brachial and femoral artery. Failed 
radial artery puncture was the main reason for inability to cannulate the coronmy artery. 
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Procedural PTCA sllccesrales were comparable in the three groups. After PTCA via the percu-
taneous brachial route, bleeding complications were more frequently encountered; 4.1 %, ver-
sus 0% (p=0.03) in the radial group and 1.3% (p=ns) ill the femoral group. 
The transradial approach is theoretically an ideal technique for coronary stenting since both 
stent thrombosis and bleeding can be reduced by giving full anticoagulation in an ambulant 
patient, treated via a low risk entry site. By manual crimping of a bare Palmaz Schatz stent on 
low-profile bal100n catheters, we were able to deliver these stents via the radial artery. The 
technique of transradial artery stenting is described in a case report (chapter 4.6.1.) and results 
of this technique are described ill 20 patients (chapter 4.6.2) and in 100 patients (chapter 
4.6.3). In this final series, we were able to demonstrate high procedural (96%) and clinical 
success rates (93%). Stent thrombosis was encountered in I patient (l %) and another patient 
had a radial artery bleeding requiring vascular surgery (1 %). 
Because of the important role of intravascular ultrasound during coronary stenting, it was 
necessary to demonstrate the feasibility of transradial ultrasound controlled stent implantation 
via 6F guiding catheters. Feasibility of transradial ultrasollnd control1ed stenting with miniatu-
rized vascular ultrasound transducers, is demostrated in 8 patients (12 stents) (chapter 4,6.4). 
\Ve found improved stellt expansion after high pressure dilatations with balloons of interme-
diate compliance, compared to the results after delivery with equally sized compliant balloons 
at 10-12 atmospheres, 
Transradial implantation of bare stents has the potential for significant cost savings, when 
compared to the traditional transfemoral stent technique, using SF guiding catheters and she-
ath protected stent delivery systems. Savings are potentially achieved by a reduction of costs 
associated with use of material (less balloon catheters), with diagnosis and treatment of blee-
ding complications and by a shorter hospitalization time. \Ve compared the costs of these 
items in 35 patients after elective single stent implantation via the radial artery to those of 25 
patients, participating in the Bcncstent study in our clinic, who received a stellt via the femor-
al artcry (chapter 4.6.5). Overall, the mean cost per patient in the first group was 67% of costs 
in the second group. 
The transradial approach for stcnting allows the patient to be mobilized immediately after the 
procedure. Together with the high success rate and the low complication rate, hospital stay 
was relatively short, compared to historical series. Patients on a preprocedural adequate level 
of oral anticoagulation could be discharged the day following stellt implantation (n=22 in the 
series of 100 patients), if no complications were observed. Since acute stellt thrombosis is an 
extremely rare event, there is no argument to kecp patients inhospital, if adequate local hemo-
stasis is obtained in an ambulant patient 011 a therapeutic level of anticoagulation. \Ve conduc-
ted a pilot study (20 patients) to the feasibility of transradial outpatient coronary stenting 
(chapter 4.6.6). 
Since no complications \vere associated with this outpatient strategy, the 95% confidence 
interval for an event-free outpatient procedure runs from 0-16.S%. A feasibility study in 100 
patients is presently conducted in our department. 
Thus the transradial approach can be considered as a major breakthrough in the optimalization 
of coronary stenting, since this approach is effective, safe and is associated with increased 
patient comfort (early mobilization) and cost effectiveness. 
Another means to reduce the risk for stent thrombosis and local bleeding complications is the 
use of non-thrombogenic, heparin coated coronary stents, which allows withdrawal or at least 
a reduction of anticoagulants. Results of a pilot study on the use of heparin coated stents in 
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patients with stable angina and a de novo lesion in a native coronary artery (Benestent 11-
pilot study; phase 1,2,3 and 4) are described in chapter 4.7. 
In 4 patient groups, heparinization after sheath removal was gradually delayed to 36 hours. In 
the fourth group, no heparin was administered after the procedure and the patients were tre-
ated with antiplatelet drugs instead of antivitamin K. The heparin-coated stellt was well tole-
rated. No stellt thrombosis was encountered. A trend towards less access- related bleeding 
complications was observed. This study contlnns the feasibility of a randomized trial testing 
this new stent. 
CLINICAL CONSEQUENCES 
\-Vhat do all these findings mean for day-to-day care of patients, selected for coronary stenl 
implantation? 
Elective as well as emergent coronary stenting, for reduction of restenosis and for improve-
ment of suboptimal PTCA results, respectively, should he finalized by high-pressure dilata-
tions of the freshly implanted stent, to a diameter, at least corresponding to the reference dia-
meter of the stented segment, in order to reduce the risk for stent- occlusion. An optimal stellt 
result provides a good safe-guard against thrombotic stent- occlusion. Variability of results of 
prothrombin fragment FI+2- monitoring in the week following stent implantation, limits the 
value of this costly and time consuming tool, in the prevention of stent- thrombosis. 
The main hazard of coronary stenting through 8F guiding catheters via the femoral artery 
under full anticoagulation is a local bleeding complication, \"hich can not be prevented by 
percutaneous insertion of collagen plugs. 
One effective strategy to prevent bleeding complications is the transradial artery stent techni-
que. This approach is techllicaI1y more delicate and difficult than the trans femoral technique, 
since the radial artery is smaller and the guiding catheters arc preshaped for the femoral 
approach. Despite these limitations, we have shown that the transradial approach can safely 
and effectively be applied in patients undergoing coronary balloon angioplasty and coronary 
stenting, without losing the possibilty to apply bailout techniques and intravascular ultra-
sound. The dramatic reduction of bleeding complications is evident, resulting in reduction of 
costs, since less diagnostic and therapeutic procedures are required for treatment of these 
complications. No ischemic damage to the hand or forearm was observed. The combination of 
effective and safe hemostasis ano reliable stellt results makes coronary stenting on an outpa-
tient basis possible, which will contribute to further cost- reduction. 
Another promising technique to reduce the risks for stellt thrombosis as well as bleeding com-
plications, is the use of non-thrombogenic heparin coated stents. These stents allow patients 
to be treated with a simplified anticoagulation regimen. Its effect on restenosis and cost 
savings will be explored in a randomized multicenter study. 
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SAMENVATTING 
Jmplantatic van roestvrij stalen coronaire stellts is een vcelhelovendc techniek tel' verbetering 
van suboptimale resultaten na perclltane transluminale coronaire ballon angioplastiek (PTCA) 
en ter preventie van restcnose l1a PTCA. 
Er zijn cehter twee belangrijke beperkingen aan deze tcchniek verbondcn. In de l11ctalen 
stents kan thrombose optredcn, am thrombotische occlusie van de stent te voorkomen worden 
de patienten na stent implantatie veelalnabehandeld met eell complcxe combinatie vall stol-
lingsrcllllllcrs. lntcnsieve ontstolling l1a een artericie catheterisatie procedure, kan gepaard 
gaallll1ct ernstige bloedingcomplicaties. 
Beide, potentieel levensbcdreigende, complicaties beperken de aigcl11cnc toepasbaarheid van 
de stent techniek. Oak gaan deze complicaties gaan gepaard met ollgemak vaal' de patient, 
langdurlg ziekenhuis verblijf en met hoge kosten. 
Dit proefschrift geeft eell overzicht van ollze inspanl1ing om het klinische resultaat van coro-
naire Pahnaz Schatz stellt implantatie te optimaliseren. 
SAMENVATTING VAN DE DEVINDINGEN 
Eerst worden de resultaten ell complicaties besproken van stent implalltatie voor de twee 
belangrijkste indicaties in ollze kliniek. 
De eerste ervaring met de Palmaz Schatz stellt werd in OilS centrum opgedaan gedurende de 
behandeling van suboptimale PTCA resllitaten als alternatief voor acute coronaire bypass 
chirurgie (hoofdstuk 2.1 en 2.2). Pr'ocedureel succes van stent implantatie werd bereikt in 
89% . Echter, 23% van de 39 niet-chirurgisch bchalldelde patienten, ontwikkelde stcnt throm-
bose en belangrijke hloedingscomplicatics werden gezien bij 3 patienten (8%). 
De klinische en angiografische resllltaten na stent ill1plantatie waren betel' dan na conventio-
l1c1c PTCA bij geselectccrde patientcn met stabiele angina pectoris en cen primaire laesie in 
eell kransslagader (Benestent-I stlldie; hoofdstuk 2.3). Echter, de voordelen werden ten dele 
teniet gedaan door stent thrombose (3.5%) en door bloedings- complicalies, waarvoor een 
chimrgische ingrcep of het toedienen van bloedtransfusies noodzakelijk was (13.5%). 
!vlultivariate analyse van de stellt populatie (hoofdstuk 3.1) leerde dat de kans op stent throm-
bose groter is naarmate de preprocedurele krallsslagadcr diameter kleiner is, als de patient 
vroeger een hartinfarct heeft doorgemaakt en als er Ila de procedure eell bloeding optreedt. 
VrOllwcn hebben cen grotere knns op een bloedingscomplicatie. 
Oplossingen voor stellt thrombose en bloedingscomplkaties werden gezocht in verbetering 
faJ van de implantatie tcchniek, [bl van de controie op ontstolJing, [cl van lokale hemostase 
en (dl in de selectie van een veiliger punctiepiaats en [e] in de vermindering van de thrombo-
geniciteit van de stent (hoofdstuk 4). 
laJ De toepassing van intravasculaire echografic speelt een belangrijke rol in de beoordeling 
van de mate en kwaliteit van stent expansie in de kransslagader (hoofdstuk 4.1). 
Wij constatccrden met behulp van deze techniek dat 21 van de 29 stents (72%), na ailevering 
met het "Stent Delivery System" onvoldoende ontplooid \varen. Verhetering werd verkregen 
na hoge inflatiedrukken met groterc ball onnen vun geringerc complianlie. Deze bevilldingen 
zijn in overeenstcmming met observaties van andere onderzoekcrs en tegenwoordig wordt 
routinematig het acute stellt resultaat geoptimaliseerd miJdeJs nadilataties met hogc inflatie-
drukkcn, 
[b 1 Optimale olltstolling vcreist optimale monitoring hiervan. Door diverse onderzoekers wer-
den Prothrombine fragment Fl+2 bepalingen aanbevolen. \Vij konden echter geen relatie con-
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stateren tussen verhoogde prothrombine fragment FI+2- waarden en stelll thrombose in een 
prospectieve stutlie (hoofdstuk 4.2). Blocdafname en -bepaling waren correct uitgevoerd. Dc 
sterke variabiliteit van de uitkomsten kan eventueel samenhangen met het [eit clat de plasma-
monsters eerst waren ingevroren, totdat be paling plaatsvond. 
Het bleek echter dat bij patienten, die ook eell hloeding hadden tloorgemaakt, hogere waarden 
werden gevonden. Dit is verklaarbaar uit het feit clat de vorming van thrombine een natuurlijk 
antwoord is op iedere bloetling. Vanwege de variabiliteit van de uitkomsten en vanwege het 
[eit dat thrombusvonning, secundair aan een bloeding niet kan worden gedifferentieerd van 
thrombusvonning bij dreigende stentocclusie, hebben wij besloten prothrombine fragment 
Fl+2- monitoring niet als routine na stent implantatie in te vocren. 
[c] f\1et enthollsiasme werd de collageen-plug (Vasoseal) ge'introduceerd op onze afdelillg. 
\Vij koesterden de verwachting dat deze noviteit veilige en vroege mobilisatie van de gehepa-
riniseerde patient zou toelaten. Tevens zOll het lllogelijk zijn op hoog niveau te kunnen he pari-
niseren, otlmiddellijk nadat hemostase middels de Vasoseal zOll zijn verkregen. In een rctro-
spectieve studic, waarbij paticnten met en zonder Vasoseal na stent implantatie met elkaar 
werden vergcleken, hleek il1e1erdaad dat er sprake was van een optimaler heparil1isatie, Er 
werden minder subtherapelltische APTIs gevonden in de patienten met cen Vasoseal; 7% van 
233 APTIs versus 20% vau 168 APTTs (hoofdstuk 4.3). Lokale bloedingen konden eehter 
niet worden vermcden, hetgeen de toepashaarheid van dcze, ook kostbare, plug bepcrkt. 
[d] Een andere methode om tot vcrbeterde hemostase te komen, is het gebruik van de kleine-
re, 6 French (F), geleidecatheters. \Vij hcbben onderzoek gedaan naal' de haalbaarheid van de 
arteria radialis, als port d'entree, Er Zijll immel'S cen aantal thcoretische voordelen aan deze 
methode verbonden: de oppcrvlakkige ligging van de arteria radialis maakt dit vat gemakke-
lijk afdrukbaar, er lopen geen belangrijke aders en zenuwen naast de polsslagaeler en de colla-
ternle verbindingen met de arteria 1Iinaris beschermen de hand tegcn ischemie in geval van 
een postoperatieve arteria radialis afsluiting. 
\Vij hebben als voorwaarde voor de transradiale PTCA techniek met 6F geleidecatheters 
gesteld dat de patient met autoperfusieballonnen en met stents behandeld moeten kunnen Wor-
den, indien e1e PTCA een onvoldoende resultaat geeft, In hoofdstuk 4.4.1, worden ollze erva-
ringen beschreven met nieuwe perfusieballonnen, opgeyoercl door 6F geleidecatheters. 
Alhoewel el' weI enige frictie voelbaar was, koncien cleze hallonnen wei tel' plaatse van de ste-
nose worden gcbmcht. Re-introductie, nadat de ballon uit de catheter was teruggetrokken, 
faalde bij 3 van de 5 patienten. Dc toepasbaarheid van perfusiebatlonnen en stents tel' verhete-
ring van suboptimnle PTCA resultatell wordt beschreven bij 13 patienten (hoofdstuk 4.4.2.). 
\Vij hebben hiermee tins aangetoond dat PTCA door 6F geleiJecatheters de 2 cathetertechnie-
ken, om tot verbetering van PTCA resultatcn te komen, niet uitsluit. 
Vervolgens hebben \vij een prospectieve studie verricht nam de resultaten van transradiale 
PTCA in een serie van 100 patienten (hoofdstuk 4.5.1.). Bij 94 patienten kon de kransslagader 
worden gecannuleerd, De procedure verliep succesvol bij 98%. Bij 10 patienten bleek de arte-
ria radialis te zijn afgesloten voor ontslag uit het ziekenhuis, uoch spontane rekannlisatie vond 
plaats bij 5 patiCnten. Belangrijke bloedingscomplicaties of ischemie van de hand zijn niet 
opgetreden. 
Gestimuleerd door deze resultaten, hebben wij een gerandomiseerde studie opgezet (de 
ACCESS- studie) naar cannulatie- en catheterisatiesllcces en bloedingscomplicaties, bij percu-
tane transradiale, -brachiale en -femora Ie hal10n coronaire angioplastiek met 6P geleidecnthe-
ters. Een interim-analyse werd verricht na inclusie van 450 patiCnten (hoofdstuk 4.5.2.). Bij 
92.1 % van de patienten uit de radialis- groep kon de kransslagnder worden gecannulcercl, 
tegen 96.6% (p=O.03) an 100% (p=O.OOI) van de patienten nit respeetievelijk de braehialis-
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en de femoralis- groep. Procedureel PTCA succcs was vergelijkbaar in de 3 grocpcn. Meer 
bloedingscomplicaties traden op na PTCA via de arteria brachialis (4. I %), versus 0% na 
transradiale PTCA (p=O.03) en l.3% na transfeillorale PTCA (p=NS). Dc ACCESS- studie 
wordt gccontinueerd totdat 900 patienten zijn gci'nc1udeerd. 
De trallsradiale benadcring is theoretisch ideaal voor patienten, die een stent geYmplanteerd 
krijgen, omdat stellt thrombose kan worden voorkomell, door optimaal te ontstol1en, zonder 
een belangrijk bloedingsrisico. De combinatie van manueel gemonteerdc stellts op hallonca-
the tel's met eell laag profiel, bleek goed compatibel met 6F geleidecatheters. De techniek van 
transradiale coronaire Palmaz Schatz stellt imphmtatie wonIt beschreven in een casu'(stische 
medcdeling (hoofdstllk 4.6.1.) en de resuitatcn worden beschreven bij 20 patiCnten (hoofdstllk 
4.6.2.) en bij 100 patienten (hoofdstuk 4.6.3.). In deze laatste serie verllleidden wij een 96% 
procedureel succes en 93% klinisch sllcces. Stellt thrombose werd bij I patient (I %) gecon-
stateerd en I patient (l %) had cen helangrijke lokalc bloeding. 
Gezien de helangrijke rol van intravasculaire echografic gedurende stentimplantaties, hebben 
wij een haalbnarheidsstlldie gedaan naar transradiale 1Iitrasoon gelcide coronaire Palmaz 
Schatz stent illlplantatie bij 8 patienten {12 stents} (hoofdstuk 4.6.4.). 
\Vij constateerden betere stellt expansie na hoge druk- inflaties met semi-compliant ballonnen, 
vergeleken met de expansie na atlevering met 10-12 atmosfeer met compliant ballollmateri-
aal. 
Transradiale stcnt- implantatie is goedkoper dan de traditionele transfemorale techniek, met 
SF geleidecatheters en het Stent Delivery System. \Vij vergeleken de kosten tussen 25 patien-
ten, die op deze wijze gestent zijn (Benestent- populatie OLVG) en 35 patienten na electieve 
stent implantatie via de polsslagader. Kosten werden bespaard op materiaal verbruik, diagnos-
tiek en behandeling van bloedingscomplicaties en op ziekcnhuis- opnameduur. De totale kos-
ten na cell transradiale stentimplantatie bedroegen 67% van de kosten van de traditionele 
methode (hoofdstuk 4.6.5.). 
Na een transradiale stent- behandelillg is de patient ollmiddcllijk mobie!. Daar hemostase 
effcctief kan worden verkregen en daar de kans op stent occlusie, na een optimaal (leuut resul-
taat, gering is, resteren er weinig argumenten Olll goed ontstoldc patientell klinisch te houden, 
na cell sllccesvol1e ingrccp. 
Bij 20 patientcll hebben wij cell pilot-sludie verricht naar de mogclijkheid om op poliklinische 
basis Palm<lz Schatz coronaire stents te impiantercil (hoofdstuk 4.6.6.). 
Bij geen van dcze zorgvuldig gesclccteerde patienten hebben zich complicalies voorgedaan, 
gerelateerd aan het poliklinisch protocol (betrollwbaarheidsinterval voor een ongecomplicecrd 
beloop; 0-16.8%). Thans wortH de sllldie naar eell grotere grocp patienten uitgebreid. 
Dus de transradiale benadering vour Palmaz Schatz coronaire stenl implantatie kan als een 
doorbraak worden beschollwd, daar deze techniek effectief en veilig is. De patiCnt- en budget 
vriendelijkheid zijn belangrijke additionele voordelen. 
Een andere methode om zowel de kans op stellt thrombose als op blocdingscomplicaties te 
vcrkleinen, is het gebruik van niet-thrombogene, heparine- gecoate, stellts in l'ombinatie met 
cen sterk vercenvoudigd olltstollingsbeleid. Resultaten van de pilot- stud ie, betreffende hepa-
rine-gecoate stents bij patienten met stabicle angina pectoris en een de novo stenose in een 
kransslagadcr (Benestent-II pilot study; fase 1,2,3,en 4) worden beschreven in hoofdstuk 4.7. 
In de cerste 3 fasen werd de heparinisatie na verwijderen van de sheath, uitgcsteld van 6 naar 
12 naal' 36 uur. In de 4e fase werd geen heparine post-procedureel mcer toegediend en wenl 
antivitamine K vervangen door plaatjesaggrcgatieremmers. Er wertl gcen stent thrombose 
217 
waargenomen en er was een afname van het aantallokale blaedingscomplicaties te canstate-
reno Deze studie bevcsligt de haalbaarheid van een gerandomiseen.le stud ie, waarbij resultaten 
van PTCA zullen worden vcrgeleken met resultatcn na implantatie met deze stent. 
KLINISCHE BETEKENIS 
Wat betekent dit allemaal voor de dagelijkse praktijk? 
Electief stenten tel' preventie van restenose en spoedimpJantaties tel' vcrbetering van subopti-
male PTCA resultaten zijn 2 (kiinisch) geaccepteerde indicaties voor Palmaz Schatz coronuire 
stents. Gedurende de vmege ervaring werden stentimplantaties te vaak gccomplicecrd door 
thrombotische stentocclusie en door lokale bloedingen. 
Een optimaal acuut stenlresultaat is waarschijnlijk de beste beveiligillg tegen het optreden van 
stent thrombose en plaatst het ontstollingsbeleid in een ander perspectief. 
De stents dienen te worden nagedilatecrd met mindel' compliant balJon materiaal en met hoge 
inllatiedrukken. Gestl'eefd moel worden naal' een optimale verhouding tussell stent diameter 
en diameter van de kransslagader (tenminstel: I). 
De variahiliteit van prothrombine Fl+2- bepalingcn in de week na stent implantatie, beperkt 
de waarde van deze kostbare en tijJrovende tcchniek en is als routine niet aan te bevelen. 
Het sllbcutaan plaatsen van collagcen-pluggen tel' preventie van liesblaedingen na een SF pro-
cedure onder volledige ontstolling, vindt geen grate navolging. In onze ervaring heeft dat 
ondel'meer te maken met het feit Jat blaedingscomplicaties niet kunnen worden voorkomcn 
en dat deze zelfs dagen na de insertie kllnnen optreJen. 
Een effectieve mcthode om bloedingscomplicaties tc voorkomcn is de transradiale stcnt tech-
niek. Deze benadering is technisch moeilijker dan de transfemorale techniek, dual' de arteria 
radialis kleiner is en daar de meeste geleidecatheters niet op deze benadering zijn ontworpen. 
Deze beperkingen ten spijt, hehhen wij aangetoond dat de radialis tcchniek effcctief en veilig 
kan worden toegepast voor PTCA en Palmaz Schatz cOl"Onaire stentimplantaties. Transradiulc 
coronair angioplastiek sluit de toepassillg vall "bail-ollt" technieken en intravaseulaire ccho-
grafie niet uit. 
De belangrijke reductic in bloedingscomplicaties heeft ook een kostenreductie tot gevolg, 
daar mindel' diagnostische en therapeutische verrichtingen noodzakelijk worden en daar de 
opnameduur kan worden bekort. lschemische complicaties aall de hand, bij patienten met col-
laterale verbindingen met de arlria ulnaris, zijn niet waargenomen. 
De combinatie van elTectieve en veilige hemostase met cen betrouwbaar stentresuitaat, maakt 
deze bchandeling op poliklinische basis mogelijk, hetgeen zal bijdragen tat eell verdere kos-
tenreductie. 
Ecn andere veelbelovende techniek ter be.strijding van stent thrombose ell locale blocJings-
compiicaties is het gebruik van heparine-gecoatc stents. Deze stents maken het mogelijk de 
complexe ontstollingsregimes te vervangen door veiligel' plaatjesaggregatieremmende regi-
mes. Het effect op restenose ell kosten-reductie wordt in een gerandomiseerd muIticentrisch 
onderzoek geevalucerd. 
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